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The clonal expansion of mitochondrial DNA (mtDNA) point mutations and associated defects 
of oxidative phosphorylation (OXPHOS) are observed within the ageing colorectal 
epithelium. Clonally expanded mtDNA point mutations are also observed within colorectal 
tumours, however whether these mutations are passive bystanders or if they functionally 
contribute to tumour progression is unknown. In order to address this, a mouse model was 
developed in which PolγA mediated mtDNA mutation accumulation preceded the intestinal 
Lgr5+ stem cell specific deletion of Apc. In comparison with controls, mice harbouring 
OXPHOS defects demonstrated an accelerated clinical deterioration characterised by 
anaemia, impaired thermoregulation and weight loss. The reduced survival of these animals 
was attributed to a significantly greater intestinal adenoma burden in which a prominent 
complex I defect was revealed following immunofluorescent quantification of OXPHOS 
protein levels. A double thymidine analogue labelling technique demonstrated accelerated 
proliferation within complex I deficient intestinal adenomas while apoptotic cells were 
significantly fewer.  
Total RNA sequencing of OXPHOS deficient intestinal crypts prior to Apc deletion identified 
the upregulation of transcripts specific to the de novo serine synthesis pathway and 
mitochondrial one-carbon cycle (Whitehall, 2019). These pathways provide essential 
nucleotides, antioxidants and anabolic precursors vital to maximal tumour growth. RNA 
sequencing results were validated at the protein level within OXPHOS deficient intestinal 
crypts and adenomas and were further demonstrated to be upregulated in response to an 
age-related accumulation of OXPHOS defects in the murine small intestine and colon. Finally, 
these data are directly translatable to the normal human colonic epithelium in which the 
upregulation of serine synthesis and mitochondrial one-carbon cycle enzymes was identified 
within OXPHOS deficient crypts. These data show that age-related OXPHOS deficiency 
creates a permissive metabolic environment which in the event of malignant transformation, 
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Chapter 1. Introduction 
 
Worldwide, colorectal cancer (CRC) is the third most commonly diagnosed cancer in men 
and the second most commonly diagnosed malignancy in women. In 2018, colorectal cancer 
accounted for 9.2% of global cancer deaths with 5-year survival rates in the UK reported as 
relatively poor at approximately 50% (Arnold et al., 2019). The incidence of CRC rises steeply 
from around 50-55 years of age and as such, CRC and indeed many malignancies are strongly 
associated with advancing age. Described by López-Otín and colleagues in 2013, the 
pathology of ageing is characterised by nine molecular hallmarks which together lead to the 
manifestation of an ageing phenotype (López-Otín et al., 2013). A similar set of hallmarks has 
been described with regard to cancer (Hanahan & Weinberg, 2011). While some hallmarks 
such as proteostasis and cellular senescence are divergent between the two pathologies of 
ageing and cancer, several are shared. Perturbed mitochondrial function is one such 
common hallmark. 
Previous work carried out within the group has demonstrated an exponential increase in the 
frequency of colonic crypts harbouring clonally expanded somatic mitochondrial DNA point 
mutations and associated defects of oxidative phosphorylation (OXPHOS) within the ageing 
colorectal epithelium (Taylor et al., 2003). A similar mtDNA mutational spectrum has also 
been observed within human colorectal cancers (Ericson et al., 2012; He et al., 2010; Larman 
et al., 2012; Polyak et al., 1998). The enrichment of somatic mtDNA mutations and their co-
segregation with oxidative phosphorylation defects as colorectal adenomas progress to 
carcinoma suggests a contribution to tumorigenesis (Smith et al., 2020), however whether 
this is active, or passive remains to be elucidated. In the absence of experimental evidence 
supporting or refuting the role of age-associated mtDNA mutations in the development of 
colorectal cancer, this thesis aims to address this with the use of a biologically relevant 
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1.1. Mitochondria 
 
Mitochondria are organelles present in the cytoplasm of almost every eukaryotic cell. They 
were first described by Altmann in the 1890s as ‘‘bioblasts’’; “elementary organisms” that 
live inside cells and carry out vital functions (Altmann, 1894). Mitochondria very closely 
resemble bacteria, and as such, are thought to have evolved from them via a process known 
as endosymbiosis. Endosymbiosis describes the engulfment of free living, respiring 
Eubacteria by anaerobic, hydrogen dependant Archaebacteria creating primitive eukaryotic 
cells (Martin & Müller, 1998; Sagan, 1967). 
 
Mitochondria play an essential role in metabolism, converting carbohydrates and fatty acids 
into ATP, the energy currency of the cell via a process known as oxidative phosphorylation 
(Belitzer & Tsybakova, 1939). Alongside this critical function, mitochondria are also involved 
in cytosolic calcium regulation (McCormack et al., 1990), apoptosis (Liu et al., 1996), and the 
biosynthesis of haem and iron sulphur (Fe-S) clusters (Sano et al., 1959). 
 
Unlike other organelles, mitochondria contain their own genome, mitochondrial DNA 
(mtDNA). This circular, self-replicating, double stranded molecule was fully sequenced in 
1981 and comprises 16,569 base pairs in humans. The mitochondrial genome encodes a 
proportion of the proteins essential for ATP production, the additional proteins required are 
encoded by the nuclear genome (Anderson et al., 1981). 
 
1.1.1. Mitochondrial structure 
 
The first high resolution electron micrograph images of mitochondria were produced in 1952 
(Palade, 1952). Individual mitochondria are typically shown as rod shaped, double plasma 
membrane encased organelles which these early works placed as measuring around 2.5µm 
in length and 0.5 µm in width. A schematic is shown in Figure 1-1.  
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Figure 1-1. Schematic detailing the basic structure of a mitochondrion. The outer mitochondrial membrane houses an inner 
mitochondrial membrane which is folded into connected projections known as cristae. Respiratory chain proteins 
comprising the mitochondrial oxidative phosphorylation system are located on the inner mitochondrial membrane with the 
inner matrix containing multiple copies of the mitochondrial genome.  
 
The outer mitochondrial membrane (OMM) is a porous structure which presents no barrier 
to the passage of ions and small uncharged molecules. These molecules traverse the 
membrane through the abundant voltage-dependant ion channels (VDAC). Larger molecules 
such as mitochondrial precursor proteins are transported across the OMM by dedicated 
translocases of the outer membrane (TOMs), with sorting and assembly of these precursors 
being facilitated by the sorting and assembly machinery (SAM) complex of proteins, also 
present in the OMM (Wiedemann et al., 2003). 
 
The OMM surrounds the inner mitochondrial membrane (IMM), and the space between the 
two is termed the intermembrane space. The inner mitochondrial membrane is extensively 
folded into cristae which protrude into the mitochondrial matrix within. In contrast to the 
porous OMM, transport across the IMM is tightly regulated. This results in an 
electrochemical membrane potential across the membrane fundamental to oxidative 
phosphorylation. Molecules and ions may only pass across the IMM via specific transport 
proteins of which there are several types. Like the TOM proteins of the outer membrane, 
translocase of the inner membrane (TIM) proteins allow the movement of proteins across 
the IMM. The ATP/ADP carrier complex exports ATP from the mitochondrial matrix into the 
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cytoplasm while importing ADP back into the matrix for resynthesis of ATP (Pebay-Peyroula 
et al., 2003).  
 
The innermost compartment of mitochondria is the matrix. It houses multiple copies of the 
mitochondrial genome in addition to the mitochondrial transcription and translation 
machinery. Replication of mitochondrial DNA occurs in the matrix as does fatty acid 
oxidation and the tricarboxylic acid (TCA) cycle, both reactions being important precursors to 
oxidative phosphorylation. 
 
1.1.2. Mitochondrial functions 
 
1.1.2.1. ATP synthesis 
 
A major function of mitochondria is the production of cellular energy in the form of 
adenosine triphosphate (ATP). This occurs via oxidative phosphorylation on the IMM with 
the carriage of electrons from one respiratory protein complex to the next (Hatefi, 1985). 
ATP can be generated with the breakdown of lipids proteins and nucleotides; however, the 
primary source of cellular energy is derived from the breakdown of carbohydrates which, via 
a series of biochemical reactions, provide the substrates for oxidative phosphorylation (Berg 
et al., 2012). In the cytoplasm, glycolysis essentially describes the conversion of one 
molecule of glucose into two molecules of pyruvate. A net gain of two molecules of ATP, two 
molecules of water and one molecule of NADH are also generated during glycolysis, which 
can occur in both presence and absence of oxygen. In the absence of oxygen, pyruvate is 
converted to lactate which can be resynthesised to glucose via the Cori cycle in the liver, 
however under aerobic conditions pyruvate is transported into the mitochondrial matrix by 
the mitochondrial pyruvate carrier (MPC) (Papa et al., 1971) . The subsequent 
decarboxylation of pyruvate by pyruvate dehydrogenase (PDH) generates acetyl-coA; the 
primary substrate of the ensuing series of reactions encompassing the TCA cycle within the 
mitochondrial matrix. The completion of all eight stages of the TCA cycle generates one 
molecule of GTP, two of carbon dioxide, three molecules of NADH and one of FADH2. NADH 
and FADH2 are important electron carriers or reducing equivalents which are fundamental to 
the next stage of aerobic respiration; oxidative phosphorylation (Berg et al., 2012). The 
donation of electrons from NADH and FADH2 to complexes I and II of the mitochondrial 
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electron transport chain permits the coupled translocation of protons from the 
mitochondrial matrix to the cristae lumen. This maintains an electrochemical gradient which 
is used by complex V at the end of the chain of respiratory protein complexes. The 
movement of protons from an area of high concentration in the cristae lumen to that of a 
lower concentration in the matrix provides a proton motive force sufficient to drive the 
phosphorylation of adenosine diphosphate (ADP) to ATP by complex V (Mitchell, 1961). The 
depiction of glycolysis and the TCA cycle are presented in Figure 1-2. 
 
 
Figure 1-2. Glycolysis and the tricarboxylic acid cycle. A net gain of two ATP molecules and two molecules of pyruvate are 
generated from one molecule of glucose. The TCA cycle; a series of enzyme catalysed reactions occurring within the 
mitochondrial matrix. GTP and CO2 are produced, as are the electron carriers NADH and FADH2. NADH and FADH2 donate 
electrons to Complexes I and II of the mitochondrial respiratory chain respectively. 
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1.1.2.1.1. Complex I 
 
Complex I, also known as NADH-ubiquinone oxidoreductase, is a large, multi-subunit enzyme 
representing the first respiratory complex of the mitochondrial oxidative phosphorylation 
system. Mammalian complex I consists of a total of 45 subunits, 7 of which are encoded by 
mtDNA (ND1-ND6 and ND4L) (Carroll et al., 2006; Chomyn et al., 1986; Chomyn et al., 1985). 
The remaining 38 subunits are encoded by the nuclear genome  and together all subunits 
comprise three distinct functional modules (Ragan & Hatefi, 1986). The hydrophilic 
peripheral arm which protrudes into the mitochondrial matrix constitutes the electron input 
module (N module) and an electron output module (Q module), while the hydrophobic 
membrane embedded arm (P module) facilitates proton translocation (Hunte et al., 2010; 
Wikström, 1984). Complex I catalyses the oxidation of NADH to NAD+ with the resultant two 
electrons being transferred to the flavin mononucleotide (FMN) group of the peripheral arm. 
This group then passes the electrons to ubiquinone in the inner mitochondrial membrane via 
a chain of iron-sulphur clusters (Hinchliffe & Sazanov, 2005). On accepting electrons, 
ubiquinone is reduced to ubiquinol, which transfers these electrons to complex III. Four 
protons are released into the mitochondrial intermembrane space which contributes to the 
creation of the proton gradient which drives ATP synthesis by ATP synthase at the end of the 
respiratory chain (Mitchell, 1961). 
 
1.1.2.1.2. Complex II 
 
Mitochondrial complex II, also known as succinate dehydrogenase or succinate-ubiquinone 
oxidoreductase, is composed of four subunits (SDHA-D) which are all encoded by the nuclear 
genome. The hydrophobic subunits C and D are embedded within the inner mitochondrial 
membrane, with the catalytic subunits, A and B projecting into the matrix. Complex II has 
dual functionality; it has a role in the TCA cycle in addition to its role in the electron 
transport chain. In the TCA cycle, subunit SDHA catalyses the oxidation of succinate to 
fumarate generating FADH2. FADH2 is oxidised to FAD+ releasing two electrons which are 
transferred to ubiquinone via Fe-S and haem prosthetic groups thus permitting the 
subsequent reduction of ubiquinone to ubiquinol. Ubiquinol is then released from SDH-C and 
subsequently transfers electrons to complex III (Hagerhall, 1997). 
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1.1.2.1.3. Complex III 
 
Complex III, also known as ubiquinol: cytochrome c oxidoreductase, is composed of 11 
subunits, one of which; cyt b, is encoded by the mitochondrial genome. Complex III catalyses 
electron transfer from ubiquinol to cytochrome c. This is coupled with the transfer of two 
protons across the inner mitochondrial membrane (Mitchell, 1976). Complex III possesses 
two quinone binding sites; one quinone oxidation site (QO or QP) and one quinone reduction 
site (Qi or QN). When ubiquinol (QH2) binds QO, one electron is transferred to the Rieske iron 
sulphur cluster, on to cytochrome c1, then to cytochrome c. The other electron takes a 
different route via cytochrome b and the haem groups to the Qi site where it reduces 
ubiquinone (Q) to the unstable semi-ubiquinone Q-. A second molecule of QH2 binds QO with 
the same electron bifurcation occurring again. An additional cytochrome c is reduced and 
simultaneously at Qi, Q- receives a second electron and is further reduced to Q. This is 
known as the Q cycle and facilitates the transfer of electrons between respiratory chain 
complexes in addition to the translocation of two protons across the inner mitochondrial 
membrane for each molecule of QH2 entering the cycle (Mitchell, 1975a, 1975b).  
 
1.1.2.1.4. Complex IV  
 
Complex IV, also known as cytochrome c oxidase (COX), is composed of 14 subunits and 
represents the final enzyme of the mitochondrial respiratory chain. Complex IV was initially 
considered to be composed of 13 subunits, however in 2012 the NDUFA4 subunit of complex 
I was reassigned to complex IV and placed at the location of dimerisation of the enzyme 
(Balsa et al., 2012; Zong et al., 2018). Initially resolved as a monomer (Fuller et al., 1979), it is 
currently suggested that dimerisation of complex IV is reversible with transition between the 
two forms occurring continuously (Ramzan et al., 2019). 
 
Three of the 14 subunits of complex IV; COX I, II and III are encoded by the mtDNA and 
comprise the catalytic core of the complex (reviewed in Capaldi, 1990). The remaining 11 
subunits are encoded by the nuclear DNA and are thought to be involved in enzyme 
assembly and regulation of enzyme activity (Galati et al., 2009; Li et al., 2006). The basic 
function of complex IV is the acceptance of electrons from cytochrome c in order to facilitate 
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the reduction of oxygen (O2) into H2O (Hatefi, 1985). Simultaneously, four protons are 
translocated across the inner mitochondrial membrane (Wikström, 1977). Complex IV 
contains four redox-active metal groups that facilitate this function. Electrons from 
cytochrome c are received by CuA within subunit COXII. They are transferred to the haem 
a3-CuB group of subunit COXI via haem a, also of COXI. Four electrons are transferred one at 
a time to an O2 molecule bound at haem a3, with the formation of water and translocation 
of four protons (Faxén et al., 2005).  
 
1.1.2.1.5. Complex V 
 
Complex V, also known as FOF1 ATP synthase, is comprised of 16 subunits, two of which are 
encoded by the mitochondrial genome. Its main function is to synthesise ATP using the H+ 
electrochemical gradient set up by the transport of H+ ions across the IMM from the matrix 
to the intermembrane space by complexes I, III and IV. Complex V is comprised of two 
domains, the FO domain, which is fixed within the membrane, and the F1 domain, which 
projects into the matrix (Yoshida et al., 2001). The FO domain comprises eight hydrophobic c 
subunits, which form a c ring. The c ring allows protons to pass from the intermembrane 
space back into the matrix. The F1 domain constitutes five subunits in total (α, β, γ, δ and ε), 
with 3α and 3β subunits making up the stationary ring, and the γ, δ and ε subunits forming 
the rotary stalk (Wittig et al., 2008). The flow of H+ ions through the FO domain drives the 
rotation of the c ring around the central stalk. Protonation and deprotonation of glutamate 
residues within c ring subunits result in conformational changes which then drive the 
rotation of α and β subunits of the F1 domain, allowing the formation of ATP from ADP and 




Although traditionally depicted as discrete units adjacent to one another within the inner 
mitochondrial membrane, the respiratory chain complexes can reportedly assemble into 
multi-complex structural units known as supercomplexes (Schägger & Pfeiffer, 2000). Known 
as the ‘respirasome’, the association of complex I with complexes III and IV, is described as 
the predominant supercomplex formation (Gu et al., 2016). An increased stability of 
  9 
individual complexes is reportedly enhanced by supercomplex formation (Acín-Pérez et al., 
2004; Diaz et al., 2006; Schägger et al., 2004). Additional advantages include a reduced 
reactive oxygen species generation by complex I (Maranzana et al., 2013), and an 
augmented electron flux efficiency through the respiratory chain (Lapuente-Brun et al., 
2013); both as a result of supercomplex formation. 
 
1.1.2.2. Calcium homeostasis 
 
Mitochondria play an important role in the buffering of intracellular calcium (Ca2+). In doing 
so, they regulate metabolism, cell signalling and cell survival; functions of the cell which are 
sensitive to variations in cytosolic Ca2+. With regards to metabolism, enzymes critical to the 
TCA cycle rely on Ca2+mediated activation. The stimulatory effect of Ca2+ on the TCA cycle 
subsequently increases the rate of ATP production by OXPHOS via the increased availability 
of metabolic substrates (Jouaville et al., 1999; McCormack et al., 1990). 
 
The OMM is permeable to small ions and uncharged molecules, and therefore presents little 
barrier to the passage of Ca2+. The tightly regulated IMM possesses a dedicated, selective 
channel; the mitochondrial Ca2+ uniporter (MCU), which facilitates the transport of Ca2+ 
across the IMM (Kirichok et al., 2004). A massive influx of Ca2+ into the mitochondrial matrix 
is generally associated with cell death via necrosis or apoptosis, particularly when in 




Apoptosis, also known as programmed cell death, is a process by which cellular populations 
are maintained during the normal development and ageing of an organism. This homeostatic 
mechanism is characterised by a distinct set of morphological features including chromatin 
condensation, cell shrinkage and plasma membrane blebbing which precedes the death of 
the cell (reviewed in Saraste & Pulkki, 2000). There are two apoptotic signalling pathways 
that are well conserved between different animal species and represent the predominant 
routes by which cell death is programmed. One responds to extrinsic stress-mediated 
signals, and the apoptotic machinery is activated following ligand binding to cell surface 
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receptors. The other is initiated in response to intrinsic signals and is orchestrated by the 
mitochondrion (reviewed in Elmore, 2007). 
 
Mitochondria act in response to death signals such as DNA damage, oncogene activation or 
withdrawal of growth factors which ultimately leads to apoptosis. Upon receipt of these 
signals, pro-apoptotic effector members of the Bcl-2 family (for example Bax and Bak) 
promote mitochondrial outer membrane permeability (MOMP) which allows the release of 
cytochrome c. While Bax and Bak promote apoptosis, other members of the Bcl-2 family, for 
example Bcl-2 itself and Bcl-xL, are anti-apoptotic regulators (Kharbanda et al., 1997; Yang et 
al., 1997). In conjunction with support from the Bcl-2 subgroup; the BH3-only pro-apoptotic 
proteins (Zha et al., 1996), the balance between pro- and anti-apoptotic regulators 
determines the fate of the cell.  
 
As cytochrome c is released from the mitochondria into the cytoplasm, it binds and activates 
the apoptotic protease activating factor-1 (Apaf-1) which in an ATP-dependant manner 
forms the apoptosome. The apoptosome facilitates the cleavage of procaspase-9 forming 
the active caspase-9. Caspase-9 then activates further caspase proteases, namely 3, 6, and 7, 
mediating the death of the cell via the breakdown of its constituents (Li et al., 1997). 
 
1.1.2.4. Iron sulphur cluster biogenesis 
 
Iron-sulphur clusters (Fe-S) and haem are cofactors which are synthesised within the 
mitochondrial matrix. They function within numerous processes of the cell such as electron 
transport, the TCA cycle and DNA and RNA metabolism (reviewed in Rouault, 2019). The 
transport of iron into the mitochondrial matrix is facilitated by mitoferrins 1 and 2 (Mrfn1 
and Mrfn2) in mammalian cells (Paradkar et al., 2009). In the matrix, the Fe-S synthesis 
machinery consists of a scaffold protein known as ISCU and sulphur generating cysteine 
desulphurase (NFS1) in addition to its functionally required partner; ISD11 (Pandey et al., 
2012; Shi et al., 2010; Shi et al., 2009). ISD11 has been shown to stabilise NFS1 and also 
interact with the acyl carrier protein (ACP) (Van Vranken et al., 2016). Together these 
components form the core Fe-S cluster synthesis complex. Following initial cluster assembly 
on ISCU, the transfer of sulphur from NFS1 to ISCU is promoted by frataxin (FXN) completing 
cluster synthesis (Bridwell-Rabb et al., 2014; Fox et al., 2019). The delivery of newly 
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synthesised Fe-S clusters to recipient proteins is achieved via chaperone mediated transfer. 
In mammalian cells HSPA9 and HSC20 coordinate the direct transfer of Fe-S clusters to 
respiratory chain complexes (Maio et al., 2017; Uhrigshardt et al., 2010). In complexes I to III, 
the ability of Fe-S clusters to accept and donate electrons renders them fundamental to the 
transport of electrons in oxidative phosphorylation. Nuclear DNA polymerases also contain 
Fe-S clusters which assist in the stabilisation and formation of active enzymatic complexes 
(Netz et al., 2011), and their involvement in the maintenance of genome stability has also 
been described (Stehling et al., 2012). Fe-S clusters also function as regulators of cellular iron 
concentrations; yeast that are deficient in enzymes that release sulphur from cysteine for 
Fe-S formation demonstrate accumulation of iron within the mitochondrial matrix (Li et al., 
1999).  
 
1.1.2.5. ROS production 
 
Mitochondria and the electron transport chain specifically, have long been regarded as 
major producers of cellular reactive oxygen species (Jensen, 1966). The demonstration that 
isolated mitochondria generate peroxide (H2O2) (Loschen et al., 1971) was closely followed 
by the identification of the superoxide radical (O2-), as the precursor of H2O2, catalysed by 
the mitochondria-specific superoxide dismutase (MnSOD) (Loschen et al., 1974; Weisiger & 
Fridovich, 1973). Reactive oxygen species are primarily produced by complexes I (Hinkle et 
al., 1967) and III of the electron transport chain (Cadenas et al., 1977; Turrens et al., 1985). 
At complex I, a high NADH/NAD+ ratio can lead to a fully reduced FMN site and subsequent 
reduction of oxygen generating O2-. Additionally, an abundant electron supply leading to a 
reduced coenzyme Q /ubiquinone pool can lead to reverse electron transport (RET) back 
through complex I when coupled with a high protonmotive force (reviewed in Murphy, 
2009). At complex III, superoxide generation has been shown to originate from the QO site as 
inhibition of the Qi site with antimycin promotes O2- production (Cadenas et al., 1977; 
Turrens et al., 1985). An increase in membrane potential can enhance ROS production at 
complex III (Rottenberg et al., 2009), while the location of the site of origin; the QO site, has 
important implications for the effects of complex III generated ROS. In contrast to the matrix 
protruding FMN site of complex I, the QO site of complex III is parallel to the inner 
mitochondrial membrane and as such, ROS can be released into the intermembrane space in 
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addition to the matrix (Muller et al., 2004; St-Pierre et al., 2002). While ROS have been 
generally considered as harmful by virtue of the damage they can exert upon cellular 
components such as DNA and proteins, they are also involved in the regulation of cellular 
signalling pathways such as the response to hypoxia (Chandel et al., 1998), NF-κB, and TNFα-
mediated cell death (Kamata et al., 2005). The close proximity to the cytoplasm of complex 
III generated intermembrane space resident ROS may therefore deem these species of 
particular importance in signal transduction pathways (Bell et al., 2007). 
 
1.2. Mitochondrial biogenesis 
 
The biogenesis of mitochondria requires the convergence of multiple events. Nuclear and 
mtDNA encoded mitochondrial proteins must be synthesised, mitochondrial proteins must 
be imported, cofactors such as haem and Fe-S clusters must be formed, and the 
mitochondrial genome replicated. The PGC-1 family of coactivators are major players in 
mitochondrial biogenesis, with peroxisome proliferator activated receptor γ coactivator 1 α 
(PGC-1α) being key. PGC-1α activates nuclear respiratory factors 1 and 2 (NRF1 and NRF2); 
transcription factors which are responsible for the activation of mitochondrial gene 
promoters (Scarpulla, 2008; Virbasius et al., 1993a; Virbasius et al., 1993b). 
 
Following external stimuli such as increased exercise, a decrease in temperature or 
decreased nutrient availability, mitochondrial mass increases to meet new metabolic 
demands. Such stimuli increase intracellular Ca2+levels and thus activate kinases such as 
calcium/calmodulin-dependent protein kinase (CaMK) or protein kinase C (PKC). Subsequent 
activation of p38 mitogen-activated protein kinase (p38 MAPK) by CaMK increases PGC-1α 
expression and mitochondrial biogenesis as a result (Wright et al., 2007). 
 
1.3. Mitochondrial dynamics 
 
1.3.1. Mitochondrial fusion 
 
Mitochondria do not always exist as single entities; the double membranes of adjoining 
mitochondria can fuse together, creating a syncytium of interlinked organelles. The size, 
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shape and subcellular locations of mitochondrial networks is maintained by balancing 
mitochondrial fusion with the opposing state of fission and has a marked effect on the 
viability of the organelles and cellular processes in which they participate. The dynamin 
related protein family (DRP) members mitofusin 1 and 2 (MFN1 and MFN2) facilitate outer 
mitochondrial membrane fusion, with mutations in the gene encoding the latter causing 
Charcot-Marie-Tooth neuropathy type 2A, a progressive axonal condition characterised by 
distal muscle weakness, atrophy and sensory loss (Zuchner et al., 2004). Similarly, mutation 
of the gene encoding OPA1; the dynamin related GTPase responsible for inner mitochondrial 
membrane fusion, causes autosomal dominant optic atrophy (ADOA); the most common 
inherited optic neuropathy (Alexander et al., 2000). The process of fusion is initiated by the 
interaction between two outer membrane anchored MFN1 molecules on adjacent 
organelles. Earlier studies have proposed that contacts between MFN1 molecules are 
established via the HR2 domains of each protein (Koshiba et al., 2004), however more recent 
works have described the association of GTPase domains as the fusion-promoting 
interaction (Cao et al., 2017; Qi et al., 2016). Regardless of the specific MFN1 region involved 
in mitochondrial tethering, it is generally understood that the subsequent stages in fusion 
are facilitated by MFN conformational change, GTPase hydrolysis and outer membrane 
fusion (Ishihara et al., 2004; Legros et al., 2002). Following outer membrane fusion, OPA1 
and MFN1 mediate fusion of the inner membrane (Cipolat et al., 2004), however for this to 
occur, OPA1 must be appropriately processed. The enzyme is proteolytically cleaved in order 
to generate short OPA1 fragments (S-OPA1), primarily catalysed by the ATP-dependent zinc 
metalloprotease; YME1L1 (Griparic et al., 2007). Although the specific mechanism by which 
OPA1 mediates fusion has not been fully elucidated, it has been proposed that S-OPA1 
enhances the interaction of long, unprocessed OPA1 with the inner mitochondrial 
membrane lipid cardiolipin. In contrast to this heterotypic interaction, the homotypic 
interaction of OPA1 reportedly supports cristae structure (Ban et al., 2017). Similarly, while 
the second mitofusin MFN2 is required for fusion, its precise mechanistic action is unclear 
and the protein has also been shown to play a supportive role with regards mitochondrial-
endoplasmic reticulum contact (de Brito & Scorrano, 2008). 
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1.3.2. Mitochondrial fission 
 
Mitochondrial fission describes the division of single mitochondria into two distinct 
organelles and like fusion, is required to maintain mitochondrial function. Fission also allows 
damaged mitochondria to be isolated and removed via autophagy (Twig et al., 2008). The 
major orchestrator of mitochondrial fission is an evolutionarily conserved dynamin related 
GTPase known as DRP1 which was first described in yeast and Caenorhabditis elegans 
(Bleazard et al., 1999; Labrousse et al., 1999). DRP1 is a soluble cytosolic protein which 
requires post-translational modification to allow its translocation to the outer mitochondrial 
membrane (Chang & Blackstone, 2007; Cribbs & Strack, 2007). DRP1 recruitment to the 
outer membrane also relies on colocalisation with the outer membrane bound proteins; 
mitochondrial fission factor (Mff) (Gandre-Babbe & van der Bliek, 2008) and mitochondrial 
dynamic proteins 49 and 51 (MiD49 and MiD51) (Losón et al., 2013; Palmer et al., 2011). The 
subsequent binding of GTP to DRP1 promotes linear polymerisation of DRP1 supported by 
MiD49 and MiD51. GTP hydrolysis facilitates the dissociation of MiD49 and MiD51 while 
DRP1 polymers shorten into closed, constrictive rings (Kalia et al., 2018). These events 
commonly occur at sites of mitochondrial contact with the endoplasmic reticulum (ER). The 
ER is described as an important participant in the process of mitochondrial fission by 
marking the site of division and providing an initial mechanical force (Friedman et al., 2011). 
It has recently been demonstrated that that DRP1 also provides the final constrictive force 
required for the separation of mitochondria (Fonseca et al., 2019; Kamerkar et al., 2018).  
 
The importance of mitochondrial fission with regard to the distribution and integrity of 
mtDNA has been demonstrated via the knockdown of key mediators. In comparison to 
control cardiomyocytes in which small nucleoids were dispersed throughout the 
mitochondrial network, the examination of fluorescent micrographs of cardiomyocytes from 
muscle-specific DRP1-KO mice revealed an enlargement and aggregation of mtDNA 
nucleoids. Also demonstrated was a respiratory defect and a mosaic pattern of COX1 
fluorescent labelling, with larger nucleoids displaying an increased intensity in comparison to 
those that were smaller (Ishihara et al., 2015).  
 
Appropriate mitochondrial dynamics are additionally required to facilitate apoptosis (Frank 
et al., 2001; Scorrano et al., 2002), mitosis (Taguchi et al., 2007) and with reference to the 
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intestinal tract; the maintenance of stemness (Katajisto et al., 2015). Accordingly, 
mitochondrial dynamics are critical to the life and death of the cell.  
 
1.4. The mitochondrial genome 
 
Unlike other organelles, mitochondria contain their own genome; mtDNA. This circular, self-
replicating, double stranded mtDNA was fully sequenced in 1981 and comprises 16,569 base 
pairs in humans (Anderson et al., 1981). The circular genome consists of the heavy (H) G rich 
strand and the light (L) C rich strand. Together they encode 37 genes of which 22 are transfer 
RNAs, 2 are ribosomal RNAs (12S and 16S ribosomal subunits) and the remaining 13 encode 
polypeptides involved in oxidative phosphorylation. The mitochondrial genome is very 
compact, and unlike that of the nucleus, does not contain any introns. There is only one 
major non-coding region, known as the D-loop. It contains OH; the origin of heavy strand 
replication and also HSP, the heavy strand transcription promoter.  
 
Small numbers of non-coding bases separate coding sequences, and in some instances, there 
is an overlap of protein encoding regions (Anderson et al., 1981; Fearnley & Walker, 1986). 
Furthermore, complete termination codons are not associated with all genes. Instead, 
endonucleocytic cleavage and polyadenylation at sites typically before and after tRNA 
sequences processes polycistronic RNA molecules prior to their maturation (Ojala et al., 
1981).  
 
In contrast to the nuclear genome which is packaged into nucleosomal structural units by 
association with histones, mtDNA lacks histone support and is instead organised into 
discrete units known as nucleoids which the earliest reports describe as containing one or 
two mtDNA molecules (Satoh & Kuroiwa, 1991). Nucleoid organisation ensures the 
appropriate distribution of mtDNA throughout the mitochondrial network and core 
components have been proposed to comprise factors which are involved in mitochondrial 
replication and transcription. Further to its role as the mtDNA transcription factor, 
mitochondrial transcription factor A (TFAM) provides a key packaging function central to the 
nucleoid structure (Kaufman et al., 2007). Additional core components include the dedicated 
mitochondrial DNA polymerase gamma (Polγ), mitochondrial RNA polymerase (POLRMT), 
mitochondrial single-strand binding protein (mtSSB) and the mitochondrial helicase TWINKLE 
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to varying degrees depending on functional demand (Rajala et al., 2014). Peripherally, 
proteins such as ATPase AAA domain-containing protein 3 (ATAD3) and the prohibitins 1 and 
2 (PHB1 and PHB2) facilitate inner mitochondrial membrane tethering while also mediating 
ribosomal contact and thus supporting protein synthesis (He et al., 2012). This central DNA 
and protein core surrounded by peripheral proteins forms the multi-layered model of 
mitochondrial nucleoid organisation (Bogenhagen et al., 2008; Wang & Bogenhagen, 2006) 
however more recently, alternative models have been proposed. Using electron microscopy, 
cryo-ET microscopy and super-resolution microscopy it was demonstrated that the 
mitochondrial nucleoid consists of a single mtDNA molecule compacted by cross-strand 
binding of approximately 1000 molecules of TFAM per mtDNA molecule in the absence of 
additional proteins (Kukat et al., 2015; Kukat et al., 2011). Furthermore, the abundance of 
TFAM and thus the level of DNA compaction has been shown to impact the proportion of 
mtDNA molecules available for transcription or replication (Farge et al., 2014). Nucleoid 
organisation therefore supports mitochondrial form and function. A schematic of the 
mitochondrial genome is depicted in Figure 1-3. 
 
 
Figure 1-3. The human mitochondrial genome. The outer circle depicts the heavy strand with the inner circle representing 
the light strand. Genes encoding proteins of the mitochondrial respiratory chain are shown as coloured blocks labelled 
accordingly (MT-ND1–6, MT-COI–III, MT-ATP6 and 8 and MT-CYB). The blue blocks denote the two ribosomal RNAs and red 
dashes represent each of the 22 tRNAs. 
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1.4.1. Mitochondrial DNA replication 
 
In addition to containing their own DNA, mitochondria also have their own machinery for its 
replication. The mitochondrial replisome consists of several key proteins. The mitochondrial 
DNA polymerase gamma, Polγ, is encoded by the nuclear genome. The RNA dependant DNA 
polymerase activity of Polγ was first described in 1970 (Baltimore, 1970; Temin & Mizutani, 
1970) , however it wasn’t until 1975 that Polγ was named as such (Weissbach et al., 1975) 
and in 1977 it was found to be localised to the mitochondria (Bolden et al., 1977). Human 
Polγ was first characterised as two distinct polypeptides of 140 kDa and 54 kDa in size (Gray 
& Wong, 1992). The larger 140 kDa subunit, PolγA, is now known to represent the catalytic 
domain of the enzyme with 3’-5’ exonuclease proofreading activity (Longley et al., 1998). 
The smaller accessory subunit, PolγB, has been characterised as a 55 kDa polypeptide and 
constitutes the processivity component of the complex. Both subunits bind double stranded 
DNA with moderate strength, however when in their functional configuration as a PolγAB2 
heterotrimer (Yakubovskaya et al., 2006), PolγB substantially enhances the affinity of Polγ 
for DNA, preventing dissociation and thus increasing the catalytic capacity and processivity 
of the polymerase (Lim et al., 1999). 
 
Also encoded by the nuclear genome and fundamental to the mitochondrial replisome is the 
mitochondrial helicase, TWINKLE. As Polγ is unable to utilise double stranded DNA as a 
template, the ATP dependant helicase TWINKLE unwinds the double stranded DNA in a 5’-3’ 
direction to form single strands of DNA prior to polymerase replication (Korhonen et al., 
2004). The mitochondrial single-stranded binding protein (mtSSB) stabilises the single 
stranded DNA generated by TWINKLE, and also has a stimulatory effect on the helicase 
(Korhonen et al., 2003). The mitochondrial replisome also contains a DNA dependant 
mitochondrial RNA polymerase (POLRMT), which is responsible for the synthesis of RNA 
primers required for DNA replication (Kühl et al., 2016) with the removal of these primers by 
encoding ribonuclease H1 (RNase H1) (Holmes et al., 2015). It is unclear exactly how mtDNA 
replicates, and as such there are two main schools of thought in which both asynchronous 
and synchronous replication mechanisms have been described. Furthermore, the 
mechanism of replication has recently been described as tissue specific and associated with 
the OXPHOS activity level of the tissue in question (Herbers et al., 2019). 
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1.4.1.1. Asynchronous mtDNA replication  
 
The strand displacement model of mitochondrial DNA replication, also known as 
asynchronous or asymmetric strand displacement, was first described in 1972 (Robberson et 
al., 1972). Replication begins at the heavy strand origin of replication (OH) with TWINKLE 
unwinding the double stranded DNA and mtSSB binding to the parental H strand as it is 
exposed (Miralles Fuste et al., 2014). POLRMT synthesises an RNA primer to enable Polγ to 
proceed and the new H strand is produced independently until the replisome reaches the 
second origin of replication on the light strand (OL). The exposure of single stranded DNA at 
OL causes the exposed parental H strand to fold into a stem-loop conformation (Martens & 
Clayton, 1979) which prevents mtSSB from binding but does allow POLMRT to initiate 
synthesis of RNA (Fuste et al., 2010). The short RNA primer provides a template from which 
Polγ can begin light strand synthesis. Each strand is now synthesised simultaneously until 
completion and ligated into a closed circular form (Berk & Clayton, 1974). 
 
The RNA incorporation throughout the lagging strand (RITOLS) model is similar to the strand 
displacement model in that replication begins at or very close to OH and proceeds until OL is 
exposed, allowing replication of the light strand. In the strand displacement model, the 
displaced parental strand is stabilised by the mtSSB, however in the RITOLS model, RNA 
intermediates bind the parental strand and are later replaced by DNA via maturation 
(Yasukawa et al., 2006). 
 
1.4.1.2. Synchronous mtDNA replication 
 
Detection of replication intermediates also led to the proposition of a third mechanism of 
mtDNA replication; the coupled leading - lagging strand model, also known as the 
synchronous model (Holt et al., 2000).The use of two-dimensional agarose gel 
electrophoresis identified partially single-stranded replication intermediates in cultured cells 
in which maintenance synthesis of the mitochondrial genome was occurring in growing cells. 
This was in contrast to the double stranded intermediates observed in cells in which 
proliferative replication was taking place. The presence of double stranded intermediates is 
suggestive of a bidirectional, coupled replication, with leading and lagging strand replication 
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occurring simultaneously. This is hypothesised to be the preferred mode of replication in 
cells undergoing rapid proliferation as opposed to those that are maintaining the 
mitochondrial genome (Holt et al., 2000). 
 
Following replication, the parent and newly synthesised mtDNA molecules remain 
connected to one another and must be separated. The presence of structures known as 
catenanes, describing the linked branches of reportedly newly replicated molecules of 
mtDNA, was documented in 1967 following electron microscopic investigation of human 
mitochondria (Hudson & Vinograd, 1967). Until recently, the enzymatic mediators of the 
separation of mitochondrial catenanes had remained elusive, however recent work has 
identified the mitochondrial isoform of Top3α; a type IA topoisomerase as indispensable for 
the separation of newly replicated mtDNA molecules (Nicholls et al., 2018). 
 
1.4.2. Mitochondrial DNA transcription 
 
Transcription of mtDNA is carried out by a group of dedicated proteins. They are all encoded 
by the nuclear genome, and the group comprises mtRNA polymerase (POLRMT), 
mitochondrial transcription factor A (TFAM) and the mitochondrial transcription factor B2; 
mtTFB2 (Falkenberg et al., 2002). Within the D-loop; the major non-coding region of the 
mitochondrial genome, transcription can initiate from one heavy strand promoter, HSP and 
one light strand promoter region, LSP.  
 
As a result of experiments in which nascent RNA transcripts were labelled and mapped to 
the mitochondrial genome, it was initially believed that transcription of the genes encoding 
both rRNA genes and two tRNA genes (tRNAPhe and tRNAVal), and transcription of the 
majority of the genes remaining on the H strand initiated from two different promoters: 
HSP1 and HSP2 respectively (Cantatore & Attardi, 1980; Chang & Clayton, 1984; Montoya et 
al., 1982; Montoya et al., 1983). However, it was subsequently demonstrated that HSP2 is 
not recognised by POLRMT and cannot be transcribed in vitro using purified components of 
the transcription system (Litonin et al., 2010). Accordingly, it is currently understood that 
heavy strand transcription initiates from only one promoter. 
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Formation of the transcription initiation complex begins with the TFAM mediated 
introduction of a sharp U-bend in the promoter DNA This structural conformation facilitates 
the recruitment of POLRMT and is required for transcription initiation (Ngo et al., 2011). The 
subsequent binding of mtTFB2 induces promoter melting and a conformational change in 
POLRMT; both of which facilitate promoter opening and transcription initiation (Hillen et al., 
2017; Posse & Gustafsson, 2017). The interaction of the mitochondrial transcription 
elongation factor (TEFM) with the catalytic region of POLRMT and the release of mtTFB2 
allows transcription to enter the elongation phase (Minczuk et al., 2011). TEFM forms a 
‘sliding clamp’ downstream of POLMRT and thus ensures high processivity (Hillen et al., 
2017).  
 
Despite the discovery of mitochondrial termination factor 1 (mTERF1) (Kruse et al., 1989) 
and its demonstration as an efficient transcription termination factor in vitro (Asin-Cayuela 
et al., 2005), the exact mechanism of the process in vivo remains somewhat unclear. Initially 
reported as the mediator of termination of HSP-driven transcription via an unwinding and 
base flipping mechanism at the tRNALeu (UUR) termination site (Martin et al., 2005a; Shang & 
Clayton, 1994; Yakubovskaya et al., 2010) the protein has since been shown to be 
dispensable for transcription from HSP promoter regions and is suggested only to be 
required for light strand transcription termination (Terzioglu et al., 2013). Accordingly, 
further investigation may be required to elucidate additional factors that may be involved in 
mitochondrial transcription termination. 
 
1.4.3. Post-transcriptional mtRNA processing and modification 
 
In order to generate each of the proteins encoded by the mitochondrial genome, the 
maturation of nascent precursor polycistronic transcripts is required prior to translation. This 
involves endonucleocytic processing followed by various post-transcriptional modifications 
which vary depending on the nature of the transcript. Primary processing events take place 
in structures known as RNA granules which are typically located in close proximity to mtDNA 
nucleoids (Antonicka et al., 2013; Iborra et al., 2004; Jourdain et al., 2013). As described by 
Ojala and colleagues in 1981, the endonucleocytic cleavage of the precursor mRNA occurs at 
sites before and after tRNA coding regions releasing the mt-mRNA and mt-rRNA transcripts 
situated between them (Ojala et al., 1981). The enzymatic machinery responsible for this 
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cleavage comprises RNaseP facilitating 5′ mt-tRNA processing, with processing at the 3’ end 
of mt-tRNAs carried out by RNaseZ (Brzezniak et al., 2011; Holzmann et al., 2008). In the 
instance of mt-mRNAs which are not delimited by mt-tRNAs, members of the Fas-activated 
serine/threonine kinase (FASTK) family of proteins have been implicated in their processing 
and thus mitochondrial gene expression (Jourdain et al., 2015). 
 
Following mt-tRNA release, mt-tRNA maturation involves the addition of a 3’ CCA 
trinucleotide by tRNA nucleotidyltransferase TRNT1 (Nagaike et al., 2001). In certain species 
of mt-tRNA, the removal of aberrant poly(A) tails by the exoribonuclease PDE12 is also 
required, the ablation of the PDE12 gene leading to perturbed mt-tRNA aminoacylation, 
reduced OXPHOS subunit expression and impaired respiration in human embryonic kidney 
cell lines as a result (Pearce et al., 2017). Given the limited number of mitochondrial tRNAs in 
comparison to that of the nucleus, the required gene expression relies on a vast array of 
post-transcriptional RNA processing events which regarding those of mitochondrial tRNAs, 
are particularly complex. Modifications at position 34 of the anticodon loop of mt-tRNAs and 
position 37 immediately adjacent are especially common and facilitate the recognition of 
multiple codons by single mt-tRNAs (reviewed in Rebelo-Guiomar et al., 2019).  
The maturation of mitochondrial mRNA transcripts firstly involves the 3’ polyadenylation of 
all species with the exception of the MT-ND6 mRNA, carried out by the polyadenylic acid 
RNA polymerase (mtPAP) (Tomecki et al., 2004). In seven of the thirteen mRNA transcripts 
this adds a stop codon to the reading frame. Polyadenylation is also required to stabilise 
specific mRNAs such as CO1 and CO2, however in the case of ND1 and ND2 transcripts, the 
opposite is observed as deadenylation increases the steady state levels of these species 
(Nagaike et al., 2005; Rorbach et al., 2011).  
 
A total of ten post-transcriptional modification sites have been described with regard to 
mitochondrial rRNAs, which in contrast to those of bacterial and eukaryotic cytoplasmic 
ribosomes at over 30 and 200 respectively, is comparatively low. At each of these ten sites, 
the chemical modification is either methylation, 2′-O-ribose methylation or 
pseudouridylation with the final two enzymes responsible for these modifications; N4-
methylcytidine (m4C) methyltransferase (METTL15) and tRNA (uracil(54)-C(5))-
methyltransferase homologue (TRMT2B) having recently been identified (Powell & Minczuk, 
2020; Van Haute et al., 2019). Owing to their key roles in the regulation of mitochondrial 
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gene expression, mutations causing defects in the enzymes responsible for the post-
transcriptional modification of mitochondrial RNA manifest as a wide variety of clinical 
conditions (Bohnsack & Sloan, 2018). Accordingly, this represents an important area of 
mitochondrial biology, the understanding of which may assist in the development of 
therapeutic interventions to alleviate such pathologies.  
 
1.4.4. Mitochondrial DNA translation 
 
The mitochondrial translation machinery, also known as the mitoribosome, consists of a 
small 28S subunit and a large 39S subunit and is responsible for the synthesis of each of the 
mitochondrially encoded subunits of the electron transport chain. In addition to 82 nuclear 
genome encoded proteins, the 12S rRNA located in the small 28S subunit and the 16S rRNA 
located in the large 39S subunit form the mature mitoribosome (Greber et al., 2015). 
Mitochondrial ribosomes have a much lower rRNA content when compared to their cytosolic 
counterparts (Pietromonaco et al., 1991) however they contain their own tRNAs; a set of 22 
which translate all codons of the polycistronic molecules produced at transcription.  
 
Mitochondrial translation utilises either AUG or AUA start codons and follows an initiation, 
elongation and termination sequence. Initiation begins with mitochondrial initiation factor 3 
(IF3MT) mediated dissociation of the two subunits of the mitoribosome. IF3MT is also 
thought to aid mRNA binding to the small subunit of the ribosome and positioning of the 
start codon at the P site of the mitoribosome (Bhargava & Spremulli, 2005; Haque & 
Spremulli, 2008). At the P site, fMet-tRNA binds the start codon, assisted by mitochondrial 
initiation factor 2 (IF2MT) (Liao & Spremulli, 1990; Ma & Spremulli, 1996). Elongation 
proceeds when the large subunit of the mitoribosome re-joins the complex and initiation 
factors are subsequently released. The first step of elongation involves the formation of a 
complex comprising a GTP bound mitochondrial elongation factor Tu (mtEFTu) and an 
aminoacyl tRNA (aa-tRNA). This complex carries the tRNA to the A site of the mitoribosome 
where codon: anticodon recognition causes GTP to be hydrolysed and mtEFTu is released 
and its GTP restored by mitochondrial elongation factor Ts (mtEFTs) (Cai et al., 2000). The 
aminoacyl tRNA moves to the peptidyl transferase centre of the large subunit where the 
peptide bond formation takes place. Mitochondrial elongation factor mtEFG1-GTP catalyses 
the movement of tRNAs in the A and P sites to the P and exit sites of the ribosome. The exit 
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of the tRNA allows another elongation cycle to occur at the next codon of the mRNA. 
Termination of translation occurs when the presence of a stop codon (UAA or UAG in 
humans) at the A site is recognised by mitochondrial release factor 1a (mtRF1a) which 
possesses a peptidyl-tRNA hydrolase activity owing to a GGQ motif (Frolova et al., 1999). 
Upon stop codon recognition, the movement of the GGQ domain of mtRF1a into the 
peptidyl transferase centre causes hydrolysis of the bond between the P site tRNA and the 
completed polypeptide facilitating its subsequent release (Soleimanpour-Lichaei et al., 
2007). In the case of MT-CO1 and MT-ND6 mRNAs which lack the putative UAA or UAG stop 
codons, a mitoribosome frameshift is believed to facilitate mtRF1a recognition and thus 
termination (Temperley et al., 2010). Following the release of the polypeptide, dissociation 
of the ribosomal subunits, mRNAs and deacetylated tRNAs is promoted by the ribosomal 
recycling factors, mtRRF1 and mtEFG2 (Rorbach et al., 2008; Tsuboi et al., 2009). After their 
own ensuing release, the transcription cycle may subsequently resume.  
 
1.4.5. Mitochondrial DNA mutagenesis and repair 
 
The mutational rate of mtDNA is reportedly much higher than that of the nucleus with this 
historically being attributed to an absence of protective histones, an incompetent DNA 
repair system and the proximity of the mitochondrial genome to the reactive oxygen species 
generated by the electron transport chain. While the mutagenic potential of ROS has been 
well studied; the generation of the hydroxyl radical (•OH) following the reaction of H2O2 
with ferric iron being particularly damaging to DNA (Henle et al., 1996), the nucleoid 
packaging of mtDNA has been reported to offer protection against mutagenic agents 
(Guliaeva et al., 2006). Furthermore, the presence of the majority of DNA repair pathways 
have been described within mitochondria with the most prevalent oxidative DNA base 
lesion, 8-oxodG being repaired via base excision repair (BER) with greater efficiency in 
mitochondria in comparison to the nucleus (Thorslund et al., 2002). Although the repair of 
double strand breaks via homologous recombination (HR) or non-homologous end joining 
(NHEJ) has been described in the mitochondria of plants (Manchekar et al., 2006), yeast 
(Foury & Lahaye, 1987) and Drosophila melanogaster (Morel et al., 2008), recombination 
events following induced double strand breaks in mammalian mitochondria are at a 
reportedly low frequency and also promote the formation of mtDNA deletions (D'Aurelio et 
al., 2004; Srivastava & Moraes, 2005). Single strand break repair (SSBR) (Sykora et al., 2011), 
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mismatch repair (MMR) (Mason et al., 2003), and direct reversal repair of alkylated purines 
(Myers et al., 1988) have all been localised to mitochondria with the main notable exception 
being nucleotide excision repair (NER). In the event of irreparable mtDNA damage, genome 
degradation by components of the mtDNA replication machinery (Nissanka et al., 2018; 
Peeva et al., 2018) facilitates mtDNA turnover, homeostasis and thus evasion of the 
accumulation of damaged mtDNA molecules (Gross & Rabinowitz, 1969). 
 
Despite such competent mtDNA repair mechanisms in place, the mtDNA mutation rate 
remains much higher in comparison to that of the nucleus (Wallace, 1989). Accumulating 
evidence suggests that contrary to earlier considerations, ROS may not be the primary 
source of mtDNA mutagenesis. Although ROS induced 8-oxodG formation can lead to 
mitochondrial DNA polymerase (Polγ) mediated misincorporation of an A base in place of C 
and subsequent incorporation of T in place of 8-oxodG, the resultant G:C to T:A transversion 
is superseded by the G:C to A:T transition in terms of frequency of reporting (Greaves et al., 
2014; Kennedy et al., 2013). Furthermore, in mice with deficient mitochondrial base-excision 
repair and increased exposure to ROS and oxidative damage via superoxide dismutase 2 
(Sod2) knockout, no mtDNA mutational load changes were observed (Kauppila et al., 2018). 
As transition mutations are associated with errors in Polγ mediated replication, base 
misincorporation and miscopying events are considered a major contributor to a significant 
number of mutations of human mitochondrial DNA (Zheng et al., 2006). 
 
In terms of inherited pathological mtDNA mutations, the first were reported in 1988 (Holt et 
al., 1988; Wallace et al., 1988) and since then a great many more have been elucidated. The 
Mitomap.org database lists all mutations and polymorphisms of mtDNA currently known. 
The most common types of mutations are point mutations with a pathogenic population 
prevalence being estimated at 1 in 200 (Chinnery et al., 2012; Elliott et al., 2008). Point 
mutations; the transition of a single nucleotide to another, can occur in any of the 
mitochondrial tRNA, rRNA and protein encoding genes and are often maternally inherited. 
The most common mtDNA disease causing point mutation of the mitochondrial genome is a 
single nucleotide transition from A to G at position 3243 (m.3243A>G) within the tRNALeu 
(UUR) (MT-TL1) gene. Mutations in tRNA encoding genes such as MT-TL1 are thought to hinder 
overall mitochondrial protein synthesis (Mariotti et al., 1994). Clinically, this mutation 
frequently gives rise to maternally inherited diabetes and deafness (MIDD) (van den 
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Ouweland et al., 1992), and is also associated with mitochondrial encephalomyopathy, lactic 
acidosis and stroke-like episodes (MELAS) (Goto et al., 1990). The m.8344A>G substitution in 
the MT-TK gene encoding tRNALys also causes a debilitating neurological disorder; myoclonic 
epilepsy with ragged-red fibres (MERRF) (Wallace et al., 1988). 
 
In contrast to mtDNA point mutations, single large-scale mtDNA deletions are not typically 
inherited; they are acquired sporadically within the developing embryo   (Chinnery et al., 
2004; Holt et al., 1988). Three major clinical phenotypes are associated with single, large-
scale mtDNA deletions. Chronic progressive external ophthalmoplegia (CPEO) is the most 
common but least severe of the three. Kearns-Sayre syndrome (KSS) is a disorder 
characterised by ptosis and retinopathy presenting before the age of 20. Multiple systems 
may be affected in cases of KSS with pathologies such as hearing loss, ataxia, 
cardiomyopathy and cardiac conduction defects being observed (Mancuso et al., 2015). The 
most severe and least common syndrome associated with single, large-scale mtDNA 
deletions is Pearson syndrome. Pearson syndrome is a fatal disorder presenting in infancy 
with sideroblastic anaemia and pancreatic insufficiency/failure (Rotig et al., 1990). The 
formation of mtDNA deletions was initially proposed to be due to a slipped replication error 
in which strand displacement allows the mis-annealing of a repeat region on the heavy 
strand with a complementary sequence on the light strand. The single stranded loop which 
forms is degraded and both a wild type and deleted mtDNA molecule are generated upon 
the completion of replication (Shoffner et al., 1989). This mechanism results in the flanking 
of the deleted region by repeat sequences which thus does not account for deleted regions 
flanked by partial or no repeat regions at all. As such a similar model has recently been 
proposed in which the chance dissociation of the replication machinery during the 
replication of a repeat region of the parental heavy strand may permit incorrect 
reassociation with a downstream repeat sequence. This results in the loss of the sequence 
between the repeats as replication is completed. While this ‘copy-choice recombination’ 
mechanism is promoted by repeat sequences it can also account for deletion formation in 
the absence of repeat sequences (Persson et al., 2019). As previously mentioned, double 
strand breaks within mtDNA can promote deletion formation (Srivastava & Moraes, 2005). 
When this occurs, the partial degradation of the linear DNA by the replication machinery 
with subsequent recombination of free ends describes the final known mechanism of 
mtDNA deletion formation (Fukui & Moraes, 2009; Nissanka et al., 2018). 
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1.5. Mitochondrial genetics 
 
1.5.1. Maternal inheritance 
 
MtDNA is inherited strictly through the maternal lineage in mammals. This is known as 
uniparental or more specifically, maternal inheritance and is a widely accepted process 
(Giles et al., 1980). Despite this, paternal mtDNA transmission has been reported in inter-
species bred mice (Gyllensten et al., 1991), following in vitro embryo manipulation in cattle 
(St John & Schatten, 2004) and in an isolated case of paternally transmitted human 
mitochondrial disease (Schwartz & Vissing, 2002). These rare findings have questioned the 
dogma of maternal mtDNA inheritance and additionally the mechanisms by which it is 
maintained remains unclear. Fertilisation of most mammalian oocytes by sperm results in a 
zygote in which paternally derived mtDNA is excessively diluted by the maternal mtDNA. At 
a much lower copy number than that of the oocyte, the paternal mtDNA is thought to be 
diluted to such an extent that it is undetectable in the next generation. This has shaped the 
so-called simple dilution model of uniparental mode of mtDNA inheritance (Gyllensten et al., 
1991), however this hypothesis has been refuted by a recent study utilising ultra-deep 
sequencing in a human cohort. The failure to identity common mtDNA population 
haplotypes in any of the individuals studied, as would be expected if there were frequent 
paternal leakage in the human population suggests an active mechanism of paternal mtDNA 
elimination (Pyle et al., 2015). The ubiquitin labelling of parental mitochondria within the 
oocyte and their subsequent elimination via lysosomes and/or proteasomes has been 
described in mammals (Sutovsky et al., 1999, 2000) as has the involvement of the E3 
ubiquitin ligases, PARKIN and MUL1, in mediating mitophagy of paternal mitochondria 
(Rojansky et al., 2016). The direct elimination of sperm mtDNA however has not been 
demonstrated and further reports of parental mtDNA which has escaped the constraints of 
such active removal mechanisms have been documented (Luo et al., 2018). Given the rarity 
of such reports and the recent observation that paternally inherited large nuclear-encoded 
mitochondrial segments (NUMTs) can mimic paternally inherited mtDNA heteroplasmy (Wei 
et al., 2020), the inheritance of mtDNA as strictly maternal remains the established mode of 
transmission. 
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In asexual populations, the genome can be at an increased risk of extinction due to the 
accumulation of unfavourable mutations which may otherwise have been purged as a result 
of genetic recombination. This is known as Muller’s ratchet (Muller, 1964) and as an 
effectively asexual population, the mitochondrial genome is vulnerable to this process. The 
highly variable transmission of mtDNA mutation load from mother to child (Larsson et al., 
1992a; Larsson et al., 1992b), in addition to the observed rapid expansion of variant mtDNA 
molecules from mother to offspring in animal studies led to the development of the mtDNA 
genetic bottleneck hypothesis (Hauswirth & Laipis, 1982) in which a segregation or selection 
of mtDNA molecules at the primordial germ cell level protects against the effects of Muller’s 
ratchet. The segregation of mtDNA molecules occurs as cell division events generate 
primordial germ cells in the developing embryo, each daughter cell containing a fraction of 
the mtDNA molecules present in the parent cell. Subsequent rapid replication of the 
selected mtDNA molecules ensues as these cells then mature into oocytes (Cao et al., 2007). 
In the case of mutated mtDNA molecules, the level of heteroplasmy within the primordial 
germ cell therefore dictates the transmission to the next generation in the event of 
fertilisation. 
 
1.5.2. Heteroplasmy and the threshold effect 
 
Hundreds to thousands of copies of the mitochondrial genome are present within each cell. 
Homoplasmy describes the state in which all copies of mtDNA are identical whereas 
heteroplasmy refers to the state in which there is more than one mtDNA variant in a cell.  
(Lightowlers et al., 1997; Wallace, 2010). The heteroplasmic mutant mtDNA population, or 
mutation load, is expressed as the percentage of mutant versus wild type mtDNA clones. At 
low levels, cells and tissues are largely unaffected by mutant copies of the mitochondrial 
genome as wild type mtDNA molecules are able to compensate for mutant clones. A 
threshold level must be reached before mitochondrial function is compromised and a 
biochemical defect is observed. This threshold level, however, differs between specific 
mutations and their affected tissues. For example, the common point mutations m.3243A>G 
and m.8344A>G must typically reach a mutation load of 80-90% before their respective 
conditions of MELAS and MERRF are manifested (Chinnery et al., 1997). In contrast, a rare 
m.14723T>C point mutation within the mt-tRNAGlu (MTTE) gene segregates with a 
biochemical defect as evidenced by COX deficient muscle fibres at a heteroplasmy as low as 
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7% (Alston et al., 2010). Large scale mtDNA deletions, frequently observed in cases of 
chronic progressive external ophthalmoplegia (CPEO), are typically associated with a 
threshold level of approximately 60% (Hayashi et al., 1991). 
 
1.5.3. Clonal expansion 
 
Clonal expansion describes the process by which a mutated molecule of mtDNA accumulates 
within a cell over time to become the dominant species. At present, it is unclear exactly how 
this occurs, however there are several mechanistic theories. The first is based upon the 
theory that copies of mtDNA in which there are mutations in the form of large-scale 
deletions, have an advantage over wild type molecules due to their smaller genome taking 
less time to replicate (Wallace, 1989). This is known as the ‘survival of the smallest’ theory 
however, with regard to point mutations in which genome size is unaffected, this 
mechanism is unable to account for expansion of these clones as is observed in mitotic 
tissues (Fellous et al., 2009; McDonald et al., 2008; Taylor et al., 2003). Support for the 
survival of the smallest hypothesis with regard to mtDNA deletions has been provided with 
the use of the PstI mouse model in which the largest induced mtDNA deletions in CNS 
neurons accumulated faster than smaller deletions (Fukui & Moraes, 2009). Arguing against 
this mechanism on observational and experimentally simulated grounds; Kowald and 
colleagues reported that while a reduction in genome size can theoretically provide a 
selective advantage, as genome size further reduces in relation to mtDNA molecule half-life, 
this advantage is lost. Additionally, this mechanism while plausible in longer lived species, 
cannot account for mutant mtDNA clonal expansion in shorter lived species (Kowald et al., 
2014).  
 
Two further theories also centre on mutated mitochondria possessing a replicative 
advantage over their wild type counterparts; however, the size of the genome is not a factor 
and thus they can also be applied to the clonal expansion of point mutations. Mitochondria 
with mutated genomes affecting their respiratory capacity were hypothesised to evade 
lysosomal degradation and therefore persist and replicate, whereas fully functional 
mitochondria suffered increased damage and death due to an increased production of ROS 
(de Grey, 1997). A postulated slower metabolic rate of mitochondria harbouring mtDNA 
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mutations and resultant reduction in ROS production led to the hypothesis being dubbed the 
‘survival of the slowest’ theory. This theory has also been disputed with the observation that 
damaged or dysfunctional mitochondria undergo degradation in preference of those that are 
fully functional (Kim & Lemasters, 2011; Twig et al., 2008). 
 
The third and least challenged clonal expansion theory is known as random genetic drift. 
MtDNA replicates independently of the nuclear genome and the cell cycle. Replication is 
continuous but random with different molecules of mtDNA replicating at different times, 
producing a small number of replicates with each cycle. It is entirely plausible that a mutated 
copy of mtDNA may, by chance, replicate more frequently than a wild type copy and 
accumulate within a cell, influencing the cell’s heteroplasmy. It is also plausible that it will 
not, having little or no effect on heteroplasmy and subsequent biochemical function. This 
may be true at a particular point in time but via this alternative mechanism of clonal 
expansion, known as random genetic drift or relaxed replication, mutated copies of mtDNA 
while present, have the potential to accumulate and manifest pathologically with time 
(Chinnery & Samuels, 1999) . Computational modelling of random genetic drift also 
supported the theory that mutations occurring in childhood or early adulthood, having had 
an extended period of time to propagate, may have the potential to expand to greater levels 
than mutations occurring later in life (Elson et al., 2001). Importantly, this hypothesis is able 
to account for both the expansion of mtDNA point mutations in dividing tissues and those 
that occur in short lived species in addition to humans (Baines et al., 2014; Greaves et al., 
2014; Stamp et al., 2018). 
 
With regard to the clonal expansion of mtDNA deletions, two additional mechanistic 
theories have been recently proposed. The negative feedback loop theory posits that a 
deletion that removes the protein product of that gene also removes the negative feedback 
inhibition of transcription of the genome. Theoretically this bestows a replicative advantage 
on the mutant genome and is supported by both experimental and computer simulated data 
(Kowald & Kirkwood, 2014; Kowald & Kirkwood, 2018). Finally, the perinuclear niche theory 
proposes that should mtDNA deletions arise in the perinuclear region of skeletal muscle 
fibres, via retrograde stress signalling to the nucleus, replication of these mutant molecules 
is triggered, and clonal expansion ensues (Vincent et al., 2018).  
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1.5.4. Mitotic segregation 
 
Replication of the mitochondrial genome occurs independently of the cell cycle, however 
mitochondrial dynamics and morphology coordinate with particular cell cycle stages in order 
to facilitate the partitioning of mitochondria to daughter cells at cell division. Prior to 
division, the mitochondrial genome must replicate to ensure sufficient copies are 
transmitted to daughter cells. Between G1 and S phase the fusion of mitochondria is 
promoted, and the network can be visualised as an extensive, hyperfused system (Mitra et 
al., 2009). In the early stages of mitosis, the phosphorylation of the fission promoting DRP1 
results in fragmentation of the mitochondrial network prior to their segregation as the cell 
divides (Taguchi et al., 2007). As the segregation of mitochondria at mitosis is a stochastic 
process, should there be a heteroplasmic variant present within the parent cell, daughter 
cells have equal chances of acquiring more, less or the same level of mutant mtDNA 
molecules as the cell from which they are descended. Accordingly, mitotic segregation may 
inadvertently contribute to, and potentially accelerate, the clonal expansion of mutant 
clones as has been demonstrated using simulated modelling within normal buccal epithelial 





The ageing process has been described as the accumulation of molecular and cellular 
damage that results in reduced function in adulthood, diminished fecundity and an 
increased probability of death (Kirkwood, 2008). As the average human life expectancy has 
risen steadily over the past two centuries, an increasing proportion of the population today 
and those of the future will be represented by individuals over the age of 65. This trend 
brings with it an increased need to understand the complex mechanisms by which the 
process of ageing occurs and accordingly obtain a position from which associated disease 
and frailty may be challenged.  
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1.6.1. Evolutionary theories of ageing 
 
The variation in life expectancy observed among different species formed the basis from 
which initial evolutionary theories of ageing developed. The genomic differences between 
species were hypothesised as the underpinning determinant of longevity according to a pre-
determined genetic programme. In 1891 August Weismann proposed that such 
programming existed in order to facilitate the demise of older generations, removing the 
burden they place upon younger members of the population and thus allowing the younger, 
more valuable individuals to flourish (Weismann et al., 1891). An alternative theory was 
proposed by Peter Medawar in 1952 and is known as the mutation accumulation theory. 
Medawar’s theory postulates that ageing is the result of an accumulation of mutations 
within the genome of an individual that collectively contribute to a physiological 
deterioration or an ageing phenotype. Genes which are beneficial to the organism, acting 
early in life facilitating optimal health and reproduction were proposed to be subject to 
natural selection and transmitted to offspring. Conversely, late acting genes which may be 
detrimental to health later in life but posed negligible risk in an organism’s youth were 
suggested to be effectively resistant to natural selection pressures and thus permitted to 
accumulate in subsequent generations (Medawar, 1952). Following on from the work of 
Medawar, the antagonistic pleiotropy theory was developed by George Williams. This theory 
proposed that genes that increase reproductive advantage and propagation of the species 
are naturally selected and favoured, despite any adverse effects that those same genes may 
have later in life (Williams, 1957). With limited evidence documenting specific genes 
supportive of antagonistic pleiotropic and mutation accumulation theories, evolutionary 
theories of ageing have deviated somewhat towards a more physiological rather than 
genetic basis. The disposable soma theory of ageing as described by Thomas Kirkwood in 
1977 describes the process of ageing as the allocation of finite organismal energy into the 
maintenance of the germline regardless of the consequential detriment to the ‘disposable 
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1.6.2. Molecular theories of ageing 
 
The advances in science, technology and medicine that have developed since Weismann’s 
evolutionary observations have allowed gerontologists to gain intricate knowledge and 
expand theoretical hypotheses to a cellular and molecular level. Accordingly, experimentally 
derived modern theories of ageing have been described, and centralise around a time-
dependant accumulation of cellular damage (reviewed in López-Otín et al., 2013). 
 
Throughout the lifetime of an organism, physical and chemical mediated damage is incurred 
both as result of exogenous insult and during the normal metabolic and homeostatic 
processes a cell undergoes. Despite the numerous repair mechanisms which organisms have 
evolved in order to rectify DNA damage, the continuous exposure to endogenous and 
exogenous mutagens over time can lead to an accumulation of DNA damage and thus 
increasing genomic instability with advancing age (reviewed in Moskalev et al., 2013). 
Increasing age has also been associated with a reduction in the efficacy of the majority of 
DNA damage repair mechanisms (Hart & Setlow, 1974) and age-associated changes in the 
patterns of usage of different repair mechanisms has also been described (Engels et al., 
2007). An imbalance between the rate of genomic damage and that by which it can be 
repaired inevitably results in cellular dysfunction and a decline in tissue functionality and 
homeostasis. 
 
Damage to DNA is exhibited in numerous forms and can extend from single nucleotide point 
mutations to the loss or gain of entire chromosomes. The frequency of chromosomal 
aberrations has been documented to increase in both mice and humans with advancing age 
(Ramsey et al., 1995; Tucker et al., 1999). At the extremities of chromosomes, telomeres 
form protective, repetitive clusters which are also susceptible to a degeneration that is 
associated with increasing age. As DNA polymerase is incapable of fully replicating the 
telomeric ends of linear DNA, in the absence of telomerase enzymes which carry out this 
function, each replication of the cell results in a progressive telomere attrition until a critical 
or threshold level is reached and the cell enters replicative senescence (Greider & Blackburn, 
1985; Harley et al., 1990; Hayflick & Moorhead, 1961; Olovnikov, 1973; Watson, 1972) thus 
describing the telomere hypothesis of ageing (Harley et al., 1992).Telomerase enzymes 
expressed in embryonic and some adult stem cells extend the 3’ ends of telomeres and 
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effectively counteract the countdown to senescence observed in somatic cells that lack this 
enzyme. The importance of telomerase in the pathophysiology of ageing has been 
demonstrated in vitro by the significant extension of the lifespan of normal human 
telomerase-lacking cells by the introduction of telomerase (Bodnar et al., 1998), and also in 
vivo with telomerase gene therapy delaying ageing and extending the lifespan of mice 
(Bernardes de Jesus et al., 2012). Current understanding is that regulation of telomere 
length is much more complex than a simple ‘biological clock’. Inflammation and oxidative 
stress, both of which can increase with advancing age, have been demonstrated to also 
accelerate the damage to and loss of telomere integrity (Jurk et al., 2014; von Zglinicki, 
2002). 
 
1.6.3. Mitochondrial free radical theory of ageing 
 
Initially described in 1956, the free radical theory of ageing proposed that cellular oxidative 
stress is central to the ageing process (Harman, 1956). Mitochondria, as major producers of 
reactive oxygen species, have since been implicated in this theory and thus led to its revision 
as the mitochondrial free radical theory of ageing (MFRTA) (Harman, 1972). As a by-product 
of oxidative phosphorylation, mitochondria generate around 90% of cellular reactive oxygen 
species (Balaban et al., 2005). Due to the close proximity of mtDNA to the source of ROS; the 
electron transport chain, the mitochondrial genome is postulated to be subject to ROS 
mediated damage and mutation. This mutation may impair OXPHOS function, leading to 
increased production of ROS which in turn precipitates further mtDNA mutation and cellular 
damage. This process has been described as the vicious cycle, contributing to molecular 
theories of ageing and decline (Harman, 1972). Experimental support for the MFRTA can be 
taken from numerous animal models, for example a decrease in oxidative stress and 
increased longevity has been achieved in mice via the overexpression of mitochondrially 
targeted catalase (Schriner et al., 2005), while production of the superoxide anion radical in 
the liver and muscle is reportedly lower in longer-lived species (Sohal et al., 1989). 
Furthermore, in humans, the total levels of oxidised protein in several tissue types has been 
shown to increase with advancing age (Moskovitz et al., 2002). Despite evidence such as this, 
the MFRTA has been challenged in more recent times. The naked mole rat is an extremely 
long-lived rodent with a lifespan up to 15 times longer than that of the mouse in spite of 
evidence of high levels of oxidative damage (reviewed in Lewis et al., 2013). Additionally, the 
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overexpression of superoxide dismutase 2 (Sod2), an O2− scavenging antioxidant enzyme, 
while attenuating lipid peroxidation, oxidative stress and an age-associated reduction in 
mitochondrial ATP production, did not alter age-associated pathology nor longevity in mice 
(Jang et al., 2009). The converse also applies, in that mice deficient in Sod2 and glutathione 
peroxidase 1 (Gpx1), also an antioxidant enzyme, have elevated oxidative damage and age-
related pathologies such as tumour incidence, however no reduction in longevity is observed 
(Zhang et al., 2009). These seemingly contradictory findings may be reconciled by the 
gradual elucidation of additional roles of reactive oxygen species. No longer are they 
exclusively considered as damaging agents, rather the fine tuning of their generation in 
response to cellular stressors and subsequent involvement in cell signalling pathways now 
deems them essential to the promotion of cellular survival (reviewed in Sena & Chandel, 
2012). 
 
1.6.4. Mitochondrial dysfunction and ageing  
 
Over the past three decades, the accumulation of mtDNA mutations in a variety of aged, 
post-mitotic tissues has been well documented. In 1989, Muller-Hocker described an 
association between increasing age and the frequency of COX deficient cardiomyocytes 
(Muller-Hocker, 1989). A similar phenomenon has also been observed in the brain, with a 
significantly higher frequency  of the common 4977 nucleotide pair deletion, mtDNA4977, 
detected in aged brain tissues when compared to younger controls (Corral-Debrinski et al., 
1992). Several different brain regions were investigated, the putamen and cortical regions 
being more profoundly affected than occipital and parietal regions, with this particular 
deletion being barely detected in the cerebellum. The differences observed between 
different regions suggest a cell type specific variation in mtDNA mutations amongst cells of 
the same tissue type. In 1998, Brierley et al. described the clonal expansion of different 
mtDNA deletions within individual skeletal muscle fibres in aged subjects (Brierley et al., 
1998). Additionally, Bender et al., reported a significant accumulation of mtDNA deletions in 
aged substantia nigra neurons (Bender et al., 2006). These observations provide an 
important indication of an association between mtDNA mutations and the role they may 
play in the ageing process. 
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Age-related mtDNA defects have also been observed in mitotic tissues maintained by adult 
stem cells. The detection of mtDNA point mutations in the human aged colon by Taylor et 
al., represented the first such finding (Taylor et al., 2003). Readily identifiable as COX 
deficient crypts using COX/SDH enzyme histochemistry, the subsequent single-cell laser 
microdissection and whole genome mtDNA sequencing revealed pathogenic mtDNA point 
mutations in COX deficient crypts, the majority of which were transitions involving G 
residues (Taylor et al., 2003). The presence of single mutations in entirely COX deficient 
crypts implied the expansion of stem cell derived mtDNA mutations from parent stem cells 
to all progeny. Similarly, the demonstration of continuous COX deficient ribbons in partially 
deficient crypts also supported this mechanism (Taylor et al., 2003). Identical point 
mutations have since been shown to be present in the two arms of a bifurcating crypt and 
also in adjacent crypts. This suggests that mtDNA mutations first clonally expand within a 
crypt which then divides by fission, allowing the mutation to propagate through the tissue 
(Greaves et al., 2006). Additional studies have shown that this is not exclusive to the colonic 
epithelium; OXPHOS defects and mtDNA point mutations have been detected in a variety of 
mitotic tissues such as the liver (Fellous et al., 2009) and the stomach (McDonald et al., 
2008). The consequences of mtDNA mutation accumulation with age extend beyond the 
impairment of oxidative phosphorylation and the functional decline that this elicits. For 
example, mitochondrial dysfunction and ROS production facilitate telomere shortening and 
promote cellular senescence; both additional hallmarks of ageing (Passos et al., 2007). 
Understanding the mechanisms by which mitochondrial dysfunction can promote the ageing 
phenotype may therefore have important implications in the treatment or even the 
prevention of age-related diseases. 
 
1.6.5. Stem cells, ageing and mitochondria  
 
Almost all mammalian tissues are maintained by small numbers of specialised cells known as 
adult stem cells. Residing within specific compartments known as niches, the relationship 
between stem cells and their niche serves to support tissue homeostasis by maintaining tight 
control over self-renewal, differentiation and regeneration following injury. As adult stem 
cells possess the capacity to self-renew, they are the longest living cell type and as such are 
placed at an increased risk of sustaining molecular damage over time (reviewed in Liu & 
Rando, 2011). Accordingly, with advancing age, stem cell populations exhibit a decline in 
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function and regenerative capacity, however the accumulation of molecular damage 
represents just one mechanism by which stem cell ageing arises. Extrinsic to the stem cells 
themselves, circulatory systemic factors such as cytokines, hormones and immune system 
related components have been shown to change with age and impact stem cell function 
(Elabd et al., 2014; Sinha et al., 2014) . As demonstrated by heterochronic parabiosis 
experiments in which the surgical pairing of young and old animals allows the circulatory 
system to be shared, the exposure of young neural stem cells to an ageing systemic 
circulation facilitated a decline in the activity of these cells (Villeda et al., 2011). The 
converse is also true and aged skeletal muscle stem cells (satellite cells) are rejuvenated by 
exposure to a young milieu (Conboy et al., 2005). 
 
Age-related changes in epigenetic modifications such as DNA methylation have also been 
described. In aged haematopoietic stem cells (HSCs), the reduction of methylation marks at 
transcription factor binding sites of self-renewal promoting genes is coupled with increased 
methylation of those associated with differentiation (Sun et al., 2014). Perturbations in 
epigenetic modifications are also linked with metabolic functions which are additionally 
dysregulated in an age-associated manner. Stem cells in a quiescent state are often 
associated with a glycolytic metabolic phenotype (Simsek et al., 2010; Takubo et al., 2013; 
Zheng et al., 2016) which upon differentiation switches to a metabolism relying on oxidative 
phosphorylation (O'Brien et al., 2015; Wüst et al., 2018; Zheng et al., 2016). The homeostasis 
of stem cells relies heavily on the balance between glycolysis and OXPHOS and the 
availability of specific cofactors and epigenetic modifiers generated by each process. For 
example, in response to low levels of oxygen within the HSC niche, quiescence is maintained 
via activation of hypoxia-inducible factor 1, (HIF-1) which restricts the entry of pyruvate into 
the TCA cycle and subsequent oxidative phosphorylation in the mitochondria by its 
activation of pyruvate dehydrogenase kinase (PDHK) (Takubo et al., 2013). The 
predominance of a glycolytic metabolism favours the generation of the cofactor acetyl-CoA 
and histone acetylation in HSCs maintaining pluripotency (Moussaieff et al., 2015), whereas 
oxidative phosphorylation supports the maintenance of α−ketoglutarate (α-KG) levels 
favouring demethylation of DNA and HSC differentiation (Ho et al., 2017). Evidently, 
perturbations in this balance can have major implications on stem cell fate and have been 
linked with the age-associated impairment of autophagy in murine HSCs (Ho et al., 2017) and 
impaired glucose uptake resulting from reduced expression of the glucose transporter 3 
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(GLUT3) in aged pluripotent stem cells (Zhang et al., 2017); both of which may promote 
aberrant differentiation at the expense of maintaining stemness.  
 
Mitochondria have been implicated in the pathophysiology of stem cell ageing by several 
additional mechanisms. A reduction in intracellular levels of the critical cofactor NAD+ has 
been described in association with advancing age (Braidy et al., 2011; Massudi et al., 2012). 
This has consequences for countless processes within the cell, however with regard to 
ageing, the involvement of a family of NAD+ dependant enzymes known as sirtuins is 
becoming apparent. The NAD+-dependent deacetylase and mono-ADP-ribosyl transferase 
activity of sirtuins facilitates their regulation of proteins involved senescence, apoptosis, 
differentiation, and metabolism. Of seven known mammalian sirtuins, three are located 
within the mitochondria; SIRT3, 4 and 5, however the activities of the remaining sirtuins are 
intricately involved with mitochondrial function (reviewed in Michan & Sinclair, 2007). SIRT3 
is downregulated with increasing age and as such, its promotion of antioxidant activity and 
ROS scavenging is impaired. In haematopoietic stem cells, SIRT3 deficiency results in a 
reduction in pool size and in self-renewal capacity (Brown et al., 2013). Mechanistically, the 
deacetylation of FOXO3a of the forkhead family of transcription factors by SIRT3 promotes 
the expression of the mitochondrial antioxidant SOD2, however an additional role of SIRT3 in 
the induction of mitophagy as part of the UPRmt (mitochondrial unfolded protein response) 
in cells exposed to proteotoxic stress has been described (Papa & Germain, 2014). An 
additional sirtuin, SIRT7 is also linked to another axis of the UPRmt and has been shown to 
decrease in expression in ageing HSCs rendering them less capable of dealing with an age-
related increased level of mitochondrial protein folding stress (Mohrin et al., 2015). A 
premature HSC ageing phenotype with increased apoptosis, a myeloid differentiation bias 
and reduced regenerative potential in SIRT7 deficient mice was subsequently rescued by 
SIRT7 overexpression and linked to the repression of nuclear respiratory factor 1 (NRF1). This 
reduces mitochondrial biogenesis and respiration alleviating protein folding stress (Mohrin 
et al., 2015). Similarly, SIRT1, although its primary localisation is nuclear, its activation is 
linked to the regulation of mitochondrial function and stem cell ageing via several 
mechanisms such as the promotion of mitochondrial biogenesis (Cantó et al., 2009), 
autophagy (Huang et al., 2015), and the upregulation of antioxidant gene expression via 
FOXO3 activation thus preventing the induction of senescence (Hori et al., 2013).  
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Stem cell fate has been shown to be sensitive to levels of reactive oxygen species which are 
primarily produced by the mitochondrial oxidative phosphorylation system. Increasing levels 
of ROS with advancing age are associated with a loss of stemness whereas low levels of ROS 
reportedly bestow HSCs with a greater capacity for self-renewal (Jang & Sharkis, 2007). 
Furthermore, increased levels of ROS lead to the activation of p38 MAPK, a member of the 
mitogen-activated protein kinase family which subsequently upregulates p16Ink4a and p19Arf 
in the HSC population inducing senescence and thus limiting stem cell lifespan (Ito et al., 
2006). The activation of p38 MAPK has been further implicated in the age-related exhaustion 
of intestinal stem cells. In comparison to young animals, aged murine intestinal Lgr5+ stem 
cells demonstrated an increased activation of the nutrient and growth factor sensing 
mammalian target of rapamycin complex 1 (MTORC1). The Lgr5+ specific deletion of an 
MTORC1 suppressor, tuberous sclerosis 1(Tsc1), induced a premature intestinal ageing 
phenotype in young mice which was ameliorated with administration of the MTORC1 
inhibitor rapamycin. In the absence of rapamycin, Tsc1 ablation led to mTORC1 activation, 
increased mitogen-activated protein kinase kinase 6 (MKK6) expression, p38 MAPK 
activation, and the enhancement of p53 expression. Subsequently this resulted in the 
exhaustion of intestinal stem cells in addition to reductions in villus size and density, which 
again could be rescued by p38 MAPK or p53 inhibition (He et al., 2020). Given that 
mitochondrial ROS can activate p38 and drive intestinal crypt differentiation (Rodríguez-
Colman et al., 2017), the involvement of mitochondria in stem cell homeostasis and ageing is 
further supported.  
 
Collectively, the mechanisms involved in stem cell ageing have grave implications with 
regard the development of pathologies associated with advancing age such as degenerative 
disorders and cancer. The understanding of age-related changes at the stem cell level, 
particularly those that are targetable such as epigenetic and metabolic aberrations may 
therefore assist in the development of therapeutics with the aim of rejuvenating stem cell 
function and thus ameliorating the disorders their functional decline may promote 
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1.6.6. Mouse models of mitochondrial dysfunction and ageing 
 
Mouse models of disease are extensively used to recapitulate a wide array of pathologies 
seen in humans. Mice breed prolifically, are short-lived, and most importantly share a similar 
anatomy, physiology and genome with humans. These features make them an excellent 
comparator in the study of human disease and over decades of use, they have significantly 
contributed to a greater understanding of many human conditions.  
 
Genetically engineered mouse models of disease are conventionally created by targeting 
modified genetic constructs into mouse embryonic stem (ES) cells. These vectors either carry 
a mutation in the gene of interest, or the gene of interest is flanked by recombination sites 
such as LoxP sites. A selection cassette such as one which confers neomycin resistance is also 
included in the construct and is similarly flanked by recombination sites to enable 
subsequent in vivo excision. Once transfected into the ES cells, clones which have 
successfully integrated the ‘foreign’ DNA via homologous recombination are selected using 
Southern blotting, injected into mouse blastocysts and implanted into a pseudo-pregnant 
female mouse. The resultant chimeric mice are crossed with wild-type animals to produce 
founder animals in which the genetic manipulation will be transmitted through the germline. 
The first report of a mitochondrial mouse model of disease was published in 1995 and 
described the effect of inactivation of the intra-mitochondrial free radical scavenging 
enzyme, manganese superoxide dismutase (MnSOD) via homologous recombination of a 
mutated vector into the mouse MnSOD gene (Sod2) (Li et al., 1995). Since then, further 
models involving the inactivation of antioxidant genes have been developed, in addition to 
many more in which genes involved in mtDNA replication, transcription, translation, 
mitochondrial dynamics, protein quality control and OXPHOS components themselves have 
been manipulated in order to model mitochondrial disease or dysfunction.  
 
Human mitochondrial transcription factor 1 (mtTF1) was first isolated from human 
mitochondria in 1985 (Fisher & Clayton, 1985), then later sequenced and characterised as a 
nuclear genome encoded DNA binding protein (Parisi & Clayton, 1991). Now known as 
TFAM, the disruption of the gene encoding this transcription factor has been utilised to 
model disorders of mitochondrial DNA mutation in place of unsuccessful attempts at direct 
manipulation of the mitochondrial genome itself. Initial studies demonstrated the essential 
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requirement for TFAM for mtDNA maintenance and mitochondrial biogenesis, as 
homozygous knock-out mice (Tfam-/-) were severely depleted of mtDNA and embryonically 
lethal. Their heterozygous knock-out counterparts (Tfam+/-) also demonstrated a profound 
reduction in mtDNA copy number with an associated respiratory chain deficiency in the 
heart (Larsson et al., 1998). Interestingly, despite the global reduction in mtDNA copy 
number, not all tissues were uniformly affected in terms of mtDNA transcripts and OXPHOS 
dysfunction, suggesting the existence of translational compensatory mechanisms such as an 
increased stability of mtDNA transcripts in some tissues to a greater degree than in others.  
 
The discovery of the Cre-Lox system in the P1 bacteriophage (Sternberg, 1979; Sternberg & 
Hamilton, 1981) has allowed the development of cell-type specific animal models of disease, 
thus facilitating the dissection of multiple pathologies into tissue specific entities. The 
technique was used to disrupt TFAM in a tissue specific manner. Cre-recombinase enzymes 
catalyse the recombination between two LoxP sites, excising the genetic material between 
them. If Cre is situated under a tissue specific promoter, the gene of interest around which 
the LoxP sites are inserted will only be lost in those specific cell types. Heart and muscle 
specific Tfam disruption was investigated by crossing TfamloxP/loxP mice with mice expressing 
the Cre-recombinase gene under muscle creatinine kinase promoter control (Wang et al., 
1999). This model faithfully reproduced the physiological and biochemical elements of the 
dilated cardiomyopathy observed in Kearns-Sayre syndrome. Similarly, with Cre-
recombinase under the control of the insulin-2 promoter expressed in pancreatic β cells, 
Tfam disruption led to the development of mitochondrial diabetes and β cell loss in older 
animals (Silva et al., 2000). An adult-onset neurodegeneration with progressive symptoms of 
tremor and rigidity was also modelled in mice with a dopamine transporter Cre transgene 
(Ekstrand et al., 2007). Reduced levels of mtDNA expression and respiratory chain enzyme 
activity in midbrain dopaminergic neurons of these animals resulted in a Parkinsonism 
characterised by a progressive loss of these cell types. Although these models provide an 
excellent means by which mitochondrial disorders initiated by an mtDNA transcription 
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As discussed in 1.6.4, mitochondrial dysfunction has been associated with ageing in a 
multitude of both mitotic and post-mitotic tissue types with increased levels of mutated 
mtDNA in these aged tissues contributing to their functional decline. Tissue-specificity is 
observed with regard to the type of mutation found in different tissue types. Large scale 
mtDNA deletions are most frequent in post-mitotic tissues such as the brain (Bender et al., 
2006), and mtDNA point mutations are more commonly reported within mitotic tissues such 
as the intestine (Greaves et al., 2012). In order to investigate the link between mtDNA 
mutation accumulation and ageing, the PolγA mutator mouse was developed in 2004 
(Trifunovic et al., 2004). Knock-in mice harbour an altered catalytic PolγA subunit containing 
an alanine instead of the highly conserved aspartate residue at the second proofreading 
domain (D257A). This confers a reduction of exonuclease activity on the catalytic PolγA 
subunit, making mtDNA three to five times more susceptible to mutation events during 
replication. Mice with the homozygous PolγAmut/mut genotype demonstrated an increased 
load of somatic mtDNA point mutations in the brain, heart and liver. Furthermore, mice 
demonstrated an advanced ageing phenotype characterised by weight loss, curvature of the 
spine (kyphosis), hair loss (alopecia), reduced subcutaneous fat, anaemia and osteoporosis. 
A very similar mouse was developed in 2005, again with an aspartate to alanine substitution 
at residue 257 of the conserved proofreading domain of PolgA impairing the exonuclease 
activity of the enzyme (Kujoth et al., 2005). The models differ in the constructs and 
recombination enzyme systems used in their generation and as a result the Trifunovic mouse 
retains two LoxP sites flanking the PolγA gene whereas the Kujoth mouse contains one 
residual LoxP site; an important consideration to be made if animals are to be crossed with 
other models utilising Cre-Lox technology. Observations made by Trifunovic et al. were 
corroborated by Kujoth et al., however somewhat surprisingly, neither model could attribute 
these findings to an increase in oxidative stress as would be predicted by the mitochondrial 
free radical theory of ageing (Trifunovic et al., 2005).  The aspersions that were cast upon the 
involvement of oxidative stress and free radicals in the propagation of ageing were later 
refuted by studies that reported increased levels of hydrogen peroxide in aged mtDNA 
mutator mice in vivo (Logan et al., 2014), increased markers of oxidative damage within the 
skeletal muscle of mutator mice (Kolesar et al., 2014), and the extension of lifespan and 
delayed onset of progeroid features in mutator mice treated with a mitochondrially targeted 
antioxidant (Shabalina et al., 2017). Despite these findings potentially reinstating the role of 
reactive oxygen species in the ageing process, their additional involvement in critical 
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physiological processes as signalling molecules suggests there is a much greater complexity 
than the historical ‘vicious cycle’ would suggest. 
 
The ability of the mutator mouse to accurately model human ageing has also been 
challenged. Firstly, the level of mtDNA mutation is much higher in the mouse than in aged 
human tissues (Khrapko et al., 2006) , and despite a significant increase in mtDNA mutation 
load, the heterozygous PolγA mouse did not present with a premature ageing phenotype 
(Vermulst et al., 2007). Nonetheless, the mutator mouse remains a widely accepted model 
of premature ageing associated with mtDNA mutation.  
 
1.7. The intestinal tract 
 
1.7.1. Intestinal structure and function 
 
The overarching function of the small intestine is to absorb essential nutrients from ingested 
food in order to provide the body with energy. Distal to the stomach in which the 
mechanical process of digestion begins, carbohydrates, proteins, fats, minerals and vitamins 
are absorbed by the small intestine which comprises the duodenum, jejunum and ileum and 
measures approximately 24 feet long in humans The chemical digestion which precedes 
absorption is facilitated by secretions from the liver, gall bladder and exocrine pancreas 
which are discharged into the duodenum (McCance & Huether, 2015). In order to maximise 
nutrient absorption, the luminal surface of the small intestine is organised into Kerckring’s 
folds upon which villi and microvilli project into the lumen increasing surface area by a factor 
of 600 beyond that of a simple cylindrical tube. Depending on the substrate, nutrients 
traverse the epithelial membrane via passive diffusion, carrier-mediated diffusion, active 
transport or pinocytosis (Caspary, 1992). 
 
Distal to the ileum is the large intestine or colon; the main function of which is to absorb 
water and electrolytes from dietary waste before it is expelled from the anus. The colon 
consists of four sections: the ascending, transverse, descending and sigmoid colon. 
Additionally, each section has four distinct layers: the mucosa, the muscularis mucosae, the 
submucosa, and the muscularis externa comprising circular and longitudinal muscle layers. 
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The colorectal mucosa forms millions of epithelial invaginations known as crypts. The base of 
a colorectal crypt rests on the muscularis mucosae and extends upwards to the mucosal 
surface of the large intestine where it opens into the gut lumen. 
 
Although the majority of consumed food is digested in the stomach and small intestine, a 
proportion of ingested fat, protein and carbohydrate passes into the colon where it is 
metabolised into hydrogen, carbon dioxide, methane and short chain fatty acids (Cummings, 
1975). Non-digestible food components such as resistant starch and dietary fibre are subject 
to microbial fermentation in the colon generating hydrogen, carbon dioxide and methane 
gas. The short chain fatty acids butyrate, acetate and propionate are also produced from 
starch and fibre fermentation. Butyrate is the colonocyte’s preferred energy source and is 
subject to oxidation by the colonic epithelium (Roediger, 1982) whereas propionate and 
acetate are absorbed and used by the liver for gluconeogenesis and as fuel, respectively 
(Priebe et al., 2002). The production of short chain fatty acids thus has a beneficial role for 
the organism, however by-products which pose a more detrimental effect are also yielded. 
Fermentation products of protein breakdown also include short and branched chain fatty 
acids with the additional generation of potentially toxic metabolites such as phenols, 
sulphides, amines and ammonia. Ammonia can be reabsorbed, and the nitrogen utilised by 
colonic bacteria to facilitate their growth and metabolism, however amines and nitrates can 
also be used by colonic bacteria to produce N-nitrosamines. These have been shown  
experimentally to be carcinogenic compounds (Mirvish, 1995) and are associated with a 
significantly increased colorectal cancer risk in individuals with a high dietary intake of N-
nitrosamine or N-nitrosodiumethylamine (Knekt et al., 1999). Furthermore, the generation 
of hydrogen sulphide via the action of sulphate reducing bacteria has been implicated in the 
modification of expression of DNA repair, inflammatory and cell-cycle progression genes in 
human intestinal epithelial cells (Attene-Ramos et al., 2010) with the perturbation of 
intestinal epithelial cell viability and permeability being mediated by phenol exposure 
(McCall et al., 2009; Pedersen et al., 2002). The colonic metabolism of protein and the 
resultant metabolites have thus been associated with an increased risk of inflammatory 
intestinal pathologies such as ulcerative colitis and Crohn’s disease (Hou et al., 2011). 
Although a ‘Western diet’ high in fat and animal protein has long been associated with 
colorectal cancer (Drasar & Irving, 1973), it is considered that the potentially toxic and 
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carcinogenic effects of a high protein diet are compensated for by a balanced diet high in 
resistant starch or fibre. 
 
The base of an intestinal crypt is known as the proliferative compartment and is populated 
by a pool of intestinal stem cells (ISCs). These multipotent cells generate transit amplifying 
progenitor cells (TAs) which divide a limited number of times, migrating upwards along the 
crypt axis before they differentiate into the functional cell lineages of the crypt. In the colon, 
these include goblet cells (secretory), enterocytes (absorptive), and gastrointestinal 
hormone secreting enteroendocrine cells (Umar, 2010). Small intestinal crypts contain a 
fourth cell type; the Paneth cell. Paneth cells secrete granules containing lysozyme, 
secretory phospholipase A2, and alpha defensins; proteins that are involved in host defence 
and immunity (Ouellette, 1997). Figure 1-4 depicts crypt and crypt-villous structure in the 
colon and small intestine respectively. 
 
 
Figure 1-4. Crypt and crypt-villus structures in the colon and small intestine. In the small intestine (left), the stem cell zone 
or stem cell niche at the base of the crypt comprises Paneth cells intercalated between the stem cells which are responsible 
for generation of each of the differentiated intestinal epithelial lineages. Immediate progeny of crypt base stem cells form 
the transit amplifying cellular compartment; cells of which differentiate into the mature epithelial cells which populate the 
remainder of the crypt and villus projections. In the colon (right) there are no villus projections or Paneth cells. 
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1.7.2. Intestinal crypt stem cells 
 
Initially described by Cheng and Leblond as crypt base columnar cells, stem cells are termed 
as such owing to their abilities to proliferate, self-maintain, produce of a variety of 
differentiated, functional progeny, regenerate the tissue after injury, and possess a flexibility 
in the use of these options (Cheng & Leblond, 1974; Potten & Loeffler, 1990). The 
mammalian intestinal epithelium has an extremely high turnover rate, with complete 
renewal occurring every 4-5 days (van der Flier & Clevers, 2009). It is understood that this 
process is maintained by a non-uniform population of stem cells capable of generating all 
intestinal lineages. Early studies aimed at characterising these stem cells utilised mutation-
induced markers which facilitated the identification of stem cell descendants within the 
mouse intestine (Winton et al., 1988) however technological advances have greatly 
expanded current knowledge. Due to its establishment as a notable target of Wnt signalling 
in intestinal crypts, the Lgr5 (leucine-rich-repeat-containing G protein-coupled receptor 5) 
was selected for investigation as a potential intestinal stem cell marker. The Lgr5-EGFP-Ires-
CreERT2 mouse model was engineered and crossed with mice bearing a Cre inducible 
Rosa26-lacZ reporter gene which upon the administration of tamoxifen, facilitated lineage 
tracing as lacZ was continuously expressed in Lgr5+ cells and their progeny (Barker et al., 
2007). Indeed, these experiments demonstrated that Lgr5 expressing cells were able to 
generate each of the differentiated cell types observed in the mouse small intestine and 
colon. It is now understood that Lgr5+ cells are the crypt base columnar cells; actively cycling 
stem cells largely responsible for homeostatic maintenance of the colonic and small 
intestinal epithelium. In the small intestinal crypt base, between six and eight cells situated 
between the Paneth cells were identified as Lgr5 expressing stem cells, with smaller 
numbers being identified in the colonic crypt base (Barker et al., 2007). 
 
By virtue of their label-retaining capacity, an additional population of slowly cycling cells 
located at the +4 position above the intestinal crypt base have also been purported to be 
intestinal stem cells (Potten et al., 1974). Bmi1 is a member of the Polycomb group gene 
family and plays an essential role in the self-renewal of hematopoietic and neural stem cells. 
Investigations into the potential involvement of Bmi1 in the maintenance of intestinal stem 
cell populations demonstrated that Bmi1 was indeed expressed in the +4 intestinal cells. 
Again with the use of continuous labelling methodologies in mouse models, it was also 
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shown that these cells possessed the capacity to proliferate, expand, self-renew and give rise 
to all the differentiated cell lineages of the small intestine epithelium (Sangiorgi & Capecchi, 
2008).  
 
Lgr5+ stem cells have been described as an actively cycling, Wnt sensitive, proliferative 
population responsible for homeostatic maintenance of the intestinal epithelium. In 
contrast, Bmi1+ cells are reported to act as a reserve pool of quiescent, Wnt insensitive stem 
cells with minimal involvement in tissue homeostasis, able to repopulate the Lgr5+ pool 
following injury (Tian et al., 2011; Yan et al., 2012). Despite these distinct functionalities, it 
has since been demonstrated that Lgr5+ cells can also express +4 markers such as Bmi1 
(Munoz et al., 2012) Furthermore, it has been shown that +4 cells express the atypical 
homeobox gene Hopx, and while they can give rise to Lgr5 expressing stem cells, the 
converse is also true;  Lgr5+ cells can give rise to +4 cells expressing Hopx (Takeda et al., 
2011). Investigations such as this highlight a plasticity within the intestinal stem cell 
compartments which has been further evidenced by studies observing the tissue response to 
injury. Not only is there an interconversion between stem cell populations but following 
exposure to radiation mediated damage and ablation of Lgr5+ cells, committed secretory 
precursors can be recalled back to the stem cell pool fuelling regeneration and epithelial 
restoration (Buczacki et al., 2013). A recent paper, however, has challenged the validity of 
the +4-reserve stem cell concept with the demonstration that following Lgr5+ stem cell 
depletion, the pool is regenerated almost entirely via the dedifferentiation of immediate 
Lgr5+ progeny. Via Lgr5+ continuous labelling and the ablation of the master transcriptional 
regulators of the secretory and enterocyte lineages; Atoh1 and Rbpj respectively, 
regeneration of the stem cell pool was shown to be driven by the dedifferentiation of both 
precursor populations and not +4 ‘reserve’ stem cells (Murata et al., 2020). Furthermore, the 
group demonstrate the post-injury regenerative requirement of the Wnt target gene Ascl2, 
the loss of which has been previously implicated in impaired intestinal stem cell survival (van 
der Flier et al., 2009). RNA sequencing of regenerating Ascl2+ cells and immunoprecipitation 
identification of Ascl2 target promoter regions further highlighted the upregulation of the IL-
11 receptor gene Il11ra1 in facilitating stem cell regeneration with IL-11 supplementation 
enhancing the organoid formation of Ascl2+ cells (Murata et al., 2020). 
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1.7.3. The stem cell niche 
 
Not only are the crypt stem cells themselves critical for the maintenance of epithelial 
homeostasis, their position within the crypt and their corresponding interaction with 
multiple signalling systems and extracellular cues are required to coordinate cellular activity. 
This complex interplay is known as the stem cell niche (Medema & Vermeulen, 2011). The 
major orchestrator of stem cell self-renewal and proliferation is the Wnt signalling pathway. 
The Wnt signalling system is a critical pathway that regulates self-renewal in stem cells of 
the colon, epidermis and haematopoietic system (reviewed in Reya & Clevers, 2005). The 
adenomatous polyposis coli (APC) protein is a key player in this pathway, as are several other 
cytosolic components namely, GSK- 3β, axin, the axin binding molecule Dishevelled (Dsh), 
and the central figure β-catenin. Together, these components form what is known as the 
destruction complex. 
 
In the absence of Wnt ligand signals, the accumulation of β-catenin is prevented by the 
actions of the destruction complex. The destruction complex mediates the phosphorylation 
of β-catenin and targets it for proteasomal degradation (Aberle et al., 1997). When renewal 
signals are received via extracellular Wnt ligand binding to the cell surface receptors Frizzled 
and Lrp5/6, β-catenin is destabilised, released from the destruction complex and 
accumulates in the cytoplasm. It is now free to translocate to the nucleus where it binds 
transcription factors of the TCF/LEF family, primarily Tcf-4 (Behrens et al., 1996; Korinek et 
al., 1997), facilitating the activation of target genes such as the oncogene c-myc and cyclin 
D1 (He et al., 1998; Shtutman et al., 1999; Tetsu & McCormick, 1999). Fundamentally this 
results in proliferation; however, the pathway also provides differentiation and positional 
cues (reviewed in Nusse & Clevers, 2017). In addition to the Wnt ligands themselves, R-
spondin proteins are also required to facilitate Wnt activation. In the absence of R-spondin, 
the ubiquitin ligases RNF43 and ZNRF3 constitutively degrade Frizzled Wnt receptors (Hao et 
al., 2012; Koo et al., 2012). However, when R-spondin proteins are present, these secreted 
factors bind to Lgr4 and Lgr5 receptors and facilitate the sequestration of RNF43 and ZNRF3. 
This enhances the stability of Frizzled Wnt receptors and thus potentiates Wnt signalling 
(Carmon et al., 2011; de Lau et al., 2011). The pathway is depicted schematically in Figure 1-
5. 
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Figure 1-5. The Wnt signalling system. In the absence of Wnt ligand and R-spondin activation, the ubiquitin ligases RNF43 
and ZNRF3 constitutively degrade Frizzled Wnt receptors. This facilitates the phosphorylation of β-catenin by the 
destruction complex, targeting it for proteasomal degradation. Wnt target genes are thus repressed. In the presence of Wnt 
ligand and R-spondin activation, RNF43 and ZNRF3 are sequestered allowing the destabilisation of the destruction complex. 
β-catenin is able to translocate to the nucleus and target gene transcription activated. Image adapted from (Morgan et al., 
2018). 
 
Bone morphogenetic protein (BMP) signalling represents the second major system crucial to 
the control of self-renewal and proliferation of stem cells in the intestinal crypt. In contrast 
to Wnt signalling however, BMP activation inhibits the proliferative response and promotes 
cellular differentiation (Haramis et al., 2004; He et al., 2004).BMP ligands are members of 
the TGFβ family and exert their actions by binding to type II receptors and recruiting type I 
receptors which together facilitate the translocation of Smad transcription family members 
to the nucleus (Heldin et al., 1997). BMP family members BMP2 and BMP4 are the 
predominant isoforms within the intestine and are secreted by mesenchymal cells (Haramis 
et al., 2004; Hardwick et al., 2004). In addition to the Smad mediated regulation of gene 
expression, these proteins reportedly inhibit Wnt signalling in a more direct manner. The 
inactivation of the tumour suppressor PTEN has been shown to activate Akt and promote 
the nuclear localisation of β-catenin (Persad et al., 2001). Similarly, the inactivation of BMP 
signalling in Bmpr1a receptor knockout mice was shown to associate with increased levels of 
inactive PTEN, activated Akt and nuclear β-catenin in intestinal stem cells indicating an 
additional means by which BMP can regulate stem cell self-renewal (He et al., 2004). 
Additionally, BMP signalling and Smad activation has also been shown to restrict Lgr5+ stem 
cell self-renewal via the recruitment of histone deacetylase 1 (HDAC1) which epigenetically 
represses the transcription of stem cell signature genes such as Lgr5 and Sox9 thus inhibiting 
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their stemness (Qi et al., 2017). Interestingly, this study failed to identify an increase in 
nuclear localisation of β-catenin in Bmpr1a deficient mice and as such the mechanism by 
which BMP directly inhibits Wnt signalling remains somewhat unclear. Regulation of BMP 
signalling is achieved with important input from the mesenchymal tissue surrounding the 
intestinal crypt. In addition to the secretion of R-spondin1, myofibroblasts also secrete 
Noggin, an antagonist of BMP signalling (Lei et al., 2014).  
 
The Notch signalling pathway represents the key means by which intestinal early progenitor 
cell fate is controlled and differentiation decisions are made. Enterocyte differentiation is 
driven by the activation of Notch signalling. Following the binding of Notch ligands such as 
Dll1 and Dll4, the Notch intracellular domain (NICD) of the Notch receptor is proteolytically 
cleaved and translocates to the nucleus where it facilitates the expression of target genes 
such as that encoding the Hes1 Notch effector transcription factor (Heitzler et al., 1996; 
Oellers et al., 1994). Accordingly, the expansion of secretory epithelial cell and decreased 
absorptive cell populations are observed in mice lacking Hes1 (Jensen et al., 2000). 
Conversely, mice with increased expression of NICD demonstrate an increase in stem cell 
proliferation with an associated decrease in secretory epithelial cell numbers (Fre et al., 
2005). The activation of the Hes1 transcription factor results in the repression of another 
transcription factor; Atoh1. Atoh1 is considered the master regulator of the intestinal 
secretory cell lineage and thus directs Notch inactivated cells to become goblet, 
enteroendocrine, and Paneth cells (Yang et al., 2001). Notch signalling acts over very short 
distances as cells respond to ligands expressed by their neighbours. The cell in which Notch 
signalling is activated and thus Atoh1 is repressed expresses a reduced frequency of cell 
surface Notch ligands. Accordingly, Notch is not activated in neighbouring cells, Atoh1 
repression is released and these cells are committed to the secretory lineage. This process is 
known as lateral inhibition and ensures a proportional distribution of different cell types 
within the intestinal crypt (reviewed in Sancho et al., 2015). Additional players in the Notch 
mediated control of cell fate decision making have recently been identified; namely the 
transcriptional co-repressors Mtg8 and Mtg16. These proteins were found to be expressed 
at high levels in early progenitor cells leaving the intestinal niche as a result of Notch signal 
loss at the +4/5 cell position. While the loss of Notch classically results in the activation of 
Atoh1 secretory lineage commitment, Mtg8 and Mtg16 expression begins to dominate as a 
result of the loss of Notch repression. This inhibits Atoh1 expression in addition to stem cell 
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gene expression and the expression of cell surface Notch ligands. Thus Mtg8/Mtg16 
expression promotes intestinal niche exit, enterocyte differentiation in the cells in which 
they are highly expressed, and the lateral inhibition of adjacent cells driving the neighbour 
secretory differentiation (Baulies et al., 2020).  
 
It is becoming apparent that the positioning of a stem cell within the niche and its resultant 
exposure to the differing gradients of signalling molecules is of as equal importance as the 
inherent clonogenicity and functional capacity of the stem cell itself. Indeed, Wnt isoforms 
and their downstream effectors are differentially expressed throughout the crypt-villus axis 
with those involved in proliferation and differentiation being expressed at the highest level 
at the crypt base (Gregorieff et al., 2005). Conversely, BMP activity increases along the crypt 
axis in the opposite direction with the crypt base being shielded from BMP activation by the 
secretion of BMP antagonists such as Gremlin1 and Noggin by Paneth and mesenchymal 
cells (Kosinski et al., 2007; Stzepourginski et al., 2017). The secretion of essential 
components of stem cell maintenance by Paneth cells dictates that stem cell homeostasis is 
shaped by the proximity of the two cell types. Paneth cells secrete Wnt3, an agonist of 
Wnt/βcatenin, epidermal growth factor (EGF), transforming growth factor α (TGF α) and 
Delta-like ligand1/4 (Dll1/4, ligands of Notch receptors) (Sato et al., 2011b). Accordingly, the 
immediacy and abundance of Paneth cell contact influences the potential for individual stem 
cells to become the dominant clone of the crypt. Those Lgr5+ stem cells which are centrally 
placed and in contact with the greatest number of Paneth cells possess a survival advantage 
over those in contact with fewer Paneth cells at the niche border (Ritsma et al., 2014). 
 
In contrast to small the small intestine, the colonic crypt stem cell population is less well 
characterised. Colonic crypts do not contain +4 cells, Bmi1+ or Paneth cells however in place 
of the small intestinal Paneth cell, supportive cKIT+ (CD117) and Reg4+ cells secrete growth 
factors and Notch ligands which support Lgr5+ cell homeostasis within the colonic crypt 





  51 
1.7.4. Intestinal ageing 
 
With increasing age numerous physiological changes occur within the gastrointestinal tract, 
collectively contributing to a functional decline. Colonic transit time is often increased in the 
ageing intestine and is linked with a reduction in the contractility of smooth muscle 
(reviewed in O'Mahony et al., 2002) and also myenteric neuron loss and changes in the gut 
microbiota (reviewed in Saffrey, 2013). The digestive function of the intestine is impaired 
with age and contributing to this are associated changes in the levels of hormones such as 
cholecystokinin (CCK) which stimulates the release of digestive enzymes from the pancreas 
(reviewed in Moss et al., 2012). Although found to be largely increased post-prandially in the 
elderly, a decreased sensitivity of the gall bladder to CCK has been reported with advancing 
age (Masclee et al., 1988). The reduction in absorptive capacity of the intestine in ageing 
individuals has previously been attributed to villus degeneration, with decreases in intestinal 
villus height (Höhn et al., 1978) and intestinal surface area (Keelan et al., 1985) described in 
ageing animal models. Further histological changes such as fewer, larger intestinal villi and 
reduced numbers of small intestinal crypts have been described in aged compared to young 
mice (Martin et al., 1998), however these findings have not been corroborated in humans 
nor have such changes been strongly linked with defective absorption.  
 
In addition to the absorptive and digestive functions of the intestine, the epithelial surface of 
the intestine acts as a barrier against digestive enzymes and acid, microbes and ingested 
material all of which may be harmful to the underlying tissue. Epithelial enterocytes apically 
linked by tight junctions of claudin, zonulin and occludin proteins maintain a physical barrier 
in conjunction with the secretion of Muc2 containing mucus and antimicrobial peptides from 
goblet and Paneth cells respectively. Additionally, the immunoglobulin IgA is secreted by 
plasma cells into the luminal space in response to the presence of commensal bacteria 
(Macpherson et al., 2000). The diminishing integrity of the mucosal barrier and subsequent 
increase in intestinal permeability has been associated with increasing age for some time 
(Hollander & Tarnawski, 1985) however, the complex interplay between mucosal immunity, 
chronic inflammation and the host microbiota in driving this phenotype is more recent in its 
investigation. Although a recent study comparing numerous parameters such as mucus layer 
thickness, goblet and Paneth cell abundance and the transcriptomic analysis of genes related 
to innate and adaptive immunity of the young versus old murine intestine reports an 
  52 
extensive impairment of barrier function with increasing age (Sovran et al., 2019), an equally 
comprehensive study in humans refutes the ‘leaky gut hypothesis’ and details the 
maintenance of intestinal barrier function in aged individuals (Wilms et al., 2020). The 
concept of ‘inflammageing’ in which a global pro-inflammatory phenotype evolves as the 
ability to deal with continuous antigenic exposure and stress decreases with advancing age 
(Franceschi et al., 2000) is supported by the work of Sovran et al. It is also supported by a 
study of the age-associated changes in innate immunity in the human small intestine (Man 
et al., 2015). Man et al. describe the increased expression of the pro-inflammatory cytokine 
interleukin-6 (IL-6) within the ageing ileum and an associated increased permeability to 
solutes mediated by the IL-6 induced expression of the tight junction protein claudin-2. In 
contrast, the work of Wilms et al. detected no differences in the expression of tight junction 
proteins in human colonic biopsies. These discrepancies may reflect differences in ileal 
versus colonic physiology, however the putative association of impaired barrier function and 
resultant increasing intestinal permeability with advancing age in human populations still 
requires further investigation. 
 
In contrast, work characterising the intestinal microbiota of ageing populations is more 
abundant. Alterations in the function and physiology of the intestinal tract in concert with 
the dampened immunity, lifestyle changes and comorbidities of older age have implications 
on the gut microbiota profile which in turn impacts intestinal health and beyond. 
Disturbances in intestinal microbiota composition have been implicated in the pathogenesis 
of conditions such as diabetes (reviewed in Bleau et al., 2015) and Parkinson’s disease 
(Forsyth et al., 2011), in addition to intestinal specific pathologies and as such represent a 
wide-ranging challenge to human health. Although a specific elderly microbiome profile has 
not been characterised, likely due to many confounding factors which may influence this 
signature more so than age, a general trend towards a decreased abundance of 
bifidobacteria coupled with increased levels of streptococci and Enterobacteriaceae has 
been observed (reviewed in An et al., 2018). Interestingly, the first extensive 
characterisation of elderly versus young faecal microbiota report an increased abundance of 
lactobacilli in the elderly profile (Mitsuoka, 1990), a genus which has also been documented 
as significantly increased in PolγAmut/mut versus PolγA+/+ stool (Houghton et al., 2018). 
Probiotic supplementation with lactobacilli is generally considered to be advantageous in 
terms of host health. Lactate and urolithin A are the major metabolites of lactobacilli and in 
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addition to short chain fatty acids produced by numerous bacterial strains represent the key 
compounds by which intestinal health is promoted (Franco-Obregón & Gilbert, 2017). 
Microbiome diversity is promoted by urolithin A and also by short chain fatty acids such as 
butyrate. Furthermore, these compounds enhance their own production by augmenting the 
growth of bacterial strains that produce them. Butyrate is the primary colonocyte energy 
source, and its production is further facilitated by lactobacilli and bifidobacteria, as the 
lactate they generate can subsequently be converted to butyrate by alternate colonic 
bacterial strains. The connection between microbiome metabolites and mitochondria is an 
area which has received recent attention, and butyrate has been shown to rescue fatty acid 
β oxidation, oxidative phosphorylation and TCA cycling in mice in which these processes 
have been diminished by a germ-free intestinal environment (Donohoe et al., 2011). With 
reference to Lactobacillus supplementation, this has been shown to drive intestinal barrier 
repair via peroxisome proliferator activated receptor alpha (PPARα) activation and 
restoration of mitochondrial structure and fatty acid β-oxidation in the Simian 
immunodeficiency virus (SIV)-inflamed intestinal lumen of rhesus macaques (Crakes et al., 
2019). With this in mind it may be presumed that an abundance of lactobacilli in the 
PolγAmut/mut colon could alleviate mitochondrial dysfunction to some extent. Also described 
in the PolγAmut/mut colon is a decreasing bacterial diversity from 4 months of age in 
comparison to PolγA+/+ animals (Houghton et al., 2018) and as such, the benefit of profuse 
lactobacilli may therefore be negated by an apparent dysbiosis associated with this 
advanced ageing phenotype.  
 
1.8. Colorectal cancer 
 
After breast cancer in women and lung and prostate cancer in men, colorectal cancer (CRC) 
is respectively the second and third most commonly diagnosed cancer worldwide, and age is 
the biggest risk factor for CRC development. In 2018, colorectal cancer accounted for 9.2% of 
global cancer deaths (Bray et al., 2018). In addition to age, additional risk factors include 
environmental components such as smoking, a diet high in processed foods and alcohol and 
a sedentary lifestyle (Botteri et al., 2008; Cai et al., 2014; Wolin et al., 2009). While 
approximately 60-65% of colorectal cancers are sporadic, the remaining 35-40% are 
associated with genetic components that are heritable and confer an increased propensity 
towards CRC development (Graff et al., 2017; Lichtenstein et al., 2000). Although the 
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hereditary intestinal cancer syndromes such as Lynch syndrome and familial adenomatous 
polyposis (FAP) contribute to a relatively small (~5%) proportion of CRC cases (Jasperson et 
al., 2010), the genetic events that underlie these conditions are frequently observed in 
sporadic CRC and thus represent important molecular changes highly relevant to CRC 
pathogenesis (Muzny et al., 2012). 
 
FAP is an autosomal dominant inherited condition characterised by the development of 
multiple polyps throughout the intestine. These polyps have the propensity to become 
malignant and as such, the condition places sufferers at an increased risk of colorectal 
cancer (Vogelstein & Kinzler, 2002). The APC gene resides in band q21-q22 of chromosome 5 
and encodes a 312 kDa tumour suppressor protein (Groden et al., 1991; Kinzler et al., 1991). 
In cases of FAP, one copy of the gene is mutated, and its tumour suppressor function is 
perturbed. This truncating mutation is inherited with a somatically acquired mutational 
event impairing tumour suppression function at the second APC locus permitting the 
development of multiple benign polyps. This occurs as a result of the negative regulation the 
APC protein has on the Wnt signalling system; a critical pathway that controls self-renewal in 
stem cells of the colon, epidermis and haematopoietic system (reviewed in Reya & Clevers, 
2005). The increased risk of colorectal cancer in FAP patients occurs as additional genetic 
and epigenetic changes facilitate disease progression. As APC is mutated in a large 
proportion of colorectal cancers it is considered a major event in tumorigenesis and forms 
the initiating event in the adenoma-carcinoma sequence; a pathway that leads to 
approximately 80% of CRCs (Fearon & Vogelstein, 1990). 
 
Historically, colorectal cancers have been classified using the Dukes system in which the 
stages A, B, C and D indicate the extent of tumour growth from the lowest stage (A) where 
the tumour remains epithelial in its location to more advanced stages in which the tumour 
has grown through the bowel musculature (B), to regional lymph nodes (C) and to the most 
advanced stage of metastatic dissemination (D) (Dukes, 1932). Using similar principles, the 
tumour, node, metastases (TNM) staging system has been developed by the American Joint 
Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) and is widely used 
in the evaluation of CRC patient prognosis today, however the disparity in prognosis 
between patients of the same stage has deemed this system unsatisfactory (Dienstmann et 
al., 2017). Colorectal cancers are extremely heterogeneous in nature with tumour location 
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(left-sided versus right-sided), molecular features (microsatellite instability, MSI; 
chromosome instability, CIN; and CpG island methylator phenotype, CIMP discussed further 
in subsequent sections) and the tumour microenvironment all contributing to patient 
survival but not assessed by TNM staging. Accordingly, additional systems have been 
developed in order to better stratify the disease and thus patient outcome. As a result of 
several large genomic investigations, the consensus molecular subtypes (CMS) of colorectal 
cancer were described in 2015 (Guinney et al., 2015). Each subtype (MSI immune, CMS1; 
canonical, CMS2; metabolic, CMS3; and mesenchymal, CMS4) possesses a distinct set of 
molecular features which can assist in the prediction of patient outcome and response to 
particular therapies. While this specific subtyping is beneficial with regards patient 
management, the transcriptomic, genomic and proteomic analyses required to delineate 
CRCs in this manner are not readily applicable to routine pathology (reviewed in Roseweir et 
al., 2017). As such, several histological subtyping protocols have been developed in order to 
provide additional prognostic value with the use of routine histological tissue sections. The 
tumour microenvironment, in particular the stromal and immune infiltrate is an important 
determinant of CRC progression and is easily evaluated with the analysis of H&E and 
immunohistochemically labelled tissue sections. The Galon Immunoscore (GI) (Galon et al., 
2006; Galon et al., 2014; Pagès et al., 2010), Klintrup- Mäkinen (KM) grade (Klintrup et al., 
2005) and combined KM/tumour stroma percentage (TSP), the Glasgow Microenvironment 
Score (GMS) (Park et al., 2015) have been shown to associate with CMS subtyping, patient 
prognosis and with adjuvant chemotherapy response (Alexander et al., 2020; Becht et al., 
2016; Marliot et al., 2020; Roseweir et al., 2020).  
 
While surgical resection is the most common primary treatment for colorectal cancer, this is 
not always curative and treatment regimens are guided by TNM stage, tumour location, 
histological, molecular and phenotypic characteristics, and patient specific factors such as 
age or existing comorbidities. For example, patients in which tumour invasion of the colonic 
musculature has not occurred, adjuvant therapies are not always administered. In patients in 
which lymph node involvement or metastases are detected, a combination of 
chemotherapy, targeted therapies and immunotherapies are often required to target 
residual malignant cells, prevent recurrence and to restrict the growth of inoperable lesions. 
Fluoropyrimidine-based therapeutics have been the mainstay of CRC adjuvant 
chemotherapies for over 50 years (Heidelberger et al., 1957) with the addition of oxaliplatin 
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(forming the FOLFOX regime) further improving survival (André et al., 2009; Kuebler et al., 
2007). Left-sided colorectal cancer patients with microsatellite stable lesions benefit more 
from fluoropyrimidine based regimes in comparison to patients with right-sided MSI high or 
CMS4 lesions in which these conventional therapies are less effective (De Sousa E Melo et 
al., 2013; Ribic et al., 2003). Additionally, the specific fluoropyrimidine administered has 
been shown to have differential effects within CMS immune subtype stage III or GMS low 
tumours with these lesions responding better to FOLFOX rather than the fluoropyrimidine 
precursor capecitabine based CAPOX regime (Alexander et al., 2020; Roseweir et al., 2020). 
Targeted therapeutics such as anti-VEGF monoclonal antibodies which target angiogenesis 
(bevacizumab, regorafenib) and anti-EGFR therapies (cetuximab and panitumumab) are also 
selected based upon tumour classifications. While patients with left-sided lesions can benefit 
from anti-VEGF and anti-EGFR therapeutics, right-sided lesions are largely refractory to anti-
EGFR agents (Venook et al., 2016). Similarly, RAS and RAF mutational status are important 
determinants of targeted therapies with RAS and RAF wild type lesions responding well to 
targeted agents in addition to conventional chemotherapies while no benefit is seen in RAF 
mutant lesions (Heinemann et al., 2014; Pietrantonio et al., 2015; Venook et al., 2017). 
Finally, immunotherapeutic agents constitute an additional arm of CRC treatments in which 
much like chemo and targeted therapeutics, response to treatment is influenced by specific 
tumour characteristics. For example, the anti-PD-1 inhibitor pembrolizumab has shown 
promise in the treatment of right-sided/MSI-high/CMS1 tumours in comparison to MSI 
stable lesions (Le et al., 2015). To summarise, the appropriate staging and subtyping of 
colorectal cancers is vital in guiding the selection of efficacious treatment plans in order to 
provide patients with the most favourable outcomes. 
 
1.8.1. The adenoma-carcinoma sequence and chromosome instability 
 
The seminal work by Fearon and Vogelstein, describes the development of CRC as an 
accumulation of mutations, each facilitating progression through individual stages in what is 
referred to as the adenoma–carcinoma sequence (Fearon & Vogelstein, 1990). In this model, 
the primary mutational event activates the Wnt pathway and initiates the epithelial 
transition from normal to polypoid tissue. Subsequent mutations over a number of years 
drive progression to adenoma and carcinoma. Typical mutational events within this pathway 
include the oncogenic activation of RAS genes. The Ras proteins encoded by RAS genes are 
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small GTPases that relay signals from the cell surface to the nucleus via effector pathways 
such as the PI3K-Akt survival pathway (Rodríguez-Viciana et al., 1994; Sjölander et al., 1991) 
and the RAS-RAF-MEK-ERK-MAPK mitogenic pathway (Moodie et al., 1993; Warne et al., 
1993). Their tumorigenic effects are mediated when mutant oncogenic Ras proteins are 
locked in an active GTP bound state, constitutively activating their target pathways (Trahey 
& McCormick, 1987). Chromosomal instability (CIN) is a characteristic feature of colorectal 
malignancies that evolve via this pathway with deletion of the long arm of chromosome 18 
being a common event associated with poor prognosis (Popat & Houlston, 2005). Residing at 
this location are genes encoding members of the SMAD family of proteins that function as 
mediators of the TGFβ and BMP signalling pathways (reviewed in Attisano & Tuen Lee-
Hoeflich, 2001). SMAD4 loss in particular is associated with colorectal cancer, concomitant 
inactivation of TGFβ facilitating tumour progression following Apc loss (Takaku et al., 1998)  
and resistance to fluorouracil-based therapeutics (Boulay et al., 2002). 
 
A critical event in the adenoma-carcinoma sequence that promotes invasive transition of CIN 
phenotype CRCs is inactivation of the tumour suppressor p53 (Baker et al., 1989; Baker et al., 
1990a; Baker et al., 1990b). First discovered in 1979 as a protein bound to the simian (SV40) 
oncogenic DNA virus, and initially thought to be a proto-oncogene (Lane & Crawford, 1979; 
Linzer & Levine, 1979; Rotter et al., 1980), the p53 tumour suppressor protein encoded by 
the TP53 gene is mutated in around 50% of human colorectal cancers (Bouaoun et al., 2016). 
Wild type p53 is activated in response to cellular stress, and via its function as a transcription 
factor can induce metabolic homeostasis, DNA repair and antioxidant defence, and under 
severe stress, cellular senescence, cell-cycle arrest, and apoptosis (Levine & Oren, 2009). 
Due to such functions, the loss of wild type p53 as is the case in roughly half of all human 
cancers has a fundamental role in tumour development. In addition to loss of the wild-type 
function of p53, point mutations in the Tp53 gene can confer gain of function properties on 
the mutant protein which in the cancer setting can promote tumour progression via an 
increased level of genome instability or enhanced metastatic potential (Lang et al., 2004; 
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1.8.2. The serrated pathway and molecular phenotypes 
 
Despite the high prevalence of APC loss in human colorectal cancer, this event is not 
essential for tumorigenesis and around 20% of cases are wild type for APC. Lesions within 
this group differ histopathologically from those of the ‘classical’ APC loss Wnt-dependant 
pathway and they present with a more “saw-toothed” or serrated morphology than 
‘traditional’ adenocarcinomas (Hawkins et al., 2002). Accordingly, they are termed serrated 
lesions and precursor foci are categorised into sessile serrated and the less frequently 
diagnosed traditional serrated adenoma. While APC and Wnt driven CRCs originate in the 
stem cell compartment of the intestinal crypt (Barker et al., 2009), serrated CRCs originate 
from progenitor cells outside the stem cell niche. In the case of traditional serrated 
adenomas, the disruption of BMP signalling as a result of increased expression of the BMP 
antagonist GREM1 drives progenitor cell expansion and ectopic crypt formation (Davis et al., 
2015). This precedes a major genetic event which is common to the majority of serrated 
adenomas; the acquisition of an activating mutation within the BRAF proto-oncogene 
(Kambara et al., 2004). RAF proteins exist in three forms within humans: ARAF, BRAF and 
CRAF. These serine/threonine kinases function downstream of RAS proteins as part of the 
RAS-RAF-MEK-ERK-MAP kinase pathway (Carragher et al., 2010; Davies et al., 2002; Marais & 
Marshall, 1996). An activating mutation in the BRAF gene brings about constitutive signalling 
through this pathway, and although primarily associated with malignant melanoma, BRAF 
mutations are associated with an incidence of up to 22% in colorectal cancer (Davies et al., 
2002; Garnett & Marais, 2004). Also common within lesions developing via this pathway, 
more so with those of the traditional serrated phenotype, is an activating mutation in the 
KRAS gene (Jass et al., 2006; O'Brien et al., 2006). BRAF and KRAS mutations, however, are 
considered to be mutually exclusive from one another (Rajagopalan et al., 2002). In contrast 
to the chromosomal instability observed in APC-Wnt mediated colorectal neoplasms, 
colorectal tumours of the serrated phenotype are typically characterised by a CpG island 
methylator phenotype (CIMP) which leads to high levels of epigenetic modulation of gene 
expression via DNA hypermethylation at CG repeats within gene promoter regions (Toyota 
et al., 1999). Methylation of tumour suppressor promoters such as that of the p16 cell cycle 
regulation protein allows benign serrated lesions to evade the oncogene induced senescence 
associated with initiating BRAF mutations (Michaloglou et al., 2005; Serrano et al., 1997). 
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Also secondary to CIMP, aberrant methylation of DNA mismatch repair genes leads to an 
additional CRC molecular phenotype known as microsatellite instability (MSI) (Weisenberger 
et al., 2006). Microsatellite instability describes the frequent insertion and/or deletion of 
nucleotides at microsatellite sequences throughout the genome and while often observed in 
association with BRAF-mediated CIMP, this phenotype also occurs independently of CIMP as 
is demonstrated by hereditary non-polyposis colon cancer (HNPCC), also known as Lynch 
Syndrome. HNPCC is characterised by a susceptibility to colorectal cancer that is inherited in 
an autosomal dominant manner. First studied by Warthin in 1913 (Warthin, 1913) and later 
described by Lynch (Lynch et al., 1966), Lynch syndrome is caused by a defective DNA 
mismatch repair system attributable to a germline mutation in at least one of the mismatch 
repair genes; mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6) 
and post meiotic segregation increased 2 (PMS2). Microsatellite instable colorectal cancers 
also occur via somatic acquisition of mutations in DNA mismatch repair genes and are 
estimated to account for 10-15% of sporadic CRCs (Ionov et al., 1993). Progression of 
microsatellite instable CRCs is associated with the inactivation of tumour suppressor 
function via microsatellite mutation of the TGFβ receptor gene TGFβR2 (Markowitz et al., 
1995) and the apoptosis promoting BAX (Rampino et al., 1997). 
 
While the serrated pathways of colorectal carcinogenesis have traditionally been considered 
as occurring independently of the Wnt activation epitomised by APC loss mediated 
colorectal carcinogenesis, recent studies identifying the presence of Wnt activating 
mutations in both sessile and traditional serrated colorectal cancers (Giannakis et al., 2014; 
Sekine et al., 2016; Seshagiri et al., 2012) suggests that despite their fundamental 
differences there is much overlap between CRC phenotypes. Figure 1-6 depicts the 
molecular pathways of colorectal carcinogenesis. 
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Figure 1-6. Molecular pathways of colorectal carcinogenesis. Major genetic events contributing to tumorigenesis are 
indicated with black arrows. The conventional APC-Wnt mediated adenoma-carcinoma sequence is presented above the 
schematic with the serrated pathway being presented below. Dashed lines indicated events associated with a microsatellite 
unstable phenotype. Image adapted from (Kaiser et al., 2014). 
 
1.8.3. Colorectal cancer stem cells 
 
Colorectal cancer is an extremely heterogeneous disease, demonstrating a great variety of 
genotypic and phenotypic traits. The cell of origin likely contributes to this inter-tumoral 
heterogeneity and plays an important role in defining tumour features. Specific activation of 
Wnt signalling in Lgr5+ and Bmi1+ stem cells results in adenoma generation, leading to the 
supposition that intestinal stem cells are the cells of origin of colorectal cancer (Barker et al., 
2009; Sangiorgi & Capecchi, 2008). Capable of generating an extensive adenoma burden at a 
rapid rate, these models provide insights into a cell-autonomous mode of tumour initiation, 
however multiple epigenetic and micro-environmental factors create a more complex 
interplay in the human situation. 
 
It is suggested that a hierarchical organisation exists within human colorectal cancers with a 
small population of cancer stem cells (CSCs) driving tumour growth and self-renewal, in 
addition to a larger population of tumour cells at advanced stages of differentiation 
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(Vermeulen et al., 2008). CSCs are defined as such by their ability to generate a phenotypic 
copy of the original tumour and its differentiated progeny upon xenotransplantation (Clarke 
et al., 2006). Furthermore, CSCs are considered important drivers in disease relapse. While 
non-stem tumour cells may be eradicated by conventional chemotherapies, cancer stem 
cells may persist and facilitate subsequent tumour recurrence (reviewed in Batlle & Clevers, 
2017). Much as normal stem cells respond to niche signals; it is becoming apparent that CSCs 
are also influenced by their micro-environment to the extent that differentiated tumour cells 
can acquire CSC characteristics in response to myofibroblast-derived signals (Vermeulen et 
al., 2010). Additionally, an increase in signalling mediated by NF-kB, a transcription factor 
involved in regulation of inflammation, has been shown to enhance Wnt activation and bring 
about the de-differentiation of non-stem cells bestowing them with tumour-initiating 
capabilities (Schwitalla et al., 2013). Together, such observations suggest that stemness is in 
fact a fluid state with the convergence of genetic, epigenetic and micro-environmental 
factors shaping the stem cell pool, the malignancies they drive and indeed a plasticity that 
provides them with chemotherapeutic resistance.  
 
Numerous molecular markers have been identified and posited as colorectal cancer stem 
cell specific. For example, epithelial cell adhesion molecule (EpCAM) and CD166 (Dalerba et 
al., 2007), aldehyde dehydrogenase 1 (ALDH1) (Huang et al., 2009) and Lgr5 (Barker et al., 
2009; Barker et al., 2007) have been well characterised. Originally identified as a marker of 
haematopoietic stem and progenitor cells; CD133 (Yin et al., 1997), as also known as 
prominin-1 glycoprotein has also been described as a colorectal cancer stem cell marker with 
CD133+ colon cancer cells capable of reproducing the original tumour in immunodeficient 
mice (O'Brien et al., 2007; Ricci-Vitiani et al., 2007). Furthermore, the expression of CD133 
has been associated with an enhanced apoptotic evasion via the production of IL-4 by 
CD133+ species (Todaro et al., 2007). A contradictory report, however, describes the same 
property in CD133- cells, thus questioning the stem cell specificity of the marker. The same 
study however identifies the metastatic CD133- population as more aggressive and positive 
in the expression of another CRC stem cell marker; CD44 (Shmelkov et al., 2008). CD44 is a 
transmembrane glycoprotein involved in the regulation of cell-cell interactions, migration 
and adhesion (Spring et al., 1988). The malignant potential of CD44+ cells were first 
described in rat pancreatic carcinoma and mammary adenocarcinoma cell lines (Günthert et 
al., 1991) however CD44+ colon cancer cells have since been characterised as tumorigenic in 
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nude mice with CD44 knockdown inhibiting xenograft growth (Du et al., 2008). The 
interaction of CD44 with components of the extracellular matrix, namely hyaluronan has 
additionally been described as a key connection that promotes colon carcinoma cell invasion 
(Kim et al., 2004). Given the involvement of colorectal cancer stem cells in critical aspects of 
tumour biology, an in depth understanding of these species aided by their specific markers 
may elucidate their vulnerabilities. In addition to traditional therapeutics that eliminate the 
non-stem tumour bulk, this may represent an important means by which the persistent 
cancer stem cells are also targeted and the efficacy of cancer therapies augmented. 
 
1.8.4. Mouse models of intestinal cancer 
 
One of the first mouse models of intestinal cancer was developed in 1990 during a mouse 
germline mutagenesis project (Moser et al., 1990). Male mice were treated with the 
mutagen ethylnitrosourea (ENU) and subsequently mated with females. A progressive 
anaemia was reported in the offspring of this cross, as was the incidence of multiple 
adenomas throughout the length of the murine intestine. Described as Min/+ (multiple 
intestinal neoplasia) mice, their phenotype was later shown to be caused by a nonsense 
mutation in codon 850 of the murine homolog of the APC tumour suppressor gene (Su et al., 
1992). The administration of ENU caused a loss of function mutation at codon 850 of the 
murine Apc gene with spontaneous loss of heterozygosity occurring as the second APC allele 
is lost during adulthood. This model mimics the inherited autosomal dominant human 
disorder of familial adenomatous polyposis coli (FAP) in which a germline APC mutation is 
inherited, allowing the development of multiple colorectal polyps with loss of heterozygosity 
(Groden et al., 1991). Malignant transformation of these polyps occurs following additional 
genetic and epigenetic changes and as such, FAP patients are at great risk of the 
development of colorectal carcinoma. Although the APC gene is mutated in the majority of 
human colorectal cancers (Goss & Groden, 2000), malignant transformation of adenomas in 
mice carrying an APC mutation alone are very rare. This is likely due to the large tumour 
burden and resultant bowel obstruction coupled with the short life span of the animal. In 
order to model another hereditary colorectal cancer syndrome, homozygous Msh2−/− 
germline knock out mice were developed in 1995 (Reitmair et al., 1995). Despite its similarity 
to human HNPCC, and its promise for use in such modelling, the MSH2 mutation was not 
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restricted to the intestine. Its global effect on the MSH2 genes of other tissues and organ 
systems resulted in the prolific development of lymphoma and hence a reduced lifespan.  
 
Villin is an actin binding protein associated with the microfilament core of mammalian 
intestinal epithelial cell microvilli (Bretscher & Weber, 1979). The Cre-Lox system has been 
utilised to excise MSH2 specifically in intestinal cells by crossing Msh2LoxP mice with animals 
carrying a Villin-Cre transgene (Kucherlapati et al., 2010). Cre-Lox technology has also been 
used to excise APC in a tissue-specific manner with additional experimental control in the 
form of inducible Cre expression (Sansom et al., 2004). CYP1A is a member of the 
cytochrome P450 family extensively expressed in the intestine. It becomes transcriptionally 
active upon the addition of lipophilic xenobiotics such as β-napthoflavone. If Cre is inserted 
under the CYP1A promoter, administration of β-napthoflavone initiates expression of Cre 
and the subsequent recombination of LoxP sites. This AhCre mouse has been crossed with 
strains of mice expressing defective forms of other genes implicated in the development of 
CRC. The consequences of the loss of the p53 tumour suppressor was shown when the 
AhCre Apcfl/+ mouse was crossed with animals containing an inducible knock-in allele of 
mutated p53 (Tp53172H/+). Invasive adenocarcinoma had not been observed in the 
aforementioned mouse models, however all mice in the AhCre Apcfl/+, Tp53172H/+cohort 
demonstrated invasive adenocarcinoma, providing an excellent model for the later stages of 
CRC and the role that mutant p53 plays in its development (Muller et al., 2009).  
 
In 2007, the Wnt target gene Lgr5 (leucine-rich-repeat-containing G-protein-coupled 
receptor 5) was discovered as a marker of stem cells of the small intestine and colon. (Barker 
et al., 2007). The later identification of Lgr5 positive stem cells as the cells-of-origin of 
intestinal cancer, marked an extremely important discovery in the study of colorectal cancer 
and hence the mouse models used to characterise it (Barker et al., 2009). A gene knock in 
model was created via homologous recombination of EGFP-IRES-creERT2 into the first exon 
of Lgr5. This cassette expressing enhanced green fluorescent protein (EGFP) allowed for 
microscopic visualisation of Lgr5 positive crypt base stem cells, with the creERT2 component 
of the cassette allowing for Cre-Lox mediated gene excision. With the previously described 
AhCre Apcfl/+ mouse, deletion of Apc occurred in all cell types throughout the intestine. The 
discovery of the Lgr5 gene enabled stem-cell specific deletion of Apc to be induced by 
crossing the Lgr5-EGFP-IRES-creERT2 mice with Apcflox/flox mice (Barker et al., 2009). An 
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intraperitoneal (IP) injection of tamoxifen allowed translocation of creERT2 to the nucleus, 
recombination of LoxP sites and excision of Apc. With the induced loss of Apc, 
microadenomas formed throughout the small intestine and colon. Upon histological analysis, 
these lesions were found to be expressing high levels of β-catenin, indicative of Wnt 
signalling activation mediated through deletion of Apc.  
 
Although the APC gene is lost in the majority of human colorectal cancers, APC loss alone is 
not sufficient to drive the progression of adenoma to carcinoma, to invasive disease and 
metastases. According to the classical pathway described by Fearon and Vogelstein, the 
progression from an adenomatous lesion to full-blown metastatic disease is a multistep 
sequence initiated by the loss of APC but propagated to more advanced disease stages by 
additional genetic and epigenetic changes (Fearon & Vogelstein, 1990). As around 40% of 
human colorectal cancers carry a mutation in the KRAS proto-oncogene (The Cancer 
Genome Atlas et al., 2012), mouse models combining oncogenic Kras mutations with Apc 
loss have been developed in order to better recapitulate human pathology. Mice with both 
Apc loss and the expression of an oncogenic KrasV12 allele display accelerated adenoma 
growth and stromal invasion in comparison to mice bearing mutated Apc alone (Janssen et 
al., 2006; Sansom et al., 2006). Similarly, the introduction of a loss of function mutation in 
the p53 tumour suppressor gene in mice with an Apc Min/+ background increased tumour 
burden and invasiveness (Halberg et al., 2000). 
 
Mouse models of intestinal cancer with Apc loss as the initiating mutation are often 
characterised by a rapid accumulation of adenoma burden predominantly within the small 
intestine. Animals in which both copies of Apc are lost simultaneously quickly become ill with 
euthanasia becoming necessary as soon as 5 days post Apc deletion (Sansom et al., 2004). In 
order to extend the latency of disease potentially allowing pathology to progress, a Cre-
expressing adenovirus was surgically administered to only the colons of mice homozygous 
for floxed Apc. In line with human colorectal cancer, this method restricted the development 
of adenomas to the distal colon, with a lower level of Cre-recombination reducing tumour 
multiplicity. A small proportion of these lesions demonstrated invasion of the muscularis 
with stromal reactions and were thus classified as carcinomas. The progression of adenoma 
to carcinoma was further enhanced by the addition of an activated Kras allele with around 
20% of animals demonstrating liver metastases, thus describing the first report of a 
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metastatic Apc mouse model of colorectal cancer (Hung et al., 2010). Further evidence 
supporting the role of Kras mutations in driving and maintaining colorectal cancer invasion 
and metastases comes from a similar model described in 2017 in which mice were 
administered with a syringe-delivered colonic tamoxifen enema in order to restrict Cre-
recombination to the colon (Boutin et al., 2017). CreERT2 expression was controlled by the 
intestine specific Villin promoter, and the excision of floxed Apc and p53 genes achieved 
upon induction with tamoxifen. These iKAP mice also harbour an inducible tet-O-LSL-KrasG12D 
allele, which upon the administration of doxycycline facilitates the activation of the most 
common glycine (G) to aspartic acid (D) substitution at codon 12 of the Kras gene. When 
compared to mice with only Apc and p53 deactivation (iAP), iKAP mice demonstrated an 
increased incidence of invasion and metastases. No metastases were observed in iAP mice 
whereas 25% of iKAP mice progressed through a complete adenoma-adenocarcinoma-
metastases sequence. Further support for the role of activating Kras mutations in colorectal 
cancer invasion and metastasis was evidenced upon the histological analysis of tumours. GFP 
tagged Krasmut were identified via anti-GFP antibody labelling with activation status verified 
with the use of an anti-pERK antibody; pERK signalling being a downstream consequence of 
Kras activation. As is the case in human CRC, a heterogeneous population of Kras clones 
were observed within the same tumour. Interestingly, within these heterogeneous lesions, 
GFP/pERK positive (Krasmut) clones were localised to the invasive front of the tumour with 
GFP/pERK negative clones comprising the tumour bulk. The overwhelming presence of 
GFP/pERK positive cells within tumour metastases strongly suggests the selection of Krasmut 
clones, highlighting the role of oncogenic Kras in CRC progression.  
 
Modelling the serrated pathway of colorectal carcinogenesis, Carragher et al. describe a an 
intestine specific Braf V600E mutation in driving the development of hyperplastic intestinal 
crypts with a serrated epithelium via activation of the MEK/ERK cascade (Carragher et al., 
2010). However, this mutation alone was not sufficient to maintain the hyperproliferative 
phenotype and oncogene induced crypt senescence was observed at later time points. High 
levels of expression of the senescence marker p16Ink4A corroborated this observation, with 
subsequent inactivation of p16Ink4A allowing tumour progression. This senescence 
inactivation and tumour progression was found to be associated with the de novo 
methylation of multiple CpG islands within p16Ink4A exon 1, a finding that was corroborated 
at a later date by another Braf V600E induced mouse model of intestinal tumorigenesis (Rad et 
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al., 2013). The inactivation of p16 or expression of a gain of function mutant p53 in these 
mice permitted the development of metastases in 25% of animals. 
 
Commonly found in CRCs with high rates of microsatellite instability are mutations in the 
TGFBR2 gene which encodes a receptor for the cytokine, transforming growth factor β (TGF-
β). TGF-β has an inhibitory effect on epithelial cell growth and thus loss of this inhibition is 
associated with tumour development (Wu et al., 1992). Loss of TGF-β signalling via intestine 
specific deletion of the Tgfbr2 gene in mice is not sufficient for tumorigenesis. However, the 
loss of Pten, a negative regulator of the PI3K/Akt pro-survival pathway which is hyperactive 
in 40% of CRCs, results in the development of adenomas progressing to carcinomas with an 
8% incidence of metastases  (Parsons et al., 2005; Yu et al., 2014). Similarly, lung and 
regional lymph node metastases are observed in mice with an activating Kras mutation in 
addition to Tgfbr2 loss. This cooperation facilitates the development of metastases in 15% of 
these animals, notably without the involvement of Apc (Trobridge et al., 2009). 
 
1.8.5. Organoid models of intestinal cancer 
 
Genetically engineered mouse models (GEMMs) have undoubtedly been fundamental in the 
understanding of the pathophysiology of many types of cancer. The discovery of novel 
cancer genes and the elucidation of signalling pathways involved in tumorigenesis are to 
name but two areas in which substantial knowledge has been gleaned from the use of 
animal models. Despite their obvious merit, it has been argued that animal models of cancer 
do not faithfully recapitulate human disease with species-specific differences influencing de 
novo tumour development and responses to therapeutics. The generation and 
establishment of GEMM colonies is also time consuming and can be costly due to animal 
housing expenses over lengthy study periods. In order to maintain the pathophysiological 
features of human malignancies, models utilising human tissue have been developed. 
Patient-derived primary tumour samples provide the material from which 2D cancer cell 
lines are expanded. Although they are relatively quick to set up and easier to maintain than 
animal models, not all clones expand efficiently and those that do may have acquired 
multiple genetic changes rendering them significantly distinct from the original tumour from 
which they were derived. Despite the first long-term culture of normal human cells and their 
formation into 3D tissue structures being described in 1975 (Rheinwald & Green, 1975), it 
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has not been until the last decade that the use of “organoids” in cancer biology research has 
become well-established. Defined as 3D tissue structures that mimic the cellular lineage and 
spatial organisation of the organ system from which they are derived, organoids are initiated 
from either pluripotent embryonic stem cells, induced pluripotent stem cells or organ 
specific adult stem cells (Clevers, 2016). With regard to intestinal culture and generation of 
intestinal organoids, Evans et al. succeeded in isolating crypt and villus units from rat small 
intestine, maintaining their structural integrity and propagating the cultures for up to 1 
month (Evans et al., 1992). They describe the proliferation of intestinal epithelial cells in vitro 
as being critically dependent upon this structural integrity and the provision of factors by 
stromal cells which are otherwise absent in 2D culture systems; a significant limitation of 
such systems. With the later identification of Lgr5+ stem cells as the crypt base columnar 
(CBC) stem cells from which all intestinal epithelial cell types originate (Barker et al., 2007) 
and the elucidation of the growth factors which tightly control their self-renewing capacity, 
more robust organoid culture techniques have been developed. Embedded within a laminin-
rich, crypt base mimicking 3D gel matrix, single Lgr5+ stem cells were provided with essential 
components of the stem cell niche. Polarised small intestinal crypt-villus units developed, 
self-renewed and under the correct conditions could be maintained indefinitely, notably 
without the requirement for a supportive stromal cell network (Sato et al., 2009).  
 
The major orchestrator of stem cell self-renewal and proliferation is the Wnt signalling 
pathway. Briefly, extracellular Wnt binds to the cell surface receptors, Frizzled (Fz) and 
Lrp5/6 which results in an accumulation of cytoplasmic β- catenin. Translocation of β- 
catenin to the nucleus and its subsequent interaction with TCF/LEF transcription factors 
facilitates the activation of target genes such as c-myc and cyclin D1, initiating proliferation. 
Indeed, mice lacking the Tcf4 transcription factor do not maintain proliferative crypt-villus 
units; their epithelium consists of differentiated, non-dividing cells (Korinek et al., 1998). R-
spondin1 is a Wnt agonist which acts via the Lgr5 receptor (Kim et al., 2005) and is thus an 
essential component of the crypt culture media. The addition of Wnt3a, another Wnt 
agonist, indefinitely extends the growth period of normal colon crypt cultures, overcoming 
the inherent low level of Wnt produced in the colon in comparison to the small intestine 
(Sato et al., 2011a). Further essential components of the culture media include the mitogenic 
epidermal growth factor (EGF) and Noggin, an inhibitor of the BMP pathway. BMP signalling 
represents the second major system crucial to the control of self-renewal and proliferation 
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of stem cells in the intestinal crypt, acting as an inhibitor of these processes by supressing 
Wnt signalling (He et al., 2004). Fine tuning of the media is required under certain 
circumstances such as in the case of single cell starting material as opposed to whole 
intestinal crypts. Anchorage-dependant single cells which have been dissociated from the 
extracellular matrix (ECM) undergo anoikis, a form of cell death initiated by the removal of 
the supportive signals their ECM anchorage provides. When added to the media, the Rho 
kinase inhibitor Y-27632 inhibits this process enabling cellular survival (Watanabe et al., 
2007).  
 
As APC loss is concomitant with constitutive Wnt activation, culture of APC deficient 
adenomas or adenocarcinomas does not require R-spondin1. Similarly, Sato and colleagues 
found the addition of Noggin and EGF to the media to be non-essential to the long-term 
propagation of mouse Apc deficient adenoma organoids nor human adenocarcinoma 
organoids. Recent advances in genetic engineering techniques such as clustered regularly 
interspaced short palindromic repeat (CRISPR)-Cas9 technologies are easily applied to 
organoid cultures, and as such increase the capacity for genome manipulation, further 
validating cancer organoids as invaluable research tools (Cho et al., 2013; Cong et al., 2013; 
Jinek et al., 2012; Jinek et al., 2013; Mali et al., 2013). The system has been used to introduce 
key colorectal cancer mutations into normal human intestinal organoids, thus modelling the 
sequential occurrence of these genetic events in vitro (Drost et al., 2015; Matano et al., 
2015). Applying knowledge gained in the laboratory back to patients within the clinic is the 
unanimous end goal of biomedical research. With an expanding range of treatment options 
for cancer patients alongside the extremely heterogeneous nature of the disease, it is often 
difficult to predict which patients will respond to which therapies, if at all, with many 
undergoing arduous rounds of chemotherapy and only experiencing side effects. The use of 
patient derived colorectal cancer organoids successfully predicted patient response to 
irinotecan-based therapies in over 80% of patients included in a recent study (Ooft et al., 
2019). Cancer organoids can be maintained long-term, retaining the genotypic and 
phenotypic features of the tumour from which they are derived, with this recent work 
supporting their role in a translational as well as basic research setting. While the 
advantages of organoid models in terms of reproducibility, ease of genetic manipulation, 
relative cost and experimental duration are evident, there are disadvantages associated with 
their use. Although organoids provide a superior representation of tissue structure and 
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physiology in comparison to 2D cell lines, the complexity of an organoid system is inferior to 
alternative models. In the cancer setting, the interaction of malignant cells with the tumour 
microenvironment (TME) is critical to tumour survival, however this interaction cannot be 
recapitulated with an organoid model. Patient-derived explant (PDE) cultures provide a 
model by which the removal and subsequent culture of a fresh tumour resection retains the 
original stromal architecture in addition to that of the tumour. Given the preservation of 
intra-tumour heterogeneity in addition to the microenvironment, patient derived explant 
models offer a valuable platform from which patient-specific therapeutic responses can be 
evaluated (Brijwani et al., 2017; Majumder et al., 2015). Alternatively, patient derived 
organoids may be co-cultured with patient derived TME cells such as immune cells or cancer 
associated fibroblasts in order to better model cellular interactions and thus improve 
biological relevance (reviewed in Fiorini et al., 2020). 
 
1.8.6. Mitochondria and malignancy 
 
Almost 100 years ago, Otto Warburg postulated that tumour cells preferentially utilise 
aerobic glycolysis as their primary means of energy production. In comparison to non-
malignant tissues, the uptake and utilisation of glucose by tumours was described as 
considerably elevated (Warburg, 1956). This characteristic, which is observed despite the 
availability of sufficient oxygen, is still utilised today in aiding tumour diagnosis and 
treatment monitoring as the uptake of radioactively labelled glucose can subsequently be 
imaged with positron emission tomography (PET) (reviewed in Almuhaideb et al., 2011). In 
terms of ATP production, glycolysis represents a much less efficient system yielding two 
molecules of ATP per molecule of glucose in comparison to the 36 generated via 
mitochondrial oxidative phosphorylation. Although in part compensated for by the increased 
expression of glucose transporters and concomitant increase in uptake of glucose, a 
predominantly glycolytic metabolism bestows tumour cells with a greater abundance of 
glycolytic intermediates available for diversion into biosynthetic pathways such as the 
branching of glucose-6-phosphate into the pentose phosphate pathway, key enzymes of 
which are commonly overexpressed in cancer (Wang et al., 2011; Xu et al., 2009). This 
pathway generates ribose sugars required for nucleic acid synthesis and also NADPH which 
supports fatty acid synthesis and antioxidant defence (reviewed in Patra & Hay, 2014). 
Similarly, the diversion of fructose-6-phosphate into the hexosamine pathway has been 
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shown to provide substrates required for glycosylation of proteins contributing to increased 
proliferation and progression of colorectal cancer (Vasconcelos-dos-Santos et al., 2017). The 
primary growth and proliferation concerns of the tumour are thus facilitated by a glycolytic 
shift, however it is becoming apparent that this shift is not an event that occurs passively but 
as a result of active reprogramming driven by the tumour itself (reviewed in Hanahan & 
Weinberg, 2011). Growing evidence suggests that the main function of oncogenes and 
tumour suppressors is to regulate metabolism, having evolved primarily for this purpose. 
Members of the MYC family of transcription factors are commonly deregulated, 
overexpressed and oncogenic in many human cancers. MYC has been shown to promote 
tumour anabolism via an upregulation of the glucose transporter GLUT1 and increasing the 
expression of glycolytic enzymes such as glyceraldehyde-3- phosphate dehydrogenase 
(GAPDH) and phosphofructokinase (PFK) (Osthus et al., 2000). Conversely, the tumour 
suppressor p53 can inhibit glycolysis via the downregulation of GLUT1/4 (Schwartzenberg-
Bar-Yoseph et al., 2004) and can regulate the balance between oxidative and glycolytic 
metabolism (Matoba et al., 2006). Additionally, the abundance of mutant copies of 
activating Kras has been shown to correlate with enhanced glycolysis, increased glucose-
derived TCA metabolites and glutathione production facilitating detoxification in mouse non-
small cell lung cancer (NSCLC) (Kerr et al., 2016). While glycolysis remains one of the most 
frequently altered metabolic pathways amongst multiple forms of cancer (Gaude & Frezza, 
2016; Hu et al., 2013), this represents just one of the numerous means by which metabolism 
is altered in cancer.  
 
Contrary to Warburg’s hypothesis that the aerobic glycolysis observed in tumour metabolism 
occurs on account of defective mitochondria, many tumours retain oxidative 
phosphorylative capacity and in fact tumorigenicity is inhibited in tumour cells depleted of 
mtDNA (Cavalli et al., 1997; Tan et al., 2015). Resident within the mitochondrial matrix, the 
enzymes of the TCA cycle generate ATP and reducing equivalents which provide electrons to 
the electron transport chain. This classical mechanism is observed in non-proliferating 
tissues, however in proliferating cells, precursors derived from TCA intermediates are 
frequently utilised as precursors from which lipids, nucleic acids and proteins are 
synthesised. Furthermore, metabolites themselves have additional downstream functions 
that further modulate tumour behaviour, specifically due to their function in epigenetic 
modification (reviewed in Reid et al., 2017). The initial finding that gain of function 
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mutations in genes encoding both the cytoplasmic and mitochondrial isoforms of isocitrate 
dehydrogenase (IDH1 and IDH2 respectively) result in a neomorphic enzyme activity led to 
an increased understanding of this phenomenon (Dang et al., 2009; Ward et al., 2010). The 
usual catalytic interconversion of isocitrate and α −ketoglutarate (α-KG) by IDH1 and IDH2 is 
replaced by the reduction of α-KG generating the (R)-2-hydroxyglutarate (R-2HG) 
oncometabolite, which subsequently causes histone and DNA hypermethylation via its 
inhibition of α-KG-dependant demethylase enzymes (Figueroa et al., 2010; Lu et al., 2012). 
Similarly, loss of function mutations in additional TCA cycle enzymes fumarate hydratase 
(FH) and succinate dehydrogenase (SDH) can have pro-tumorigenic consequences for the cell 
due to an accumulation of their substrates fumarate and succinate. Also described as 
oncometabolites, the accumulation of fumarate and succinate, like R-2HG, can give rise to 
widespread histone and DNA hypermethylation due to the inhibition of α-KG-dependant 
demethylases (Jiang et al., 2015; Xiao et al., 2012). Resulting from a loss of function mutation 
in FH, the accumulation of fumarate has also been shown to promote epithelial-to-
mesenchymal-transition (EMT) by inhibiting the demethylation of an anti-metastatic miRNA 
cluster (Sciacovelli et al., 2016), while the loss of either FH or SDH and accompanying 
accumulation of substrates can further promote tumour survival via hypoxia-inducible factor 
1 (HIF-1) stabilisation mediated angiogenesis and glycolytic adaptation (Isaacs et al., 2005; 
Selak et al., 2005).  
 
Since the early observation that tumour cells generate greater quantities of hydrogen 
peroxide than normal cells, mitochondrial reactive oxygen species have shared a relationship 
with malignancy (Szatrowski & Nathan, 1991). Early works demonstrated that 
overexpression of the mitochondrial superoxide dismutase supressed neoplastic 
transformation (St. Clair et al., 1992) while more recently the knockdown of genes involved 
in the regulation of autophagy predisposes cells to increased ROS, secondary mutations and 
transformation (Park et al., 2016). Further to their mutagenic potential, ROS are important 
mediators of both pro- and anti-tumorigenic signalling. Hydrogen peroxide in particular has 
been shown to oxidise and inactivate the PTEN tumour suppressor thus removing negative 
regulation of the PI3K/Akt/mTOR survival pathway (Lee et al., 2002), while KRAS induced 
mitochondrial ROS generation activates EGFR signalling via NF-κB transcription factor 
mediated expression of epidermal growth factor receptor and its ligands in pancreatic acinar 
cells (Liou et al., 2016). The progression of malignancy to metastatic disease has also been 
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demonstrated to involve regulatory input from reactive oxygen species. Tyrosine kinases 
central to the cell adhesion response are reportedly activated by ROS thus promoting 
anchorage independent growth of transformed cells (Giannoni et al., 2005). Furthermore, an 
increased ROS production elicited by mutations in the mitochondrial oxidative 
phosphorylation complex I gene ND6 was shown to promote the metastatic potential of 
murine tumour cells with ROS scavenger pre-treatment reducing the effect (Ishikawa et al., 
2008). Concomitant with matrix detachment however is a further increase in ROS production 
which can subsequently inhibit distant metastases (Piskounova et al., 2015; Schafer et al., 
2009). Excessive oxidative stress can promote apoptotic cell death via activation of the JNK 
and p38 signalling pathways (Ichijo et al., 1997), therefore in order to migrate and survive, 
tumour cells must employ antioxidant machinery to counteract such stresses. The balance 
between pro- and anti-tumorigenic ROS signalling is evidently key to tumour survival and as 
such highlights the central role of mitochondria in the tumorigenic process. As mitochondria 
and compensatory metabolic reprogramming have been implicated in the development of 
tumour resistance to chemotherapeutic agents, successful treatment regimens are likely to 
consist of a combination first-line agents and metabolic modulators aimed at disabling 
metabolic plasticity and thus tumour survival (reviewed in Desbats et al., 2020). 
 
1.8.7. MtDNA mutations and malignancy 
 
Mutations of the mitochondrial genome have been reported in human cancers for decades. 
Initial reports documenting the presence of mtDNA deletions within human renal 
oncocytomas (Welter et al., 1989) were followed by studies documenting D-loop deletions 
within gastric adenocarcinomas (Burgart et al., 1995), ND1 deletions within renal cell 
carcinoma (RCC) (Horton et al., 1996) and extensive 4977 bp mtDNA deletions within breast 
cancer (Bianchi et al., 1995). With regard to point mutations, a number of studies 
subsequently reported the presence of clonally expanded somatic mtDNA point mutations in 
different tumour types. D-loop mutations were identified in colorectal and gastric tumours 
(Alonso et al., 1997) and mutations within the D-loop and protein coding genes (primarily 
ND4) were reported within bladder, head and neck, and lung malignancies (Fliss et al., 2000). 
Within ovarian carcinomas, mutations within the 16S and 12S rRNA genes, the D-loop and 
the cytochrome b gene were most frequent (Liu et al., 2001). In 1998, the seminal work by 
Polyak et al. was the first to report the presence of somatic mtDNA mutations at 
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homoplasmic levels in solid human tumours (Polyak et al., 1998). The comparison of the 
mtDNA sequence of ten human colorectal cancer cell lines with that of the patient-matched 
normal colon identified homoplasmic mtDNA point mutations within seven of the lines 
analysed. The majority of mutations were purine (G>A) transitions; however, pyrimidine 
transitions (T>C) were also identified with affected genes including those encoding the 16S 
and 12S rRNAs and protein coding genes (ND1, ND4L, ND5, cyt b, COXI, COXII, COXIII). These 
findings were corroborated by the documentation of similar mutational spectra within 
subsequent studies of colorectal cancers (Ericson et al., 2012; He et al., 2010; Larman et al., 
2012). Consistent with the mutational spectrum of oxidative damage (Beckman & Ames, 
1997; Cadet et al., 1997), the mtDNA mutational profile observed in colorectal cancers is also 
very similar to that observed within normal ageing colonic crypts (Greaves et al., 2010; 
Greaves et al., 2012; Taylor et al., 2003). Furthermore, the detection of pathogenic 
truncating mtDNA mutations at high levels of heteroplasmy and homoplasmy within 
colorectal cancers (Yuan et al., 2020) strongly implies that age-related somatic mtDNA 
mutations are enriched as normal crypts transform into malignant lesions. 
 
Whether these mutations are passive bystanders or if they functionally contribute to the 
progression of malignancy remains unascertained. Accordingly, the aim of this thesis is to 
investigate the effect of age-related mtDNA mutations on intestinal tumour formation and 
progression.  
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1.9. Aims of study 
 
With the knowledge that the accumulation of mtDNA mutations in replicating tissues 
contributes to a decline in the functionality of ageing tissue, it has been hypothesised that 
mitochondrial function may be involved in neoplastic progression; a pathology also strongly 
associated with increasing age. Given that the spectrum of mtDNA mutations within 
colorectal carcinoma are similar to those observed in human ageing (Smith et al., 2020), it 
remains to be established whether these defects occur passively or if they actively 
contribute to tumour development. The overriding aim of this thesis is to investigate the 
effect age-related mtDNA mutations on intestinal tumour formation and progression with 
the use of a genetically engineered mouse model of disease. This is to be achieved by 
meeting the following objectives. 
1. To investigate the effect of age-related mtDNA mutations on intestinal tumour 
development through the generation and characterisation of a novel mouse model of 
intestinal cancer.  
2. To describe mitochondrial OXPHOS function in the adenomas detected in the mouse 
model generated in objective 1.  
3. To investigate the effect of mtDNA mutations and mitochondrial OXPHOS deficiency 
on the rates of cell proliferation and apoptosis in intestinal adenomas in the mouse.  
4. To determine the metabolic pathways upregulated in response to age-related 
mitochondrial OXPHOS defects in both the mouse model and normal aged human 
crypts.  
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2.1.1. Equipment and software 
 
2100 Antigen Retriever (Aptum Biologics Ltd) 
Aperio CS2 digital slide scanner (Leica Biosystems) 
Aperio ImageScope digital pathology slide viewing software (Leica Biosystems) 
AxioCam MRm monochrome digital camera (Zeiss) 
Electrothermal MH8517 paraffin section flotation bath (Cole-Parmer) 
GraphPad Prism 8.4.3 statistical software (GraphPad) 
Identichip radio frequency identification chips (Biotherm) 
ImageJ (National Institutes of Health) 
Leica MZ75 stereomicroscope (Leica Microsystems) 
MBF Biosciences CX9000 colour digital camera 
Microm HM 325 rotary microtome (Thermo Fisher Scientific) 
Nikon A1R point scanning confocal microscope (Nikon) 
NIS-Elements imaging software (Nikon) 
Olympus BX-51 Stereology microscope 
Zeiss AxioImager M1 Epifluorescent and brightfield microscope (Zeiss) 
Zeiss Celldiscoverer 7 fluorescent microscope (Zeiss) 
Zeiss LSM 800 confocal laser scanning microscope (Zeiss) 
Zen 2.5 Blue microscope software (Zeiss) 
Zeiss Zen Lite microscope software (Zeiss) 
 






10% Neutral buffered formalin (HT501128, Sigma Aldrich) 
Alcoholic eosin Y (RBC-0201-00A, CellPath) 
CldU (5-chloro-2’-deoxyuridine, C6891, Sigma Aldrich) 
DPX (SEA-1300-00A, CellPath) 
Ethylenediamine tetra-acetic acid, (EDTA) Tetrasodium Salt, Dihydrate SDS (15700, 
Affymetrix) 
Goat serum (G9023, Sigma Aldrich) 
Histoclear clearing agent (HS-200, National Diagnostics) 
IsoFlo (Isofluorane, 50019100, Zoetis) 
IdU (5-iodo-2’-deoxyuridine, I7125-5G, Sigma Aldrich) 
Mayer’s haematoxylin (HS315, TCS Biosciences) 
Oxoid PBS Tablets (BR0014G, Thermo Scientific) 
Prolong Gold antifade mountant (P36930, Invitrogen) 
Sunflower seed oil from Helianthus annuus (S5007, Sigma Aldrich)  
Tamoxifen (T5648, Sigma Aldrich) 
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2.1.2.2. Antibodies 
 
Affinity isolated anti-PHGDH antibody produced in rabbit (HPA021241, Sigma Aldrich) 
Biotinylated goat polyclonal anti-GFP (ab6658, Abcam) 
Donkey anti-mouse IgG highly cross-adsorbed secondary antibody, Alexa Fluor 488 
conjugated (A21202, Invitrogen) 
Donkey anti-rabbit preadsorbed secondary antibody, Alexa Fluor 750 conjugated (ab175728, 
Abcam) 
Donkey anti-rat AffiniPure Cy™5 conjugated secondary antibody (712-175-153, Jackson 
ImmunoResearch) 
EnVision+ System- HRP labelled polymer anti-rabbit detection kit (Dako, K4003)  
Goat anti-mouse IgG1 cross-adsorbed secondary antibody, Alexa Fluor 647 conjugated 
(A21240, Invitrogen) 
Goat anti-mouse IgG2a cross-adsorbed secondary antibody, Alexa Fluor 546 conjugated 
(A21133, Invitrogen) 
Goat anti-mouse IgG2b cross-adsorbed secondary antibody, Alexa Fluor 546 conjugated 
(A21143, Invitrogen) 
Goat anti-mouse IgG1 cross-adsorbed secondary antibody, biotin-XX (A10519, Invitrogen) 
Goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 488 conjugated 
(A11008, Invitrogen) 
Hoechst 33342, trihydrochloride, trihydrate (H3570, Invitrogen) 
Mouse monoclonal anti-ATPB IgG1 (ab14730, Abcam) 
Mouse monoclonal anti-IdU (Abcam, ab181664) 
Mouse monoclonal anti-MTCO1 IgG2a (ab14705, Abcam) 
Mouse monoclonal anti-NDUFB8 IgG1 (ab110242, Abcam) 
Mouse monoclonal anti-UQCRFS1 IgG2b (ab14746, Abcam) 
Rabbit polyclonal anti-β-catenin primary antibody (ab6302, Abcam) 
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Rabbit polyclonal anti-MTHFD2 primary antibody (ab151447, Abcam) 
Rabbit polyclonal anti-active caspase 3 antibody (AB3623, Merck Millipore) 
Rat monoclonal anti-BrdU (NB500-169, Novus Biologicals)  
Recombinant rabbit anti-PSAT1 polyclonal primary antibody (NBP1-32920, Novus Biologicals) 
Recombinant rabbit anti-TOMM20 monoclonal primary antibody (ab186734, Abcam) 
Streptavidin Alexa Fluor 546 conjugate (S11225, Invitrogen) 
Streptavidin Alexa Fluor 647 conjugate (S32357, Invitrogen) 
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2.2. Methods 
 
2.2.1. Human colorectal carcinoma and mucosal samples 
 
Samples used were obtained from 12 patients undergone either surgical colorectal tumour 
resection or polyp removal.  Informed written consent was obtained prior to surgery and 
samples were coded to maintain patient confidentiality. This project was approved by the 
Joint Ethics Committee of Newcastle and North Tyneside Health Authority (2001/188) and 
the National Research Ethics Committee London-Stanmore (11/LO/1613). Clinical details 




Age Sex Specimen 
Region 
Tumour Pathology Grade Staging 
31 
 







73 M Colon - - - 
48 
 












64 M Right colon Tubular adenoma with mild 
dysplasia 
- - 


















64 M Rectum - - - 
67 60 F Rectum Adenocarcinoma - - 
Dukes’ B 









Table 2-1. Clinical details of human samples included in this study. The age of patients at the time of surgery ranged from 58 
to 85 years. Eight patients were male, and four were female. Original tumour locations ranged from the caecum and right 
colon to the rectum. Tumour pathology was moderately differentiated in 7 cases, well differentiated in one case and 
undisclosed in three. The sample from patient 57 was categorised as a tubular adenoma with mild dysplasia. Pathology and 
grading information for patients 37, 65, and 67 was limited. Staging ranged from Dukes’ A – C where data was available. 
Dukes’ A = invasion of the basement membrane without breaching of the colon wall; B = tumour has breached the colon 
wall without evidence of lymph node metastasis; C = evidence of lymph node metastasis. 
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2.2.2. PolγAmut/mut /Lgr5-EGFP-Ires-CreERT2/ Apcflox/flox experimental mice 
 
Heterozygous mitochondrial mutator mice (PolγA+/mut) were kindly donated by Tomas Prolla, 
Department of Genetics and Medical Genetics, University of Wisconsin, Madison, USA. Lgr5-
EGFP-Ires-CreERT2 and Apcflox/flox mice were kindly donated by Karen Vousden, Beatson 
Institute for Cancer Research, Glasgow, UK. Detailed breeding schedules are presented in 
3.3.1. with the final cross only presented here in Figure 2-1. A maximum of six mice were 
housed per individually ventilated cage (IVC) at the Comparative Biology Centre at Newcastle 
University. Mice were fed an RM3 expanded chow provided by Special Diet Services (SDS) 





Figure 2-1. Breeding schedule depicting the mating of PolγA+/mut/Apcflox/flox males with Lgr5+/-/Apcflox/flox females. F1 
generation PolγA+/+ /Lgr5+/-/Apcflox/flox animals highlighted accordingly were used as experimental control animals. Crossing 
of F1 generation animals highlighted in blue boxes permitted the generation of PolγAmut/mut/ Lgr5+/-/Apcflox/flox experimental 
animals. PolγA+/mut /Lgr5+/-/Apcflox/flox experimental animals were obtained at the F1 generation. 
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2.2.3. Genotyping 
 
2.2.3.1. DNA isolation from mouse ear notches 
 
At three weeks of age mice were weaned and ear notches were samples. 47.5μL of lysis buffer (1M 
Tris-HCl, 0.5 M EDTA, 10% SDS in dH2O) was added to each ear notch followed by 2.5μL of proteinase 
K (20mg/mL) and vortexed. Ear notches were incubated on the orbital shaker overnight at 56°C at 
1200 rpm. Notches were diluted 1:10 in distilled water. 
 
2.2.3.2. Polymerase chain reaction (PCR) 
 
The 1:10 diluted ear notch DNA lysates were amplified in 25μL PCR reaction volumes comprising 
23μL master mix 5U/μL TakaRa ExTaqTM, 10X Ex Taq buffer (20mM Mg2+), 2.5 mM dNTPs, 10μM 
forward primer, 10μM reverse primer in distilled water plus 2μL tissue lysate. Primer sequences and 
PCR reaction parameters used are outlined in Table 2-2. 
 




Forward: GCCTCGCTTTCTCCGTGACT  
Reverse: GGATGTGGCCCAGGCTGTAACTCA  
 
Initial denaturation at 94°C for 1 min 
followed by 35 cycles of  
• denaturation at 94 °C for 20s,  
• primer annealing at 64°C for 20s,  
• extension at 68°C for 45s. 





Reverse: GCCAGATTACGTATATCCTGGCAGC  
 
Initial denaturation at 94°C for 1 min 
followed by 35 cycles of  
• denaturation at 94°C for 20s,  
• primer annealing at 62°C for 20s,  
• extension at 68°C for 45s. 
Final extension at 72°C for 5 mins. 
APC P3 Forward 
APC P4 Reverse  
 
Forward: GTTCTGTATCATGGAAAGATAGGTGGTC 
Reverse: CACTCAAAACGCTTTTGAGGGTTG  
 
Initial denaturation at 94°C for 1 min 
followed by 35 cycles of  
• denaturation at 94°C for 20s,  
• primer annealing at 60°C for 20s,  
• extension at 68°C for 45s. 
Final extension at 72°C for 5 mins.  
Table 2-2. Primer sequences and cycling parameters for PCR.  
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2.2.3.3. Agarose gel electrophoresis 
 
For each PCR product, 1μL was mixed and loaded with 5μL loading dye comprising 0.25% (w/v) 
bromophenol blue, 30% (w/v) glycerol in distilled water onto a 1.5% agarose gel. PCR Ranger 100bp 
DNA ladder (Norgen) was also loaded into the gel which contained SYBR® Safe DNA Gel stain 
(Invitrogen) for visualisation of DNA. Gel electrophoresis was run at 120V for 45 minutes in 1X Tris 
acetate-EDTA buffer (Sigma). PCR products were visualised on a BIO-RAD ChemiDoc MP Imaging 
System. Animal genotypes were determined by the size of PCR products as presented in Table 2-3. 
For Lgr5 genotyping, primer sequences target the Cre component where present. Accordingly, a 
298bp PCR product indicates Cre presence and an Lgr5-CreERT2 genotype, whereas no band 
indicates Cre absence and a wild-type Lgr5 genotype. Ear notch sampling, PCR and agarose gel 
electrophoresis was performed by Carla Bradshaw, Senior Animal Technician. 
 










Table 2-3. PCR product sizes for mouse genotype determination following PCR amplification and gel electrophoresis. 
 
2.2.4. RFID chip insertion 
 
All experimental animals were fitted with radio frequency identification chips (RFID) 
(Identichip, Biotherm) for the purposes of identification and the measurement of body 
temperature. Chip implants were inserted under the skin on the flank of each mouse 
between the front and back legs. Mice were under isoflurane anaesthesia (IsoFlo, Zoetis) 
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throughout the procedure which was performed by Carla Bradshaw at the Comparative 
Biology Centre, Newcastle University. Chips were implanted one month prior to Apc deletion 
through tamoxifen administration. 
  
2.2.5. Induction regime 
 
The fusion of a mutated oestrogen receptor ligand binding domain (LBD) with a Cre 
recombinase enzyme results in temporal control of this enzyme upon the addition of 
synthetic but not endogenous oestrogens (Feil et al., 1996; Feil et al., 1997; Zhang et al., 
1996). In mice, the sensitivity of the CreERT2 fusion protein to the synthetic oestrogen 4-
hydroxy-tamoxifen is ten-fold higher than that of its predecessor CreERT and is thus widely 
used (Indra et al., 1999). When expressed, CreERT2 is sequestered in the cytosol by heat 
shock proteins until the administration of 4-hydroxy-tamoxifen, or tamoxifen, which is 
converted to 4-hydroxy-tamoxifen in the liver. The synthetic oestrogen receptor antagonist 
permits translocation of CreERT2 to the nucleus where the recombination of the LoxP 
flanked gene of interest is catalysed by the recombinase.  
 
Tamoxifen (T5648, Sigma Aldrich) was administered via intraperitoneal injection to 
experimental animals over the course of four days at a concentration of 10mg/ml in 
sunflower oil. 300µl (3mg) was administered on day one, and 200µl (2mg) administered each 
subsequent day. Carla Bradshaw, Senior Animal Technician performed the procedures within 
the Comparative Biology Centre, Newcastle University. 
 
2.2.6. Clinical scoring of experimental mice 
 
All mice were monitored daily until the experimental endpoint or clinical signs dictated that 
they be humanely killed. Number of days post tamoxifen induction was recorded for each 
mouse for the purposes of survival curve generation. Table 2-4 describes the clinical signs 
that were monitored during the experimental period. Animals were culled when they had 
three moderate or one severe symptom. 
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Score 
 0 1 2 3 
Weight No weight loss/gain 5-15% weight loss 15-20% weight loss Over 20% weight loss 
Coat  Normal Slight lack of grooming Starey (piloerection)   
Skin tone Normal Tents, returns to normal in 1-2 
seconds 
Tents, persists   
Behaviour Normal Subdued but responsive. Animal 
shows normal behaviour 
patterns. Interacts with peers 
Subdued- animal shows 
subdued behaviour. Little peer 
interaction. May show 
aggression 
Animal unresponsive to extraneous 




Normal Transient hunched posture, 








None None Abdominal distension up to the 
size expected in late pregnancy 
Severe abdominal distension 
beyond that of late pregnancy 
affecting locomotor and/or 
breathing patterns 
Foot colour None Whitening of feet due to mild 
anaemia 
Whitening of feet due to 
moderate anaemia 
Feet are completely white due to 
severe anaemia 
Faeces None No diarrhoea or transient 
diarrhoea 
Intermittent or continuous 
diarrhoea (>72h). No 
dehydration 
Continuous diarrhoea (>72 h) with 
faecal soiling of perineum and/or 
dehydration 
 
Table 2-4. Clinical signs monitored during experimental periods and deviations away from normal. A score of zero represents a normal presentation of the clinical sign in question. A score of 1 
represents a mild presentation with scores of 2 and 3 denoting moderate and severe presentations respectively.  
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2.2.7. Necropsy 
 
Mice underwent a standard necropsy in which samples of skin, heart, lungs, spleen, liver, 
pancreas, stomach, and kidneys were taken and fixed in 10% neutral buffered formalin 
(HT501128, Sigma Aldrich). The length of the intestine was flushed with formalin, opened 
along its length and pinned out flat for fixation. The small intestine was divided into three 
segments of equal length, SI1 being the most proximal and SI3 the most distal. The colon and 
caecum were also flushed, opened and pinned flat for fixation. After 24 hours fixation, the 
formalin was disposed of and any visible adenomas counted using a dissecting microscope. 
Only adenomas greater than 1mm x 1mm were included in the count. Following macroscopic 
analysis, all segments of intestine were rolled up distal end first, processed and paraffin wax 
embedded. This process is shown in Figure 2-2. 
 
 
Figure 2-2. Mouse intestine dissection at necropsy. Intestinal segments are flushed with 10% neutral buffered formalin 
before being opened out longitudinally and pinned flat on a paraffin wax filled Petri dish. Intestines are fixed in 10% NBF for 
24 hours before rolling up distal to proximal and processing for paraffin wax embedding.  
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2.2.8. Haematoxylin and eosin staining 
 
After trimming blocks to full face, 4µm sections were cut using a Microm HM325 rotary 
microtome (Thermo Scientific Microm). Immediately prior to staining, sections were 
incubated for 1 hour at 60°C. They were deparaffinised in two changes of Histoclear (HS-200, 
National Diagnostics) and rehydrated through graded ethanol (100% EtOH, 95% EtOH, and 
70% EtOH) to distilled water. Slides were washed well in water and stained with Mayer’s 
haematoxylin (TCS Biosciences) for 10 minutes. Following a wash in water, nuclei were blued 
using Scott’s tap water for 30 seconds. Following a wash in water sections were stained in 
alcoholic eosin (CellPath). Slides were washed in water, dehydrated in a graded ethanol 
series, cleared in two changes of Histoclear and mounted in DPX (CellPath). 
 
2.2.9. Immunohistochemical methods 
 
2.2.9.1. Section preparation 
 
After trimming blocks to full face, 4µm sections were cut using a Microm HM325 rotary 
microtome (Thermo Scientific Microm). Immediately prior to staining, sections were 
incubated for 1 hour at 60°C. They were deparaffinised in two changes of Histoclear (HS-200, 
National Diagnostics) and rehydrated through graded ethanol (100% EtOH, 95% EtOH, and 
70% EtOH) to distilled water. Antigenic sites were exposed in a heated, pressurised antigen 
retrieval unit (2100 Antigen Retriever, Aptum Biologics Ltd.) with either 1mM EDTA pH8.0 
(beta catenin IHC) or 1mM citrate buffer pH6.0 (cleaved caspase 3 and serine synthesis 
pathway enzyme IHC) used as retrieval solution. Following the 20-minute warm up, 20-
minute cool down cycle, slides were rinsed in distilled water. The activity of any endogenous 
peroxidase enzymes was blocked using the peroxidase block solution included in the 
EnVision+ System- HRP labelled polymer anti-rabbit detection kit (Dako, K4003). Non-specific 
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2.2.9.2. Beta catenin immunohistochemistry 
 
Subsequent to the preparation steps outlined in 2.2.9.1., sections were incubated overnight 
in a 1:1000 dilution of rabbit anti-β-catenin (ab6302, Abcam) in 10% NGS at 4°C. Slides were 
washed for 3x5 minutes on a rocking platform in TBST prior to incubation in secondary 
antibody (polymer HRP-labelled anti-rabbit, Dako Envision) for 30 minutes at room 
temperature. Sections were again washed for 3x5 minutes in TBST. β-catenin bound 
peroxidase was then visualised with DAB following a 10-minute incubation in DAB 
chromogen-substrate solution at room temperature. Slides were washed well in water, 
counterstained with Mayer’s haematoxylin (TCS Biosciences) dehydrated in a graded ethanol 
series, cleared in two changes of Histoclear and mounted in DPX (CellPath). 
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2.2.9.3 Cleaved caspase 3 immunohistochemistry 
 
Sections were prepared as outlined in 2.2.9.1. A concentration of 1:10 of rabbit polyclonal 
anti-active (cleaved) caspase 3 was recommended by the manufacturer for 
immunohistochemical detection of the target protein. Optimisation of the antibody involved 
evaluating the staining intensities obtained with 1:10, 1:15, 1:20, 1:25, 1:30, 1:35 and 1:40 
dilutions of primary antibody in 10% NGS. An increased level of background staining was 
observed at the stronger concentrations which had reduced sufficiently at 1:35 therefore 
1:35 was selected as the most appropriate concentration. Blocked sections were thus 
incubated in rabbit polyclonal anti-active caspase 3 antibody (AB3623, Merck Millipore) at a 
1:35 dilution in 10% NGS overnight at 4°C. 
 
Slides were washed for 3x5 minutes on a rocking platform in TBST prior to incubation in 
secondary antibody (polymer HRP-labelled anti-rabbit, Dako Envision) for 30 minutes at 
room temperature. Sections were again washed for 3x5 minutes in TBST. Active caspase 3 
bound peroxidase was then visualised with DAB following a 10-minute incubation in DAB 
chromogen-substrate solution at room temperature. Slides were washed well in water, 
counterstained with Mayer’s haematoxylin (TCS Biosciences) dehydrated in a graded ethanol 
series, cleared in two changes of Histoclear and mounted in DPX (CellPath). 
 
2.2.9.4. Serine synthesis pathway enzyme immunohistochemistry 
 
Subsequent to the preliminary steps outlined in 2.2.9.1., sections were incubated overnight 
in either a 1:4000 dilution of anti-PHGDH (HPA021241, Sigma Aldrich), a 1:600 dilution of 
anti-PSAT1 (NBP1-32920, Novus Biologicals) or a 1:600 dilution of anti-MTHFD2 (ab151447, 
Abcam). All antibodies were diluted in 10% NGS and sections incubated overnight at 4°C. 
The EnVision+ System- HRP labelled polymer anti-rabbit detection kit (Dako) was used and 
bound antibody visualised with DAB. Sections were counterstained with Mayer’s 
haematoxylin (HS315, TCS Biosciences). Adenomas and regions of non-transformed mucosa 
were imaged using an Olympus BX-51 microscope and MBF Biosciences CX9000 colour 
digital camera. 
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2.2.10. Double thymidine analogue labelling 
 
The administration of thymidine analogues results in their incorporation into the DNA of 
replicating cells during S phase of the cell cycle. Subsequent labelling using 
immunohistochemical or immunofluorescent assays allows identification and quantification 
of the number of cells which have replicated from the time of administration to the time of 
death. The thymidine analogue cohort was established in which five PolγAmut/mut and five 
PolγA+/+ mice were aged to six months prior to administration of tamoxifen to induce Apc 
deletion as per the regime outlined in 2.2.5. At 15 days post Apc deletion, these animals 
underwent a series of intraperitoneal injections of the thymidine analogues CldU and IdU 
and were humanely killed at 16 days post Apc deletion. This time point was chosen from an 
animal welfare perspective. Mice had demonstrated signs of deteriorating health as early as 
20 days post Apc deletion and it was deemed inappropriate to subject the animals to further 
procedures beyond this point. IP injections of thymidine analogues were therefore 
scheduled to take place prior to the deterioration of health. CldU (5-chloro-2’-deoxyuridine, 
C6891, Sigma Aldrich) was made up at a concentration of 5mg/ml in PBS (Oxoid PBS Tablets, 
BR0014G, Thermo Scientific) pH 7.4 and filter sterilised. IdU (5-iodo-2’-deoxyuridine, I7125-
5G, Sigma Aldrich) was also prepared at a concentration of 5mg/ml in PBS, however it was 
necessary to heat the solution in a water bath at 55°C overnight to allow the IdU to fully 
dissolve. The pH was adjusted to pH7.4 at this point and the solution maintained at 55°C 
until filter sterilisation immediately prior to use. The necessary in vivo concentration of each 
analogue was 50mg/kg therefore 10µl of 5mg/ml solution was required per gram of mouse 
weight. Analogues were injected intraperitoneally by Carla Bradshaw according to the 
schedule shown in Table 2-5.  
 
 Day 15 post Apc deletion Day 16 post Apc deletion 
10am IP CldU 50mg/kg 
 
IP IdU 50mg/kg 
6pm 
 
IP CldU 50mg/kg - 
 
Table 2-5. Thymidine analogue injection schedule for experimental animals. Animals were humanely sacrificed four hours 
after the final IP administration of IdU, 16 days post Apc deletion. 
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All animals were humanely culled 4 hours after IP IdU and necropsy harvesting performed as 
outlined in 2.2.7. Injections were performed within the Comparative Biology Centre, 
Newcastle University by Carla Bradshaw, Senior Animal Technician.  
 
2.2.11. Immunofluorescent methods 
 
2.2.11.1. Section preparation 
 
Following tissue processing, paraffin wax embedding and trimming blocks to full face, 4µm 
sections were cut using a Microm HM325 rotary microtome (Thermo Scientific Microm). 
Immediately prior to staining, sections were incubated for 1 hour at 60°C. They were 
deparaffinised in two changes of Histoclear (HS-200, National Diagnostics) and rehydrated 
through graded ethanol (100% EtOH, 95% EtOH, and 70% EtOH) to distilled water. Antigenic 
sites were exposed in a heated, pressurised antigen retrieval unit (2100 Antigen Retriever, 
Aptum Biologics Ltd.) with either 1mM citrate buffer pH6.0 (for thymidine analogue and 
serine synthesis pathway enzyme IF) or 1mM EDTA pH8.0 (for mitochondrial OXPHOS IF) 
used as retrieval solution. Following the 20-minute warm up, 20-minute cool down cycle, 
slides were rinsed in distilled water. Non-specific binding sites were blocked in 10% normal 
goat serum (NGS) for 1 hour at room temperature. 
 
2.2.11.2. Thymidine analogue immunofluorescence 
 
Subsequent to the preparation steps outlined in 2.2.11.1., sections were incubated overnight 
in a primary antibody cocktail. The primary antibody cocktail was optimised to include 
mouse monoclonal anti-IdU (Abcam, ab181664) at a 1:100 dilution, rat monoclonal anti-
BrdU (NB500-169, Novus Biologicals) at a 1:100 dilution and biotinylated goat polyclonal 
anti-GFP (Abcam, ab6658) at a 1:100 dilution. All antibodies were diluted in 10% normal goat 
serum and sections incubated in primary cocktails overnight at 4°C.  
 
Slides were washed for 3x5 minutes on a rocking platform in TBST prior to incubation in 
fluorophore conjugated antibody cocktails. The secondary antibody cocktail was optimised 
to include donkey anti-mouse IgG highly cross-adsorbed secondary antibody, Alexa Fluor 488 
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conjugated (A21202, Invitrogen) at a dilution of 1:150, donkey anti-rat AffiniPure Cy™5 
conjugated secondary antibody (712-175-153, Jackson ImmunoResearch) at a dilution of 
1:150, streptavidin Alexa Fluor 546 conjugate (S11225, Invitrogen) at a 1:200 dilution and 
donkey anti-rabbit preadsorbed secondary antibody, Alexa Fluor 750 conjugated (ab175728, 
Abcam) at a dilution of 1:50. All fluorophore conjugated antibodies were diluted in 10% NGS 
and sections incubated in fluorophore cocktail for 2 hours at room temperature in the dark. 
Following 3x5 minutes on a rocking platform in TBST, sections were incubated in a 1:1200 
solution of Hoescht nucleic acid stain (H3570, Invitrogen) for 15 minutes at room 
temperature in the dark. Following a final 3x5 minute wash in TBST, slides were mounted in 
Prolong Gold antifade mountant (P36930, Invitrogen). 
 
2.2.11.3. Mitochondrial OXPHOS protein subunit immunofluorescence 
 
Following the preparation steps outlined in 2.2.11.1., sections were incubated overnight in 
primary antibody cocktail. Primary antibody cocktail for section 1 included mouse anti-
NDUFB8 IgG1 monoclonal primary antibody (ab110242, Abcam) at a 1:50 dilution, mouse 
anti-UQCRFS1 IgG2b monoclonal primary antibody (ab14746, Abcam) at a 1:100 dilution and 
recombinant rabbit anti-TOMM20 monoclonal primary antibody (ab186734, Abcam) at a 
1:100 dilution. Primary antibody cocktail for section 2 included mouse anti-MTCO1 IgG2a 
monoclonal primary antibody (ab14705, Abcam) at 1:50 dilution, mouse anti-ATPB IgG1 
monoclonal primary antibody (ab14730, Abcam) at a 1:100 dilution, dilution and 
recombinant rabbit anti-TOMM20 monoclonal primary antibody (ab186734, Abcam) at a 
1:100 dilution. All antibodies were diluted in 10% normal goat serum and sections incubated 
in primary cocktails overnight at 4°C.  
 
Slides were washed for 3x5 minutes on a rocking platform in TBST prior to incubation in 
fluorophore conjugated antibody cocktails. Sections labelled with anti-NDUFB8 required a 
biotin amplification step therefore a biotinylated anti-IgG1 secondary antibody step was 
included for these sections only. These sections were incubated in goat anti-mouse IgG1 
cross-adsorbed secondary antibody, biotin-XX (A10519, Invitrogen) at a 1:200 dilution in 10% 
NGS for 2 hours at room temperature followed by 3x5 minute washes on a rocking platform 
in TBST. The fluorophore conjugated antibody cocktail for section 1 (NDUFB8 and UQCRFS1) 
included goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 488 
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conjugated (A11008, Invitrogen) at a 1:200 dilution, streptavidin Alexa Fluor 647 conjugate 
(S32357, Invitrogen) at a 1:200 dilution and goat anti-mouse IgG2b cross-adsorbed 
secondary antibody, Alexa Fluor 546 conjugated (A21143, Invitrogen) also at a 1:200 
dilution. The fluorophore conjugated antibody cocktail for section 2 (MTCO1 and ATPB) 
included goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 488 
conjugated (A11008, Invitrogen) at a 1:200 dilution, goat anti-mouse IgG2a cross-adsorbed 
secondary antibody, Alexa Fluor 546 conjugated (A21133, Invitrogen) and goat anti-mouse 
IgG1 cross-adsorbed secondary antibody, Alexa Fluor 647 (A21240, Invitrogen) also at a 
1:200 dilution. 
 
All fluorophore conjugated antibodies were diluted in 10% NGS and sections incubated in 
cocktails for 2 hours at room temperature in the dark. Following 3x5 minutes on a rocking 
platform in TBST, sections were incubated in a 1:1200 solution of Hoescht nucleic acid stain 
(H3570, Invitrogen) for 15 minutes at room temperature in the dark. Following a final 3x5 
minute wash in TBST, slides were mounted in Prolong Gold antifade mountant (P36930, 
Invitrogen). 
 
2.2.11.4. Serine synthesis pathway enzyme immunofluorescence 
 
2.2.11.4.1. Mouse samples 
 
In order to investigate the expression of the serine synthesis pathway enzymes PHGDH and 
PSAT1 and mitochondrial one carbon pathway enzyme MTHFD2 within normal non-
transformed murine intestine, (3x) 4µm serial sections were taken from colon and small 
intestine formalin fixed paraffin embedded (FFPE) blocks from three PolγAmut/mut and three 
PolγA+/+ mice per age group. Age groups of 1, 3, 6, 9 and 12 months were included in the 
analysis and sections prepared as outlined in 2.2.11.1. Sections were incubated overnight in 
either a 1:2000 dilution of anti-PHGDH (HPA021241, Sigma Aldrich), a 1:300 dilution of anti-
PSAT1 (NBP1-32920, Novus Biologicals) or a 1:300 dilution of anti-MTHFD2 (ab151447, 
Abcam). All antibodies were diluted in 10% NGS and sections incubated overnight at 4°C. 
Slides were washed for 3x5 minutes on a rocking platform in TBST prior to incubation in 
fluorophore conjugated secondary antibody. For all sections, goat anti-rabbit IgG (H+L) 
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cross-adsorbed secondary antibody, Alexa Fluor 488 conjugated (A11008, Invitrogen) was 
used at 1:200 in 10% NGS dilution and sections incubated for 2 hours at room temperature 
in the dark. Following 3x5 minutes on a rocking platform in TBST, sections were incubated in 
a 1:1200 solution of Hoescht nucleic acid stain (H3570, Invitrogen) for 15 minutes at room 
temperature in the dark. Following a final 3x5 minute wash in TBST, slides were mounted in 
Prolong Gold antifade mountant (P36930, Invitrogen). 
 
2.2.11.4.2. Human samples 
 
In order to categorise normal human colonic crypts as either OXPHOS normal or OXPHOS 
deficient and subsequently correlate OXPHOS status with the level of expression of the 
enzymes PHGDH, PSAT1 and MTHFD2, 4 x 4µm serial sections were taken from normal 
colonic mucosal biopsies from 12 patients who had undergone either surgical colorectal 
tumour resection or polyp removal. Serial sections were labelled according to the schematic 
shown in Figure 2-3. 
 
 
Figure 2-3. Schematic outlining labelling protocol of SSP enzymes and OXPHOS subunit proteins present in normal human 
colon biopsies. A ribbon of sections was cut at a thickness of 4µm with one sequential section on each slide. Antibodies 
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2.2.11.4.2.1. OXPHOS subunit protein immunofluorescence 
 
In order to categorise normal human colonic crypts as OXPHOS normal or deficient, the 
quadruple immunofluorescence protocol described by Rocha et al was applied to tissue 
sections (Rocha et al., 2015). This method was validated in skeletal muscle with the use of 
anti-VDAC1 as a mitochondrial mass marker, however the use of this antibody on intestinal 
tissue sections did not facilitate punctate labelling and was therefore replaced with a 
recombinant rabbit anti-TOMM20 monoclonal primary antibody (ab186734, Abcam). 
Following the preparation steps outlined in 2.2.11.1., sections were incubated overnight in 
primary antibody cocktail. Primary antibody cocktail included mouse anti-NDUFB8 IgG1 
monoclonal primary antibody (ab110242, Abcam) at a 1:50 dilution, mouse anti-MTCO1 
IgG2a monoclonal primary antibody (ab14705, Abcam) at 1:50 dilution, and recombinant 
rabbit anti-TOMM20 monoclonal primary antibody (ab186734, Abcam) at a 1:100 dilution. 
All antibodies were diluted in 10% normal goat serum and sections incubated in primary 
cocktails overnight at 4°C.  
 
Slides were washed for 3x5 minutes on a rocking platform in TBST prior to incubation in 
fluorophore conjugated antibody cocktails. A biotin amplification step was required for 
adequate detection of anti-NDUFB8 required therefore a biotinylated anti-IgG1 secondary 
antibody step was included. Sections were incubated in goat anti-mouse IgG1 cross-
adsorbed secondary antibody, biotin-XX (A10519, Invitrogen) at a 1:200 dilution in 10% NGS 
for 2 hours at room temperature followed by 3x5 minute washes on a rocking platform in 
TBST. 
 
The fluorophore conjugated antibody cocktail consisted of goat anti-rabbit IgG (H+L) cross-
adsorbed secondary antibody, Alexa Fluor 488 conjugated (A11008, Invitrogen) at a 1:200 
dilution, streptavidin Alexa Fluor 647 conjugate (S32357, Invitrogen) at a 1:200 dilution and 
goat anti-mouse IgG2a cross-adsorbed secondary antibody, Alexa Fluor 546 conjugated 
(A21133, Invitrogen) also at a 1:200 dilution. All fluorophore conjugated antibodies were 
diluted in 10% NGS and sections incubated in cocktails for 2 hours at room temperature in 
the dark. Following 3x5 minutes on a rocking platform in TBST, sections were incubated in a 
1:1200 solution of Hoescht nucleic acid stain (H3570, Invitrogen) for 15 minutes at room 
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temperature in the dark. Following a final 3x5 minute wash in TBST, slides were mounted in 
Prolong Gold antifade mountant (P36930, Invitrogen). 
 
2.2.11.4.2.2. Combined serine synthesis pathway enzyme and OXPHOS subunit 
immunofluorescence 
 
Following the preparation steps outlined in 2.2.11.1., sections were incubated overnight in 
primary antibody cocktail. Primary antibody cocktails consisted of mouse anti-NDUFB8 IgG1 
monoclonal primary antibody (ab110242, Abcam) at a 1:50 dilution, mouse anti-MTCO1 
IgG2a monoclonal primary antibody (ab14705, Abcam) at 1:50 dilution with one of either 
anti-PHGDH (HPA021241, Sigma Aldrich) at a 1:300 dilution, anti-PSAT1 (NBP1-32920, Novus 
Biologicals) at a 1:90 dilution or anti-MTHFD2 (ab151447, Abcam) at a 1:90 dilution. All 
antibodies were diluted in 10% normal goat serum and sections incubated in primary 
cocktails overnight at 4°C.  
 
Following the overnight incubation, slides were washed for 3x5 minutes on a rocking 
platform in TBST prior to incubation in fluorophore conjugated antibody cocktails. A biotin 
amplification step was required for adequate detection of anti-NDUFB8 required therefore a 
biotinylated anti-IgG1 secondary antibody step was included. Sections were incubated in 
goat anti-mouse IgG1 cross-adsorbed secondary antibody, biotin-XX (A10519, Invitrogen) at 
a 1:200 dilution in 10% NGS for 2 hours at room temperature followed by 3x5 minute 
washes on a rocking platform in TBST. 
 
The fluorophore conjugated antibody cocktail consisted of goat anti-rabbit IgG (H+L) cross-
adsorbed secondary antibody, Alexa Fluor 488 conjugated (A11008, Invitrogen) at a 1:200 
dilution, streptavidin Alexa Fluor 647 conjugate (S32357, Invitrogen) at a 1:200 dilution and 
goat anti-mouse IgG2a cross-adsorbed secondary antibody, Alexa Fluor 546 conjugated 
(A21133, Invitrogen) also at a 1:200 dilution. All fluorophore conjugated antibodies were 
diluted in 10% NGS and sections incubated in cocktails for 2 hours at room temperature in 
the dark. Following 3x5 minutes on a rocking platform in TBST, sections were incubated in a 
1:1200 solution of Hoescht nucleic acid stain (H3570, Invitrogen) for 15 minutes at room 
temperature in the dark. Following a final 3x5 minute wash in TBST, slides were mounted in 
Prolong Gold antifade mountant (P36930, Invitrogen). 
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2.2.12. Microscopy and image analysis 
 
2.2.12.1. Beta catenin immunohistochemistry imaging and analysis 
 
Beta catenin labelled mouse sections were scanned into a Leica Aperio Slidescanner situated 
at the Northern Institute for Cancer Research (NICR), Newcastle University. Using the 
associated ImageScope software (Leica), the frequency of all visible adenomas per section 
was recorded, and their individual and total area measured by manually selecting each 
adenomatous region. Adenomas were classed as such based on their pattern of β-catenin 
expression. Beta catenin intense foci (adenomas) were identified as clusters of cells that 
showed both increased nuclear and cytoplasmic β-catenin when compared to normal, non-
transformed, surrounding mucosa. The area of the clusters of β-catenin intense cells was 
measured, with cells being categorised as belonging to the same cluster or foci if there were 
no normal cells in between them. 
 
Within ImageScope, individual adenomata were manually selected and each recorded as a 
layer region in which the area was listed in µm2. The total area these layer regions 
circumscribed per section was then calculated and in order to determine the proportion of 
each tissue section comprised of adenoma, the Positive Pixel Count algorithm was used. 
Applying this algorithm to each section generated multiple parameters including the total 
area of positive pixels (or stained tissue) present in mm2. The proportion of each tissue 
section comprised of adenoma was thus represented as a percentage of the total area of 
each section.  
 
2.2.12.2. Cleaved caspase 3 immunohistochemistry imaging and analysis 
 
Following labelling with anti-cleaved caspase 3 antibody as described in 2.2.9.3., a minimum 
of 10 adenomas were selected at random from each colonic section of PolγAmut/mut (n=7) and 
PolγA+/+ (n=9) animals culled at 23 days post Apc deletion. Adenomas were imaged with a 
x10 objective using bright field microscopy on a Zeiss AxioImager M1 microscope. A 
minimum of 10 adenomas were similarly selected at random from small intestinal sections 
of PolγAmut/mut (n=9) and PolγA+/+ (n=9) animals culled at 23 days post Apc deletion imaged in 
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the same way. Using the events tool to record frequencies, the total number of nuclei per 
foci and the number of cleaved caspase 3 positive cells per foci were manually counted using 
Zen Lite software (Zeiss). 
 
2.2.12.3. Thymidine analogue immunofluorescence imaging and analysis 
 
All labelled sections were imaged using a Zeiss AxioImager M1 fluorescent microscope and 
Zen 2.5 Blue microscope software (Zeiss). Filter cubes for Alexa Fluor fluorophores at 
405 nm, 488 nm, 546 nm and 647 nm wavelengths were used and images acquired with an 
AxioCam MRm monochrome digital camera. Exposure times were optimised for each 
channel, verified against no primary antibody control sections and settings maintained 
throughout image acquisition. For each section from each mouse, eighteen tumour foci were 
selected at random and labelled cells counted manually using the events tool within Zen Lite 
software (Zeiss) For each adenoma, the frequencies of nuclei, Lgr5+ cells and cells 
incorporating one or both thymidine analogues were quantified. For the Lgr5+ stem cell 
population, cells incorporating one or both thymidine analogues were also quantified in the 
same manner. 
 
2.2.12.4. Mitochondrial dysfunction immunofluorescence imaging, analysis and Z score 
generation 
 
Following quadruple immunofluorescence labelling as described in 2.2.11.3., adenomas 
were manually identified within the colonic and small intestinal tissue of PolγAmut/mut, 
PolγA+/mut and PolγA+/+ mice culled at 23 days post Apc deletion and images acquired using a 
Nikon A1R inverted point scanning confocal microscope with a x20 Plan-Apochromat 
objective. In order to avoid pixel over or undersaturation, laser power was optimised for 
each channel using labelled and unlabelled PolγA+/+ tissues. Excitatory emission was detected 
at wavelengths of 405, 488, 546 and 647nm within an intensity range of 0 to 4095. 
Confocal images were subsequently converted into TIF format using NIS Elements software 
(Nikon) and analysed using Image J software (NIH). Adenomas were selected as regions of 
interest (ROI) and fluorophore mean intensity values recorded for each channel. Following 
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the collection of fluorophore mean intensity data, values in the 488nm channel (TOMM20) 
and 546nm channel (MTCO1 or UQCRFS1) were background corrected by subtracting the 
mean intensity of a no primary control (NPC) from the ROI mean. Due to the use of an 
additional biotin amplification step in the detection of NDUFB8 protein and thus the 
increased possibility of non-specific secondary antibody binding due to this, NDUFB8 mean 
intensity values (647nm) were corrected according to mitochondrial mass. This involved the 
grouping of ROIs according to mean TOMM20 expression percentiles and their correction by 
using the mean 647nm intensity value of the matching no primary control from that 
percentile. Corrected values were then normalised by log transformation. Z-scores were 
calculated based on the control population and adenomas (and non-transformed crypts) 
categorised as normal (z > -3), intermediate positive (-4.5 ≤ z < -3.0), intermediate negative (-
6 ≤ z < -4.5) and negative (z < -6) for each protein. 
 
2.2.12.5. Serine synthesis enzyme immunofluorescence imaging and analysis 
 
2.2.12.5.1. Mouse samples 
 
All labelled sections were imaged using a Zeiss Celldiscoverer 7 fluorescent microscope 
(Zeiss). Using the tiling function, the entire section was scanned at a x10 magnification using 
a x20 Plan-Apochromat objective with 0.5x Tubelens Optavar. For PHGDH imaging, 470nm 
and 365nm laser LED modules were set at exposure times of 80ms and 30ms respectively 
with both light source intensities set at 50%. For PSAT1 and MTHFD2 imaging, 470nm LED 
exposure time was set to 120ms. All settings remained fixed within groups and images were 
acquired with a Hamamatsu Fusion imaging device. Individual tile images were acquired with 
a 10% overlap and stitching, and fusion of tiles was carried out by the software using the 
365nm channel as a reference. Quantification of PHGDH, PSAT1 and MTHFD2 expression 
levels was achieved by using the spline contour tool within Zen Lite software and selecting 
20 crypts at random from each section.  
 
Following whole slide scanning and SSP/1C enzyme quantification, representative regions 
were selected at random from one mouse per age group for each protein with specific 
regions being mapped across each labelled section. This process was carried out for both 
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colonic and small intestinal samples and high-resolution images were acquired using an 
LSM800 confocal laser scanning microscope with Airyscan detector (Zeiss). The Airyscan 
detector is a formation of 32 individual detector elements in a compound eye arrangement. 
Each element functions as an individual confocal pinhole, the diameter of which is relative to 
the maximum diameter of the detector itself; 6 elements. If a 1.25 AU pinhole is selected, 
the pinhole diameter of each individual element is one sixth of this value; 0.2 AU. The light 
collection efficiency of a large pinhole (e.g. 1.25 AU) is combined with the increased 
resolution of imaging with a small pinhole (0.2 AU) with the use of an Airyscan detector 
(Huff, 2015). A x10 Plan-Apochromat objective was used for image acquisition in conjunction 
with a bidirectional, linear frame scan mode. Settings applied to each group are outlined in 
Table 2-6.  
 
















405nm 0.99% 5.00 AU 2.06µs 750 V 0 




405nm 0.99% 5.00 AU 2.06µs 750 V 0 





405nm 0.99% 5.00 AU 2.06µs 750 V 0 





405nm 1.05% 5.94 AU 2.06µs 750 V 0 





405nm 1.05% 5.94 AU 2.06µs 750 V 0 





405nm 1.05% 5.94 AU 2.06µs 750 V 0 
488nm 2.00% 5.74 AU 2.06µs 750 V 0 
 
Table 2-6. LSM800 confocal microscope settings used in serine synthesis enzyme immunofluorescence image acquisition.  
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Acquired images measured 4096x4096 pixels in size and were subjected to Airyscan 
processing prior to visualising using Zen 2.5 Blue microscopy software (Zeiss). Airyscan 
processing utilises a deconvolution and pixel reassignment algorithm which is applied to 
each of the 32 detector channels individually. Identical histogram settings were applied to 
the resultant images to permit appropriate visual comparisons. 
 
2.2.12.5.2. Human samples 
 
All labelled sections were imaged using a Zeiss Celldiscoverer 7 fluorescent microscope 
(Zeiss). Using the tiling function, the entire section was scanned at a x10 magnification using 
a x20 Plan-Apochromat objective with 0.5x Tubelens Optavar. For OXPHOS section imaging, 
625nm, 567nm, 470nm and 365nm LED modules were set at exposure times of 105ms, 
200ms, 78ms and 16ms respectively. For PHGDH/NDUFB8/MTCO1 section imaging, 625nm, 
567nm, 470nm and 365nm LED modules were set at exposure times of 300ms, 200ms, 
100ms and 16ms respectively. For PSAT1/NDUFB8/MTCO1 section imaging, 625nm, 567nm, 
470nm and 365nm LED modules were set at exposure times of 300ms, 400ms, 120ms and 
20ms respectively. For MTHFD2/NDUFB8/MTCO1 section imaging, 625nm, 567nm, 470nm 
and 365nm LED modules were set at exposure times of 165ms, 200ms, 120ms and 16ms 
respectively. All light source intensities were set at 100%. All settings remained fixed within 
groups and images were acquired with an Axiocam 506 imaging device. 
 
Analysis of OXPHOS labelled sections was undertaken using Zen Lite software (Zeiss). Using 
the spline contour tool, any crypt which appeared to be visually deficient in either NDUFB8 
or MTCO1 was manually selected. This population formed the OXPHOS deficient crypt 
category which differed in quantity between subjects within a range of n=8 to n=110. At 
least an equal number of crypts demonstrating no visual deficiency of either of these 
proteins was selected at random in the same manner thus forming the normal crypt 
category. On a patient-by-patient basis, individual crypt Z scores were calculated using the 
method outlined in 2.2.11.4. Any outliers which deviated from the original classification as a 
result of this analysis were recategorised accordingly.  
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The same OXPHOS deficient and OXPHOS normal crypts were identified in adjacent serial 
sections labelled with PHGDH/NDUFB8/MTCO1, PSAT1/NDUFB8/MTCO1 and 
MTHFD2/NDUFB8/MTCO1. The spline contour tool was used to manually select these crypts 
however fluorophore intensity data were extracted from the 488nm channel only. These 
data represent the expression of each of the SSP/1C enzymes within the OXPHOS normal 
and deficient crypt compartments and were binned as such prior to enzyme expression level 
comparison.  
 
2.2.13. Antibody validation and controls 
 
The specificity of antibodies against mitochondrial OXPHOS protein complex subunits were 
previously validated in patients with known mutations in mtDNA or nuclear encoded 
complex I and complex IV subunits (Rocha et al., 2015). Similarly, antibodies targeting the 
UQCRFS1 subunit of complex III and ATPB subunit of complex V have been validated within 
the group in fibroblasts and skeletal muscle of patients harbouring pathogenic variants in 
genes known to impair complex III and complex V assembly (Oláhová et al., 2019; Thompson 
et al., 2018; Tuppen et al., 2010). All OXPHOS antibodies used in the current study are 
regularly used within the department and bind to proteins of the expected band size upon 
western blot analysis. As 6-month-old PolγA+/+ colonic and small intestinal normal non-
transformed crypts do not harbour age-related mtDNA mutations and thus do not exhibit 
OXPHOS protein defects (Greaves et al., 2011), they were used as internal positive controls 
in OXPHOS assays. 
Antibodies targeting serine synthesis and mitochondrial one carbon cycle enzymes were 
previously validated and recommended for use by Prof. Owen Sansom, Beatson Institute for 
Cancer Research, Glasgow. Although specific positive controls were not used in individual 
SSP enzyme IHC/IF assays, the increased levels of these enzymes within Apc deficient 
adenomas in comparison to normal crypts in our model and the corroboration of this 
observation with those of the Sansom group using the same antibodies (Maddocks et al., 
2017) confirmed the validity of the assay. The specificity of antibodies against thymidine 
analogues was previously validated in mice exposed to single thymidine analogues (Stamp, 
2015). No primary controls (NPCs) were included in all assays.  
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2.2.14. Statistical analysis 
 
With the exception of linear mixed effect model analyses which were carried out by Dr 
Alasdair Blain using the R programming language, all statistical analyses were performed 
using GraphPad Prism (version 8.4.3). Where pre-existing data supported a prediction in the 
direction of a difference between samples, a one-tailed test was used. In all other instances, 
two-tailed tests were used.  
  
  103 
Chapter 3. Development and characterisation of a mouse model to investigate 




Given the association of mitochondrial dysfunction and the accumulation of mtDNA 
mutations with increasing age, the development of two similar mouse models in 2004 and 
2005 allowed the potential causative effect of mtDNA mutation accumulation on the ageing 
process to be investigated (Kujoth et al., 2005; Trifunovic et al., 2004). Although developed 
against different C57Bl/6 backgrounds using slightly different methodologies, both models 
share the same amino acid substitution at the same conserved residue within the 
mitochondrial polymerase gamma (PolγA) gene. This aspartate to alanine substitution at 
residue 257 of the conserved proofreading domain of PolγA impairs the exonuclease activity 
of the enzyme resulting in an up to eightfold increase in the likelihood of point mutations 
occurring during replication of the mitochondrial genome (Kujoth et al., 2005). In 
homozygous PolγA mice, multiple tissue types were shown by Southern blot to harbour 
shorter species of mtDNA representing deletions of the mitochondrial genome, however 
unlike the point mutational burden, the level of mtDNA deletions did not increase with age. 
Without evidence of specific mutational hotspots, the random generation of cumulative 
levels of mtDNA point mutations was the prevailing molecular phenotype in mutator mice 
(Trifunovic et al., 2004). Tissues analysed in both models including the brain, heart, liver, 
sperm and duodenum showed that transition mutations represented the largest class of 
mutation in mutator mice. This was reportedly attributed to nucleotide misincorporation by 
the polymerase (Kujoth et al., 2005).  
 
In both models, the lifespan of mutator mice is significantly reduced compared with wild-
type controls with mutator mice surviving a median of 11-13 months in comparison to a 28-
month maximum survival of wild type animals. Clinically, PolγA mutator mice appear 
phenotypically comparable to their wild-type counterparts until around six months of age. At 
this time point, numerous progeroid features become apparent. First noted was the 
appearance of alopecia and a slight kyphosis (curvature of the spine) (Trifunovic et al., 2004). 
Weight loss was also noted in mutator mice from 6 months of age. X-ray densitometry of 4 
and 9 month old mutator mice revealed a significant reduction in percentage body fat in 
mutator versus wild type animals at both time points (Trifunovic et al., 2004) and at 9 
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months of age, a significant loss of muscle mass (sarcopenia) was demonstrated by a 
reduced weight of gastrocnemius and quadriceps muscles in mutator versus wild type 
animals (Kujoth et al., 2005). Sarcopenia and a reduction in body fat both contribute to an 
overall decrease in body weight and are both also common features of ageing in humans 
(Rosenberg, 1997; Roubenoff, 1999). Also demonstrated using X-ray densitometry was a 
reduction in bone mineral composition (BMC) and bone mineral density (BMD) in 9-month-
old mutator mice, consistent with the development of osteoporosis in ageing humans 
(Trifunovic et al., 2004). Recent in vivo analyses of PolγAmut/mut and wild-type lumbar spines, 
femurs and tibiae further demonstrate a significantly accelerated rate of bone loss 
associated with age-related mitochondrial respiratory chain deficiency in osteoblasts and 
osteoclasts in PolγAmut/mut animals. In vitro investigations revealed a severely impaired 
mineralised matrix formation and increased osteoclast resorption by PolγAmut/mut femur cells 
(Dobson et al., 2020). 
 
In comparison to their wild-type counterparts, 6-month-old PolγA mutator mice present with 
significantly reduced peripheral blood haemoglobin levels with an anaemia characterised by 
enlarged (macrocytic), pale coloured (hypochromic) erythrocytes (Trifunovic et al., 2004). 
The maturation of erythrocytes involves their migration from the bone marrow into the 
peripheral blood when intracellular haemoglobin levels are sufficient. They enucleate and 
mature further within the circulation with removal of their mitochondria and clearing of 
transferrin receptors. The mechanism by which anaemia develops in the PolγA mouse has 
been elucidated and is reported to be due to a perturbation in these maturation steps, 
initiated by mutated mtDNA and resultant alterations in ROS within immature erythrocytes 
(Ahlqvist et al., 2015). In comparison to wild-type animals, 11-month-old PolγAmut/mut mice 
showed an increased frequency of reticulocytes: immature erythrocytes, with significantly 
elevated mitochondrial retention. The mitophagy marker NIX, indicated that the active 
removal of mitochondria was also significantly reduced in PolγAmut/mut reticulocytes. The 
transferrin receptor (TfR) was also found to be abnormally retained within PolγAmut/mut 
reticulocytes, causing increased loading of free iron within these cells. As free iron is highly 
reactive with oxygen, reactive oxygen species are generated in reticulocytes in which both 
TfR and mitochondria are retained. Cell surface proteins which are normally appropriated to 
the inner cell membrane as erythrocytes mature remain on the surface due to oxidative 
damage to the enzymes that facilitate their segregation. These cell surface proteins label the 
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erythrocytes for premature destruction by splenic macrophages, as indicated by significantly 
increased levels of iron loaded activated macrophages within the spleen of PolγAmut/mut mice 
(Ahlqvist et al., 2015). 
 
Additional observations taken from the Trifunovic mouse included an enlargement of the 
hearts of 9-month-old mutator mice and the presence of a mosaic pattern of 
cardiomyocytes demonstrating reduced cytochrome c oxidase (COX) activity as evidenced by 
enzyme histochemical COX/SDH labelling. This phenotype is also demonstrated in humans 
with the frequency of COX deficient cardiomyocytes increasing with advancing age (Muller-
Hocker, 1989). Histological analysis of the testes of 9-month-old mutator mice also revealed 
an absence of sperm and severe testicular tubular degeneration in concordance with the 
age-related decline in fertility observed in humans (Trifunovic et al., 2004). In the absence of 
evidence of increased markers of oxidative damage or defective cellular proliferation in 
mutator versus wild-type animals, Kujoth et al. suggest that the earlier induction of a 
caspase 3–mediated apoptotic pathway present in the normal ageing of wild type animals 
may be the underlying cause. Increased levels of cleaved caspase 3 were shown to be 
present within the heart, liver, skeletal muscle and testes of 30-month-old versus 5-month-
old wild type mice which may contribute to the functional decline of tissues observed in 
normal ageing. Cleaved-caspase 3 levels are significantly increased at a much earlier stage in 
mutator mice compared to age matched wild-type controls; 3 months of age in duodenum, 
liver, testis, and thymus and 9 months of age in post-mitotic tissues such as the brain and 
skeletal muscle (Kujoth et al., 2005).  
 
With regard to the intestinal phenotype of the Kujoth model, it has been shown that the 
pattern of somatic mtDNA mutations within the colon of aged PolγA+/mut mice is similar to 
that which is seen in aged humans. The spectrum of mutations is shown to be similarly 
random in both species, and subjection to selection pressures is not evident (Baines et al., 
2014). Additionally, computer simulation models suggest that predominantly asymmetric 
stem cell division coupled with random genetic drift is sufficient to drive the clonal 
expansion of somatic mtDNA mutations in mitotic tissues resulting in respiratory chain 
deficiency in both PolγA+/mut mice and humans (Baines et al., 2014; Stamp et al., 2018). A 
similar situation is described within the small intestine of PolγA+/mut mice in which mtDNA 
point mutations with high levels of heteroplasmy were identified within COX negative villi of 
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15-month-old mice (Vermulst et al., 2008). The demonstration of an age-related intestinal 
pathology in PolγA+/mut mice and an absence of COX negative villi in aged matched wild type 
control mice further supports the appropriate application of this model for use in this study. 
Additionally, the Kujoth mouse is utilised due to its retention of only one LoxP site at the 
PolγA locus following homologous recombination and neomycin cassette excision. The 
Trifunovic mouse retains two LoxP sites thus rendering it incompatible with other mouse 
models in which Cre mediated excision is to be used. 
 
Having identified a suitable model of age-related mitochondrial dysfunction in the intestine, 
an appropriate model of intestinal tumorigenesis was subsequently required in order to 
investigate this in vivo. Requirements of the model included biological relevance to human 
colorectal cancer and a temporospatial inducibility of tumorigenesis following an 
appropriate time period of intestinal mtDNA mutation accumulation. Lineage tracing 
experiments in which Lgr5-EGFP-IRES-creERT2 mice were crossed with mice bearing a Cre 
inducible Rosa26-lacZ reporter gene identified Lgr5 positive cells as being pluripotent and 
capable of maintaining the self-renewal of the murine colonic and small intestinal epithelium 
(Barker et al., 2007). The subsequent crossing of Lgr5-EGFP-IRES-creERT2 mice with Apcflox/flox 
mice enabled stem cell specific deletion of Apc to be induced upon creERT2 activation with 
tamoxifen. The loss of Apc from Lgr5+ cells initiated the development of and allowed the 
rapid expansion of numerous adenomas throughout the intestines of experimental animals 
with this pathology leading to their necessary culling at 36 days post Apc deletion (Barker et 
al., 2009). Immunohistochemical analysis demonstrated increased levels of β-catenin 
expression in isolated crypt base cells from as early as 3 days and 8 days post tamoxifen 
induction in the small intestine and colon respectively. This is indicative of Wnt signalling 
activation concurrent with Apc loss, also confirmed immunohistochemically by high levels of 
expression of the Wnt target gene c-myc within small intestinal lesions from 8 days post Apc 
deletion. In contrast, the deletion of Apc from non-stem transit amplifying and villous 
compartment cells using the β-naphthoflavone activated Ah-Cre/Apcflox/flox/Rosa26R mouse 
facilitated the development of β-cateninhigh clusters of cells, however these foci, despite 
their persistence, did not expand, nor did they progress to adenomas. As such, Lgr5+ve cells 
were identified as the cells of origin of intestinal cancer and the Lgr5-EGFP-
IREScreERT2/Apcflox/flox mouse selected as an established inducible model of intestinal cancer 
appropriate for use in this study.  
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In 2012, Woo and colleagues describe a mouse model of intestinal neoplasia (ApcMin/+) in 
which intestinal adenoma growth is promoted by mtDNA instability elicited by a Tfam+/- 
genotype also present within the model. TFAM is required for the expression and 
maintenance of mtDNA and the loss of one Tfam allele drives a mild phenotype in which 
mtDNA is slightly depleted and more susceptible to oxidative damage than wild type cells. In 
comparison with ApcMin/+ Tfam+/+ mice, ApcMin/+ Tfam+/- mice demonstrated a significantly 
greater frequency and size of small intestinal adenomas suggesting that Tfam+/- mediated 
mitochondrial genome instability enhances intestinal tumour growth (Woo et al., 2012). 
Although highly relevant, the work of Woo and colleagues does not specifically address the 
accumulation of somatic mtDNA mutations that have been extensively linked with both 
ageing and numerous cancer types. Nor does it address the temporospatial occurrence of 
events that may cause mtDNA instability and/or tumorigenesis. Accordingly, the Lgr5-EGFP-
IREScreERT2/Apcflox/flox mouse was selected for this study due to its intestinal stem cell 
specific inducible deletion of Apc (Barker et al., 2009). In order to investigate the potential 
effect of an age-related accumulation of somatic mtDNA mutations on the growth of 
intestinal adenomas that develop within this model, it was crossed with the PolγA mutator 
mouse and aged sufficiently prior to an intestinal stem-cell derived tumour initiation 
providing the final model for this study. Specifically, the Kujoth variant of the PolγA mutator 
mouse was selected due to its retention of only one LoxP site at the PolγA locus (Kujoth et 
al., 2005). Use of the Trifunovic PolγA mutator mouse in which two LoxP sites flanking the 
PolγA locus are retained would not be compatible with the Cre/LoxP mediated Apc deletion 
utilised within the Lgr5-EGFP-IREScreERT2/Apcflox/flox mouse as excision of PolγA would also 
occur with tamoxifen administration. Furthermore, it has been demonstrated that the 
pattern of somatic mtDNA mutations within the colon of aged Kujoth PolγA+/mut mice is 
similar to that which is seen in aged humans with PolγA derived mtDNA mutations also 
reaching high levels of heteroplasmy within the COX negative small intestinal crypts of 15-
month-old Kujoth PolγA+/mut mice (Baines et al., 2014; Vermulst et al., 2008). The intestinal 
phenotype and retention of only one LoxP site within the Kujoth model therefore provided 
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3.2. Aims of study 
 
Having identified suitable mouse models of both inducible intestinal cancer and a premature 
ageing phenotype caused by the accumulation of mtDNA mutations, the aims of this study 
were to: 
1. Generate a transgenic mouse model to be used to investigate the role of mtDNA 
mutations in intestinal cancer development. 
2. Evaluate the clinical phenotype of this mouse model with regards clinical symptoms, 
their severity and their effect on lifespan.  
3. Macroscopically and microscopically examine adenoma burden comparing 
frequency, size and total burden across experimental groups all culled at the same 
time point post Apc deletion. 
4. Assess the toxicity and potential effect on lifespan of the tamoxifen regime used to 
induce tumorigenesis in experimental animals.  
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3.3. Results 
 
3.3.1. Generation of a transgenic mouse model 
 
Each of the three mouse lines required to generate the appropriate transgenic model were 
obtained separately. In order to cross these lines successfully, specific features pertaining to 
the phenotypes of each line were taken into consideration. All animal breeding was 
undertaken by Dr Laura Greaves and Carla Bradshaw. Features characteristic to each model 
were also used to develop a clinical scoring protocol in which appropriate symptoms would 
be gauged. As PolγA mutator mice present with weight loss and anaemia, animals were 
weighed daily, and the colour of extremities assessed. The condition of the coat of a mouse 
can often be an indicator pain or distress; a lack of grooming is noted when health is 
deteriorating. Similarly, the presence of piloerection can indicate dehydration (Burkholder et 
al., 2012). As greying of the fur and alopecia are reported in PolγA mutators, particular 
attention was paid to coat condition in experimental animals.  
 
As adenomas extensively develop within the intestine of ApcMin mice, premature death 
occurs due to chronic anaemia and intestinal obstruction; effects which are secondary to the 
adenoma burden itself (Shoemaker et al., 1997). Accordingly, experimental animals were 
monitored for signs of intestinal blockage such as abdominal distension, diarrhoea and 
reduced mobility. In addition to observing the colour of extremities, stools were checked for 
the presence a blood, also an indicator of intestinal pathology and associated anaemia. 
Details of clinical symptoms monitored, and scores given for aberrations can be found in 
Table 2-4.  
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3.3.1.1. PolγAmut/mut mitochondrial mutator mice breeding 
 
Homozygous PolγAmut/mut mice of both genders present with reduced fertility. The testes of 
male mutator mice are smaller than those of wild type males at 3 months of age and by 9 
months of age, a complete absence of sperm is noted in male mutator mice. Female 
homozygous mutator mice only give birth to one litter and do not become pregnant a 
second time after 4 months of age despite continuous exposure to male mice (Trifunovic et 
al., 2004). In order to propagate our colony of PolγA+/+, PolγA+/mut and PolγAmut/mut animals, 
four PolγA+/mut male mice were donated from a well-established colony and mated with 
female C57Bl/6J wild type mice as shown in Figure 3-1. In Figure 3-1 and subsequent 
breeding schedules, green mice denote a PolγAmut/mut genotype while blue and red mice 




Figure 3-1. Mitochondrial mutator mouse breeding schedule. PolγA+/mut male mice were mated with C57Bl/6J wild type 
female mice in order to generate PolγA+/mut and PolγA+/+ males and females. Subsequent mating of heterozygous animals 
propagated the colony permitting the generation of PolγAmut/mut animals. Green mice denote PolγAmut/mut genotype while 
blue and red mice denote PolγA+/mut and PolγA+/+ genotypes respectively. 
  
  111 
3.3.1.2. Lgr5-EGFP-Ires-CreERT2 and Apcflox/flox mice breeding 
 
Homozygous Lgr5-/- mice present with a craniofacial defect in which the tongue is fused to 
the floor of the oral cavity. This causes a suckling defect in which air is swallowed and 
mutant neonates die within 24 hours of birth (Morita et al., 2004). As such, breeding 
schemes were designed to avoid the generation of this lethal phenotype. There were no 
breeding issues with Apcflox/flox mice. Lgr5+/- males were donated and mated with Apcflox/flox 
females and only offspring with Lgr5+/- and Lgr5+/+ genotypes subsequently crossed to 
generate Lgr5+/-/Apcflox/flox females for use in experimental animal generation. This cross is 
depicted as shown in Figure 3-2. 
 
Simultaneously, Apcflox/flox females were also crossed with PolγA+/mut males. This is shown in 
Figure 3-3. Subsequent mating of males and females from the F1 generation provided 
PolγA+/mut/Apcflox/flox males for use in generating experimental animals.  
 
 
Figure 3-2. Lgr5-EGFP-Ires-CreERT2 and Apcflox/flox mice breeding schedule. Lgr5+/- males were mated with Apcflox/flox females. 
Subsequent mating of males and females from the F1 generation provided Lgr5+/-/Apcflox/flox females (highlighted in red box) 
for use in generating experimental animals. 
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Figure 3-3. PolγA+/mut and Apcflox/flox breeding schedule. PolγA+/mut males were mated with Apcflox/flox females. Subsequent 
mating of males and females from the F1 generation provided PolγA+/mut /Apcflox/flox males (highlighted in red box) for use in 




3.3.1.3. Experimental animal generation 
 
Generation of experimental animals was achieved by mating PolγA+/mut/Apcflox/flox males and 
Lgr5+/-/Apcflox/flox females. This cross generated control PolγA+/+/Lgr5+/-/Apcflox/flox and 
experimental PolγA+/mut/Lgr5+/-/Apcflox/flox F1 animals. Mating PolγA+/mut/Lgr5+/-/Apcflox/flox and 
PolγA+/mut/Lgr5+/+/Apcflox/flox males and females from this generation produced 
PolγAmut/mut/Lgr5+/-/Apcflox/flox experimental animals. As mtDNA mutations in the germline are 
transmitted to offspring (Giles et al., 1980), ‘control’ PolγA+/+ /Lgr5+/-/Apcflox/flox animals from 
PolγA+/mut mothers (also generated in this cross) are not truly wild type and were not used 
experimentally. In order to minimise this transmission, control animals from the F1 
generation only were used as such. The generation of experimental animals is depicted in 
Figure 3-4.  
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Figure 3-4. Breeding schedule depicting the mating of PolγA+/mut/Apcflox/flox males with Lgr5+/-/Apcflox/flox females. F1 
generation PolγA+/+ /Lgr5+/-/Apcflox/flox animals highlighted accordingly were used as experimental control animals. Crossing 
of F1 generation animals highlighted in blue boxes permitted the generation of PolγAmut/mut/ Lgr5+/-/Apcflox/flox experimental 
animals. PolγA+/mut /Lgr5+/-/Apcflox/flox experimental animals were obtained at the F1 generation. 
 
3.3.1.4. Experimental cohorts 
 
In order to address different experimental objectives, several cohorts were established. Each 
of these cohorts are outlined in Table 3-1 alongside the rationale behind the development of 
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6 months Lifespan  
 
To investigate whether mtDNA mutations decrease the 
lifespan of animals post Apc deletion.  
Lifespan (12)  
 






12 months Lifespan  
 
As above. No PolγAmut/mut animals included as systemic 
mitochondrial dysfunction limits survival of these mice to 
~12 months of age (Trifunovic et al., 2004). Mosaic 
pattern of OXPHOS defects observed in PolγA+/mut mouse 
intestine allows for intra mouse comparison and control. 
 
Day 23 (6)  
 










induced at 6 
months of age) 
All animals sacrificed at the same time point post Apc 
deletion to allow direct comparison of rate of tumour 
progression.  
 
Day 23 (12)  
 






12 months 23 days post Apc 
deletion 






6 months Lifespan  
 
Assessment of the toxicity and potential effect on lifespan 









6 months 16 days post Apc 
deletion 
Thymidine analogue incorporation to explore cell cycle 
kinetics within adenomas of PolγA+/+ versus PolγAmut/mut 
mice.  
 
Table 3-1. Experimental cohorts used in this study.
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3.3.2. Lifespan cohorts (6 and 12 months) 
 
Mitochondrial OXPHOS dysfunction is not commonly observed in the intestine of normal 
ageing mice. By six months of age, both PolγAmut/mut and PolγA+/mut mice demonstrate 
significantly greater frequencies of COX deficient crypts when compared to wild type 
animals. Up to 60% of colonic crypts of PolγAmut/mut mice are COX deficient by the age of six 
months whereas only ~5% are COX deficient in PolγA+/mut mice of the same age (Baines et al., 
2014). There is no evidence of COX deficiency in the colonic crypts of PolγA+/+ mice at 6 
months of age (Greaves et al., 2011). As such, PolγAmut/mut (n=23), PolγA+/mut (n=17) and 
PolγA+/+ (n=15) mice were aged to six months before beginning the intraperitoneal tamoxifen 
regime for tumour induction. Intraperitoneal tamoxifen (T5648, Sigma Aldrich) was 
administered over the course of four days at a concentration of 10mg/ml in sunflower oil. 
Day one; 300µl (3mg), day two to four; 200µl (2mg) each day (2.2.5.).  
 
By 12 months of age, a 40% loss of complex I (NDUFB8) and a 20% loss of complex IV 
(MTCO1) is reported in colonic crypts of PolγA+/mut mice (Stamp, 2015). A mosaic pattern of 
OXPHOS defects within these animals allows intra-mouse comparisons to be made while also 
providing internal controls. Furthermore, as PolγA+/- mice do not present with a premature 
ageing phenotype (Kujoth et al., 2005; Trifunovic et al., 2004) the systemic effects of the 
PolγA mutation on adenoma development in these animals is greatly reduced. As such, a 
further cohort of PolγA+/mut (n=14) and PolγA+/+ (n=11) animals were aged to 12 months prior 
to tamoxifen induction. As described in 2.2.6 and presented in Table 2-2 all mice were 
monitored daily and clinical scores recorded until such scores dictated that they be 
humanely killed. Mice were euthanised using the Schedule 1 approved method of 







  116 
3.3.2.1. Investigating the effect of mtDNA mutations on lifespan post-Apc deletion 
 
In order to investigate the effect of age-related mitochondrial dysfunction on intestinal 
adenoma growth and ascertain if this has any impact on longevity following intestinal Apc 
deletion, survival analyses of experimental animals were carried out. All animals were aged 
to six months to allow an accumulation of PolγA mediated mtDNA mutations in PolγA+/mut 
and PolγAmut/mut mice prior to tamoxifen induction and Apc deletion. Survival curves of 
animals monitored are shown in Figure 3-5. PolγAmut/mut and PolγA+/mut animals showed 
clinical signs of deteriorating health much earlier than PolγA+/+ wild type animals. When 
compared to PolγA+/+ and PolγA+/mut mice, PolγAmut/mut mice have significantly shorter 
lifespans (P<0.0001, Mantel-Cox log rank test). 
 
 
Figure 3-5. Kaplan-Meier survival curve depicting survival times of PolγA+/+ (n=15), PolγA+/mut (n=17) and PolγAmut/mut (n=23) 
mice aged to 6 months prior to Apc deletion. PolγAmut/mut mice have significantly shorter lifespans in comparison to PolγA+/+ 
and PolγA+/mut animals. Mantel-Cox log rank test P<0.0001. 
 
Given that at 12 months of age, PolγA+/mut mice display colonic crypt respiratory chain 
deficiency comparable to 70-year-old human subjects (Stamp, 2015), in order to investigate 
the effect of this burden post-Apc deletion at a level comparable to humans, a survival 
analysis was carried out in PolγA+/+ and PolγA+/mut mice aged to 12 months prior to Apc 
deletion. Survival curves of animals monitored are shown in Figure 3-6. PolγA+/mut mice aged 
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to 12 months prior to Apc deletion have significantly shorter lifespans post Apc deletion than 
PolγA+/+ mice (P=0.0211, Mantel-Cox log rank test). 
 
 
Figure 3-6. Kaplan-Meier survival curve depicting survival times of PolγA+/+ mice (n=11) and PolγA+/mut (n=14) aged to 12 
months prior to Apc deletion. PolγA+/+ mice have significantly shorter lifespans in comparison to PolγA+/mut animals. Mantel-
Cox log rank test, P=0.0211. 
 
3.3.2.2. Investigating the effect of mtDNA mutations on body mass post-Apc deletion 
 
Defined as a significant reduction in body weight resulting largely from the loss of adipose 
tissue and skeletal muscle, cancer cachexia is a co-morbid condition that affects the majority 
of cancer patients with advanced disease (Fearon et al., 2012). Cachexia as evidenced by 
unintentional weight loss is most common in intestinal cancer over all other cancer types 
(reviewed in Tan & Fearon, 2008). Weight loss can be used as an indicator of health in 
animal models, particularly in those of intestinal cancer where occlusion of the intestine may 
occur. As such, all experimental animals were weighed daily as part of their clinical 
monitoring protocol. Presented in Figure 3-7, weight loss is noted in all experimental groups 
from approximately ten days post Apc deletion. A significant negative correlation of mean 
body mass with time post Apc deletion is detected in each group (PolγA+/+ r2=0.6031, 
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Figure 3-7. Mean body mass measurements of experimental animals following Apc deletion at six months of age. PolγA+/+ 
(n=15), PolγA+/mut (n=15) and PolγAmut/mut (n=20). Weight was measured each day during and following the IP tamoxifen Apc 
deletion regime. Pearson correlation analyses detect a significant negative correlation in all groups. PolγA+/+ r2=0.6031, 
P<0.0001, PolγA+/mut r2=0.1481, P=0.0187, PolγAmut/mut r2=0.3088, P=0.0048. Mean body mass significantly decreases in all 
groups following tamoxifen induction of Apc deletion. Data are represented as mean ± SEM.  
 
An initial drop in mean body mass from days 1 to 4 (PolγA+/mut and PolγAmut/mut) was 
attributed to stress experienced by the animals caused by daily intraperitoneal injections 
during this time period. The subsequent steady increase in mean body mass would correlate 
with the removal of this stressor upon completion of the IP regime. This is not apparent 
within the PolγA+/+group and may reflect a decreased intervention tolerance within the 
PolγAmut/mut and PolγA+/mut groups due to their phenotype. The exclusion of these initial 4 
days post Apc deletion may allow a more appropriate analysis of weight loss as the effect of 
stress of the induction regime on this measure is removed. In fact, the correlation of body 
mass with days post Apc deletion is strengthened by this as evidenced by an increase in r2 
values in all groups (PolγA+/+ r2=0.7843, P<0.0001, PolγA+/mut r2=0.3574, P=0.0002, 
PolγAmut/mut r2=0.7052, P<0.0001, Pearson correlation analyses). Subsequent linear 
regression analysis followed by analysis of covariance allows the comparison of rates of 
weight loss from the point at which the induction regime stressor is removed. A significant 
slope deviation from zero is detected in all cases (PolγA+/+ P<0.0001, PolγA+/mut P=0.0002, 
PolγAmut/mut P<0.0001, linear regression) while significant differences between slopes were 
detected in all comparisons (PolγA+/+ versus PolγA+/mut P=0.0008, PolγA+/+ versus PolγAmut/mut 
P=0.0011, PolγA+/mut versus PolγAmut/mut P<0.0001, analysis of covariance). These data are 
presented in Figure 3-8. The weight loss observed in our model post Apc deletion is 
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consistent with that seen in other mouse models of Apc deletion (Muller et al., 2009) and is 
likely due to the functional decline or blockage of the intestine as the adenomas grow in 
addition to a reduced intake as the condition of the animals deteriorates. This is exacerbated 
in PolγAmut/mut animals in comparison with PolγA+/+ and PolγA+/mut mice following Apc 
deletion at 6 months of age. 
 
 
Figure 3-8. Correlation and linear regression analyses of mean body mass measurements over time from day 5 post Apc 
deletion. A significant negative correlation of body temperature with increasing time post Apc deletion is detected in all 
groups (PolγA+/+ r2=0.7843, P<0.0001, PolγA+/mut r2=0.3574, P=0.0002, PolγAmut/mut r2=0.7052, P<0.0001, Pearson correlation 
analyses). Comparison of linear regression slopes detected a significant difference between all groups (PolγA+/+ versus 
PolγA+/mut P=0.0008, PolγA+/+ versus PolγAmut/mut P=0.0011, PolγA+/mut versus PolγAmut/mut P<0.0001, analysis of covariance). 




In patients with FAP, as adenomas become larger and more numerous they may bleed, 
patients presenting with rectal bleeding and anaemia as a result (Half et al., 2009). Iron 
deficiency and anaemia are also common in colorectal cancer (Edna et al., 2012; Ludwig et 
al., 2004; Wilson et al., 2017), and their presence often associated with poor outcome 
(Ludwig et al., 2013; Zacharakis et al., 2010).  
 
Anaemia is also a prominent clinical symptom in mouse models of intestinal cancer. By 2 
months of age, heterozygous ApcMin mice become anaemic with death occurring around 4 
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months of age. This is attributed to an extensive adenoma burden and secondary anaemia 
due to this burden (Moser et al., 1990). As such, as part of the clinical scoring of our cohort, 
all experimental animals were monitored for the appearance of pale extremities and blood 
in the stools. Within experimental groups in which Apc was deleted at 6 months of age 
(PolγA+/+ (n=19), PolγA+/mut (n=24) and PolγAmut/mut (n=29)), 63.2% of PolγA+/+, 75% of 
PolγA+/mut and 93.1% of PolγAmut/mut animals presented with pale extremities categorised as 
mild. Moderate paling of the extremities was identified in 26.3% of PolγA+/+, 54.2% of 
PolγA+/mut and 41.4% of PolγAmut/mut animals at the clinical endpoint. Severe paling of the 
extremities was not observed in any PolγA+/+ animals, however 4.2% of PolγA+/mut and 6.9% 
of PolγAmut/mut animals were observed as such at the clinical endpoint. No experimental 
animals presented with pale extremities at the point of Apc deletion. These data suggest 
that while anaemia develops in all genotypes following Apc deletion at 6 months of age, this 
symptom is exacerbated in the presence of both the heterozygous and homozygous PolγA 
mutation. The development of anaemia in PolγA+/+ mice post Apc deletion in the absence of 
an mtDNA mutational background demonstrates that the intestinal pathology of the model 




As the appearance of pale extremities in our experimental cohort was a subjective 
observation, and an impairment of thermoregulation is associated with iron-deficiency 
anaemia in both animal (Dillmann et al., 1979) and human studies (Martinez-Torres et al., 
1984), an objective measure of body temperature was used as an additional marker of 
anaemia in this study. 
 
As part of daily clinical monitoring, body temperature was measured using subcutaneous 
RFID chips in all experimental animals. At the point of Apc deletion, a significant difference in 
body temperature was not detected between PolγA+/+ and PolγA+/mut or between PolγA+/+ 
and PolγAmut/mut (P=0.3301 and P=0.7391 respectively, one-way ANOVA with by Tukey’s 
multiple comparisons test). However, a significantly greater experimental starting 
temperature was detected in PolγA+/mut mice in comparison with PolγAmut/mut animals 
(P=0.0075, one-way ANOVA with by Tukey’s multiple comparisons test). As shown in Figure 
3-9, PolγA+/+, PolγA+/mut and PolγAmut/mut experimental groups demonstrate a significant 
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negative correlation of body temperature with increasing time post Apc deletion (PolγA+/+ 
r2=0.6325, P=0.0183, PolγA+/mut r2=0.8325, P=0.0016, PolγAmut/mut r2=0.7466, P=0.0265, 
Pearson correlation analyses). Linear regression analyses detect a significant slope deviation 
from zero in all cases (PolγA+/+ P=0.0002, PolγA+/mut P<0.0001, PolγAmut/mut P<0.0001). 
Comparison of the slopes using an analysis of covariance detected a significant difference 
between PolγA+/+ and PolγA+/mut (P=0.0140) and between PolγA+/+ and PolγAmut/mut 
(P=0.0284). A significant difference was not detected and between PolγA+/mut and 
PolγAmut/mut (P=0.9669, analysis of covariance). This suggests that anaemia and impaired 
thermoregulation are exacerbated in PolγA+/mut and PolγAmut/mut mice in comparison to 
PolγA+/+ animals following Apc deletion at 6 months of age. 
 
 
Figure 3-9. Body temperature as measured using subcutaneous RFID chips in PolγA+/+ (n=19), PolγA+/mut (n=24) and 
PolγAmut/mut (n=29) at 0, 5, 10, 15, 20, 25, 30 and 35-days post Apc deletion. A significant negative correlation of body 
temperature with increasing time post Apc deletion is detected in all groups (PolγA+/+ r2=0.6325, P=0.0183, PolγA+/mut 
r2=0.8325, P=0.0016, PolγAmut/mut r2=0.7466, P=0.0265, Pearson correlation analyses). Comparison of linear regression 
slopes detected a significant difference between PolγA+/+ and PolγA+/mut (P=0.0140, analysis of covariance) and between 
PolγA+/+ and PolγAmut/mut (P=0.0284, analysis of covariance). A significant difference was not detected and between 
PolγA+/mut and PolγAmut/mut (P=0.9669, analysis of covariance). Error bars denote mean ±SEM.  
 
As plotting the body temperature of experimental animals at precise time points does not 
necessarily reflect the condition of animals at that specific time, a more appropriate 
presentation of this data may be as an association with the clinical score of the mouse. With 
the deterioration of the condition of experimental animals, the cumulative clinical score of 
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each mouse increases taking multiple observations into account. Prior to the development 
of clinical symptoms (at cumulative clinical score zero), no significant difference is detected 
between the mean body temperature of the three experimental cohorts (PolγA+/+ versus 
PolγA+/mut; P=0.4111, PolγA+/+ versus PolγAmut/mut; P=0.9819, PolγA+/mut versus PolγAmut/mut; 
P=0.4705, one-way ANOVA with by Tukey’s multiple comparisons test in all instances). 
However, as clinical condition deteriorates, there is a significant negative correlation of 
mean body temperature with increasing clinical score in all three experimental groups post 
Apc deletion (PolγA+/+ rS=0.8411, p<0.0001, PolγA+/mut rS=0.5377, both Spearman correlation 
analyses, PolγAmut/mut r2=0.8944, p<0.0001, Pearson correlation analysis). This is presented in 
Figure 3-10. These data suggest that body temperature is a good measure of the condition of 
the animal. Linear regression analyses detect a significant slope deviation from zero in all 
cases (PolγA+/+ P<0.0001, PolγA+/mut P<0.0001, PolγAmut/mut P<0.0001). Comparison of the 
slopes using an analysis of covariance detected a significant difference between PolγA+/+ and 
PolγA+/mut (P=0.0280) and between PolγA+/+ and PolγAmut/mut (P=0.0011). A significant 
difference was not detected between PolγA+/mut and PolγAmut/mut (P=0.4139, analysis of 
covariance). This suggests that the clinical deterioration is exacerbated in PolγA+/mut and 
PolγAmut/mut mice in comparison to PolγA+/+ animals following Apc deletion at 6 months of 
age. 
 
Figure 3-10. Correlation of mean body temperature with increasing clinical score. Observations in all three groups show a 
significant negative correlation. Spearman correlation analyses of PolγA+/+ (n=15), rS=0.8411, P<0.0001, PolγA+/mut (n=15), 
rS=0.5377, P=0.0202. Pearson correlation analysis of PolγAmut/mut (n=19), r2=0.8944, p<0.0001. Comparison of linear 
regression slopes detected a significant difference between PolγA+/+ and PolγA+/mut (P=0.0280, analysis of covariance) and 
between PolγA+/+ and PolγAmut/mut (P=0.0011, analysis of covariance). A significant difference was not detected between 
PolγA+/mut and PolγAmut/mut (P=0.4139, analysis of covariance). Error bars denote mean ±SEM. 
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3.3.2.5. Tamoxifen toxicity 
 
Tamoxifen is a non-steroidal anti-oestrogen drug that has been widely used in the treatment 
of breast cancer. A strong hepatocarcinogenic effect of tamoxifen has been reported in the 
rat (Greaves et al., 1993; Williams et al., 1993), with such oestrogen receptor independent 
hepatic pathologies purported to be attributable in part to oxidative stress mediated by 
tamoxifen. Accordingly, this is of concern with regard to this study and others in which 
mitochondrial function is under scrutiny and unexpected experimental perturbation would 
confound results.  
 
The tamoxifen control mouse cohort was set up in order to assess the toxicity and potential 
effect on lifespan of the tamoxifen regime used to induce tumorigenesis in experimental 
animals. Tamoxifen control animals are wild type Lgr5 and as such do not express creERT2. 
Administration of tamoxifen to these animals does not induce the development of 
adenomas as seen in Lgr5-creERT2 heterozygous animals. Ten PolγAmut/mut and ten PolγA+/+ 
animals were aged to 6 months to allow the accumulation of mtDNA mutations before 
tamoxifen induction following the same 3mg, 2mg, 2mg, 2mg IP protocol administered to 
the lifespan cohort heterozygous for Lgr5-CreERT2. Animals were regularly monitored and 
humanely sacrificed upon the observation of three moderate or one severe clinical sign of ill 
health (Table 2-1). Lifespan data for tamoxifen control animals versus their Lgr5-CreERT2 
equivalents from the lifespan 6 cohort are shown in Figure 3-11 where both PolγA+/+ and 
PolγAmut/mut tamoxifen control mice significantly outlive their adenomatous counterparts 
(P=0.002 and P<0.0001 respectively, Mantel-Cox log rank test in both instances). These data 
suggest that the tamoxifen induction regime alone does not negatively affect lifespan.  
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Figure 3-11 (A) Kaplan-Meier survival curve depicting survival times of PolγA+/+ tamoxifen control mice and Lgr5-
CreERT2/PolγA+/+ mice. PolγA+/+ tamoxifen control mice (n=10) are greatly outliving their PolγA+/+ counterparts with Lgr5-
CreERT2 and associated adenomatous phenotype (n=16), P=0.002, Mantel-Cox log rank test.  
 
 
Figure 3-11 (B) Kaplan-Meier survival curve depicting survival times of PolγAmut/mut tamoxifen controls and Lgr5-CreERT2/ 
PolγAmut/mut mice. PolγAmut/mut tamoxifen controls (n=10) are significantly outliving their PolγAmut/mut /Lgr5-creERT2 
counterparts (n=23), P<0.0001, Mantel-Cox log rank test. 
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3.3.3. Day 23 6-month cohort 
 
In order to directly compare rates of adenoma progression between PolγAmut/mut, PolγA+/mut, 
and PolγA+/+ animals the ‘Day 23’ cohort was established. As previously, experimental 
animals were aged to either six or twelve months prior to tamoxifen induction, however all 
animals were all sacrificed at the same time point post induction. This ensured that in all 
cases, tumour initiation and progression was given the same amount of time, to allow direct 
comparisons of tumour growth between genotypes. The median survival time of PolγAmut/mut 
mice was 23 days, therefore this was chosen as the endpoint of this cohort. Intraperitoneal 
tamoxifen (T5648, Sigma Aldrich) was administered to each mouse over the course of four 
days at a concentration of 10mg/ml in sunflower oil. Day one; 300µl (3mg), day two to four; 
200µl (2mg) each day (2.2.5.). All mice were monitored daily until the experiment end point. 
Mice were euthanised using the Schedule 1 approved method of concussion of the brain 
followed by cervical dislocation (Animals Scientific Procedures Act, 1986). Due to time 
constraints, further analysis focused only on animals in which Apc deletion was induced at 
six months of age. 
 
3.3.3.1. Macroscopic adenoma burden quantification 
 
In order to quantify and compare macroscopic adenoma burden, the intestines were 
removed from mice culled at 23 days post Apc deletion, flushed with 10% neutral buffered 
formalin, opened longitudinally and pinned out flat as intestinal whole mounts. Using a 
dissecting microscope, all visible adenomas were counted, and their areas measured 
throughout the entire intestine. Adenomas were included when they were a minimum of 
1mm2. In the event of multiple adenomas appearing to have merged together, the total area 
of the lesion was measured. 
 
The quantification of macroscopic adenomas throughout the intestines of this cohort 
revealed a significantly greater total adenoma burden in the PolγAmut/mut mice (n=19) 
compared with the PolγA+/mut (n=12) and PolγA+/+ (n=13) mice. The mean adenoma burden 
within PolγAmut/mut animals (434.1mm2 ± 247) is twice that of mice heterozygous for the 
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PolγA mutation (197.7mm2 ± 118.9) and almost 4.5 times the mean adenoma burden seen in 
wild type PolγA+/+ animals (96.69mm2 ± 41.94). This is shown in Figure 3-12. 
 
Figure 3-12. Total macroscopic intestinal adenoma burden of PolγA+/+ (n=13), PolγA+/mut (n=12) and PolγAmut/mut (n=19) mice 
aged to 6 months prior to Apc deletion and culled 23 days later. PolγAmut/mut have a significantly greater adenoma burden 
than PolγA+/mut (P<0.01, one-way ANOVA followed by Tukey’s multiple comparisons test) and PolγA+/+ mice (P<0.0001, one-
way ANOVA followed by Tukey’s multiple comparisons test). Each data point represents one animal and error bars denote 
mean ±SD. 
 
3.3.3.2. Microscopic adenoma burden quantification 
 
Tamoxifen induced Apc deletion causes activation of the Wnt signalling system as described 
in 1.7.3. This results in the release of β-catenin from the cytoplasmic destruction complex. It 
is destabilised and moves to the nucleus where it activates transcription factors controlling 
cell proliferation. Beta catenin accumulates in both the cytoplasm and nucleus of cells in 
which Apc deletion has occurred. In order to microscopically quantify the adenoma burden 
within PolγAmut/mut, PolγA+/mut and PolγA+/+ mice aged to six months prior to adenoma 
induction and humanely killed 23 days later, intestinal tissues were harvested and processed 
as described in 2.2.7. and sections of colon and distal small intestine were labelled with anti-
β-catenin as described in 2.2.9.1-2. The sections adjacent to those stained with anti-β-
catenin were stained with H&E in order to determine if the tumour foci were indeed 
dysplastic. This was confirmed with the guidance of a histopathologist (Dr James Sampson, 
Consultant Histopathologist, Royal Victoria Infirmary, Newcastle). Following β-catenin 
immunohistochemistry, an intense nuclear and cytoplasmic expression of β-catenin was 
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seen in the adenomas as opposed to the cell margin demarcation observed in surrounding 
normal mucosa. A representative example of this is shown in Figure 3-13.  
 
 
Figure 3-13. Pattern of beta catenin immunohistochemical labelling in the murine colonic mucosa. An intense nuclear and 
cytoplasmic expression of β-catenin can be seen in the adenomatous region highlighted by black dashed lines. Within the 
normal crypts adjacent to the adenoma, β-catenin labelling is diminished and is largely limited to the cytoplasm and 
demarcation of cell margins. Scale bar 100µm. 
 
Sections were analysed as described in 2.2.12.1, measuring the area of each adenoma in 
addition to recording the frequency of adenomas per tissue section. Figures 3-14 and 3-15 
show typical examples of beta catenin immunohistochemistry in colonic and small intestinal 
tissue sections respectively. As can be seen in the second and third columns, adenoma foci 
demonstrate a more intense staining pattern than that of the surrounding normal mucosa. 
Non-transformed cells have clear β- catenin demarcated cell margins, whereas the 
adenomata have a more widespread, increased level of β-catenin expression within the 
nucleus and cytoplasm with cell margins less clear.  
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Figure 3-14. Beta catenin immunohistochemistry on colon tissue sections from PolγA+/+ and PolγAmut/mut mice. Scale bars 
3mm (first column) and 200µm (second and third columns). Areas demarcated by black boxes within the first column are 




Figure 3-15. Beta catenin immunohistochemistry on small intestinal tissue sections from PolγA+/+ and PolγAmut/mut mice. 
Scale bars 3mm (first column) and 200µm (second and third columns). Areas demarcated by black boxes within the first 
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Within the colon of PolγAmut/mut (n=19) and PolγA+/+ (n=13) mice, the mean frequency of 
lesions was similar (128.237 ± 42.13 and 140.462 ± 83.16 respectively) with no significant 
difference detected between these two groups (P=0.8108, one-way ANOVA followed by 
Tukey’s multiple comparisons test). Within the colons of PolγA+/mut (n=11) mice, the mean 
frequency of adenomas observed (60.36 ± 23.65) was significantly lower than in both the 
PolγAmut/mut and PolγA+/+ colon (P=0.0062 and P=0.0027 respectively, one-way ANOVA with 
Tukey’s multiple comparisons test). Within the small intestine of PolγA+/+ (n=12) and 
PolγA+/mut (n=8) mice, the mean frequency of adenomas observed was similar (145.667 ± 
50.53 and 151.125 ± 47.32 respectively) with no significant difference detected (P=0.9654, 
one-way ANOVA with Tukey’s multiple comparisons test). However small intestinal sections 
from PolγAmut/mut mice (n=16) had a significantly greater mean frequency of adenomas per 
tissue section (201.3 ± 44.71) in comparison with PolγA+/+ mice (P=0.0112, one-way ANOVA 
with Tukey’s multiple comparisons test). These data are shown in Figure 3-16 A and D. 
 
In the colon of PolγAmut/mut mice, the mean size of each adenoma (16125µm ± 6148) was 
significantly greater than that of the PolγA+/+ animals (7063.27µm ± 6447) (P=0.0004, one-
way ANOVA with Tukey’s multiple comparisons test). Similarly, the mean PolγAmut/mut small 
intestinal adenoma size (72170.2µm ± 31710) was significantly greater than that of the 
PolγA+/+ animals (37690.1µm ± 7321) (P=0.0008, one-way ANOVA with Tukey’s multiple 
comparisons test). Mean adenoma size in the small intestine of PolγA+/+ and PolγA+/mut mice 
was similar (37690.1µm ± 7321 and 40800.3µm ± 9094 respectively) and as such, mean small 
intestinal adenoma size in PolγAmut/mut mice was also significantly greater than that of 
PolγA+/mut mice animals (P=0.0070, one-way ANOVA with Tukey’s multiple comparisons test). 
These data are shown in Figure 3-16 B and E. 
 
In the colon of PolγAmut/mut mice, the mean adenoma burden represented as a percentage 
proportion of the tissue section area (8.424% ± 4.417) was significantly greater than that of 
the PolγA+/+ animals (3.135% ± 2.129) (P=0.0003, one-way ANOVA followed by Tukey’s 
multiple comparisons test). The mean adenoma burden in the colon of PolγA+/+ and 
PolγA+/mut mice was similar (3.135% ± 2.129 and 3.458% ± 2.219 respectively) and as such, 
mean colonic adenoma burden in PolγAmut/mut mice was also significantly greater than that of 
PolγA+/mut mice animals (P=0.0010, one-way ANOVA followed by Tukey’s multiple 
comparisons test). In the small intestine, a similar pattern was observed. The mean adenoma 
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burden represented as a percentage proportion of the small intestinal tissue section area in 
PolγAmut/mut mice (31.51% ± 13.57) was significantly greater than that of the PolγA+/+ animals 
(18.47% ± 10.32) (P=0.0118, one-way ANOVA followed by Tukey’s multiple comparisons 
test). The mean adenoma burden in the small intestine of PolγA+/+ and PolγA+/mut mice was 
similar (18.47% ± 10.32 and 19.49% ± 4.896 respectively) and as such, mean small intestinal 
adenoma burden in PolγAmut/mut mice was also significantly greater than that of PolγA+/mut 
mice animals (P=0.0460, one-way ANOVA with Tukey’s multiple comparisons test). These 
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Figure 3-16. Quantification of the frequency of adenomas, mean adenoma size and total adenoma burden within the colon and small intestine of experimental animals. (A, B, C) Quantification 
of the frequency of adenomas, mean adenoma size and total adenoma burden within the colon of PolγA+/+ (n=13), PolγA+/mut (n=11) and PolγAmut/mut (n=19) animals. (C, D, E) Quantification of 
the frequency of adenomas, mean adenoma size and total adenoma burden within the small intestine of PolγA+/+ (n=12), PolγA+/mut (n=8) and PolγAmut/mut (n=16) animals. Each dot represents 
the mean of one mouse. Error bars ± SD. One-way ANOVA followed by Tukey’s multiple comparison test; for all panels: * P<0.05, **P<0.01, ***P<0.001. 
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3.4. Discussion 
 
As with many malignancies, age is a major risk factor for colorectal cancer. Over the decades, 
a multitude of evolutionary and molecular mechanisms have been proposed in order to 
further our understanding of the ageing process and the organismal functional decline with 
which it is associated. An accumulation of cellular damage which occurs in a time dependant 
fashion is generally considered to be fundamental to ageing, with the amalgamation of 
numerous processes leading to this damage (Kirkwood, 2005). In 2013, López-Otín and 
colleagues summarised these processes, thus describing nine hallmarks of ageing postulated 
to contribute to the manifestation of an ageing phenotype; mitochondrial dysfunction is one 
of these hallmarks (López-Otín et al., 2013). Metabolism has been implicated in the process 
of ageing since the turn of the century, at which time it was suggested that longevity was 
inversely proportional to metabolic rate (Rubner, 1883; Rubner, 1908). The free radical 
theory of ageing (Harman, 1956) and later the mitochondrial free radical theory of ageing 
(Harman, 1972) subsequently offered a mechanistic hypothesis proposing a role of 
mitochondria in ageing. Since that time, a myriad of reports has been published 
documenting the association of mitochondrial dysfunction with an ageing phenotype in 
multiple tissue types, with reports of increased levels of mitochondrial DNA deletions and 
point mutations in ageing tissues being described from the early 1990s. Cortopassi and 
Arnheim described the presence of a specific 4977 base pair deletion in the heart and brain 
of older individuals (Cortopassi & Arnheim, 1990). The mtDNA4977 ‘common deletion’ had 
previously only been associated with mitochondrial disorders such as Kearns-Sayre 
syndrome (KSS) and progressive external ophthalmoplegia (PEO). Similarly, frequencies of 
the point mutations responsible for the mitochondrial syndromes MERFF and MELAS 
(mt.8344A>G and mt.3243A>G) were also found to increase in an age-dependant manner in 
tissues such as the brain, heart and skeletal muscle (Munscher et al., 1993; Zhang et al., 
1993). As such, these studies provided early experimental evidence in support of the 
importance of an accumulation of mitochondrial DNA mutations in normal ageing. The origin 
of clonally expanded mtDNA point mutations in ageing mitotic tissues is thought likely to be 
due to Polγ mediated errors of mtDNA replication rather than by damage incurred as a result 
of oxidative stress (Greaves et al., 2014; Kennedy et al., 2013; Zheng et al., 2006) and the 
mechanism by which single mutated mtDNA species are able to expand to high levels of 
heteroplasmy and often homoplasmy in mitotic tissues is currently understood to be 
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initiated by mutational events that occur in early life. Owing to numerous rounds of mtDNA 
replication and random segregation of mitochondria as the cell divides, the mutated species 
are able to, by chance, become the dominant clone within that cell (Greaves et al., 2014). 
Furthermore, if mtDNA mutations are acquired within the long-lived stem cells that maintain 
mitotic tissues, these mutations will be propagated into the progeny of that cell resulting in 
mosaic patterns of clonal units demonstrating biochemical defects as the mutation reaches 
high levels of heteroplasmy.  
 
With regard to the colon specifically, the exponential increase in mitochondrial dysfunction 
caused by clonally expanded pathogenic point mutations of the mitochondrial genome with 
increasing age has provided strong evidence supporting the role of these mutations in the 
ageing process (Taylor et al., 2003). Furthermore, the detection of somatic mtDNA mutations 
in human colorectal tumours (Ericson et al., 2012; He et al., 2010; Larman et al., 2012; Polyak 
et al., 1998) and their similarity to those found in the normal ageing colon suggests there 
may be a link between mitochondrial dysfunction of the ageing colon and colorectal 
carcinogenesis. Computer modelling studies also report the presence of observed 
homoplasmic mtDNA mutations in human tumours (Fliss et al., 2000; Polyak et al., 1998) as 
being plausibly generated via random mutagenesis and segregation of mtDNA molecules 
(Coller et al., 2001a). Since Warburg’s initial observation that tumour cells favour glycolytic 
over oxidative energy production, even in the presence of oxygen (Warburg, 1956) it has 
become widely accepted that metabolism is altered within many types of malignancy 
(Hanahan & Weinberg, 2011). The primary concerns of the tumour are growth and 
proliferation, and a shift towards a more glycolytic metabolism assists in providing the 
anabolic requirements necessary for this growth to occur. With this in mind and given the 
similarities in mtDNA mutation spectrum and mechanisms of expansion within mutator 
mouse and human intestinal crypts and also in human intestinal tumours, it would be 
plausible to suggest that alterations in mitochondrial function that occur as a normal process 
of ageing are able to support malignant growth within those tissues should malignant 
transformation occur. Accordingly, the PolγA mutator mouse (Kujoth et al., 2005; Trifunovic 
et al., 2004) was selected as a model of accelerated mtDNA mutagenesis with a progeroid 
phenotype and crossed with the Lgr5-EGFP-IREScreERT2/Apcflox/flox inducible colorectal 
cancer mouse in order to further investigate this hypothesised link. 
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Tumorigenesis in our experimental cohort was achieved via the tamoxifen mediated Lgr5+ 
stem cell specific activation of CreERT2 and subsequent deletion of Apc. With the complex 
pharmacological actions of tamoxifen in mind, it cannot be assumed that this regimen is 
without consequence. As previously mentioned, the hepatotoxic effect of tamoxifen has 
been described with regards to its use as an anti-cancer agent and also in relation to its use 
in tamoxifen-induced gene knockout studies (Greaves et al., 1993; Hammad et al., 2018; 
Williams et al., 1993). Less well explored is the effect of tamoxifen on the gastrointestinal 
tract. However, one study reports a striking disruption of the gastric mucosa in normal mice 
administered with a 3-day 5mg/20g tamoxifen regime. Within 3 days, a dramatic loss of 
gastric parietal cells was observed as was an increase in stem/progenitor cell proliferation 
alongside the metaplasia of zymogenic chief cells (Huh et al., 2012). A single 3mg/20g dose 
elicited similar results in the stomach, however by 3 weeks, gastric histology had returned to 
almost normal. Highly relevant to this study was the finding of no small or large intestinal 
changes in mice treated with tamoxifen when compared to those that were not (Huh et al., 
2012). Interestingly, an earlier study by the same group attributed this gastric phenotype to 
a genotoxicity caused by the Cre recombinase rather than the activating tamoxifen (Huh et 
al., 2010). This phenomenon has also been described by Bohin and colleagues, whereby the 
group use a Villin-CreERT2 mouse model to demonstrate an impaired capacity of CreERT2 
activated intestinal stem cells to regenerate following an irradiation challenge compared to 
those in which CreERT2 was absent (Bohin et al., 2018). The group rule out tamoxifen alone 
as the mediator of this damage and attribute the regeneration defect to the off-target action 
of activated Cre recombinase at cryptic LoxP sites other than the target LoxP at which 
cleavage has been engineered to occur. Importantly, this genotoxicity is resolved by 7 days 
post–tamoxifen treatment. Furthermore, the defect in Lgr5-CreERT2 mice was not as 
pronounced as observed in Villin-CreERT2 animals. As villin is expressed throughout the 
entire intestinal epithelium, CreERT2 toxicity may potentially affect additional cell 
populations such as facultative stem cells involved in the regeneration response. As only 
Lgr5+ stem cells contain the CreERT2 transgene in our experiments, this may therefore 
reduce the proportion of cells involved in crypt regeneration which are exposed to CreERT2 
toxicity. Nonetheless, this study and those also discussed highlight the importance of 
appropriate controls when using a tamoxifen activated CreERT2 system. 
 
  135 
Clinical monitoring of experimental animals post Apc deletion characterised a phenotype in 
which weight loss, anaemia and a decreasing body temperature present as condition of the 
animals deteriorates. A decline in mutator mouse weight from 6 months of age is also 
reported in other studies (Kim et al., 2019; Kujoth et al., 2005; Shabalina et al., 2017; 
Trifunovic et al., 2004). In comparing our short window of weight monitoring (~40 days) to 
the extended period of body mass monitoring by Trifunovic et al. (~9 months) it would seem 
that weight loss is more pronounced in our model. Over a 3-week period from 24 to 27 
weeks of age, mean body weight of Trifunovic PolγAmut/mut mice dropped approximately 1g 
from ~29g to 28g. Over the same period of time, mean body mass of our PolγAmut/mut mice 
dropped 2.4g from 25.7g to 23.3g, over twice the weight loss of the Trifunovic mouse. It is 
clear that this additional intestinal pathology in our model exacerbates the weight loss 
already characteristic of the mutator mouse from 6 months of age.  
 
Also characteristic of the PolγA mutator mouse model is a prominent, limiting anaemia 
attributed to a requirement of mitochondrial function for the appropriate differentiation of 
haematological stem cells (Norddahl et al., 2011). With this in mind it may be surmised that 
in this study, the reduced longevity of PolγA+/mut and PolγAmut/mut experimental animals in 
comparison to PolγA+/+ mice is a direct result of this pathology. However, anaemia is also 
frequently observed in colorectal cancer patients and has been associated with poor 
prognosis and increased risk of mortality (Mörner et al., 2017; Zhen et al., 2012). While 
blood loss via tumour haemorrhage into the bowel is a major cause of anaemia seen in 
colorectal cancer, additional mechanisms are also at play such as the release of 
inflammatory cytokines from an activated immune system and their subsequent effect on 
iron absorption and erythropoiesis (Väyrynen et al., 2018) . Nutritional deficits and 
malabsorption can also lead to iron deficiency, this mechanism potentially being particularly 
relevant in mouse models due to the preponderance of adenomas being preferentially 
located in the small intestine, the major site of iron absorption. As a subjective measure of 
anaemia in this study, the appearance of pale extremities was monitored in all experimental 
animals. Although severe paling was not noted in any PolγA+/+ mice, observations of this 
symptom at a mild level were made in 63.2% of PolγA+/+ mice and 26.3% of PolγA+/+ mice at a 
moderate level. Furthermore, pale extremities were not noted in any experimental animals 
at the point of Apc deletion at six months of age whereas 63.2% of PolγA+/+, 75% of 
PolγA+/mut and 93.1% of PolγAmut/mut animals exhibited this symptom at the end point. These 
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data strongly suggest that the anaemia observed in all experimental cohorts develops as 
adenoma burden increases following Apc deletion. Although anaemia as a result of the PolγA 
mutator phenotype alone is acknowledged, the presence of this symptom in the absence of 
an mtDNA mutator phenotype in conjunction with the significantly greater adenoma burden 
observed in PolγAmut/mut animals suggests that the intestinal pathology and thus the anaemia 
exacerbated by this burden significantly contributes to mortality.  
 
Secondary to the anaemia observed in all experimental groups is a decreasing body 
temperature or impaired thermoregulation, significantly detected in all groups as their 
physical condition deteriorates. Following a deviation below the range of thermoneutrality, 
the secretion of the thyroid hormones triiodothyronine (T3) and thyroxine (T4) form part of 
the obligatory or chemical thermogenesis response which globally increases the rate of 
cellular respiration and ATP production (reviewed in Rosenzweig & Volpe, 1999). Heat is 
generated as a by-product of mitochondrial oxidative phosphorylation raising the organismal 
metabolic rate above basal. The first two steps of thyroid hormone synthesis are catalysed 
by an iron-dependant thyroid peroxidase (TPO) (reviewed in Dunn & Dunn, 2001) and as 
such, iron deficiency anaemia is associated with both an impaired thyroid metabolism and 
diminished thermoregulatory capacity (Beard et al., 1984; Beard et al., 1990). Accordingly, 
temperature was used as an objective measure of anaemia in this study. An additional 
thermoregulatory response in mammals also involves iron and mitochondria. Known as 
adaptive or non-shivering thermogenesis, this response takes place within the mitochondria 
of brown adipose tissue (BAT) (Cannon & Nedergaard, 2004; Rothwell & Stock, 1997; Smith 
& Roberts, 1964) and centralises around the unique expression of mitochondrial uncoupling 
protein-1 (UCP-1) within this tissue. The association of UCP-1 with the mitochondria of 
brown fat deposits was first described in the 1970s (Heaton et al., 1978; Ricquier & Kader, 
1976), and while other members of the UCP family are expressed in multiple tissue types, 
UCP-1 is expressed exclusively in brown adipocyte mitochondria (Cannon et al., 1982). 
Mitochondrial uncoupling proteins reside on the inner mitochondrial membrane. Essentially, 
they function as proton transporters shuttling H+ ions back into the mitochondrial matrix 
after their generation by the electron transport chain. Where this role is normally reserved 
for ATP synthase and facilitates the production of ATP, UCPs ‘uncouple’ the generation of 
ATP from oxidative phosphorylation, instead using the proton motive force to generate heat 
(Cannon & Nedergaard, 2004). Adaptive thermogenesis is stimulated by the sympathetic 
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nervous system but also has an absolute requirement for thyroid hormone (Ribeiro et al., 
2001). Additionally, the more potent thyroid hormone T3 directly stimulates UCP-1 gene 
expression (Guerra et al., 1996; Rabelo et al., 1995). Given the anaemic phenotype of both 
the PolγA mutator and intestinal cancer models, aberrant thermoregulation in our cohort is 
unsurprising. As mitochondrial abundance is of importance and oxidative phosphorylation is 
a prerequisite to UCP-1 uncoupling and heat generation, it would follow suit that 
mitochondria dysfunctional in their oxidative phosphorylation capacity would also display 
thermogenic defects. Indeed, it has been shown that PolγAmut/mut generate much less heat 
than their wild-type counterparts, with the expression of thermogenic genes such as Ucp1 
being reduced in young (2.5-month-old) PolγAmut/mut when compared to PolγA+/+ mice (Wall 
et al., 2015). With this in mind, it may be proposed that the PolγAmut/mut genotype with 
associated anaemia and thermoregulatory defect is responsible for the shortened lifespan of 
these animals in comparison to PolγA+/+ mice. However, as is the case with review of the 
subjective measures of anaemia, a review of the data regarding the objective of measure of 
temperature also implicates the intestinal pathology as the major limiting factor in our 
model. Although at the experimental start point, a significantly greater experimental starting 
temperature was detected in PolγA+/mut mice in comparison with PolγAmut/mut animals, no 
difference in starting temperature was observed between PolγA+/+ and PolγA+/mut or between 
PolγA+/+ and PolγAmut/mut animals. This suggests that while the anaemic and thermoregulatory 
defects associated with the PolγA mutator phenotype are acknowledged, no evidence of 
these pathologies is noted at the experimental start point. As a significant negative 
correlation of temperature over time post Apc deletion was detected in all groups, including 
the PolγA+/+ group, this suggests that the intestinal pathology alone is sufficient to cause 
prominent anaemic and defective thermoregulatory symptoms in experimental animals. 
Furthermore, the detection of significant differences between linear regression slopes of 
PolγA+/+ animals in comparison to both PolγA+/mut and PolγAmut/mut mice confirms an 
exacerbation of these symptoms in the presence of age-related mtDNA mutation 
accumulation. This is supported by the correlation of mean body temperature with 
increasing clinical score in which mean body temperature in association with clinical 
deterioration decreases at a significantly greater rate per clinical score unit in both PolγA+/mut 
and PolγAmut/mut mice in comparison to PolγA+/+ animals. As a significantly greater adenoma 
burden is observed within the PolγAmut/mut colon and small intestine in comparison to 
PolγA+/+ and PolγA+/mut mice, the intestinal pathology as opposed to the systemic effects of 
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the PolγA mutator phenotype is further implicated in eliciting the clinical decline of 
experimental animals post Apc deletion. 
 
With regard to adenoma frequency in the colon, there are significantly fewer adenomata 
observed in PolγA+/mut mice when compared to both the PolγA+/+ and PolγAmut/mut animals. In 
the small intestine, there are significantly fewer adenomata observed in PolγA+/+ animals 
when compared to PolγAmut/mut mice. As adenomas were manually selected, this method of 
selection is liable to subjectivity. Particularly within the small intestine where the largest 
adenomas are observed, distinguishing discrete adenomas from one another presented with 
some difficulty and may therefore account for the variation with regard to adenoma 
frequency between animals. Alternatively, this variation may suggest that adenomagenesis 
may be impaired in the PolγA+/mut colon or PolγA+/+ small intestine due to the differences in 
genotype. However, it is understood that due to random silencing of the mutant Lgr5-eGFP-
IRES-CreERT2 allele, expression of CreERT2 and thus Apc excision is variegated or mosaic 
(Barker et al., 2007; Schuijers et al., 2014) and the observation made here in relation to a 
lower adenoma frequency in PolγA+/mut mouse colon and PolγA+/+  small intestine may be a 
result of this phenomenon. Despite the variation in colonic adenoma frequency in 
experimental animals, mean adenoma size within PolγAmut/mut mice is significantly greater 
than is observed in PolγA+/+ animals. In the case of colonic adenoma burden, a significantly 
greater adenomatous burden is observed in PolγAmut/mut mice in comparison to both 
PolγA+/mut and PolγA+/+ animals. In the small intestine, mean adenoma size and mean 
adenoma burden are significantly greater in PolγAmut/mut mice when compared to PolγA+/mut 
and PolγA+/+ animals. Taken together, these data suggest that a growth advantage is 
provided by the PolγAmut/mut genotype resulting in a more substantial adenoma burden 
within this group. With reference to the clinical data, it is apparent that this greater burden 
causes a more rapid deterioration of the condition of the PolγAmut/mut group in comparison 
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3.5. Conclusion 
 
In this chapter I have described the generation of and further characterised a novel mouse 
model combining the two pathologies of age-related mitochondrial dysfunction and 
intestinal cancer. A model of mtDNA mutation accumulation with an ageing phenotype is 
provided by the PolγA mutator mouse (Kujoth et al., 2005; Trifunovic et al., 2004) which at 
six months of age demonstrates respiratory chain dysfunction in around 60% of colonic 
crypts (Baines et al., 2014). As such, in order to investigate the potential effect that 
mitochondrial dysfunction may have on tumour growth and development, mice are aged to 
six months prior to tamoxifen induced Apc deletion which initiates adenomagenesis. The 
intestinal cancer phenotype is provided by the Lgr5-EGFP-IRES-creERT2- Apcflox/flox mouse 
(Barker et al., 2009) in which numerous microadenomas form throughout the intestine and 
colon. This is recapitulated in our model, however clinically, a deterioration in health as 
evidenced primarily by anaemia, impaired thermoregulation and weight loss is exacerbated 
in mice with mitochondrial dysfunction compared to those without, significantly reducing 
their lifespan. Analysis of the size and total adenoma burden in the colon and small intestine 
at the same time points revealed a significantly greater colonic and small intestinal adenoma 
burden with larger average adenoma size in the PolγAmut/mut mice suggesting accelerated 
adenoma growth. It is therefore hypothesised that mitochondrial dysfunction caused by an 
accumulation of somatic mtDNA mutations promotes the progression of intestinal 
adenomas.  
 
3.6. Future work – pilot studies 
 
3.6.1. Reduced tamoxifen dosage cohorts 
 
The tamoxifen induced Apc deletion regimen for experimental animals thus far followed a 
3mg, 2mg, 2mg, and 2mg dosage pattern with one IP dose on each consecutive day. Lifespan 
was significantly reduced due to the rapid development of intestinal adenomas, particularly 
in PolγAmut/mut animals, thus preventing the observation of advanced stages of disease. It was 
proposed that lifespan may be extended by reducing the initial rapid adenoma accumulation 
with a lower dose of tamoxifen, potentially allowing the observation of more advanced 
disease stages such as the progression to carcinoma or metastases as seen in human 
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patients. Animals in the 2mg tamoxifen cohort were aged to 6 months prior to 
administration of a single 2mg IP dose of tamoxifen. Clinical monitoring was carried out as 
per previous cohorts and animals were humanely sacrificed when necessary to do so. Data 
for this cohort describes a significantly shorter survival of PolγAmut/mut animals when 
compared to PolγA+/mut and PolγA+/+ mice (P=0.0010, Mantel-Cox log rank test). This is 
presented in Figure 3-17. 
 
 
Figure 3-17. Kaplan-Meier survival curve depicting survival times of 2mg tamoxifen dosage PolγA+/+ (n=10), PolγA+/mut (n=14) 
and PolγAmut/mut mice (n=11) aged to 6 months prior to Apc deletion. PolγAmut/mut mice have significantly shorter lifespans in 
comparison to PolγA+/+ and PolγA+/mut animals. Mantel-Cox log rank test P=0.0017. 
 
As hypothesised, lifespan was extended with the reduction of the initiating tamoxifen 
dosage. An increase in the median survival time post Apc deletion was observed in all three 
experimental groups, the greatest increase being observed in the PolγA+/mut group in which 
the median survival of 26 days became 72.5 days survival post Apc deletion with the reduced 
tamoxifen induction dosage. 
 
In order to ascertain whether a longer lifespan facilitated the progression of adenomas to a 
more advanced phenotype, sections were cut from the paraffin embedded colons and distal 
small intestines of these mice. Sections were stained with H&E and sample images were 
assessed by Dr Simon Buczacki, Clinician Scientist & Honorary Consultant Colorectal Surgeon, 
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CRUK, Cambridge. Example H&E micrographs of PolγA+/+ and PolγA+/mut small intestinal 
adenomas are presented in Figure 3-18. 
 
Figure 3-18. H&E labelling of small intestinal adenomas from animals administered with 2mg tamoxifen (A) H&E labelling of 
a small intestinal adenoma from a PolγA+/+ animal at 103 days post Apc deletion. (B) H&E labelling of a small intestinal 
adenoma from a PolγA+/mut animal at 149 days post Apc deletion. Scale bars 200µm. 
 
Despite the observation that adenomas appear to be taking on a more traditional 
appearance, lesions are maintaining a glandular structure without disruption of the 
basement membrane or desmoplastic stromal reaction. This casts doubt upon the 
hypothesis that this experimental cohort may demonstrate more advanced stages of 
disease, however given the extended lifespan and adenomatous morphology with a reduced 
initiating dose of tamoxifen further cohorts are currently under investigation. Single 
initiating tamoxifen dosages of 0.5, 1 and 1.5mg have been administered to PolγA+/+, 
PolγA+/mut and PolγAmut/mut animals at six months of age. It is anticipated that the reduced 
level of Cre recombination in these animals may further permit the extension of lifespan and 
disease progression.  
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3.6.2. Apc heterozygote cohort 
 
In many cases of human colorectal cancer, one mutated allele of APC is inherited with a 
mutational event later in life facilitating loss of the second allele. In an attempt to 
recapitulate this human situation and assess whether the presence of mitochondrial 
dysfunction facilitates the loss of the second copy of APC, a cohort of animals heterozygous 
for the Apcflox gene were established. Fermentation of glucose into lactate in favour of 
utilising oxidative phosphorylation facilitates the generation of anabolic products required 
for a tumour mass to proliferate. In extracts of normal intestinal tissue from ApcMin/+ mice, 
elevated lactate levels were reported when compared to tissue from wild type animals. 
Additionally, levels in metabolites such as the phosphocoline/glycerophosphocoline ratio 
(PC/GPC), were reported to be significantly greater in lamina propria tissues of ApcMin/+ 
versus wild type animals (Backshall et al., 2009). The authors suggest a metabolic difference 
between these groups of animals based upon their differing levels of functional Apc may 
constitute a permissive tumorigenic environment, or ‘field cancerisation’, leading to loss of 
Apc heterozygosity and adenoma formation. Additionally, the potential increase in 
mitochondrial generation of reactive oxygen species as a result of the PolγA mutation may 
affect loss of Apc heterozygosity. Although of a less persistent and less extensive nature, 
DNA damage caused by oxidative stress is also reported to affect nuclear, in addition to 
mitochondrial DNA (Yakes & Van Houten, 1997). A cohort of animals heterozygous for the 
Apcflox gene was therefore established in order to recapitulate the human situation and 
assess whether mitochondrial dysfunction caused by PolγA mutation facilitates loss of the 
second copy of Apc.  
 
A longer disease course was predicted in this cohort due to the excision of only one copy of 
Apc at induction. To allow for this, experimental animals were induced at 4 months of age as 
opposed to six. With some animals surviving beyond 13 months post tamoxifen induction, 
this was chosen as the experimental endpoint for PolγA+/+ (n=9) and PolγA+/mut (n=9) animals. 
PolγAmut/mut animals were not included in this cohort due to their shorter lifespan not 
permitting the longer disease course required to observe a somatic loss of heterozygosity. 
Macroscopic tumour burden data from the entire intestine of experimental animals is shown 
in Figure 3-19. 
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Figure 3-19. Total intestinal macroscopic adenoma burden from PolγA+/+ (n=9) and PolγA+/mut (n=9) Apc heterozygote mice. 
No significant difference was detected between mean adenoma burden of these groups (P=0.2878, unpaired t test). 
 
No significant difference was detected between the means of the two groups (P=0.00265, 
unpaired t test) and although this suggests mitochondrial dysfunction is not contributing to 
loss of Apc heterozygosity, all tissues require further histological analysis.
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Chapter 4. Assessment of mitochondrial dysfunction within adenomas and 




4.1.1. Mitochondrial dysfunction in ageing and cancer 
 
Advancing age is a major risk factor for malignant transformation and the development 
of cancer. As such, over 50% of neoplasms occur in individuals over the age of 70 (Siegel 
et al., 2015). Similarly, as organisms age, the efficiency of mitochondrial oxidative 
phosphorylation is impaired and alterations in mitochondrial morphology and 
abundance are observed (Shigenaga et al., 1994). The development of perturbations in 
mitochondrial function are common to both pathologies and consequently lead to a 
hypothesised link between an age-associated mitochondrial dysfunction and 
tumorigenesis.  
 
Ample evidence exists documenting the accumulation of somatic mtDNA mutations in 
ageing human post-mitotic tissues such as the brain and skeletal muscle (Brierley et al., 
1998; Corral-Debrinski et al., 1992) and in numerous replicative tissues (Fellous et al., 
2009; McDonald et al., 2008; Taylor et al., 2003). The mechanisms by which these 
mutations accumulate have historically been attributed to ROS mediated mtDNA 
damage and Polγ mediated replication errors and as such the causative effect of mtDNA 
mutation accumulation with regard to ageing has been investigated with the use of the 
PolγA mutator mouse (Kujoth et al., 2005; Trifunovic et al., 2004). Specifically, in the in 
the colon, clonal expansion of early life acquired somatic mtDNA mutations has been 
shown to diminish mitochondrial oxidative phosphorylation with advancing age in both 
humans and mice (Baines et al., 2014; Greaves et al., 2014; Taylor et al., 2003). This has 
been demonstrated using a dual histochemical assay to demonstrate cytochrome c 
oxidase (COX) and succinate dehydrogenase (SDH) enzymatic activity. In this assay 
diaminobenzidine (DAB) acts as an electron donor resulting in a brown insoluble 
compound deposition at the location of COX or complex IV activity; cells with no COX 
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activity are labelled blue upon subsequent incubation in media to demonstrate SDH 
activity. Using this assay, it has been shown that the proportion of COX-deficient colonic 
crypts exponentially increases with age in humans (Taylor et al., 2003). Single crypt and 
single cell mtDNA sequencing analyses confirmed that clonally expanded mtDNA 
mutations were the underlying cause of the COX deficiency in these crypts. In addition 
to fully COX deficient crypts, partially deficient colonic crypts are observed using this 
histochemical technique. The three-dimensional reconstruction of COX/SDH labelled 
serial sections revealed ribbons of COX deficient cells which emanate from the crypt 
base right up to the apex (Taylor et al., 2003). This represents the transmission of 
mtDNA defects from the parent stem cell harbouring these defects to the progeny of 
that parent cell which subsequently migrate along the crypt axis and COX deficiency is 
preserved. Sequencing of the mtDNA of individual cells within these ribbons confirmed 
that they had a common clonal ancestor. These analyses demonstrated that colonic 
stem cells accumulate pathogenic mtDNA mutations with age. 
 
The relationship between cancer and mitochondrial dysfunction spans almost 100 years 
from the initial observations of Warburg detailing the glycolytic phenotype favoured by 
tumour cells (Warburg, 1927; Warburg, 1956), to the current understanding that 
mitochondrial function extends beyond that of energy and anabolic precursor provision 
and is intricately linked to numerous facets of cancer biology. Following appropriate 
stimuli, mitochondria are crucial in orchestrating apoptosis; a process staunchly evaded 
by tumour cells by a number of means (reviewed in Lopez & Tait, 2015). Mitochondrial 
ROS have been linked to the promotion of invasion and metastases (Ishikawa et al., 
2008) as has the regulation of mitochondrial dynamics (Zhao et al., 2013b). 
Furthermore, the recent Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium 
reported a marked enrichment of truncating mtDNA mutations in colorectal, kidney and 
thyroid cancers with an associated upregulation of mTOR and TNFα signalling. The 
activation of such oncogenic signalling pathways further implicates the role of mtDNA 
mutations in cancer development, and a link with ageing is corroborated by the 
observation that the detection of somatic mtDNA mutations at the highest levels of 
heteroplasmy positively correlate with age (Yuan et al., 2020). The selective enrichment 
of these somatic mtDNA mutations is also proposed as an alternative mechanism by 
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which they are able to reach high levels of heteroplasmy within the tumours, 
additionally indicating a physiological advantage provided by the mutations themselves 
(Yuan et al., 2020). 
 
4.2. Aims of study 
 
In the previous chapter I demonstrated that mice with mitochondrial dysfunction caused 
by an accumulation of somatic mtDNA mutations harbour a significantly greater colonic 
and small intestinal adenoma burden than those without. In this chapter I wanted to 
fully characterise the extent of mitochondrial dysfunction within the colon and small 
intestine of experimental animals compared with controls. In this chapter I aimed to; 
 
1. Quantify the expression of mitochondrial oxidative phosphorylation complexes I, 
III, IV and V within the colonic and small intestinal adenomas of PolγA+/+ and 
PolγAmut/mut mice culled at 23 days following Apc deletion at six months age. 
 
2. Quantify OXPHOS protein expression in PolγA+/mut experimental animal colonic 
and small intestinal adenomas compared with those of PolγA+/+ mice culled at 23 
days following Apc deletion at six months age. 
 
3. Utilise the mosaic pattern of OXHPOS normal and OXPHOS deficient adenomas 
within PolγA+/mut experimental animals to investigate any correlation between 
OXPHOS protein levels and adenoma size within individual mice.  
 
4. Investigate the effect of Apc deletion on expression of mitochondrial OXPHOS 
proteins by comparing their levels within colonic and small intestinal adenomas 
to those of normal non-transformed crypts within the same mice. 
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4.3. Results 
 
4.3.1. Quantification of mitochondrial OXPHOS protein levels in intestinal adenomas 
following Apc deletion in 6-month-old PolγAmut/mut and PolγA+/+ mice 
 
With the exception of complex II, each of the complexes of the mitochondrial OXPHOS 
system are encoded in part by the mitochondrial genome, part by the nuclear genome. 
As such, mutations in the mitochondrial genome should only directly affect complexes I, 
III, IV and V protein expression. To investigate the effect of the PolγA mutation on the 
intestinal tissues, the quadruple immunofluorescence assay developed within the group 
was used. This method has been optimised for diagnostic purposes to reliably and 
robustly quantify the levels of key OXPHOS proteins thus defining biochemical 
phenotypes in genetically-defined primary mitochondrial myopathies (Rocha et al., 
2015). Initially developed to quantify complex I and IV protein abundance, the method 
was adapted for this study to include the labelling of the UQCRFS1 subunit of complex III 
and the ATPB subunit of complex V in addition to NDUFB8 of complex I and MTCO1 of 
complex IV. Due to the addition of anti-UQCRFS1 and anti-ATPB to the assay, and the 
availability of antibody isotypes, the technique was further modified with the labelling of 
two adjacent serial sections in order to accommodate all antibodies. The first section 
was labelled with anti-NDUFB8 and anti-UQCRFS1 and the second with anti-MTCO1 and 
anti-ATPB. Anti-VDAC1 was initially used as a mitochondrial mass marker, however 
punctate labelling was not observed, therefore this was replaced and labelling re-
optimised using a rabbit anti-TOMM20 as a mitochondrial mass marker. The 
immunofluorescent assay protocol is outlined in 2.2.11.3. Colonic and small intestinal 
tissue samples were labelled, and fluorescent micrographs of adenomas acquired using 
a Nikon A1R inverted point scanning confocal microscope. Confocal images were 
analysed using Image J software (NIH). Adenomas were selected as regions of interest 
(ROI) and fluorophore mean intensity values recorded for each channel before their use 
in generation of z score plots as described in 2.2.12.4. In the colon, a minimum of 20 
adenomas were manually identified from PolγAmut/mut (n=9) and PolγA+/+ (n=9) mice 
culled at 23 days post Apc deletion. Example immunofluorescent panels are presented in 
Figures 4-1 and 4-2.  
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Figure 4-1. Immunofluorescent labelling of mitochondrial OXPHOS protein expression within the PolγA+/+ and PolγAmut/mut colon 23 days after Apc deletion. A Hoescht counterstain labels 
nuclei, AlexaFluor 488 labels anti-TOMM20 primary antibody, AlexaFluor 647 labels anti-NDUFB8 and AlexaFluor 546 labels anti-UQCRFS1. The white dashed line highlights a PolγAmut/mut 
adenoma deficient in complex I and complex III. Scale bars 50µm. 
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Figure 4-2. Immunofluorescent labelling of mitochondrial OXPHOS protein expression within the PolγA+/+ and PolγAmut/mut colon 23 days after Apc deletion. A Hoescht counterstain labels 
nuclei, AlexaFluor 488 labels anti-TOMM20 primary antibody, AlexaFluor 647 labels anti-MTCO1 and AlexaFluor 546 labels anti-ATPB. The white dashed line highlights a PolγAmut/mut adenoma 
deficient in complex IV. Scale bars 50µm. 
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All PolγA+/+ colonic adenomas were found to express normal levels of all OXPHOS proteins 
investigated, with the exception of one isolated adenoma demonstrating an intermediate 
positive expression of UQCRFS1. In contrast only 36.06% and 18.75% of PolγAmut/mut colonic 
adenomas demonstrate a normal level of MTCO1 and NDUFB8 respectively when compared 
to PolγA+/+ colonic adenomas (Figure 4-3). 
 
With regard to MTCO1, 63.95% of PolγAmut/mut colonic adenomas demonstrate a reduced 
level of protein expression (15.87% intermediate positive, 22.12% intermediate negative and 
25.96% negative) when compared to PolγA+/+ adenomas. With regard to NDUFB8, 81.25% of 
PolγAmut/mut colonic adenomas demonstrate a reduced level of protein expression (27.88% 
intermediate positive, 37.5% intermediate negative and 15.87% negative) in comparison to 
PolγA+/+ adenomas. Some reduction in expression of UQCRFS1 is detected in PolγAmut/mut 
colonic adenomas (10.58% intermediate positive, 5.77% intermediate negative and 6.25% 
negative) however the remaining 77.4% retain a normal UQCRFS1 expression when 
compared to PolγA+/+ adenomas. The majority of PolγAmut/mut colonic adenomas (96.15%) 
retain normal expression of the ATPB subunit of complex V with 3.85% categorised as 
demonstrating intermediate positive expression. Importantly, it is noted that OXPHOS 
protein defects are not visibly associated with a loss of mitochondrial mass. The 
maintenance of TOMM20 expression and indeed an often-increased expression of TOMM20 
in regions of adenoma suggests that the observed deficiencies are due to defects in the 
OXPHOS proteins themselves and not merely as a result of fewer numbers of mitochondria. 
These data suggest that defects in mitochondrial oxidative phosphorylation, specifically that 
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Figure 4-3. Dot plots showing z scores calculated following quantification of mitochondrial OXPHOS protein levels in colonic 
adenomas of PolγA+/+ (n=9) and PolγAmut/mut (n=9) mice. (A) Z score plot depicting complex I and III levels. (B) Z score plot 
depicting complex IV and V levels. (C) Categorical analysis of OXPHOS protein levels in PolγAmut/mut colonic adenomas (error 
bars denote mean ±SEM). 
 
A minimum of 20 adenomas from the small intestines of PolγA+/+ (n=10) mice and 
PolγAmut/mut (n=9) were identified and imaged in the same manner as per the colon. As part 
of an MRes project, PolγA+/+ (n=5) and PolγAmut/mut (n=5) were labelled and analysed by 
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Figure 4-4. Immunofluorescent labelling of mitochondrial OXPHOS protein expression within the PolγA+/+ and PolγAmut/mut small intestine 23 days after Apc deletion. A Hoescht counterstain 
labels nuclei, AlexaFluor 488 labels anti-TOMM20 primary antibody, AlexaFluor 647 labels anti-NDUFB8 and AlexaFluor 546 labels anti-UQCRFS1. The white dashed line highlights a PolγAmut/mut 
adenoma deficient in both complex I and complex III. The red dashed line highlights a PolγAmut/mut adenoma deficient in complex I with some retention of complex III expression. Scale bars 
50µm. 
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Figure 4-5. Immunofluorescent labelling of mitochondrial OXPHOS protein expression within the PolγA+/+ and PolγAmut/mut small intestine 23 days after Apc deletion. A Hoescht counterstain 
labels nuclei, AlexaFluor 488 labels anti-TOMM20 primary antibody, AlexaFluor 647 labels anti-MTCO1 and AlexaFluor 546 labels anti-ATPB. The white dashed line highlights a PolγAmut/mut 
adenoma deficient in complex IV. The red dashed line highlights a PolγAmut/mut adenoma with retained complex IV and V expression. Scale bars 50µm
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In the small intestine, all PolγA+/+ adenomas analysed were found to express normal levels of 
each OXPHOS protein investigated. In the PolγAmut/mut small intestine however, 100% of 
adenomas demonstrate reduced levels of NDUFB8 protein expression. 80.86% were 
categorised as negative in their expression of NDUFB8, 14.35% categorised as intermediate 
negative and 4.78% categorised as intermediate positive. With regard to MTCO1, 37.63% of 
PolγAmut/mut small intestinal adenomas demonstrate a reduction in expression of protein 
(26.29% intermediate positive, 5.15% intermediate negative and 6.19% negative) while the 
remaining 62.37% retained MTCO1 expression. A reduction of UQCRFS1 expression is noted 
in 9.1% of PolγAmut/mut compared to PolγA+/+ adenomas (7.18% intermediate positive, 1.44% 
intermediate negative, 0.48% negative) while ATPB expression is retained in all PolγAmut/mut 
adenomas. Interestingly, a slight shift towards increased levels of ATPB expression above 
those of the PolγA+/+ adenomas is observed in PolγA mut/mut adenomas (Figure 4-6).  
 
Collectively, OXPHOS protein expression analysis of experimental animal colonic and small 
intestinal adenomas demonstrates an extensive reduction in the levels of expression of the 
complex I subunit NDUFB8 in PolγAmut/mut compared to PolγA+/+ adenomas. This is more 
pronounced in the small intestine where all PolγA mut/mut adenomas display reduced protein 
expression. Minimal UQCRFS1 (complex III) is detected in each compartment and ATPB 
(complex V) expression is retained throughout. Although MTCO1 (complex IV) expression is 
reduced in PolγAmut/mut adenomas in both the colon and small intestine, this defect is more 
prominent in the colon where 63.95% of PolγAmut/mut colonic adenomas demonstrate a 
reduced level of protein expression in comparison with 37.63% of PolγAmut/mut small 
intestinal adenomas. This observation may imply that the loss of MTCO1 protein is better 
tolerated within the colon than the small intestine and therefore persists. 
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Figure 4-6. Dot plots showing z scores calculated following quantification of mitochondrial OXPHOS protein levels in small 
intestinal adenomas of PolγA+/+ (n=10) and PolγAmut/mut (n=9) mice. (A) Z score plot depicting complex I and III levels. (B) Z 
score plot depicting complex IV and V levels. (C) Categorical analysis of OXPHOS protein levels in PolγAmut/mut small intestinal 
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4.3.2. Quantification of mitochondrial OXPHOS protein levels in Intestinal adenomas following 
Apc deletion in 6-month-old PolγA+/mut and PolγA+/+ mice 
 
The frequency of COX deficiency within the colonic crypts of 6-month-old PolγA+/mut mice is 
markedly lower than that of 6-month-old PolγA mut/mut animals at 5% and 60% respectively 
(Baines et al., 2014). In contrast to PolγAmut/mut colon in which OXPHOS defects are extensive, 
the assessment of PolγA+/mut tissues in which there is a mosaic pattern of OXHPOS normal 
and OXPHOS deficient crypts or adenomas allows intra-mouse comparisons to be made 
using the OXPHOS normal crypts as internal controls. As results of the previous section 
identified defects in complex I and complex IV as most prominent in PolγAmut/mut colonic and 
small intestinal adenomas, in order to assess the degree of mitochondrial OXPHOS protein 
defects within the adenomas of mice heterozygous for the PolγA mutation, the 
immunofluorescence assay was adjusted accordingly. Antibodies targeting ATPB and 
UQCRFS1 were omitted, and an immunofluorescent assay using antibodies targeting 
NDUFB8, MTCO1 and TOMM20 was carried out on the colonic and intestinal samples of an 
additional subset of 6-month-old PolγA+/mut and PolγA+/+ mice all humanely sacrificed at 23 
days post Apc deletion. Fluorescent micrographs of adenomas were acquired in the same 
manner as previously described, with manual identification of a minimum of 15 adenomas 
from the colons of PolγA+/mut (n=5) and PolγA+/+ (n=4) mice culled at 23 days post Apc 
deletion. Similarly, a minimum of 15 adenomas from the small intestines of PolγA+/mut (n=4) 
and PolγA+/+ (n=4) mice were identified and imaged as such. Confocal images were analysed 
using Image J software (NIH). Adenomas were selected as regions of interest (ROI) and 
fluorophore mean intensity values recorded for each channel.  
 
Levels of OXPHOS protein expression within PolγA+/mut colonic adenomas are not reduced to 
the same degree as seen in PolγA mut/mut mice (Figure 4-7). In the colon, 18.71% of PolγA+/mut 
adenomas demonstrate reduced levels of NDUFB8 and 19.43% display reduced levels of 
MTCO1, compared with 81.25% for NDUFB8 and 63.95% for MTCO1 in PolγA mut/mut colonic 
adenomas. Levels of OXPHOS proteins within PolγA+/mut colonic adenomas are significantly 
lower than in PolγA+/+ colonic adenomas sampled in which all adenomas with the exception 
of one, express NDUFB8 and MTCO1 within a normal range (Figure 4-8).  
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Figure 4-7. Immunofluorescent labelling of mitochondrial OXPHOS protein expression within the PolγA+/+ and PolγA+/mut colon 23 days after Apc deletion. A Hoescht counterstain labels nuclei, 
AlexaFluor 488 labels anti-TOMM20 primary antibody, AlexaFluor 546 labels anti-MTCO1 and AlexaFluor 647 labels anti-NDUFB8. The white dashed line highlights a PolγA+/+ adenoma with 
retained complex IV and I expression. The red dashed line highlights a PolγA+/mut region of adenoma demonstrating reduced levels of complex IV and I. Scale bars 50µm.
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Figure 4-8. Dot plot showing z scores calculated following quantification of mitochondrial OXPHOS protein levels in colonic 
adenomas of PolγA+/+ and PolγA+/mut mice. (A) Z score plot depicting complex I and IV levels in colonic adenomas of PolγA+/+ (n=4) 
and PolγA+/mut (n=4) mice. (B) Categorical analysis of adenoma OXPHOS protein levels in PolγA+/mut (n=4) colonic adenomas (error 
bars denote mean ±SEM). 
 
 
In the small intestine, no MTCO1 defect was observed in PolγA+/+ adenomas, however 92.59% of 
PolγA+/mut adenomas sampled demonstrated a reduced level of NDUFB8 (35.8% intermediate 
positive, 39.51% intermediate negative and 17.28% negative). As expected, this does not reach the 
same level of NDUFB8 deficiency as observed within the PolγA mut/mut small intestine; 80.86% of 
PolγA mut/mut small intestinal adenomas were classified as NDUFB8 negative in comparison to 
17.28% of PolγA+/mut small intestinal adenomas (Figure 4-10). Example immunofluorescent panels 
of the PolγA+/+ and PolγA+/mut small intestine are presented in Figure 4-9. 
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Figure 4-9. Immunofluorescent labelling of mitochondrial OXPHOS protein expression within the PolγA+/+ and PolγA+/mut small intestine 23 days after Apc deletion. A Hoescht counterstain 
labels nuclei, AlexaFluor 488 labels anti-TOMM20 primary antibody, AlexaFluor 546 labels anti-MTCO1 and AlexaFluor 647 labels anti-NDUFB8. The white dashed line highlights a PolγA+/+ 
adenoma with retained complex IV and I expression. The red dashed line highlights a PolγA+/mut region of adenoma demonstrating reduced levels of complex IV and I. Scale bars 50µ
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A  B  
 
Figure 4-10. Dot plot showing z scores calculated following quantification of mitochondrial OXPHOS protein levels in small 
intestinal adenomas of PolγA+/+ and PolγA+/mut mice. (A) Z score plot depicting complex I and IV levels in small intestinal 
adenomas of PolγA+/+ (n=4) and PolγA+/mut (n=5) mice. (B) Categorical analysis of adenoma OXPHOS protein levels in 
PolγA+/mut (n=4) small intestinal adenomas (error bars denote mean ±SEM). 
 
Using the PolγA+/mut mouse in which a more mosaic pattern of OXPHOS deficiency is 
observed, this analysis aimed to ascertain if adenoma size was associated with a defect of 
either MTCO1 or NDUFB8 in favour of the other. In order to investigate the potentially 
differing contribution of each defect to adenoma growth, a further analysis was undertaken 
in which adenoma size was correlated to the level of expression of MTCO1 and NDUFB8 in 
individual adenomas. As discussed in chapter 3, differentiating small intestinal adenomas 
from one another at the microscopic level was challenging. As colonic adenoma size could be 
more accurately quantified, only adenomas of the colon were included in this analysis. The 
surface area of each PolγA+/mut colonic adenoma included in the OXPHOS protein level 
analysis was measured using Image J software generating a pixels2 value which was plotted 
against adenoma NDUFB8 and MTCO1 mean intensity individually. NDUFB8 and MTCO1 
mean intensities were expressed as a ratio to TOMM20 expression, thus accounting for 
variability in mitochondrial mass between adenomas. Data were not normally distributed 
therefore a Spearman non-parametric correlation analysis was used.  
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Adenoma size correlation with MTCO1 and NDUFB8 protein expression demonstrates a 
weak but significant negative correlation in both cases (MTCO1 rS=-0.1744, P=0.0415; 
NDUFB8 rS=-0.3150, P=0.0002). This suggests that a larger adenoma size in the PolγA+/mut 
colon is associated with lower levels of expression of both MTCO1 and NDUFB8 protein. The 
strength of each correlation, as described by Spearman’s correlation coefficient (rS) 
however, designates a slightly stronger correlation of adenoma size with NDUFB8 expression 
than that of MTCO1. This is indicated by the larger numeric value of rS NDUFB8 (-0.3150) 











Figure 4-11. Correlation of OXPHOS protein levels with colonic adenoma size in PolγA+/mut mice. (A) Correlation of colonic 
adenoma size in PolγA+/mut mice (n=5) with MTCO1 mean fluorescent intensity normalised to that of TOMM20. Spearman’s 
rank non-parametric correlation analysis indicates a weak negative correlation (rS=-0.1744, P=0.0415). (B) Correlation of 
colonic adenoma size in PolγA+/mut (n=5) mice with NDUFB8 mean fluorescent intensity normalised to that of TOMM20. 
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In order to investigate the relationship between colonic adenoma size and OXPHOS protein 
abundance across a greater range of protein levels, colonic adenomas from PolγA+/+ (n=4) 
and PolγA mut/mut (n=5) mice were analysed in the same manner as per PolγA+/mut colonic 
adenomas; the surface area of each PolγA+/+ and PolγA+/mut colonic adenoma was measured 
using Image J software generating a pixels2 value with the simultaneous acquisition of 
NDUFB8 and MTCO1 mean intensity values.  
 
The inclusion of size and OXPHOS protein expression data obtained from colonic adenomas 
of PolγA+/+ and PolγAmut/mut mice strengthened the correlation of adenoma size with 
expression of MTCO1 and NDUFB8 protein. This is evidenced by an increase in the numeric 
values of rs in both cases. A weak correlation as denoted by an rS value of -0.2608 is observed 
in the MTCO1 analysis, however a moderately strong relationship between adenoma size 
and NDUFB8 protein expression is indicated by an rS value of -0.4569 (Figure 4-12). These 
data suggest complex I deficiency is the predominant driver of the increased rate of 
adenoma growth. However, it should be noted that adenomas were not categorised into 
solely MTCO1 or NDUFB8 deficient groups, a factor which may influence the interpretation 
of the data. For example, a subset of relatively large adenomas deficient in both MTCO1 and 
NDUFB8 would lead to the strengthening of the correlation between adenoma size and the 
deficiency of both proteins without assessing the contribution of each individual defect. The 
further delineation of adenomas into solely MTCO1 or NDUFB8 deficient groups would 
therefore assist in defining the correlation between protein deficiency and adenoma size  
  






Figure 4-12. Correlation of OXPHOS protein levels with colonic adenoma size in PolγA+/+, PolγA+/mut and PolγAmut/mut mice. 
(A) Correlation of colonic adenoma size in PolγA+/+ (n=4), PolγA+/mut (n=5) and PolγAmut/mut (n=5) mice with MTCO1 mean 
fluorescent intensity normalised to that of TOMM20. Spearman’s rank non-parametric correlation analysis indicates a weak 
negative correlation (rS=-0.2608, P=<0.0001). (B) Correlation of colonic adenoma size in PolγA+/+ (n=4), PolγA+/mut (n=5) and 
PolγAmut/mut (n=5) mice with NDUFB8 mean fluorescent intensity normalised to that of TOMM20. Spearman’s rank non-
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4.3.3. Quantification of OXPHOS protein levels intestinal adenomas compared with non-
transformed mucosa in 6-month-old PolγAmut/mut and PolγA+/+ mice 
 
Whilst undertaking the analysis of OXPHOS protein levels within the adenomas of the 
PolγAmut/mut, PolγA+/mut and PolγA+/+ colon and small intestine, it was noted that PolγA+/+ 
adenomas also appeared to display lower levels of OXPHOS proteins, in comparison to 
adjacent normal non-transformed crypts, suggesting that Apc loss alone is sufficient to 
initiate metabolic remodelling in terms of OXPHOS protein expression levels. This was 
formally investigated by quantifying OXPHOS protein levels in the non-transformed crypts 
from PolγA+/+ and PolγAmut/mut colon and small intestine. A minimum of 17 crypts from 
PolγA+/+ (n=9) and PolγAmut/mut (n=7) were selected as regions of interest and fluorophore 
mean intensity values recorded for each channel as previously carried out in the adenoma 
analysis. Using the non-transformed PolγA+/+ crypts as the control population from which z 
scores were derived, additional plots were created and included all areas sampled (PolγA+/+ 
normal crypts and adenomas, PolγAmut/mut normal crypts and adenomas) for both the colon 
and small intestine. In the colon, all PolγA+/+ non-transformed normal crypts express levels of 
NFUFB8, UQCRFS1, MTCO1 and ATPB within a normal range. In the small intestine, OXPHOS 
protein levels within PolγA+/+ non-transformed normal crypts are also categorised as normal 
with the exception of two crypts demonstrating a reduced level of NDUFB8. Within PolγA+/+ 
colonic and small intestinal adenomas, reductions in the expression levels of OXPHOS 
protein subunits in comparison with those of PolγA+/+ non-transformed normal crypts are 
observed, suggesting a programmed downregulation of these proteins following Apc 
deletion. With regard to PolγAmut/mut non-transformed normal colonic and small intestinal 
crypts, reductions in OXPHOS protein levels are observed in comparison with PolγA+/+ non-
transformed normal crypts as expected. Further reductions are noted with regard to the 
comparison of OXPHOS protein levels in PolγAmut/mut colonic and small intestinal adenomas 
with those of PolγAmut/mut non-transformed normal colonic and small intestinal crypts. These 
observations suggest that while a programmed OXPHOS protein downregulation in response 
to Apc deletion is observed in the PolγA+/+ colon and intestine, this mechanism is accelerated 
in PolγAmut/mut animals (Figure 4-13). 
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Figure 4-13. Dot plots showing z scores calculated following quantification of mitochondrial OXPHOS protein levels in 
colonic and small intestinal adenomas of PolγA+/+ and PolγAmut/mut mice (A) Dot plots showing z scores calculated following 
quantification of mitochondrial OXPHOS protein levels in colonic adenomas of PolγA+/+ and PolγAmut/mut mice (n=9 per 
genotype) and normal non-transformed crypts of PolγA+/+ mice (n=9 in complex I and III analysis, n=6 in complex IV and V 
analysis) and PolγAmut/mut mice (n=9 in complex I and III analysis, n=7 in complex IV and V analysis). (B) Dot plots showing z 
scores calculated following quantification of mitochondrial OXPHOS protein levels in small intestinal adenomas from 
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In order to directly compare the expression levels of individual proteins in each 
compartment and investigate the effect of Apc loss alone on OXPHOS protein expression, 
raw mean intensity values were plotted and analysed. Raw mean intensity analysis of 
fluorophore labelled anti-TOMM20 indicates that in comparison to normal non-transformed 
crypts of the colon and small intestine, both PolγA+/+ and PolγAmut/mut adenomas 
demonstrate an increase in mitochondrial mass (Figures 4-14 A and 4-15 A, P<0.0001 in all 
instances, one-way ANOVA with Tukey’s multiple comparisons test). With regard to 
mitochondrial OXPHOS proteins, a significant decrease in the expression of each subunit 
investigated was seen in both colonic and small intestinal adenomas of PolγA+/+ adenomas 
compared to PolγA+/+ normal non-transformed crypts (P<0.0001 in all instances, one-way 
ANOVA with Tukey’s multiple comparisons test).  
 
Although mean mitochondrial mass is significantly higher in PolγAmut/mut colonic and small 
intestinal adenomas compared to normal non-transformed crypts, individual OXPHOS 
protein subunits demonstrate different patterns of expression. As may be expected in 
tissues in which there are already pronounced deficiencies of complex I or NDUFB8, 
following Apc deletion, no significant differences were detected in the expression levels of 
NDUFB8 in PolγAmut/mut colonic and small intestinal adenomas compared to normal non-
transformed crypts (Figures 4-14 B and 5-15 B; P>0.05, one-way ANOVA with Tukey’s 
multiple comparisons test). With regard to the UQCRFS1 subunit of complex III, no 
difference is detected between the expression in PolγAmut/mut colonic and small intestinal 
adenomas versus normal crypts (Figures 4-14 C and 4-15 C; P>0.05, one-way ANOVA with 
Tukey’s multiple comparisons test). Mean intensity values representing the expression of the 
MTCO1 subunit of complex IV and ATPB subunit of complex V are both shown to be 
significantly decreased in PolγAmut/mut colonic and small intestinal adenomas in comparison 
to normal non-transformed crypts in both compartments (Figures 4-14 D; P<0.05 and E 
P<0.001, 4-15 D and E; P<0.001, one-way ANOVA with Tukey’s multiple comparisons test in 
all instances). Together these data suggest that with regard to mitochondrial mass and 
mitochondrial OXPHOS subunit expression, significant metabolic remodelling is occurring in 
response to Apc deletion within the PolγA+/+ and PolγAmut/mut intestinal tract.  
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Figure 4-14. Raw mean intensity values for individual mitochondrial OXPHOS protein subunits and TOMM20 as a marker of 
mitochondrial mass within the PolγA+/+ and PolγAmut/mut colon. Each dot represents a single crypt or adenoma. Error bars 
denote mean ±SD. Data were analysed using a one-way ANOVA with Tukey’s multiple comparison test. All P values are: * 
p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
  169 
 
 
Figure 4-15. Raw mean intensity values for individual mitochondrial OXPHOS protein subunits and TOMM20 as a marker of 
mitochondrial mass within the PolγA+/+ and PolγAmut/mut small intestine. Each dot represents a single crypt or adenoma. 
Error bars denote mean ±SD. Data were analysed using a one-way ANOVA with Tukey’s multiple comparison test. All P 
values are: * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.4. Discussion 
 
Since the initial observations of Otto Warburg, in which a tumour specific preference for 
glycolytic metabolism even in the presence of oxygen was described, altered metabolism has 
been fundamentally associated with cancer (Warburg, 1927; Warburg, 1956). Despite the 
energetic inefficiency of ‘aerobic glycolysis’ versus mitochondrial oxidative phosphorylation, 
much evidence in favour of the Warburg Effect is in existence today and glycolysis remains a 
primary metabolic phenotype amongst cancers (Hu et al., 2013). Although heterogeneous 
between different malignancies, mitochondrial oxidative phosphorylation is also commonly 
found to be down regulated in human neoplasms (Gaude & Frezza, 2016); a pathology 
common to numerous ageing human tissues. With regard to the human colon specifically, 
defective oxidative phosphorylation is ascribed to an age-related expansion of somatic 
mtDNA point mutations (Greaves et al., 2010; Greaves et al., 2014; Taylor et al., 2003) and as 
such the contribution of age-related mtDNA mutations to the pathogenesis of colorectal 
cancer is investigated therein.  
 
The previous chapter detailed the development of a mouse model in which an age-related 
accumulation of PolγA mediated mtDNA mutations was established prior to the intestinal 
Lgr5 stem cell specific deletion of Apc at six months of age. The development of a 
significantly greater intestinal adenoma burden resulting in shortened lifespan in mice with 
age-related mitochondrial dysfunction compared with those without suggests that a 
permissive environment conducive to increased adenoma growth may be created by age-
related mitochondrial dysfunction. Indeed, permissive changes in mitochondrial function 
have been described within the normal human pre-malignant colorectal mucosa. An 
increased mitochondrial copy number and expression of genes governing mitochondrial 
fission and fusion, DRP1 and OPA1 respectively, have been reported as significantly 
increased in patients harbouring precancerous lesions elsewhere in the colon when 
compared to control patients. Also increased in patients compared to controls was 
expression of the uncoupling protein, UCP2 (Cruz et al., 2017). Unlike the structurally similar 
UCP1, the uncoupling activity of UCP2 remains elusive. Instead, UCP2 has been shown to 
play a more prominent role in metabolic regulation by diverting TCA cycle intermediates 
away from mitochondrial oxidative metabolism towards biosynthetic processes (Vozza et al., 
2014). Facilitating the development of a Warburg-like metabolic environment, such changes 
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are likely attributable to multiple components such as disorders of metabolic dysregulation 
including diabetes and obesity, chronic inflammation and hypoxia, all of which can 
contribute to metabolic perturbations (reviewed in Seth Nanda et al., 2020). Representing 
another potential contributor is the age-associated decline in mitochondrial function, which 
with specific regard to the impact of age-related mtDNA mutations on oxidative 
phosphorylation, may also encourage a Warburg-like environment by virtue of its 
dysfunction. 
 
Presented in this chapter is a thorough analysis of the expression of mitochondrial oxidative 
phosphorylation complex subunits within the colon and small intestine of mice following 
Lgr5 stem cell specific Apc deletion. The genotypes of PolγAmut/mut, PolγA+/mut and PolγA+/+ 
mice predispose animals to high, intermediate and negligible levels of mtDNA mutation 
respectively with the resultant intestinal phenotypes having been extensively characterised 
and compared to that of normal ageing humans (Baines et al., 2014). The aim of this study 
was to quantify the levels of OXPHOS defects within the adenomas of the PolγAmut/mut and 
PolγA+/mut mice, both of which display a significantly greater adenoma burden compared to 
PolγA+/+ mice. At each stage of the analysis, the prevailing OXPHOS defect in PolγAmut/mut and 
PolγA+/mut mice occurs in complex I of the respiratory chain. As the largest of the 
mitochondrial oxidative phosphorylation protein complexes, also occupying the largest 
proportion of the mitochondrial genome, simple probability dictates that random 
mutational events affecting mtDNA are most likely to occur within complex I genes. The 
main function of complex I is to catalyse the transfer of electrons from TCA cycle and fatty 
acid oxidation generated NADH to ubiquinone while simultaneously translocating four 
protons from the mitochondrial matrix into the intermembrane space (Wikström, 1984). In 
addition to the proton translocation by complexes III and IV, this creates the electrochemical 
gradient necessary for ATP synthesis (Mitchell, 1961). The generation of reactive oxygen 
species is also an important function of complex I and it is considered the primary source of 
mitochondrial ROS (St-Pierre et al., 2002). This occurs when errant electrons reduce oxygen 
as it gains access to the flavin moiety of the NADH binding site or the ubiquinone binding 
site, producing the superoxide anion (O2-) (Hirst et al., 2008). At a cellular level, complex I is 
thus involved in maintaining cellular redox and ROS balance which have implications for 
survival and proliferation, in addition to the role it plays in energetic and metabolic control. 
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Recent decades have seen numerous reports of mtDNA defects in multiple cancer subtypes, 
however no clear consensus has been decided upon with regard to the tumour promoting 
(Kim et al., 2016) or tumour supressing (Iommarini et al., 2014) functions these mutations 
may confer. It is becoming apparent that while mtDNA mutations alone are insufficient to 
initiate neoplastic transformation, the specific location, species and heteroplasmy of 
mutation with regard to mitochondrially encoded complex I proteins can mediate different 
effects within the tumour setting.  
 
An important event in tumour progression is the stabilisation of hypoxia inducible factor 
(HIF-1α). As its name suggests, HIF-1α mediates the activation of a response by which 
tumour cells adapt to the reduced availability of oxygen. The expression of glycolytic genes is 
upregulated (Semenza et al., 1994), pyruvate dehydrogenase kinase expression prevents the 
entry of acetyl-coA into the TCA cycle (Kim et al., 2006) and mitochondrial oxygen 
consumption is downregulated (Papandreou et al., 2006). Each of these events converge to 
inhibit mitochondrial aerobic respiration and promote a glycolytic Warburg-like phenotype, 
however a requirement for mitochondrial complex I has been shown in this context 
(Calabrese et al., 2013). Regulating the stability of HIF-1α are the prolyl hydroxylase enzymes 
(PHDs), which in turn are regulated by levels of the TCA intermediates α-ketoglutarate (α-
KG) and succinate (SA) (Selak et al., 2005). As NADH accumulation inhibits the activity of α-
ketoglutarate dehydrogenase of the TCA cycle (Bunik et al., 1990), defective complex I 
function can perturb the α-KG/SA ratio in favour of α-KG negatively affecting the hypoxic 
response. In osteosarcoma cell lines in which a homoplasmic m.3571insC mutation in the 
MT-ND1 gene disabled complex I activity, restoration of enzyme activity via allotopic 
expression of wild-type ND1 rescued the disturbed α-KG/SA ratio and HIF-1α destabilisation 
observed in mutant cells (Calabrese et al., 2013). Also demonstrated by the same group; 
homoplasmic ND1 mutations conferring a milder effect on complex I activity 
(m.3460G>A/MT-ND1) did not induce HIF1α destabilisation or inhibit tumour growth as was 
the case with severe complex I mutations (Iommarini et al., 2014). Accordingly, these 
observations have led to the understanding that while defects that exert mild effects on 
complex I may have little or no impact on tumorigenicity, those that are severe may in fact 
be detrimental to tumour growth. This may seem somewhat contradictory to the findings 
described in this work in which severe complex I defects are observed in the intestinal 
adenomas of PolγAmut/mut mice. However, the continued progression of complex I deficient 
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osteosarcoma and colorectal carcinoma cell lines in nude mouse xenografts over time 
despite a reduction in HIF-1α stabilisation suggests an activation of adaptive mechanisms 
(Kurelac et al., 2019). It is well understood that components of the tumour 
microenvironment can greatly influence tumorigenicity and also the response to 
therapeutics (reviewed in Binnewies et al., 2018). Indeed, complex I and HIF-1α deficient 
xenografts displayed stroma-associated angiogenesis with an increased infiltration of pro-
tumorigenic tumour associated macrophages at both 10- and 30-days post-transplantation. 
The elimination of macrophages from complex I deficient colon carcinoma xenografts 
substantially reduced xenograft growth in nude mice. Furthermore, the transduction of 
complex I deficient osteosarcoma cells with a constitutively expressed HIF-1α vector reduced 
the frequency of tumour associated macrophages in xenografts, thus implicating complex I 
deficiency associated HIF-1α destabilisation as the mechanism by which they are recruited 
(Kurelac et al., 2019). Although this work was conducted with the use of NDUFS3 deficient 
cell lines, this does not necessarily absolve mitochondrially encoded complex I defects of 
similar pro-tumorigenic adaptations. In-depth fluorescence-activated cell sorting (FACS) 
analysis of our PolγA+/+ and PolγAmut/mut mouse immune cell population has not detected any 
significant differences in the small intestinal immune cell microenvironment between 
genotypes prior to Apc deletion (Smith et al., 2020). However future investigations must 
include the analysis of key microenvironment components in experimental animals in which 
adenomagenesis has been induced in order to ascertain the effect the immune 
microenvironment may have on tumour growth. Interestingly, a recent study in which 
growth screens at 21%, 5%, and 1% oxygen tensions were used to identify gene sets with 
relative fitness defects in high or low oxygen revealed genes encoding complex I as 
‘selectively essential’ (Jain et al., 2020). Using CRISPR-Cas9 mediated knockouts of nuclear 
encoded subunits of mitochondrial complex I in human embryonic kidney cells, it was 
demonstrated that in conditions of very low oxygen (1%), complex I mutants grew equally as 
well as complex I competent cells (Jain et al., 2020). While hypoxia may indeed be 
therapeutic in complex I deficient mitochondrial disease models in that low oxygen delivery 
can improve cellular fitness (Jain et al., 2019; Jain et al., 2016), in oxygen-deprived tumours, 
particularly in the intestine in which oxygen levels are already physiologically low, complex I 
deficiency may inadvertently promote tumour cell fitness by virtue of its ‘buffering’ by 
hypoxia (Jain et al., 2020).  
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Additional mutations in mitochondrially encoded complex I genes have been investigated 
and further mechanisms with regard to tumour promotion described. The Akt growth and 
survival promoting pathway was reportedly activated by aberrant ROS production in human 
cell lines harbouring a heteroplasmic frameshift m.12417insA/MT-ND5 mutation leading to 
enhanced tumorigenesis (Sharma et al., 2011). Similarly, ND6 nonsense and missense 
mutations in lung adenocarcinoma cell line cybrids also activate the Akt pathway in a ROS-
dependant manner (Yuan et al., 2015). In the same study, a significant correlation between 
missense and nonsense ND6 mutations and pathological grade, tumour stage and lymph 
node metastasis were reported in human lung adenocarcinoma samples. Furthermore, the 
migratory distance of the lung adenocarcinoma cell line cybrids was significantly further in 
those with ND6 nonsense and missense mutations suggesting the promotion of migration 
and invasion by these mutations (Yuan et al., 2015). The induction of epithelial-to-
mesenchymal transition (EMT) is an important step in the progression of epithelial-derived 
carcinomas in achieving dissemination to distant sites via metastasis (reviewed in Tsai & 
Yang, 2013). Correlated with a poor prognosis, the upregulation of EMT is also associated 
with downregulation of OXPHOS in multiple cancer types (Gaude & Frezza, 2016). With 
specific regard to complex I defects, albeit nuclear encoded, the reduced expression NDUFB8 
has been implicated in EMT as highly invasive breast carcinoma cells display reduced levels 
of this protein in comparison to cells with a weakly invasive phenotype (Lunetti et al., 2019). 
At this point it would be pertinent to mention that while NDUFB8 is not a requirement of 
complex I enzyme activity, it is integral to its assembly and also to supercomplex formation 
with complex III (Lunetti et al., 2019). While mutations in mitochondrial complex I genes 
ND1, ND2 and ND6 genes can severely affect complex I assembly (Gorman et al., 2015; Kirby 
et al., 2004; Ugalde et al., 2007; Ugalde et al., 2003) and potentially expression of NDUFB8, 
mutations in ND3 and ND5 may affect complex I assembly in varying degrees (McFarland et 
al., 2004; Shanske et al., 2008). Defects in these genes may therefore remain undetected by 
immunofluorescent techniques targeting NDUFB8 as utilised in this study. In the absence of 
commercially available antibodies against mitochondrially encoded complex I subunits this 
does represent a limitation of the study. 
 
Complex IV, also known as cytochrome c oxidase, represents the final, rate limiting enzyme 
of the mitochondrial respiratory chain. In the current study, the expression of complex IV, 
specifically the mitochondrially encoded MTCO1 (COXI) subunit has been shown to be 
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reduced in expression within intestinal adenomas of PolγAmut/mut and PolγA+/mut mice 
compared to PolγA+/+ animals and also in PolγA+/+ intestinal adenomas compared to non-
transformed crypts. An increased risk of ovarian cancer has been associated with mutations 
in the COXI (MTCO1) gene (Permuth-Wey et al., 2011) as has an increased tumorigenicity in 
prostate cancer cybrids (Petros et al., 2005). Furthermore, the recent Pan-Cancer Analysis of 
Whole Genomes (PCAWG) Consortium report COXI as the most frequently mutated mtDNA 
protein-encoding gene in breast, cervical and bladder cancers (Yuan et al., 2020). With 
regard to nuclear encoded subunits of complex IV, the converse upregulation of and tumour 
promoting activity of these proteins has been reported in several cancer types (Bini et al., 
1997; Fu et al., 2006; Wu et al., 2000). Indeed, in a lymphoblastic leukaemia cell line 
overexpressing the anti-apoptotic Bcl-2 protein involved in tumour evasion of apoptosis, 
exposure to oxidative stress leads to a Bcl-2 mediated enhanced translocation of the 
nuclear-encoded COX5a subunit to the mitochondria resulting in enhanced COX activity 
(Chen & Pervaiz, 2010). shRNA mediated knockdown of nuclear encoded complex IV 
subunits COX4i1 and COX5b however, has been shown to elicit a glycolytic metabolic shift, 
reduced membrane potential and to induce invasive and anchorage independent growth 
characteristics in myoblasts (Srinivasan et al., 2016).  
 
As has been described in relation to complex I, the location of specific mutations and thus 
the protein subunit they affect can have differing consequences in the tumour setting. In 
addition, the cooperation of mitochondrial function with classical driver mutation mediated 
tumorigenicity such as in KRAS driven lung adenocarcinoma (Weinberg et al., 2010) adds a 
further layer of complexity. As such it is becoming apparent that a great metabolic 
heterogeneity exists among different tumour types and the contribution of OXPHOS function 
to tumorigenicity cannot be generalised. Despite the increasing interest in targeting 
mitochondrial oxidative phosphorylation as a cancer therapy, a further consideration to be 
made lies with the observation that many tumours exhibit a metabolic intra-tumoral 
heterogeneity. A glycolytic tumour bulk phenotype with small populations of cancer stem 
cells reliant on mitochondrial oxidative phosphorylation has been described within several 
tumour types including pancreatic, colonic and ovarian cancers (Pastò et al., 2014; Song et 
al., 2015; Viale et al., 2014; Ye et al., 2011). With hindsight, the inclusion of an anti-GFP 
antibody within the immunofluorescent cocktail used in this study in order to label the Lgr5+ 
stem cell population within intestinal adenomas would have been extremely useful in 
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visualising the extent of such metabolic heterogeneity in this study. This represents an 
avenue that may benefit from future investigation. 
 
4.5. Future work 
 
Given that the tumour microenvironment plays an important role in the progression of 
malignancies (reviewed in Hanahan & Weinberg, 2011), this represents an area which 
requires investigation with regard to Apc deficient adenoma growth within the intestine of 
PolγA mutator mice. The contributions of numerous components of the tumour 
microenvironment for example immune cells and mesenchymal cells such as cancer 
associated fibroblasts (CAFs) and adipocytes may be as equally influenced by age-related 
mitochondrial dysfunction as the tumour cells themselves. Although in-depth FACS analysis 
of PolγA+/+ and PolγAmut/mut mouse immune cell populations did not detect any significant 
differences in the small intestinal immune cell microenvironment between genotypes prior 
to Apc deletion, this does not reflect any changes that may occur following transformation 
as a result of tumour-secreted factors and metabolites. Accordingly, FACS analysis or 
immunohistochemical investigation of PolγA+/+ and PolγAmut/mut intestinal tissues primarily 
focusing on the major immune cell populations as per (Smith et al., 2020) would be 
extremely useful in investigating any microenvironmental changes associated with age-




In conjunction with results of the previous chapter in which a greater intestinal adenoma 
burden is observed in animals with age-associated mtDNA mutations compared to those 
without, data presented here confirms that mitochondrial dysfunction is indeed present 
within adenomas and as such may contribute to the promotion of adenoma growth in these 
animals. A prominent defect in complex I of the mitochondrial electron transport chain is 
observed in PolγAmut/mut compared to PolγA+/+ adenomas of both the colon and small 
intestine. As the largest of the mitochondrial oxidative phosphorylation protein complexes, 
also occupying the largest proportion of the mitochondrial genome, simple probability 
predicts that random mutational events affecting mtDNA are most likely to occur within 
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complex I genes. Furthermore, the subsequent loss of complex I protein may be better 
tolerated than a loss of complex III or complex V, defects of which are infrequently observed 
within PolγAmut/mut adenomas.  
 
Although the mtDNA mutational burden observed in the PolγAmut/mut intestine is significantly 
greater than that observed in the natural course of ageing in the human intestine, the same 
defect is observed in PolγA+/mut adenomas in which a similar mtDNA mutation load has been 
reported in PolγA+/mut mice at 18 months and humans at 70 years (Baines et al., 2014). 
Despite undergoing investigation at an earlier point at which the mtDNA mutational burden 
is of a lesser amplitude, early dysplastic adenomatous lesions in these mice also 
demonstrate reduced expression of mitochondrial complex I. Furthermore, a significant 
negative association between the expression of NDUFB8 used as marker of complex I, and 
the size of adenomas is observed in the PolγA+/mut colon. The additional observation that in 
comparison to non-transformed crypts, PolγA+/+ adenomas also demonstrate reduced levels 
of complex I and to a lesser degree complex IV, suggests that the down regulation of 
OXPHOS components occurs as a tumour promoting mechanism in the absence of pre-
existing mitochondrial oxidative phosphorylation defects. This is supported by the work of 
Pate et al., in which a shift towards a glycolytic metabolism is promoted by Wnt/β-catenin 
mediated transcriptional activation of pyruvate dehydrogenase kinase 1 (PDHK1) and a 
resultant inhibition of pyruvate flux to mitochondrial respiration in colorectal cancer cells 
(Pate et al., 2014). Although the specific mechanisms by which adenoma growth is promoted 
in our PolγAmut/mut and PolγA+/mut adenomas remains to be elucidated, data presented here 
suggests that these mechanisms are enhanced by age-associated mtDNA mutation induced 
mitochondrial dysfunction.  
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Chapter 5. Quantification of cell proliferation and apoptosis in adenomas of the 




5.1.1. Proliferation and apoptosis in cancer 
 
Despite the extensive heterogeneity observed between and within cancers of all 
denominations, there are fundamental characteristics which are common to all. The escape 
of tumour cells from the normal constraints that regulate cell growth and division permits 
the unchecked proliferation that is a basic requirement for malignant growth. Equally in 
order to survive, tumour cells must evade the cellular mechanisms which, in response to the 
numerous stresses of malignant growth, are in place to facilitate their removal. Sustaining 
proliferative growth and resisting cell death are therefore two critical hallmarks of cancer 
(reviewed in Hanahan & Weinberg, 2011). 
 
In order to maintain growth and progress through the cell cycle, there are various means by 
which tumour cells can manipulate growth factor signalling to their advantage. Firstly, they 
may upregulate the expression of cell surface growth factor receptors, thus increasing their 
sensitivity to mitogenic signalling. Epidermal growth factor receptor (EGFR) is one such 
receptor tyrosine kinase that has been well characterised and is frequently upregulated in 
lung and breast cancer and glioblastoma. EGFR activation in cancer is often attributed to 
genetic lesions which increase gene or protein expression (Lee et al., 2006; Red Brewer et 
al., 2013), however tumour cells may also produce EGFR ligands themselves, further 
potentiating their own growth via autocrine signalling (Wilson et al., 2012). Activating 
mutations within signal transduction pathways downstream of growth factor receptors 
represent another avenue by which tumour growth may be constitutively activated. The Ras-
Raf-ERK mitogen activated protein kinase (MAPK) and PI3K-Akt-mTOR pathways are two 
such systems which when dysregulated by the acquisition of activating mutations in pathway 
intermediates results in enhanced cellular proliferation and survival in many cancer types 
(Davies et al., 2002; Samuels et al., 2004) . Increases in proliferative signalling in cancer cells 
may also occur when negative feedback systems which usually function to inhibit signalling 
in the presence of sufficient activated protein are disabled. For example, despite the 
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preservation of the negative feedback program in BRAF V600E mutant malignant melanoma, 
these cells are resistant to feedback inhibition and transcriptional output of the Ras-Raf-ERK 
pathway is enhanced (Pratilas et al., 2009). Conversely, the therapeutic targeting of effector 
proteins such as mTORC1 in the PI3K-Akt-mTOR pathway may paradoxically lead to 
increased activation of the system as existing negative feedback is removed (Tabernero et 
al., 2008). Finally, tumour derived cytokines and miRNA containing microvesicles can induce 
the conversion of normal fibroblasts into cancer associated fibroblasts (CAFs) (Albrengues et 
al., 2015; Pang et al., 2015). The reciprocal production of cytokines, chemokines and growth 
factors by CAFs can thus promote growth but can additionally support invasion and 
metastases (Duda et al., 2010; Erez et al., 2010; Kuchnio et al., 2015) . 
 
In the process of malignant growth, tumour cells encounter numerous stressors such as 
increased DNA damage, hypoxia and nutrient deprivation. Under normal circumstances, as 
the impact of these stressors reaches a critical threshold, ‘stressed’ cells are eliminated as 
apoptotic pathways are triggered. The survival of cancer cells therefore is impacted heavily 
by their ability to evade or supress such apoptotic signalling (reviewed in Evan & Vousden, 
2001). There are two apoptotic signalling pathways that are well conserved between 
different species of animal and represent the predominant routes by which cell death is 
programmed. Known as death receptors, cell surface pro-apoptotic proteins including Fas 
(also known as CD95 or APO1), the tumour necrosis factor (TNF) receptors and the TNF-
related apoptosis inducing ligand (TRAIL) receptors, relay apoptotic signals and mediate cell 
death in response to extrinsic ligand binding (Itoh et al., 1991; Smith et al., 1994; Wiley et al., 
1995). This represents the extrinsic pathway while within the cell, mitochondria act in 
response to death signals such as DNA damage, oncogene activation or withdrawal of 
growth factors leading to apoptosis via the intrinsic pathway (reviewed in Wang & Youle, 
2009). Critical to both pathways are a group of protease enzymes known as caspases which 
once activated, proteolytically cleave cellular components facilitating the deconstruction of 
the cell. Synthesised as latent molecules, their cleavage results in their activation and is 
usually carried out by upstream caspases. The primary initiating caspase of the extrinsic 
apoptotic pathway is caspase 8, while that of the intrinsic pathway is caspase 9 (Li et al., 
1997; Muzio et al., 1996). Ultimately, both primary initiators result in the activation of a core 
group of effector caspases; caspase-3, caspase-7, and indirectly caspase-6 which induce 
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plasma membrane blebbing, cell body shrinkage, DNA fragmentation and consequent cell 
death (Fernandes-Alnemri et al., 1996; Srinivasula et al., 1998; Stennicke et al., 1998) . 
 
The mechanisms by which tumour cells evade the apoptotic machinery are diverse and 
involve the dysregulation of both extrinsic and intrinsic components. The increased 
expression of decoy death receptors which compete for death ligand binding and thus 
reduce apoptotic signalling have been described with regard to Fas (Pitti et al., 1998) and 
TRAIL mediated mechanisms (Marsters et al., 1997; Pan et al., 1997; Sheridan et al., 1997). 
Similarly, expression of key oncogenes such as Ras have been shown to down regulate the 
expression of death receptors (Fenton et al., 1998). Downstream of death receptor 
activation, the degradation of the key initiator caspase of the extrinsic apoptotic pathway; 
caspase 8, has been described in a colorectal cancer cell line further promoting apoptotic 
resistance (Zhang et al., 2005). Within the intrinsic pathway, caspase 9 activation is preceded 
by pro-apoptotic Bcl-2 family member mediated promotion of mitochondrial outer 
membrane permeability (MOMP) facilitating the release of cytochrome c (Li et al., 1997). As 
MOMP is considered the point of no return with regards cell death, the prevention of this 
phenotype via the upregulation of anti-apoptotic and down-regulation of pro-apoptotic Bcl-2 
proteins, has been frequently described in cancer (reviewed in Campbell & Tait, 2018). As for 
the extrinsic pathway and degradation of caspase 8, the inhibition of caspase 9 within the 
intrinsic pathway also mediates apoptosis evasion in cancer cells. As cytochrome c is 
released from the mitochondria, it binds and activates the apoptotic protease activating 
factor-1 (Apaf-1) forming the caspase 9 cleaving apoptosome. Diminished functioning of 
Apaf-1 has been described in terms of its allelic loss in human pancreatic cancer (Kimura et 
al., 1998), its epigenetic modification and transcriptional silencing in metastatic melanoma 
(Soengas et al., 2001) with post-translational phosphorylation of Apaf-1 also being described 
as an inhibitory mechanism (Deming et al., 2004; Martin et al., 2005b). First discovered in 
baculoviral genomes, the inhibition of apoptosis (IAP) family of proteins (Birnbaum et al., 
1994; Crook et al., 1993), particularly X-linked XIAP can perturb apoptosis by binding to and 
inhibiting caspases 9, 7 and 3 (Deveraux et al., 1998; Deveraux et al., 1997; Roy et al., 1997). 
Additional human IAP family members such as melanoma inhibitor of apoptosis (ML-IAP) 
have less potent caspase inhibiting activity than XIAP, however they exert their anti-
apoptotic effects by sequestering second mitochondria-derived activator of caspase (SMAC) 
which is released from the mitochondria concomitantly with cytochrome c. This prevents 
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SMAC from inhibiting XIAP and accordingly apoptosis is attenuated (Vucic et al., 2005). Many 
human IAP family members are overexpressed in numerous cancers, thus representing an 
important means by which apoptotic evasion is achieved in malignant tissues (reviewed in 
Fulda & Vucic, 2012). 
 
5.2. Aims of study 
 
It has been established that age-associated mitochondrial dysfunction is associated with a 
greater adenoma burden within the colon and small intestine of PolγAmut/mut compared to 
PolγA+/+ mice. In order to investigate the underlying cause of this, the aim of this study was 
to quantify the opposing processes of proliferation and apoptosis within intestinal 
adenomas. When injected intraperitoneally into the mouse, thymidine analogues 
incorporate into the DNA of cells during S phase of the cell cycle. Subsequent 
immunofluorescent labelling of these analogues allows the quantification of the number of 
cells which have replicated from the time of injection to the time of death. Using a double 
labelling method with two different thymidine analogues administered at specific time 
points, the specific objectives of this study were as follows. 
1. To identify the sub-population of Lgr5+ stem cells within PolγAmut/mut and PolγA+/+ 
colonic and intestinal adenomas using an anti-EGFP marker. 
2. To quantify, within colonic and small intestinal adenomas: 
a. The frequency of cells which have divided within 28 hours using an anti-CldU 
marker. 
b. The frequency of newly divided cells using an anti-IdU marker. 
c. The frequency of cells which have re-entered the cell cycle as identified by 
colocalisation of anti-CldU and -IdU markers. 
3. To quantify the frequencies of apoptotic cells within PolγAmut/mut and PolγA+/+ colonic 
and intestinal adenomas using anti-cleaved caspase 3 immunohistochemistry. 
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5.3. Results 
 
As described in section 2.2.10, PolγAmut/mut (n=5) and PolγA+/+ (n=5) mice were administered 
with two different thymidine analogues by intraperitoneal (IP) injection at timed intervals. 
Administration of IP CldU at two specific time points on the 15th day post Apc deletion 
facilitated exposure to this analogue for a period of 24 hours prior to administration of the 
second thymidine analogue. Cells that have replicated and synthesised DNA during these 24 
hours will incorporate CldU, detectable with an anti-CldU primary antibody. On the 16th day 
post Apc deletion, mice were administered with a single dose of the second analogue; IdU 
before humane sacrifice four hours later. Incorporation of IdU into the newly synthesised 
DNA of replicating cells and subsequent labelling with an anti-IdU antibody allows the 
quantification of cells that have re-entered the cell cycle in the four hours prior to their 
death. As the clinical condition of experimental animals had been monitored in detail in 
previous studies, it was deemed that a cull date for this study must be earlier than the 
previously used 23 days post Apc deletion. At 23 days post Apc deletion, the condition of 
PolγAmut/mut animals had deteriorated considerably and it would be unethical to subject mice 
to a series of intraperitoneal injections at this stage. Microadenomas become visible within 
the Lgr5-EGFP-Ires-CreERT2/Apcflox/flox colon at around 14 days post Apc deletion, with the 
small intestine bearing slightly larger adenomas at this time point (Barker et al., 2009). As 
such, to ensure adenoma growth while minimising distress to animals, 15 days post Apc 
deletion was chosen as an appropriate time point to administer thymidine analogues. As 
described in section 2.2.11.2, colonic and small intestinal sections from PolγAmut/mut and 
PolγA+/+ mice were immunofluorescently labelled in order to identify replicating cells in 
which CldU and IdU had been incorporated. For each mouse, 20 colonic and 20 small 
intestinal adenomas were manually identified, and immunofluorescent images acquired 
using a Zeiss AxioImager M1 fluorescent microscope. Example micrographs of typical 
labelling in the colon and small intestine are presented in Figures 5-1 and 5-2 respectively. 
Small intestinal section labelling and quantification was carried out by Matthew Hunt as part 
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Figure 5-1. Immunofluorescent identification of double thymidine analogue incorporation within colonic adenomas of PolγA+/+ and PolγAmut/mut mice. A Hoescht counterstain labels nuclei, 
AlexaFluor 546 labels anti-EGFP targeted against the EGFP construct of Lgr5+ cells, AlexaFluor 647 labels anti-CldU identifying cells which have replicated once in the 24 hour period following 
initial administration, AlexaFluor 488 labels anti-IdU primary antibody identifying cells which have replicated once in the 4 hour period prior to death. The final panel shows a merge of all 
channels in which colocalisation of both analogues is identified by a yellow/white colouration. This identifies cells which have re-entered the cell cycle within the 28 hours prior to death. The 
white dashed line highlights regions of adenoma in each panel. Scale bars 50µm. 
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Figure 5-2. Immunofluorescent identification of double thymidine analogue incorporation within small intestinal adenomas of PolγA+/+ and PolγAmut/mut mice. A Hoescht counterstain labels 
nuclei, AlexaFluor 546 labels anti-EGFP targeted against the EGFP construct of Lgr5+ cells, AlexaFluor 647 labels anti-CldU identifying cells which have replicated once in the 24 hour period 
following initial administration, AlexaFluor 488 labels anti-IdU primary antibody identifying cells which have replicated once in the 4 hour period prior to death. The final panel shows a merge 
of all channels in which colocalisation of both analogues is identified by a yellow/white colouration. This identifies cells which have re-entered the cell cycle within the 28 hours prior to death. 
The white dashed line highlights regions of adenoma in each panel. Scale bars 50µm. 
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5.3.1. Adenoma size quantification 
 
A significant difference in adenoma size between PolγAmut/mut and PolγA+/+ mice at 23 days 
post Apc deletion was observed in previous studies. In order to confirm that this difference 
was still seen at the earlier cull date of 16 days post Apc deletion, total nuclei in each colonic 
and small intestinal adenoma were identified with the use of a Hoescht nuclear counterstain 
and manually quantified. In both the colon and small intestine, PolγAmut/mut adenomas are 
significantly larger than those of PolγA+/+ mice at 16 days post Apc deletion (P<0.01, Mann-
Whitney U test, Figure 5-3). Pre-existing data supported a prediction in the direction of a 
difference between samples, therefore a one-tailed test was used. 
 
 
 A             B  
Figure 5-3. Mean frequencies of nuclei within colonic and small intestinal adenomas of thymidine analogue labelled PolγA+/+ 
and PolγAmut/mut mice. At 16 days post Apc deletion, adenomas within the colon (A) and small intestine (B) of PolγAmut/mut 
mice (n=5 in all groups) are significantly larger than those observed in PolγA+/+ mice animals (P<0.01, one-tailed Mann-
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5.3.2. Adenoma proliferation characterisation 
 
Within each adenoma, the frequency of cells incorporating only CldU, only IdU, and cells 
incorporating both analogues together were manually quantified. This respectively identified 
cells which have replicated once within the 24 hours following initial CldU administration, 
once within the four hours prior to death, and cells which have re-entered the cell cycle 
during the 28-hour period of thymidine analogue administration.  The frequencies of cells 
incorporating one or both thymidine analogues were significantly greater within both the 
colonic and small intestinal adenomas of PolγAmut/mut in comparison with PolγA+/+ mice 
(P<0.001, linear mixed effect model, Figure 5-4). The use of a linear mixed effect model 
quantifies the effect of genotype on frequency of cells per group whilst accounting for the 
variation between individual animals which is included as a random effect. PolγAmut/mut 
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A  
B  
Figure 5-4. Quantification of the frequency of thymidine analogue incorporation in all cells of colonic and small intestinal 
adenomas of PolγA+/+ and PolγAmut/mut mice (n=5 in all groups). (A) colon, (B) small intestine. Each dot represents the mean 
frequency of cells per adenoma in one animal. PolγAmut/mut adenomas are significantly more proliferative than those of 
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5.3.3. Lgr5+ stem cell proliferation characterisation 
 
A primary antibody against the EGFP component of the Lgr5-EGFP-Ires-CreERT2 construct 
allowed Lgr5+ stem cells to be identified and quantified. As the cells of origin of the 
intestinal adenomas of the mice, a difference in the frequencies of Lgr5+ stem cells between 
the PolγAmut/mut and PolγA+/+ groups could represent a factor which may contribute to the 
difference in adenoma burden observed. As in the previous section, the frequency of cells 
incorporating only CldU, only IdU, and cells incorporating both analogues together were 
manually quantified. In this analysis, only EGFP+ Lgr5+ cells were included, thus 
characterising the proliferative capacity of the stem cell compartment.  
 
Within adenomas of the PolγAmut/mut colon and small intestine, Lgr5+ stem cells are 
significantly more numerous than within PolγA+/+ adenomas (P<0.001, linear mixed effect 
model, Figure 5-5). However, a significant difference with regard to the proliferative rate of 
Lgr5+ cells is detected only within the small intestine. In the colon, no significant difference 
of single or double thymidine analogue incorporation is detected, indicating that while 
PolγAmut/mut colonic adenomas harbour a greater number of Lgr5+ stem cells, these cells are 
no more proliferative than their wild type counterparts (Figure 5-5A, linear mixed effect 
model). In addition to the significantly greater frequency of Lgr5+ stem cells within 
PolγAmut/mut small intestinal adenomas, this population demonstrates a significantly greater 
degree of single and double thymidine analogue incorporation than the PolγA+/+ Lgr5+ 
population (P<0.001, linear mixed effect model). In summary, at 16 days post Apc deletion, 
Lgr5+ stem cells are more abundant in both colonic and small intestinal PolγAmut/mut 
adenomas in comparison to PolγA+/+ adenomas, however this population is more 
proliferative only in the small intestine.  




Figure 5-5. Quantification of the frequency of thymidine analogue incorporation in Lgr5+ cells of colonic and small intestinal 
adenomas of PolγA+/+ and PolγAmut/mut mice (n=5 in all groups). (A) colon, (B) small intestine. Each dot represents the mean 
frequency of cells per adenoma in one animal. Within the small intestine (B), the Lgr5+ stem cell population of PolγAmut/mut 
adenomas is significantly more abundant and significantly more proliferative than that of PolγA+/+ adenomas (P<0.001, 
linear mixed effect model). Within the colon (A), the Lgr5+ stem cell population of PolγAmut/mut adenomas is significantly 





  190 
5.3.4. Adenoma apoptotic index 
 
In cells undergoing apoptosis, the inactive proenzyme caspase 3 is cleaved into two smaller 
fragments which re-associate to form an active caspase enzyme. This enzyme, in its active 
state, activates other caspases and appropriate targets within the apoptotic cell. 
Immunohistochemistry using an antibody against the larger (17 kDa) cleaved fragment of 
caspase 3 allows identification and quantification of apoptotic cells. Sections from the colon 
of PolγAmut/mut (n=7) and PolγA+/+ (n=9) experimental animals culled at 23 days post Apc 
deletion were labelled, and a minimum of 10 randomly selected adenomas from each 
section imaged using bright field microscopy on a Zeiss AxioImager M1 microscope. Similarly, 
small intestinal sections from PolγAmut/mut (n=9) and PolγA+/+ (n=9) 23 days post Apc deletion 
were labelled with anti-cleaved caspase 3 and imaged in the same manner. Total number of 
nuclei per foci and the number of cleaved caspase 3 (CC3) positive cells per foci were 
manually counted using Zen 2 Lite software (Zeiss). Example micrographs showing typical 
labelling within PolγA+/+ and PolγAmut/mut colonic and small intestinal adenomas are shown in 
Figure 5-6 (A). In both the colon and small intestine PolγAmut/mut adenomas harbour a 
significantly smaller proportion of apoptotic cells per foci than those of the PolγA+/+ animals 
(P<0.05 and P<0.001 for the colon and small intestine respectively, linear mixed effect 
model, Figure 5-6 (B). 
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 B   C  
Figure 5-6. Cleaved caspase 3 immunohistochemical labelling and quantification of apoptotic cells within PolγA+/+ and 
PolγAmut/mut colonic and small intestinal adenomas (A) CC3 immunohistochemical labelling within PolγA+/+ and PolγAmut/mut 
colonic and small intestinal adenomas. CC3 positive cells are highlighted with black arrows. Scale bars colon; 100µm, scale 
bars small intestine; 60µm. (B, C) Quantification of apoptotic cells in colonic and small intestinal adenomas identified using 
cleaved caspase 3 immunohistochemistry in mice 23 days post Apc deletion. (B) The proportion of apoptotic cells per 
adenoma is significantly smaller in the colon of PolγAmut/mut (n=7) compared to PolγA+/+ (n=9) mice (P<0.05, linear mixed 
effect model). (C) The proportion of apoptotic cells per adenoma is significantly greater in the small intestine of PolγAmut/mut 
(n=9) compared to PolγA+/+ (n=9) mice (P<0.001, linear mixed effect model). Each data point represents the mean of 
multiple measurements taken from >10 adenomas in one animal. Error bars denote mean ±SEM.
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5.4. Discussion 
 
Results presented in this chapter have characterised the proliferative and apoptotic indices 
of colonic and small intestinal adenomas within mice with and without pre-existing PolγA 
mediated mitochondrial dysfunction. Double thymidine analogue labelling of mice revealed 
a significantly greater rate of replication in PolγAmut/mut colonic and intestinal adenomas 
when compared to PolγA+/+ animals. The identification of the sub-population of Lgr5+ stem 
cells within adenomas allowed the proliferative index of this compartment to be 
investigated independently and while in the small intestine Lgr5+ stem cells were found to 
be significantly more proliferative within PolγAmut/mut versus PolγA+/+ adenomas, this 
significance was not observed within the colon. In the colon, although PolγAmut/mut adenomas 
in their entirety demonstrated enhanced proliferation in comparison to PolγA+/+ adenomas, 
this was not reflected in the Lgr5+ stem cell compartment and as such suggests differing 
contributions to adenoma growth derived from each cellular compartment.  
 
In contrast to the stochastic tumour theory in which all cells possess the potential to initiate 
and propagate a tumour, the cancer stem cell theory describes a tumour as originating from 
a small subpopulation of stem cells; the cancer stem cells (Bonnet & Dick, 1997). These 
subgroups of cells are capable of long-term self-renewal and can differentiate into multiple 
cell types (Reya et al., 2001). They generate progeny cancer cells responsible for maintaining 
the tumour mass, are largely resistant to conventional chemo and radiotherapies and bear 
specific molecular markers. According to this theory, it is the cancer stem cell population 
that drives tumour progression. Cell division is either symmetrical, with a division giving rise 
to daughter stem cells, or asymmetrical with a division giving rise to one daughter stem cell 
and one progenitor cell with the ability to differentiate but with limited proliferative 
capacity. This gives rise to a tumour in which there is a hierarchical organisation, descended 
from the proliferative cancer stem cell compartment, much like the tissue from which the 
tumour is derived. It may be however, that the stochastic and stem cell theories are not 
entirely independent of one another. With genomic instability and an altered 
microenvironment, the progeny of the cancer stem cells may be subject to additional 
mutagenesis events bestowing them with tumorigenic potential transforming them into new 
cells of origin. Indeed, a normal tissue response to injury sees the de-differentiation of 
committed small intestine secretory cells back to a proliferative stem cell state (Buczacki et 
  193 
al., 2013; van Es et al., 2012). Within the tumour microenvironment, it has also been 
demonstrated that an increase in inflammatory signalling, namely NF-κB also induces de-
differentiation in non-stem cells of the intestine, causing them to acquire stem-like 
proliferative qualities (Schwitalla et al., 2013). Additionally, a recent study in a colorectal 
cancer mouse model demonstrates that while fundamental to tumour initiation, Lgr5+ cells 
are not essential for tumour maintenance. Ablation of Lgr5+ cells resulted in a less efficient 
tumour growth, but a growth, nonetheless, maintained by proliferative Lgr5- cells (de Sousa 
e Melo et al., 2017). With these findings in mind, consideration of the proliferative data 
taken from the colonic adenomas of PolγAmut/mut and PolγA+/+mice may suggest that while 
imperative in adenoma initiation in this model, the growth and progression of colonic 
adenomas may not be entirely dependent on the Lgr5+ stem cell compartment.  
 
Within the small intestine, an important contribution from stem-cell supportive Paneth cells 
may be relevant. In addition to the secretion of the growth factors EGF and TGFα, and the 
Wnt and Notch signalling ligands Wnt3 and Dll4 respectively, Paneth cells also produce 
antimicrobial peptides involved in host defence and immunity. As such, Paneth cells are 
regarded as important regulators of stem cell function (Sato et al., 2011b). In normal small 
intestinal crypts, Rodriguez-Colman et al. report the reliance of crypt base Paneth cells on a 
glycolytic metabolism with their inhibition preventing organoid growth. Conversely, a 
primarily oxidative metabolic phenotype was observed in Lgr5+ stem cells with inhibition of 
mitochondrial activity impairing the growth of intestinal organoids (Rodríguez-Colman et al., 
2017). Similarly, in comparison with intestinal organoids derived from wild type mice, those 
derived from PolγAmut/mut animals demonstrate limited growth (Fox et al., 2012). This 
suggests that both cell types and metabolic signatures support normal stem cell function and 
crypt development, however the reliance of organoid Lgr5+ cells on an oxidative metabolism 
may represent an artefact of culture as in vivo, PolγAmut/mut crypts are clearly maintained by 
Lgr5+ cells despite their impaired oxidative phosphorylation (Fox et al., 2012). With 
reference to colorectal cancer, Rodríguez-Colman et al propose a scenario in which cells 
comprising the tumour bulk favour a glycolytic, Warburg-like metabolism with the Lgr5+ 
stem cells relying on OXPHOS. With regard to observations made in this chapter, the 
mitochondrial dysfunction seen in the adenomas of PolγAmut/mut animals may therefore be 
contributing to the increased proliferation of the Lgr5+ progeny: the tumour bulk, via an 
enhanced use of glycolytic metabolic pathways. The Lgr5+ stem cells themselves may exhibit 
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increased rates of proliferation within the small intestine as a result of the additional 
support they receive from the Paneth cells. Although Apc deletion abrogates the Lgr5+ 
requirement for exogenous Wnt, a recent study has identified Paneth cells as important 
modulators of immune escape in colorectal cancer. The indoleamine-2,3-dioxygenase-1 
(IDO1) tryptophan degrading enzyme was found to be expressed extensively within the 
Paneth cells of ApcMin murine adenomas with IDO1+ Paneth cells also being identified in 
human CRC. Via the depletion of tryptophan and generation of the immune-suppressive 
metabolite kynurenine, IDO1 facilitates the cell cycle arrest of cytotoxic CD8+ T-lymphocytes 
and promotes immune suppressive regulatory T cell (Treg) differentiation. Accordingly, the 
ablation of IDO1 via the deletion of the IDO1 regulatory transcription factor Stat1 resulted in 
smaller tumours with increased frequencies of CD8+ T cells and reduced numbers of 
infiltrating Treg cells in ApcMin mice (Pflügler et al., 2020). Additionally, in the context of 
inflammatory bowel disorders, Paneth cell specific mitochondrial dysfunction has recently 
been reported as central to the development of ileitis with Paneth cell abnormalities linked 
to de-differentiation (Jackson et al., 2020). Given the links between ageing, inflammation 
and tumorigenesis, Paneth cell mitochondrial dysfunction may represent an important 
mechanism by which adenoma growth is promoted within the PolγAmut/mut small intestine.  
 
The loss of Apc has profound implications for intestinal crypt homeostasis and pathology. A 
key component of the Wnt signalling pathway which regulates intestinal stem cell self-
renewal, Apc loss results in constitutive activation of a transcriptional complex that another 
critical Wnt pathway component; β-catenin forms with transcription factor 4 (Tcf-4) (Korinek 
et al., 1997). Several targets of the β-catenin-Tcf-4 transcription complex have been 
identified, one of which, the proto-oncogene c-myc has been established as the critical 
driver of the proliferative phenotype associated with Apc loss in the murine intestine 
(Sansom et al., 2007). Since early observations that Myc overexpression facilitated the 
growth of fibroblasts even in the absence of mitogenic stimulus (Armelin et al., 1984), the 
growth promoting activities of the transcription factor such as cell-cycle progression, 
promotion and differentiation inhibition have been extensively characterised. Paradoxically, 
in addition to the growth promoting capacity of Myc, a strong induction of apoptosis is also 
associated with Myc overexpression (Askew et al., 1991; Evan et al., 1992; Neiman et al., 
1991; Wyllie et al., 1987). The mechanisms by which Myc regulates apoptosis include 
activation of the p53 tumour suppressor protein (Hermeking & Eick, 1994; Wagner et al., 
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1994), the disruption of the balance of pro and anti-apoptotic effectors in favour of pro-
apoptotic components such as Bax (Dansen et al., 2006; Juin et al., 2002; Soucie et al., 2001) 
and the inhibition of anti-apoptotic mediators such as Bcl-2, Bcl-xL and Bag-1 (Eischen et al., 
2001a; Eischen et al., 2001b; Zhang et al., 2011). Myc can also augment cellular sensitivity to 
receptor conveyed death signals (Klefstrom et al., 1994), however tumour cells have evolved 
mechanisms by which Myc mediated apoptosis can be evaded. For example, Myc 
upregulation is commonly associated with anti-apoptotic Bcl-2 family member upregulation 
in human cancers (Beroukhim et al., 2010). Additionally, the abundance of Myc protein and 
the cellular environment in terms of growth factor availability or the methylation/acetylation 
status of Myc target DNA binding sites can reportedly influence Myc activity (Askew et al., 
1991; Fernandez et al., 2003; Guccione et al., 2006). Although mitochondrial dysfunction in 
terms of defective oxidative phosphorylation has been associated with increased levels of 
apoptosis (Kujoth et al., 2005; Wang et al., 2001), in the malignant context of oncogene 
activation, diminished oxidative phosphorylation may have differing consequences. Indeed, 
in mtDNA deficient p0 143B osteosarcoma cell lines in which Myc expression is reportedly 
high (Chen et al., 2018), the absence of functional oxidative phosphorylation and ensuing 
reduction in inner mitochondrial membrane potential (∆ψm) was associated with the 
reduced activation of caspase 3 and an enhanced resistance to staurosporine induced 
apoptosis (Dey & Moraes, 2000). Similarly, a reduced apoptotic index was demonstrated in 
cybrids harbouring pathogenic mitochondrial complex V mATP6 mutations in vitro and also 
in vivo in tumours derived from mutant cybrid transplantation in comparison to those 
bearing wild type mtDNA (Shidara et al., 2005). Furthermore, in tumours derived from 
cybrids harbouring a heteroplasmic complex I ND5 frameshift mutation, an increased 
tumorigenicity coupled with an enhanced apoptotic resistance is observed in comparison to 
tumours derived from cybrids bearing a homoplasmic level of the same mutation. 
Mechanistically, increased levels of mitochondrial ROS in heteroplasmic mutants are 
proposed as a means by which tumour survival is augmented in these clones (Park et al., 
2009). Further studies by the same group using the aforementioned heteroplasmic ND5 
mutant cybrids revealed a significantly increased level of Akt protein phosphorylation; a 
component of the potent PI3K-Akt pro-survival pathway which is frequently hyperactivated 
in human cancer (reviewed in Altomare & Testa, 2005). Again, attributed to increased ROS 
levels induced by complex I dysfunction, Akt activation resulted in the upregulation of 
transcription of the anti-apoptotic mediators Bcl-xL and myeloid cell leukaemia 1 (Mcl1) and 
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a transcriptional downregulation of pro-apoptotic proteins such as Bad, caspase-9 and 
FOXO1 (Sharma et al., 2011). Importantly, the introduction of the yeast NADH quinone 
oxidoreductase (NDI1) gene into mutant ND5 heteroplasmic cybrids restored complex I 
function and reversed the enhanced tumorigenicity observed in the original complex I 
defective cells. Regarding the response to anti-cancer agents, mitochondrial oxidative 
phosphorylation defects, particularly those involving complex I, have been shown to 
modulate the apoptotic response to several chemotherapeutic agents. Following treatment 
with the DNA-damaging agents etoposide and doxorubicin, caspase activation was 
significantly reduced in a complex I deficient cell line in comparison to wild type cells. In 
contrast, administration with the histone deacetylase inhibitor apicidin enhanced caspase 
activation in both complex I and grossly OXPHOS deficient cells in comparison to wild type 
cells (Yadav et al., 2015). A significantly increased mitochondrial ROS production in wild type 
cells following etoposide and apicidin treatment with a mechanistic link to cytochrome c 
release and apoptosis is also described. Interestingly however, the authors attribute the 
reduced apoptosis in complex I deficient cells following anti-cancer agent treatment in part 
to a reduction in mitochondrial ROS elicited by OXPHOS dysfunction. Given the prominent 
complex I defect, and reduced apoptosis levels seen in our PolγAmut/mut intestinal adenomas 
in comparison to PolγA+/+ adenomas this mechanism may benefit from further investigation. 
 
5.5. Future work 
 
With regard to the Lgr5+ stem cell compartment of the intestine specifically, in which 
adenomagenesis is initiated in our model, a significantly greater proliferative rate was 
detected only in the small intestine of PolγAmut/mut in comparison to PolγA+/+ mice. This may 
reflect an immunomodulatory function elicited by resident Paneth cells as recently described 
(Pflügler et al., 2020), a function which may be affected by an age-related mitochondrial 
dysfunction. This reinforces the requirement for further investigation in this area. The 
specific labelling of Paneth cells using lysozyme markers for example in conjunction with an 
immune cell marker panel as suggested in 4.5. would be extremely useful in investigation of 
the contribution of age-related mitochondrial dysfunction to the tumour immune response. 
With regard to the reduced apoptotic frequency within PolγAmut/mut adenomas, the 
mechanism by which this is facilitated remains unknown. Studies which indicate an increase 
in ROS production by complex I deficient cells as mechanistically important in diminishing 
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apoptosis (Park et al., 2009; Sharma et al., 2011) in addition to the involvement of 
mitochondrial ROS in the apoptotic response to anti-cancer agents indicate a key role for 
these species. The labelling of adenoma organoids with the fluorescent marker mitoSOX in 
order to assess ROS levels with additional experiments investigating the effect of ROS 
scavengers on survival and/or apoptosis may shed light on the underlying mechanisms 
inhibiting apoptosis in PolγAmut/mut adenomas. 
 
5.6. Conclusion  
 
In conclusion, this chapter presents quantification of the apoptotic and proliferative indices 
of colonic and small intestinal Apc-Wnt driven adenomas in mice harbouring age-related 
PolγA induced mitochondrial dysfunction in comparison to those which do not. Using a 
double-thymidine analogue labelling technique followed by fluorescent microscopic analysis, 
both colonic and small intestinal PolγAmut/mut adenomas demonstrate a significantly greater 
replicative rate in comparison to their PolγA+/+ counterparts. Lgr5+ stem cells are 
significantly more numerous in PolγAmut/mut versus PolγA+/+ adenomas with a significantly 
greater rate of replication identified within the Lgr5+ stem cell compartment of the 
PolγAmut/mut small intestine. With the use of cleaved caspase 3 immunohistochemistry, 
apoptosis within PolγAmut/mut colonic and small intestinal adenomas is shown to be a 
significantly less frequent event in comparison to PolγA+/+ adenomas. Together, the 
investigations undertaken in this chapter suggest that age-related mitochondrial dysfunction 
promotes an accelerated proliferation and reduced apoptosis in intestinal adenomas in our 
mouse model.  
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Chapter 6. Investigating the mechanisms by which mitochondrial dysfunction 




Data presented thus far have shown that when intestinal adenomas are genetically induced 
on a background of a high mtDNA mutation rate due to a homozygous or heterozygous 
mutation in the mitochondrial DNA PolγA gene (PolγAmut/mut;Lgr5-EGFP-
IREScreERT2;Apcflox/flox), this significantly shortens lifespan in comparison to control 
PolγA+/+/Lgr5-EGFP-IREScreERT2/Apcflox/flox mice. This is due to a significantly greater total 
adenoma burden, resulting from significantly higher rates of cell proliferation and lower 
levels of apoptosis in both the colon and small intestine of PolγAmut/mut when compared to 
PolγA+/+ mice. Furthermore, immunofluorescent analysis of mitochondrial respiratory chain 
enzyme expression revealed that 85% of small intestinal and 55% of colonic adenomas in 
PolγAmut/mut mice were categorised as negative or intermediate negative in their expression 
of the complex I subunit NDUFB8 with minimal respiratory chain enzyme deficiency seen in 
PolγA+/+ adenomas. These data suggest that an age-related accumulation of mtDNA 
mutations may promote the growth of adenomas within the intestine. In order to investigate 
the underlying mechanisms by which mitochondrial dysfunction may prime the intestinal 
tissue prior to tumour development, RNA sequencing analysis was performed by Dr Julia 
Whitehall on small intestinal crypt samples from PolγAmut/mut and PolγA+/+ mice in which Apc 
deletion had not been induced. 
 
As the majority of adenomas occur at the distal end of the small intestine, a small sample of 
this tissue was removed from 6-month-old PolγAmut/mut (n=4) and PolγA+/+ (n=4) mice at 
dissection. Small intestinal crypts were isolated from stromal tissue as described by Sato et 
al (Sato et al., 2009). RNA was extracted from crypt pellets and RNA integrity (RIN) scores 
analysed. Samples of RNA were then sent for total RNA Sequencing at The Genomics Core 
Facility, Institute of Genetic Medicine, Newcastle University. 
 
Following library preparation, the NextSeq 500 system (Illumina) was used to analyse all 
samples at a depth of 16 million 75 bp single reads per sample. All samples were quality 
assessed, genome aligned, and subsequent differential gene expression analysis carried out 
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by Fiona Robertson, Bioinformatician, Newcastle University. The quantity of each transcript 
was denoted by a fragments per kilobase of transcript per million mapped reads (FPKM) 
value and log transformed. An adjusted p-value of <0.05 was applied to identify significantly 
differentially expressed genes in non-transformed small intestinal crypts from 6-month-old 
PolγAmut/mut compared with PolγA+/+ mice (Figure 6-1). A cut off of -2> to >2 log2 fold change 
was applied before submitting differentially expressed gene lists to the Enrichr web-based 
enrichment tool (Chen et al., 2013; Kuleshov et al., 2016) in order to align gene signatures 
with biological functions. The highest-ranking pathways included those relating to serine 
synthesis and one-carbon metabolism. Table 6-1 presents the identification of these 
pathways alongside participating genes (Phgdh, Psat1, Psph, Mthfd2 and Aldh1l2) found to 
be significantly upregulated within the small intestinal crypts of PolγAmut/mut mice. As 
mitochondrial dysfunction has been shown to promote glutathione synthesis via the 
upregulation of de novo serine synthesis (Nikkanen et al., 2016) and cancer cells rely on 
exogenous serine uptake and de novo synthesis to provide them with the one-carbon units 
essential for their growth and proliferation (reviewed in Newman & Maddocks, 2017), these 
genes became the focus of the next stages of investigation.  




Figure 6-1. Heat map of differentially expressed genes in non-transformed small intestinal crypts from 6-month-old PolγA+/+ 
(n=4) compared with PolγAmut/mut (n=4) mice. Scale bar represents log2 (FPKM+1) values with positive values in red 
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Table 6-1. Gene set enrichment analysis identifying pathways associated with differentially expressed genes in non-
transformed small intestinal crypts from 6-month-old PolγA+/+ (n=4) compared with PolγAmut/mut (n=4) mice. Genes were 
mapped to the KEGG pathway database (2016) using the Enrichr web-based enrichment tool. 
 
6.1.1. Serine and one carbon metabolism 
 
One carbon metabolism encompasses a network of metabolic processes that facilitate the 
generation of one-carbon units (also known as methyl groups) that fuel biosynthetic 
reactions, epigenetic regulation, redox defence and amino acid homeostasis (reviewed in 
Ducker & Rabinowitz, 2017). Integral to one-carbon metabolism are the folate and 
methionine cycles which depend on folate molecules to accept and transfer the one-carbon 
units they require. One-carbon molecules can be obtained from several dietary sources, 
however in humans the main one-carbon group donor is the non-essential amino acid serine 
(Davis et al., 2004). 
 
A number of different transporters can facilitate the uptake of exogenous serine; however, it 
may also be synthesised by the cell via the diversion of glycolytic or gluconeogenic carbon 
into the de novo serine synthesis pathway (SSP) (Snell, 1984). The serine synthesis pathway 
is catalysed by three enzymes. The first, and rate-limiting enzyme of the pathway is 
phosphoglycerate dehydrogenase (PHGDH) which catalyses the NAD+ dependant oxidation 
of the glycolytic (or gluconeogenic) intermediate 3-phosphoglycerate (3PG) generating 
NADH and 3-phosphohydroxypyruvate (3PHP). Phosphoserine aminotransferase 1 (PSAT1) is 
the second enzyme of the pathway and catalyses the glutamate dependant transamination 
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of 3PHP generating α-ketoglutarate (αKG) and 3-phosphoserine (3PSer). The final enzyme, 
phosphoserine phosphatase (PSPH) catalyses the hydrolysis of 3PSer synthesising serine. 
Regulation of the SSP is achieved with the convergence of multiple feedback mechanisms. 
Serine itself acts as an inhibitor of PSPH in mammals (Neuhaus & Byrne, 1960) and also 
allosterically activates the M2 isoform of pyruvate kinase (PKM2). PKM2 catalyses the final 
step of glycolysis, thus its activation decreases the availability of upstream glycolytic 
intermediates such as 3PG that feeds into the SSP, inhibiting it accordingly (Ye et al., 2012). A 
depletion of intracellular serine is detected by the eukaryotic initiation factor 2, α subunit 
(eIF2α) kinase, GCN2 which in turn phosphorylates eIF2α leading to increased translation of 
activating transcription factor 4 (ATF4). The expression of all three enzymes of the SSP are 
induced by ATF4 and the pathway positively regulated as such (Ye et al., 2012). 
 
As previously mentioned, serine is the main donor of one-carbon units to the folate cycle. 
Folates are a group of molecules function as carriers of one carbon units and although 
diverse, they share three core structural units. A polyglutamate tail which can vary in length 
is required for retention of the molecule within the cell, and a pteridine ring and para-
aminobenzoic acid (PABA) linker function together to bind one-carbon units. Folates can be 
synthesised by most bacteria, plants and yeast however they must be ingested in the diet of 
animals (reviewed in Ducker & Rabinowitz, 2017). In order to enter the folate cycle, folates 
must be in the biologically active reduced form, tetrahydrofolate (THF). The donation of a 
one-carbon unit, typically from serine, generates glycine and 5,10-methylene-THF in which 
the 1C group is covalently bound to the 5-position nitrogen atom on the pteridine ring and 
the 10-position nitrogen atom on the PABA linker of THF (reviewed in Ducker & Rabinowitz, 
2017). This reaction is catalysed by serine hydroxymethyltransferase 1 (SHMT1) in the 
cytoplasm, but in vertebrates occurs preferentially within the mitochondria, catalysed by 
serine hydroxymethyltransferase 2 (SHMT2) (Yoshida & Kikuchi, 1970). Also localised within 
the mitochondria is the glycine cleavage system, a series of enzymes that catalyse the 
removal of one carbon units from glycine (Kikuchi, 1973). 
 
Once the 1C unit is bound to THF and 5,10-methylene-THF has been generated, the molecule 
can interconvert between different redox states, these reactions being catalysed by 
methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) in the cytoplasm and 
MTHFD2/2L/1L in the mitochondria. The fate of one-carbon units depends on the folate 
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species from which it is derived, with each redox state supporting different biosynthetic 
processes. The synthesis of purines requires 10-formyl-THF, the most oxidised 1C folate, 
which can also be derived from formate. De novo purine synthesis from 10-formyl-THF is 
catalysed by groups of enzymes which form cytoplasmic clusters named purinosomes (An et 
al., 2008; Zhao et al., 2013a). Although not located within the mitochondria, purinosomes 
are close in proximity to them and share a functional relationship with mitochondria. ATP 
and formate which are produced by mitochondrial folate metabolism are required for purine 
synthesis, similarly the products of purine synthesis are required for the synthesis of 
mitochondrial DNA (Chan et al., 2018). 10-formyl-THF is also required to formylate the 
mitochondrial tRNAMet generating fMet-tRNAMet, a critical component of the mitochondrial 
DNA translation initiation machinery (Tucker et al., 2011). 
 
The generation of the most reduced 1C folate, 5-methyl-THF from 5,10- methylene-THF is 
catalysed by methylene tetrahydrofolate reductase (MTHFR). The subsequent consumption 
of 5-methyl-THF by methionine synthase (MTR) in a vitamin B12 dependant manner permits 
the re-methylation of homocysteine to form methionine. It is at this point that the folate 
cycle intersects with the methionine cycle allowing the transfer of 1C units necessary for key 
members of this pathway namely S-adenosylmethionine (SAM) and S-adenosylhomocysteine 
(SAH), to facilitate vital epigenetic modification and methylation reactions. SAM is the 
primary mammalian methyl donor (Finkelstein, 1990), responsible for supplying 1C units to 
the methyltransferases that undertake these processes, and its ratio with SAH has been 
shown to affect their interaction with and hence the activity of these enzymes (Mentch et 
al., 2015). The hydrolysis of SAH into homocysteine and adenosine completes the 
methionine cycle and in tissues such as the liver, kidney, pancreas, intestine and brain, 
homocysteine can enter the transsulphuration pathway (Finkelstein, 2007) facilitating the 
biosynthesis of the antioxidant glutathione (Beatty & Reed, 1980). Figure 6-2 depicts the 
systems described. 
 
As folates laden with one-carbon units are unable to cross the mitochondrial membrane, 
one-carbon metabolism is compartmentalised to the mitochondria and cytoplasm with each 
region possessing distinct enzymes as described. The mitochondrial membrane is permeable 
to serine, glycine and formate, and these molecules link the two compartments (reviewed in 
Tibbetts & Appling, 2010). Although the pathway preferentially proceeds in one direction, 
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with the production of formate in the mitochondria, both compartments can exhibit 
bidirectionality relevant to the changing metabolic requirements of the cell. Thus, the serine 
synthesis pathway, one carbon cycle and methionine and transsulphuration pathways 
converge to support numerous biosynthetic and regulatory processes with mitochondria 
playing a pivotal role.  
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Figure 6-2. Schematic depicting central carbon metabolic pathways and their compartmentalisation. The diversion of glycolytic intermediates into the de novo serine synthesis pathway 
provides one carbon units for mitochondrial and cytoplasmic one carbon folate metabolism. Branching from the folate cycle are the methionine and transsulphuration pathways in addition to 
purine and pyrimidine synthesis. 
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6.2. Aims of study 
 
Previous work carried out by Dr Julia Whitehall revealed an upregulation of a particular set 
of genes within the small intestinal crypt transcriptome of 6-month-old PolγAmut/mut 
compared to PolγA+/+ mice in the absence of an adenomatous pathology. Specifically, these 
genes were involved in the uptake, biosynthesis and metabolism of the amino acid serine. 
Quantitative RT-PCR carried out by Dr Whitehall subsequently validated the findings 
elucidated by RNA sequencing in both normal non-transformed crypts and adenomas 
extracted from PolγAmut/mut and PolγA+/+ mice, however the levels of these enzymes at the 
protein level in vivo remained unknown. Furthermore, these molecular analyses were 
limited to the small intestine of experimental animals with the pathology, if any, in the colon 
also remaining unknown. Finally, of paramount importance was investigating the potential 
translation of findings in the mouse model to humans. In this chapter I aimed to: 
1. Investigate if changes in gene expression detected by RNA Seq and q-PCR translate 
into changes at the protein level in the colon and small intestine.  
2. Ascertain if these proteins are upregulated in response to an age-related 
accumulation of OXPHOS defects in the small intestine and colon of the PolγAmut/mut 
and PolγA+/+ mice. 
3. Investigate whether changes in gene expression and protein levels in response to 
OXPHOS deficiency observed in the mouse are directly translatable to the human 
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6.3. Results 
 
6.3.1. Serine synthesis pathway and one-carbon cycle enzyme immunohistochemistry  
 
RNA sequencing analysis of normal non-transformed small intestinal crypts from PolγAmut/mut 
and PolγA+/+ mice revealed an upregulation of genes involved in pathways relating to serine 
synthesis, serine uptake and one-carbon metabolism (Phgdh, Psat1, Psph, Mthfd2, Slc1a4 
and Aldh1l2). In order to confirm RNA sequencing results at the protein level and evaluate 
the expression of these proteins in the adenoma setting, immunohistochemistry using 
antibodies targeting several of the proteins encoded by these genes was carried out on 
tissue sections of colon and small intestine from animals in which tumorigenesis had been 
induced via Apc deletion. Sections from PolγAmut/mut (n=4) and PolγA+/+ (n=4) mice humanely 
sacrificed at 23 days post Apc deletion were labelled with anti-PHGDH, anti-PSAT1 and anti-
MTHFD2 as described in 2.2.9.4. Representative immunohistochemistry images showing in 
situ levels of SSP proteins in the non-transformed normal mucosa and adenomas of the 
colon and small intestine are shown in Figures 6-3 and 6-4 respectively.  
 
As can be seen in Figure 6-3 (A) and Figure 6-4 (A), in comparison to PolγA+/+ mice, the 
expression levels of PHGDH, PSAT1 and MTHFD2 proteins are increased in the normal crypt 
compartments of both the colon and small intestine of PolγAmut/mut mice. Similarly, as 
presented in Figure 6-3 (B) and Figure 6-4 (B), colonic and small intestinal adenomas from 
PolγAmut/mut mice display an upregulation of PHGDH, PSAT1 and MTHFD2 in comparison to 
PolγA+/+   adenomas. The expression of PHGDH and PSAT1 proteins appear marginally raised 
in the adenomas of PolγA+/+ mice when compared to PolγA+/+ normal mucosa, however the 
adenomas of PolγAmut/mut mice demonstrate a clear increased expression of these proteins 
when compared to all tissue compartments from all mice. These observations suggest an 
association of PolγAmut/mut induced intestinal crypt mitochondrial dysfunction with an 
upregulation of de novo serine synthesis and the mitochondrial folate cycle in these crypts. 
This confirms results of RNA sequencing analysis at the protein level. 
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Figure 6-3. Immunohistochemistry showing in situ levels of SSP proteins in the non-transformed normal mucosa and 
adenomas from the colons of PolγA+/+ and PolγAmut/mut mice. (A) normal mucosa, (B) adenomas. Representative images are 






  209 
 
Figure 6-4. Immunohistochemistry showing in situ levels of SSP proteins in the non-transformed normal mucosa and 
adenomas from the small intestines of PolγA+/+ and PolγAmut/mut mice. (A) normal mucosa, (B) adenomas. Representative 
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6.3.2. Serine synthesis pathway and one-carbon cycle enzyme immunofluorescence in non-
transformed mouse colon and small intestine 
 
In light of the results of the previous section in which serine synthesis pathway enzymes 
were found to be upregulated in the normal non-transformed intestinal crypts of 
PolγAmut/mut mice, it was hypothesised that if this was a response to the age-related 
accumulation of OXPHOS deficiency observed in the PolγAmut/mut mice (Baines et al., 2014), 
an age-related increase in the expression of SSP enzymes would also be observed in the 
normal non-transformed intestine. In order to investigate this, serial sections from the colon 
and small intestine of PolγA+/+ and PolγAmut/mut mice at 1, 3, 6, 9 and 12-months of age were 
labelled with antibodies against PHGDH, PSAT1 and MTHFD2 with one antibody per section. 
For each age group, PolγA+/+ (n=3) and PolγAmut/mut (n=3) mice were labelled according to the 
protocol outlined in 2.2.11.4.1. Quantification of SSP/one-carbon cycle enzyme protein levels 
was carried out as described in 2.2.12.5.1. Supporting the hypothesis that SSP/one-carbon 
cycle enzymes are upregulated in response to an age-related accumulation of OXPHOS 
defects in PolγAmut/mut mice, a clear age-related increase in SSP/one-carbon cycle enzyme 
protein levels are observed within the normal non-transformed crypts of the colon and small 
intestine of PolγAmut/mut mice. This is in contrast to normal crypts of PolγA+/+ mice in which an 
absence of mitochondrial dysfunction abrogates the upregulation response. Representative 
immunofluorescent images taken from PolγA+/+ and PolγAmut/mut colon samples are shown in 
Figures 6-5 to 6-7. Representative immunofluorescent images taken from PolγA+/+ and 
PolγAmut/mut small intestinal samples are shown in Figures 6-8 to 6-10. 
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Figure 6-5. Representative immunofluorescent images depicting the levels of PHGDH within 1, 3, 6, 9 and 12-month-old 
PolγA+/+ and PolγAmut/mut normal non-transformed colonic crypts. Scale bars 50µm. 
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Figure 6-6. Representative immunofluorescent images depicting the levels of PSAT1 within 1, 3, 6, 9 and 12-month-old 
PolγA+/+ and PolγAmut/mut normal non-transformed colonic crypts. Scale bars 50µm. 
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Figure 6-7. Representative immunofluorescent images depicting the levels of MTHFD2 within 1, 3, 6, 9 and 12-month-old 
PolγA+/+ and PolγAmut/mut normal non-transformed colonic crypts. Scale bars 50µm. 
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Figure 6-8. Representative immunofluorescent images depicting the levels of PHGDH within 1, 3, 6, 9 and 12-month-old 
PolγA+/+ and PolγAmut/mut normal non-transformed small intestinal crypts. Scale bars 50µm. 
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Figure 6-9. Representative immunofluorescent images depicting the levels of PSAT1 within 1, 3, 6, 9 and 12-month-old 
PolγA+/+ and PolγAmut/mut normal non-transformed small intestinal crypts. Scale bars 50µm. 
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Figure 6-10. Representative immunofluorescent images depicting the levels of MTHFD2 within 1, 3, 6, 9 and 12-month-old 
PolγA+/+ and PolγAmut/mut normal non-transformed small intestinal crypts. Scale bars 50µm. 
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Within the colon, linear regression analyses detect a significant deviation from zero with 
regard to expression levels of all three enzymes in both PolγA+/+ and PolγAmut/mut normal 
crypts with increasing age (Figure 6-11) (PolγA+/+ PHGDH P=0.0025, PSAT1 P=0.0066, 
MTHFD2 P=0.0028, PolγAmut/mut PHGDH P<0.0001, PSAT1 P<0.0001, MTHFD2 P<0.0001, 
linear regression). Despite the apparent increase in expression levels of each enzyme in both 
PolγA+/+ and PolγAmut/mut normal colonic mucosa, the comparison of regression slopes 
between genotypes detects a significant difference between these slopes (PHGDH P<0.0001, 
PSAT1 P<0.0001, MTHFD2 P=0.0005, analysis of covariance). This suggests that the rate of 
increase in expression of PHGDH, PSAT1 and MTHFD2 over time is greater within PolγAmut/mut 
colonic crypts in comparison with those of PolγA+/+ mice.  
 
Similarly, within the small intestine, linear regression analyses detect a significant deviation 
from zero with regard to expression levels of all three enzymes in both PolγA+/+ and 
PolγAmut/mut normal crypts with increasing age (Figure 6-12) (PolγA+/+ PHGDH P=0.0014, 
PSAT1 P=0.0169, MTHFD2 P=0.0005, PolγAmut/mut PHGDH P<0.0001, PSAT1 P=0.0002, 
MTHFD2 P<0.0001, linear regression). As is demonstrated within the colon, upon 
comparison of regression slopes, a significantly greater rate of increase in the expression 
level of each enzyme over time is observed in PolγAmut/mut small intestinal crypts compared 
with those of PolγA+/+ mice (PHGDH P=0.0004, PSAT1 P=0.0023, MTHFD2 <0.0001, analysis of 
covariance). These data confirm that key enzymes of the de novo serine synthesis pathway 
and mitochondrial one carbon cycle are upregulated in response to age-related mtDNA 
mutation induced mitochondrial dysfunction within the murine colon and small intestine.  
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Figure 6-11. Quantification of the expression levels of PHGDH, PSAT1 and MTHFD2 in normal non-transformed colonic 
crypts of PolγA+/+ and PolγAmut/mut mice of increasing ages (n=3 mice per genotype per age group). (A) PHGDH, (B) PSAT1, (C) 
MTHFD2. Each dot represents an individual crypt (n=20 crypts per mouse). Error bars denote mean ±SD. Expression levels 
of all three enzymes increase at a significantly greater rate in PolγAmut/mut normal crypts compared to PolγAmut/mut normal 
crypts (****P<0.0001, ***P<0.001, **P<0.01, linear regression and analysis of covariance). 
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Figure 6-12. Quantification of the expression levels of PHGDH, PSAT1 and MTHFD2 in normal non-transformed small 
intestinal crypts of PolγA+/+ and PolγAmut/mut mice of increasing ages (n=3 mice per genotype per age group). (A) PHGDH, (B) 
PSAT1, (C) MTHFD2. Each dot represents an individual crypt (n=20 crypts per mouse). Error bars denote mean ±SD. 
Expression of PHGDH increases at a significantly greater rate in PolγAmut/mut normal crypts compared to PolγAmut/mut normal 
crypts (***P<0.001, linear regression and analysis of covariance). 
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6.3.3. Serine synthesis pathway enzyme and mitochondrial OXPHOS protein 
immunofluorescence in human colon 
 
In order to assess whether findings in the mouse model were translatable to humans, levels 
of PHGDH, PSAT1 and MTHFD2 in individual crypts from normal human colon samples were 
quantified using immunofluorescence. These levels were correlated with the levels of 
expression of mitochondrial OXPHOS subunit proteins, also quantified using 
immunofluorescence. 4µm serial sections were taken from multiple biopsies (where 
available) of normal colonic mucosa taken from 12 patients who had undergone either 
surgical colorectal tumour resection or polyp removal. The first section was labelled with 
antibodies against NDUFB8, MTCO1 and PHGDH. The second section was labelled with 
antibodies against NDUFB8, MTCO1 and TOMM20 in order to quantify OXPHOS proteins and 
categorise individual crypts as OXPHOS positive or deficient based on their Z-scores. The 
third and fourth serial sections were labelled with antibodies against NDUFB8, MTCO1 and 
one of either anti-PSAT1 or anti-MTHFD2. Using antibodies against NDUFB8 and MTCO1 in 
all serial sections assisted with the identification of the same crypts across all sections and 
also confirmed that expression of OXPHOS proteins was maintained throughout all sections. 
Sections were labelled according to the protocols outlined in 2.2.11.4.2., and imaged and 
analysed as detailed in section 2.2.12.5.2.  
 
6.3.3.1. Categorisation of OXPHOS deficiency in normal human colonic crypts 
 
As described in section 2.2.12.5.2., sections labelled with antibodies against OXPHOS 
components were analysed using Zen Lite microscope software (Zeiss). An example 
micrograph showing typical labelling is presented in Figure 6-13.  
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Figure 6-13. Example micrograph of OXPHOS subunit labelling in normal human colon. (A) Nuclei are labelled with Hoescht 
nucleic acid counterstain. (B) Anti-TOMM20 with Alexa Fluor488 conjugated secondary antibody labels mitochondria 
providing a measure of mitochondrial mass. (C) The MTCO1 subunit of mitochondrial complex IV is labelled with the use of 
an Alexa Fluor 546 conjugated secondary antibody. (D) The NDUFB8 subunit of mitochondrial complex I is labelled with an 
Alexa Fluor 647 conjugated secondary antibody. (E) Merge of all channels. Scale bars 100µm. A single crypt deficient in both 
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Colonic crypts with visually apparent reductions in the expression either NDUFB8 or MTCO1 
or both proteins were categorised as OXPHOS deficient, whilst those displaying normal levels 
of these proteins were categorised as OXPHOS normal. All visually deficient crypts were 
selected and at least an equal number of normal crypts were selected per section. As such a 
method of analysis may be subjective, the generation of Z-score plots was used to confirm 
(or refute) the manual categorisation. Furthermore, expression of individual proteins was 
highly variable between patients, therefore Z-score generation facilitated standardisation of 
data and Z-score plots were generated as described in 2.2.12.4 and are presented with one 
plot per patient in Figures 6-14 and 6-15.  
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Figure 6-14. Z score plots generated in order to categorise normal human colonic crypts as OXPHOS normal or deficient in 
either NDUFB8 subunit of mitochondrial complex I or MTCO1 subunit of mitochondrial complex IV. Z-scores were calculated 
based on the control population (crypts expressing no visual deficiency of any protein) and all crypts thus categorised as 
normal (z > -3), intermediate positive (-4.5 ≤ z < -3.0), intermediate negative (-6 ≤ z < -4.5) and negative (z < -6) for each 
protein. Each dot represents an individual crypt. Black circles denote visually deficient crypts re-categorised as normal, red 
circles denote visually normal crypts re-categorised as deficient. 
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Figure 6-15. Z score plots generated in order to categorise normal human colonic crypts as OXPHOS normal or deficient in 
either NDUFB8 subunit of mitochondrial complex I or MTCO1 subunit of mitochondrial complex IV. Z-scores were calculated 
based on the control population (crypts expressing no visual deficiency of any protein) and all crypts thus categorised as 
normal (z > -3), intermediate positive (-4.5 ≤ z < -3.0), intermediate negative (-6 ≤ z < -4.5) and negative (z < -6) for each 
protein. Each dot represents an individual crypt. Black circles denote visually deficient crypts re-categorised as normal, red 
circles denote visually normal crypts re-categorised as deficient.  
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The frequency of OXPHOS deficient crypts in patient biopsies varied from n=10 in patient 67 
up to n=202 in patient 61. Interestingly, at 60 years of age, patient 67 represents one of the 
youngest patients in the cohort with the fewest OXPHOS deficient crypts while patient 61 
with the highest frequency of OXPHOS deficient crypts, represents the oldest patient in the 
cohort at 85 years of age. This is consistent with previously published findings (Greaves et 
al., 2012; Taylor et al., 2003). Similarly, the presence of a greater extent of complex IV than 
complex I deficiency is also supported by previous work (Greaves et al., 2010). In all patients, 
the proportion of OXPHOS deficient crypts categorised as MTCO1 negative was greater than 
the proportion categorised as NDUFB8 negative. No significant difference was detected 
between the mean frequencies of OXPHOS deficient crypts observed in male (63.5 ± 59.47) 
versus female (41.5 ± 23.57) patients (P=0.6828, unpaired Mann Whitney U test).  
 
 
6.3.3.2. Correlation of serine synthesis pathway enzyme expression with OXPHOS status in 
normal human colonic crypts 
 
Following the quantification of OXPHOS subunit proteins and categorisation of normal 
human crypts as OXPHOS normal or deficient, correlation of OXPHOS status with expression 
of PHGDH, PSAT1 and MTHFD2 expression was achieved by analysing the remaining serial 
sections. These three sections had been labelled with antibodies against one of the 
aforementioned SSP/1C enzymes in conjunction with antibodies targeting the NDUFB8 
subunit of mitochondrial complex I and the MTCO1 subunit of mitochondrial complex IV. 
OXPHOS subunit labelling was used as a guide to map the same crypts across all serial 
sections and thus correlate SSP enzyme expression with OXPHOS status. As described in 
section 2.2.12.5.2., all sections were imaged using a Celldiscoverer 7 fluorescent microscope 
(Zeiss) and analysed using Zen lite microscope software (Zeiss). Example micrographs of 
representative labelling are presented in Figures 6-16, 6-17 and 6-18. The results of the 
analyses are presented in Figures 6-19, 6-20 and 6-21 for PHGDH, PSAT1 and MTHFD2 
expression respectively.  
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Figure 6-16. Example micrograph of PHGDH and OXPHOS subunit labelling in normal human colon. (A) Nuclei are labelled 
with Hoescht nucleic acid counterstain. (B) The MTCO1 subunit of mitochondrial complex IV is labelled with the use of an 
Alexa Fluor 546 conjugated secondary antibody. (C) The NDUFB8 subunit of mitochondrial complex I is labelled with an 
Alexa Fluor 647 conjugated secondary antibody. (D) PHGDH protein is visualised with an Alexa Fluor 488 conjugated 
secondary antibody (E) Merge of all channels. Scale bars 100µm. Two crypts deficient in both MTCO1 and NDUFB8 are 
highlighted by the white lines. 
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Figure 6-17. Example micrograph of PSAT1 and OXPHOS subunit labelling in normal human colon. (A) Nuclei are labelled 
with Hoescht nucleic acid counterstain. (B) The MTCO1 subunit of mitochondrial complex IV is labelled with the use of an 
Alexa Fluor 546 conjugated secondary antibody. (C) The NDUFB8 subunit of mitochondrial complex I is labelled with an 
Alexa Fluor 647 conjugated secondary antibody. (D) PSAT1 protein is visualised with an Alexa Fluor 488 conjugated 
secondary antibody (E) Merge of all channels. Scale bars 100µm. One crypt deficient in both MTCO1 and NDUFB8 is 
highlighted by the white line. 
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Figure 6-18. Example micrograph of MTHFD2 and OXPHOS subunit labelling in normal human colon. (A) Nuclei are labelled 
with Hoescht nucleic acid counterstain. (B) The MTCO1 subunit of mitochondrial complex IV is labelled with the use of an 
Alexa Fluor 546 conjugated secondary antibody. (C) The NDUFB8 subunit of mitochondrial complex I is labelled with an 
Alexa Fluor 647 conjugated secondary antibody. (D) MTHFD2 protein is visualised with an Alexa Fluor 488 conjugated 
secondary antibody (E) Merge of all channels. Scale bars 100µm. Two crypts deficient in both MTCO1 and NDUFB8 are 
highlighted by the white lines. 
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Figure 6-19. Quantification of the expression levels of PHGDH in non-transformed human OXPHOS normal and OXPHOS 
deficient crypts (n=12 patients). Each dot represents an individual crypt. Error bars denote mean ±SD. Levels of PHGDH 
expression are significantly greater in OXPHOS deficient compared to OXPHOS normal crypts. P<0.001, linear mixed effect 
model. 
 
Figure 6-20. Quantification of the expression levels of PSAT1 in non-transformed human OXPHOS normal and OXPHOS 
deficient crypts (n=12 patients). Each dot represents an individual crypt. Error bars denote mean ±SD. Levels of PSAT1 
expression are significantly greater in OXPHOS deficient compared to OXPHOS normal crypts. P<0.001, linear mixed effect 
model. 
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Figure 6-21. Quantification of the expression levels of MTHFD2 in non-transformed human OXPHOS normal and OXPHOS 
deficient crypts (n=12 patients). Each dot represents an individual crypt. Error bars denote mean ±SD. Levels of MTHFD2 
expression are significantly greater in OXPHOS deficient compared to OXPHOS normal crypts. P<0.001, linear mixed effect 
model. 
 
As shown by the immunofluorescent assay and linear mixed effect model, levels of all three 
enzymes were significantly higher in crypts with OXPHOS defects than those with normal 
OXPHOS protein expression within the normal ageing human colon. On a patient-by-patient 
basis applying multiple t-tests with a Holm-Sidak multiple comparisons p value adjustment, 
the expression of PHGDH is significantly greater in OXPHOS deficient versus OXPHOS normal 
crypts in all patients investigated. With regard to PSAT1 expression, all patients with the 
exception of patient 63 demonstrate a significantly greater expression of PSAT1 in OXPHOS 
deficient crypts compared to OXPHOS normal. With regard to MTHFD2 expression, eight out 
of twelve patients demonstrate a significantly increased MTHFD2 expression in OXPHOS 
deficient versus OXPHOS normal crypts also detected using a multiple t-test analysis with 
Holm-Sidak multiple comparisons p value adjustment. In the PHGDH analysis, three patients 
(37, 60 and 61) present with particularly significant expression of this enzyme in OXPHOS 
deficient versus OXPHOS normal crypts. At 85 years of age at the time of sampling, patient 
61 is the oldest subject within the sample group by ten years and as such may represent a 
colonic crypt population in which longevity may have permitted the clonal expansion of early 
life acquired somatic mtDNA mutations to a greater level than may be observed in younger 
patients (Baines et al., 2014; Greaves et al., 2014) correspondingly eliciting a greater 
upregulation of PHGDH expression. Patient 60, which also represents the patient with the 
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most significant upregulation of PSAT1, interestingly displays a pattern of OXPHOS deficiency 
in which a complex IV defect is extensive whereas complex I expression is largely retained. 
The majority of OXPHOS deficient crypts (86.8%) demonstrate a normal expression of 
NDUFB8 (z > -3) and 13.2 % show minimal NDUFB8 protein loss and are categorised 
intermediate positive expression of NDUFB8 (-4.5 ≤ z < -3.0). No crypts are categorised as 
intermediate negative or as negative for NDUFB8 expression (-6 ≤ z < -4.5, z < -6 
respectively). Similarly, patient 61 presents with 97.03% of OXPHOS deficient crypts as 
complex IV (MTCO1) negative (z < -6) whereas only 3.47% are categorised as complex I 
(NDUFB8) negative, 3.47% categorised as complex I intermediate negative (-6 ≤ z < -4.5), 
19.8% are complex I intermediate positive and the remaining 73.26% are categorised as 
complex I normal (z > -3). Ostensibly this may suggest a stronger association of serine 
synthesis pathway upregulation with complex IV deficiency as opposed to complex I 
deficiency in human colonic crypts, however, an induction of PHGDH expression of equal 
magnitude is also observed in patient 37 in which complex I deficiency is almost as extensive 
as that of complex IV (83.7% deficient crypts are complex I deficient, 98.39% deficient crypts 
are complex IV deficient). More likely, such observations reflect the typical pattern of 
OXPHOS deficiency within the ageing human colon, in that an isolated complex I deficiency is 
much less frequent than an isolated complex IV defect, with crypts deficient in multiple 
complexes being most commonly observed (Greaves et al., 2010). Taken together the results 
of these analyses suggest that the de novo serine synthesis pathway and mitochondrial one 





As a result of molecular investigations carried out by Dr Julia Whitehall, a subset of 
differentially expressed transcripts was highlighted as being upregulated in the normal non-
transformed small intestinal crypts of PolγAmut/mut versus PolγA+/+ mice. Quantitative RT-PCR 
carried out by Dr Whitehall subsequently validated the expression of these transcripts 
(Phgdh, Psat1, Psph, Mthfd2, Slc1a4 and Aldh1l2) at the gene level detecting significantly 
increased levels of expression (P<0.0005) of all genes in PolγAmut/mut non-transformed small 
intestinal crypts versus those extracted from PolγA+/+ mice. An immunohistochemical assay 
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targeting PHGDH, PSAT1 and MTHFD2 was applied to PolγAmut/mut and PolγA+/+ colonic and 
small intestinal sections in which adenomagenesis had been induced at 6 months of age and 
animals culled at 23 days post induction. Representative images presented in Figures 6-3 and 
6-4 depict an increased abundance of these proteins within both the normal crypt and 
adenoma compartments of PolγAmut/mut in comparison to PolγA+/+ mice. These observations 
are supported by reports of increased Psat1 (and Psph) mRNA levels in intestinal tissue from 
intestinal cancer model Vil1-creER;Apcfl/fl mice when compared to non-transformed mucosa 
in wild type animals (Maddocks et al., 2017). An increase in Phgdh levels was not detected in 
Vil1-creER; Apcfl/fl adenomas until the addition of a KrasG12D mutation generating Vil1-creER; 
Apcfl/f; KrasG12D/+ mice, however the addition of this mutant allele enhanced the expression 
of SSP enzymes to a much greater extent. Again, this supports observations made here in 
which the addition of a potential accelerator mutation in the form of PolγAmut/mut serves to 
further amplify SSP enzyme expression.  
 
It was hypothesised that an age-related mitochondrial dysfunction driven upregulation of 
the serine synthesis and mitochondrial one carbon metabolism pathways may provide the 
PolγAmut/mut intestine with an advantageous, pro-oncogenic environment should a 
transforming event such as the loss of Apc subsequently occur. To address this hypothesis, 
an ageing series of PolγAmut/mut and PolγA+/+ mice were immunofluorescently labelled with 
antibodies against PHGDH, PSAT1 and MTHFD2. Analysis of both colonic and small intestinal 
crypts revealed a significant age-related increase in these proteins in response to increasing 
levels of OXPHOS deficiency in PolγAmut/mut, an effect that was notably diminished in PolγA+/+ 
intestinal crypts in which no OXPHOS deficiency is observed. A similar analysis with the 
addition of antibodies against mitochondrial OXPHOS components applied to normal non-
transformed human colonic biopsies demonstrated a supporting pattern in which each 
SSP/one-carbon enzyme was shown to be upregulated in OXPHOS deficient crypts in 
comparison to OXPHOS normal crypts.  
 
Given that mitochondria are intricately involved in one-carbon metabolism, it comes as little 
surprise that perturbations of mitochondrial function have downstream effects on this 
pathway and those that branch from it. The ‘Deletor’ mouse models a late-onset 
mitochondrial myopathy with progressive respiratory chain dysfunction caused by a 
dominant mutation of the nuclear-encoded mtDNA helicase, Twinkle (Tyynismaa et al., 
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2005). In humans, mutations of this type manifest as an adult-onset progressive external 
ophthalmoplegia (PEO) with multiple mtDNA deletions occurring as the role of Twinkle in the 
maintenance of the integrity of mtDNA is compromised (Spelbrink et al., 2001). In order to 
characterise the physiological consequences, gene expression profiles from the skeletal 
muscle of 20 to 24-month-old Deletor mice were examined by the same group that 
developed the model (Tyynismaa et al., 2010). The group identified the upregulation of 
several genes previously associated with an amino acid starvation response, including 
Mthfd2 and Psat1, their respective protein products being involved in one-carbon 
metabolism and de novo serine synthesis. The finding that alongside other upregulated 
genes, the Mthfd2 gene bears an amino acid response element that can bind stress-response 
linked transcription factor family members (ATFs), in addition to the observation that Atf5 
was also upregulated in Deletor mouse muscle supports the hypothesis that mitochondrial 
dysfunction may induce a starvation-like stress response. Furthermore, the restoration of 
previously elevated levels of Atf4, Atf5, Mthfd2, all three SSP enzymes and mitochondrial 
unfolded protein response (mtUPR) markers in Deletor mouse muscle after treatment with 
the mTORC1 inhibitor rapamycin suggests that the mTORC1 pathway, a key regulator of 
protein synthesis, cell proliferation and autophagy, regulates this response (Khan et al., 
2017; Saxton & Sabatini, 2017). Further investigations of Deletor skeletal muscle 
subsequently revealed an upregulated serine synthesis pathway with increased flux to the 
transsulphuration pathway resulting in increased glutathione synthesis. Levels of folate cycle 
intermediates were also affected, with Deletor skeletal muscle demonstrating significantly 
increased levels of certain species. A decreased level of formate, the end-product of the 
folate cycle and substrate for purine synthesis was also detected, suggesting an increased 
demand for purines in the model. Indeed, dNTP pools were found to be increased and 
imbalanced in the Deletor skeletal muscle. Interestingly, the same analysis performed in a 
mouse model bearing a recessive rather than dominant Twinkle mutation resulting in a 
phenotype of mtDNA depletion as opposed to multiple mtDNA deletions (infantile onset 
spinocerebellar ataxia – IOSCA) demonstrated the opposite effect on dNTP pools. Homology 
modelling proposed a mechanism of replisome stalling in the Deletor mouse driving 
increased dNTP synthesis, and a mechanism of increased NTP hydrolysis in the IOSCA mouse 
depleting dNTP pools. Human IOSCA and mitochondrial myopathy patients also showed 
evidence of metabolic remodelling, corroborating observations taken from the mouse 
models (Nikkanen et al., 2016).  
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Also, in humans, in a cellular model of mitochondrial DNA depletion, Bao and colleagues 
describe a strikingly similar scenario in which all SSP enzymes were upregulated in response 
to mtDNA depletion which was reversed by the inhibition of ATF4 (Bao et al., 2016). 
Mitochondrial folate metabolism was also impaired, with the generation of reduced folate 
species being favoured. The oxidation of folates requires NAD+ and as mitochondrial 
inhibition or dysfunction limits the availability of mitochondrial NAD+, it is proposed that a 
redox imbalance drives the impairment of mitochondrial folate metabolism. Branching from 
reduced folate species, an upregulation of the transsulphuration pathway was also inferred 
by transcriptional activation of transsulphuration genes and a significant decrease in cellular 
homocysteine. A low level of homocysteine remethylation to methionine suggested the 
conversion of homocysteine to cysteine by transsulphuration as being the dominant 
pathway (Bao et al., 2016). Patient derived cells harbouring pathogenic mutations of 
mitochondrial complex I also show altered glutathione levels, specifically a significant 
reduction in the ratio between reduced and oxidised glutathione (GSH/GSSG) further 
supporting the role that mitochondrial dysfunction has in the remodelling of folate 
metabolism and pathways that branch from it (Ni et al., 2019). 
 
In order to adapt to stressors such as nutrient deprivation or an accumulation of unfolded 
proteins within the endoplasmic reticulum, cellular pathways have evolved which are now 
highly conserved means by which to combat such stress. Aberrations of mtDNA expression, 
present in both PolγAmut/mut mice and aged human tissues in which somatic mtDNA 
mutations have accumulated over time are able to induce stress responses in affected 
tissues. The first such mitochondria-specific response to be described; the mitochondrial 
unfolded protein response (UPRmt) was characterised in cultured mammalian cells elicited by 
the expression of a mutant form of the mitochondrial matrix protein, ornithine 
transcarbamylase (OTC). An accumulation of mutant unfolded protein within the 
mitochondrial matrix reportedly resulted in the transcriptional upregulation of nuclear genes 
encoding mitochondrial stress proteins (Zhao et al., 2002). Further characterised in the 
Caenorhabditis elegans nematode worm, proteotoxic stress drives the relocation of stress 
activated transcription factor S1 (ATFS-1) from the mitochondria to the nucleus where amino 
acid response element (AARE) containing promoters are transcriptionally activated by ATFS-
1. The subsequent transcription of mitochondrial heat shock proteins (HSPs), proteases and 
chaperones promote the folding or clearance of abnormal proteins, activating the stress 
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response (Haynes et al., 2013; Haynes et al., 2007). Analogous to ATFS-1 in the nematode 
worm are the ATF transcription factors 3-5 in mammals which, when subjected to stresses 
derived from mtDNA expression defects also initiate a transcriptional response driven by the 
induction of AARE-regulated genes. Unlike in the worm, the stress response activated by 
ATFs in mammals drives a minimal UPRmt response and is instead characterised by the 
remodelling of multiple metabolic pathways, namely serine, glutathione, and purine 
biosynthesis. Described in the Deletor mouse model of late-onset mitochondrial myopathy 
with muscle specific remodelling of serine synthesis and one carbon metabolism (Nikkanen 
et al., 2016; Tyynismaa et al., 2010), this collective response has been termed the 
mitochondrial integrated stress response (ISRmt) and is controlled by mTORC1 (Khan et al., 
2017).  
 
Coinciding with the appearance of COX deficient muscle fibres at around 12 months of age, 
the first stage of the ISRmt is defined by a strong induction of transcription of Fgf21, Mthfd2 
and Gdf15. Fibroblast growth factor 21 (FGF21), is a circulating hormone-like cytokine with 
roles in the regulation of lipid metabolism and the fasting response (Badman et al., 2007; 
Kharitonenkov et al., 2005). Although primarily produced by the liver (Nishimura et al., 
2000), FGF21 is also secreted from adipose tissue (Muise et al., 2008) and from the muscle of 
both mice and humans with muscle-manifesting mitochondrial disorders leading to its 
identification as a useful biomarker of myopathic mitochondrial diseases (Davis et al., 2013; 
Suomalainen et al., 2011; Tyynismaa et al., 2010). A member of the transforming growth 
factor-β (TGFβ) family; growth differentiation factor 15 (GDF15) is a cytokine that although 
elevated in several conditions such as cardiovascular disease (Wollert et al., 2017), cancer 
and chronic inflammation (Breit et al., 2011), it is also elevated in the circulation of 
mitochondrial disease patients and as such, like FGF21 , GDF15 has been identified as a 
mitochondrial disease biomarker (Davis et al., 2016; Yatsuga et al., 2015).  
 
Following the initial transcriptional program of the ISRmt, the metabolic phase of the 
response initiates at around 15 months of age in Deletor mice (Forsström et al., 2019).This 
involves the activation of serine synthesis pathway genes Phgdh and Psat1 in addition to 
further elevation of mTORC1 and enhanced induction of Atf5 which increases steadily from 
the initial ISRmt. The induction of Atf3 and Atf4 begins to increase from this stage with an 
elevation in glucose uptake and transsulphuration in affected tissues. The final stage of the 
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ISRmt in Deletor muscle is characterised by a mild UPRmt response as shown by a slight 
increase in heat shock protein and protease expression between 21 and 24 months of age. 
The ISRmt is shown to be conserved in human patients with mitochondrial myopathy caused 
by either single or multiple mtDNA deletions. RNA sequencing carried out on patient muscle 
biopsies demonstrated an increased level of FGF21, MTHFD2, GDF15, PHGDH, PSAT1 and 
ATF5 with the identification of additional upregulated transcripts namely SHMT2, DDIT, ASNS 
and TRIB3. Interestingly, this gene set bears a strong resemblance to significantly 
upregulated transcripts within non-transformed small intestinal crypts from our own 6-
month-old PolγAmut/mut mice. Our analysis did not detect an upregulation of Shmt2 or Ddit 
however all other transcripts correlate (Atf5, Trib3, Phgdh, Psat1, Asns, Mthfd2 and Gdf15), 
with one particularly notable absence; that of the master regulator of the ISRmt; Fgf21. Given 
that increased serum levels of FGF21 are most strongly associated with muscle manifesting 
defects of mtDNA translation or maintenance (Lehtonen et al., 2016), it would seem 
appropriate that a muscle specific marker is absent from intestinal tissue. Furthermore, the 
induction of ISRmt components and corresponding metabolic pathways in FGF21 knock out 
mouse embryonic fibroblasts with pharmacologically induced mtDNA translation defects 
demonstrates that while intrinsic to the ISRmt in skeletal muscle, FGF21 is not an absolute 
requirement for the response in other cell types (Forsström et al., 2019). 
 
Also, intriguingly absent from our upregulated gene set is Atf4, which Forsström et al report 
as a requirement for the ISRmt in dividing cells. Here, the silencing of ATF4 using siRNA 
abrogates the expression of ATF3, CTH, PHGDH, MTHFD2, GDF15, and FGF21 in human 
fibroblasts. Numerous other works also report the central role of ATF4 in regulation of 
integrated stress responses and as such it is considered a master regulator (Harding et al., 
2003; Rutkowski & Kaufman, 2003). ATF4 mRNA is ubiquitously expressed, however in 
response to stressors, expression of ATF4 protein is largely under translational control 
(Harding et al., 2000). Increased levels of ATF4 protein have thus been shown to occur 
without a corresponding elevation of mRNA following cAMP activation in hippocampal 
neurons (Harding et al., 2000; Yukawa et al., 1999) somewhat explaining the absence of 
differentially expressed levels of ATF4 mRNA in our analysis. In addition to genes identified 
as ATF4 dependant by Forsström et al., further members of our upregulated gene set on are 
reportedly dependent on ATF4. Following amino acid deprivation, Atf4-/- mouse embryonic 
fibroblasts fail to upregulate Asns, Trib3, Mthfd2, and Atf5 (Huggins et al., 2015). The 
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similarity of significantly upregulated transcripts in normal non-transformed PolγAmut/mut 
intestinal crypts to those which are upregulated in known responses to cellular stresses 
suggests the induction of an integrated stress response initiated by PolγA mediated 
mitochondrial dysfunction in our cohort. An age-related increase in the expression of serine 
synthesis and mitochondrial one carbon cycle enzymes in the normal non-transformed 
intestine of PolγAmut/mut mice as demonstrated using immunofluorescence supports the 
association of this pathway with an age-related accumulation of mtDNA mutations. This is 
also shown in normal ageing OXPHOS deficient human colonic crypts, however further 
investigations particularly in human tissues are warranted in order to ascertain the 
involvement of key mediators of the ISRmt and thus the validity of a mechanistically 
analogous response in mitotic tissues. Interestingly, recent work carried out in the fruit fly, 
Drosophila melanogaster, has described an over-proliferation of eye progenitor cells which is 
initiated following disruption of the electron transport chain. The reduced expression of the 
Cox7a subunit of complex IV induced a glycolytic Warburg-like metabolism and associated 
reduction in cellular pH. This in conjunction with an eIF2a-kinase PERK-ATF4 mediated stress 
response, also induced by the Cox7a defect increased cellular sensitivity to Notch signalling 
resulting in substantial over proliferation (Sorge et al., 2020). This work further supports the 
notion that a similar stress response may be relevant in the human intestine. 
 
Real-time PCR was carried out on laser micro dissected adenomas from PolγAmut/mut and 
PolγA+/+ mice in which adenomagenesis was induced at 6 months of age followed by humane 
sacrifice 23 days later. Significant increases in gene expression of Phgdh, Psph, Mthfd2 and 
Aldh1l2 were detected in PolγAmut/mut compared to PolγA+/+ mice (Smith et al., 2020; 
Whitehall, 2019). A wealth of evidence exists in which these genes and the pathways their 
protein products participate in are implicated in cancer. The 1940s saw the advent of 
interest in the role of one-carbon metabolism in cancer with the observation that a dietary 
deficiency of folate reduced the frequency of malignant cells in children with acute 
leukaemia (Farber & Diamond, 1948). Administration of the folic acid antagonist aminopterin 
provided these patients with a temporary remission of their condition as a direct result of 
inhibition of the folate cycle. By competing for the folate binding site of dihydrofolate 
reductase (DHFR), the enzyme responsible for the synthesis of tetrahydrofolate (THF) from 
dietary folate, aminopterin effectively blocks the synthesis of THF and thus one-carbon 
metabolism (Osborn et al., 1958). Similarly, the discovery that tumours were able to 
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synthesise serine (and glycine) from glucose drew attention to the de novo serine synthesis 
pathway and its involvement in cancer several decades ago (Kit, 1955). Analysis of the 
activity of enzymes involved in this pathway subsequently revealed their upregulation in 
neoplastic tissues of animal models of disease (Davis et al., 1970; Knox et al., 1969; Snell, 
1985), and since then, numerous studies have reported the overexpression of SSP enzymes 
in multiple tumour types with inhibition of growth facilitated by the inhibition or knockdown 
of the enzymes (Pacold et al., 2016; Possemato et al., 2011). Exogenous serine also plays an 
important role in tumour survival, its removal inducing stress and reducing proliferation of 
cancers in which the de novo SSP is not amplified (Labuschagne et al., 2014; Maddocks et al., 
2013). 
 
With regard to regulation of the SSP and folate cycle in cancer, several oncogenes and 
tumour suppressors have been associated with the upregulation of these pathways. All three 
SSP enzymes are amplified by oncogenic cMYC, a transcription factor often aberrantly 
expressed in cancer (Sun et al., 2015). PHGDH expression has also been found to be 
positively regulated by the tumour associated transcription factors nuclear transcription 
factor Y (NFY) and specificity protein 1 (SP1) (Jun et al., 2008) and by the receptor tyrosine 
kinase oncogene HER2 in breast cancer cells (Bollig-Fischer et al., 2011). SSP enzyme 
expression is also regulated by epigenetic modifiers which have been shown to be elevated 
in multiple cancers. SSP enzyme transcription is promoted in a number of different human 
cancer cell lines by G9A, a H3K9 methyltransferase (Ding et al., 2013) while in Ewing sarcoma 
cell lines, the inhibition of the overexpressed histone methyltransferase MLL1 and 
scaffolding protein menin reduced the expression of SSP genes with confirmation of the 
requirement for the pathway being demonstrated by a reduced viability of PHGDH knock-
down xenograft tumours in nude mice (Svoboda et al., 2018). Folate cycle enzymes have also 
been shown to be regulated by oncogenes and tumour suppressors, for example an 
enhanced expression of MTHFD2 is associated with activating KRAS mutations in non-small 
cell lung cancer (NSCLC) cell lines (Moran et al., 2014). 
 
The loss of the p53 tumour suppressor, a common event in many human cancers, is largely 
associated with the gain of a proliferative advantage due to the role of the wild-type protein 
in the induction of senescence and cell death. Accompanying this proliferative advantage, 
however, is the loss of the metabolic plasticity that wild type p53 provides under conditions 
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of stress. Indeed, the depletion of serine from media reduced the proliferation and viability 
of p53−/− HCT116 cells more so than p53+/+ cells (Maddocks et al., 2013). The mechanism by 
which p53+/+ cells were able to adapt to serine starvation was attributed to the induction of 
p21, a mediator of cell cycle arrest which also facilitates the inhibition of nucleotide 
synthesis and the shunting of serine derived one-carbon units into glutathione production. 
Without the induction of this pathway and the subsequent production of glutathione, p53−/− 
cells are unable to detoxify increases in intracellular ROS associated with serine deprivation 
stress. Conversely, the loss of the tumour suppressor protein kinase C zeta type (PKCζ) 
augments the ability of colon cancer cell lines to resist glucose deprivation stress (Ma et al., 
2013). Mechanistically, these cells demonstrate reduced levels of AMPK and associated 
autophagy and also maintain levels of mTOR in contrast to cells in which PKCζ is present and 
the converse is observed. Furthermore, it was noted that PKCζ deficient cells consumed 
more glutamine than controls and that 13C-glutamine labelling followed the utilisation of this 
glutamine into the serine synthesis pathway. The subsequent gene expression analysis of 
SSP enzymes revealed that expression of PHGDH and PSAT1 was significantly greater in PKCζ 
deficient cells. These observations were corroborated in an ApcMin/+ mouse model of 
intestinal cancer in which PKCζ deficiency promoted intestinal tumorigenesis (Ma et al., 
2013). In support of these findings, Reina-Campos and colleagues describe a mouse model of 
prostate cancer in which tumorgenicity is enhanced by the deficiency of another atypical 
protein kinase C; protein kinase C lambda/iota (PKCλ/ι). PKCλ/ι deficiency was also 
associated with increased activation of mTOR and ATF4 and increased expression of PHGDH, 
MTHFD2, and PSAT1 in prostate cancer cell lines (Reina-Campos et al., 2019).  
 
The pyruvate kinase isoenzyme type-M2 (PKM2) which catalyses the final step of glycolysis is 
highly overexpressed in many tumour cells. While most adult tissues express the PKM1 
isoform, tumour cells expressing the PKM2 isoform possess a proliferative advantage over 
those that do not as evidenced by xenograft models in which the PKM1 isoform grafts 
display a diminished tumour formation capacity (Christofk et al., 2008). A shift to the PKM2 
isoform is required to drive the aerobic glycolysis favoured by tumour cells, however as the 
activity of PKM2 is regulated by the availability of serine, the metabolic remodelling it can 
facilitate extends beyond a simple glycolytic switch. In the absence of serine, PKM2 is 
inactive and as such the availability of glycolytic intermediates including the serine precursor 
3PG increase in abundance. Indeed, by blocking the serine synthesis pathway, Ye and 
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colleagues demonstrate that under serine starvation, the proliferative advantage PKM2 
colon carcinoma cells display results from increased flux through the SSP (Ye et al., 2012). 
Furthermore, the group demonstrate that in PKM1 cells, a reduction in mTOR activity and 
diminished proliferation is induced by serine starvation. In contrast, the activity of mTOR, a 
key oncogenic regulator of proliferation is maintained in PKM2 cells. As mTOR is reported to 
regulate the translation and stability of ATF4 mRNA (Park et al., 2017), and ATF4 increases 
the expression of all three SSP enzymes, it would appear that the PKM2 switch observed in 
many cancers has a key role in coordinating not only glycolysis but mTOR activation and 
serine synthesis. 
 
As outlined in 6.1.1., serine and other amino acids donate one-carbon units to the folate and 
methionine cycles supporting methylation reactions and the synthesis of nucleotides, 
antioxidants and anabolic precursors. These processes are vital to cellular survival in general, 
however in the event of malignant transformation, the support of survival and proliferation 
becomes paramount to the growing tumour and these metabolic processes are rewired 
(reviewed in Hanahan & Weinberg, 2011). In order to replicate and proliferate, tumours 
require purine and pyrimidine nucleotides, both of which are synthesised using one-carbon 
units. As serine is a major one-carbon unit donor, the inhibition of its metabolism has been 
shown to negatively affect the synthesis of purine nucleotides when serine metabolism is 
inhibited via starvation (Labuschagne et al., 2014; Maddocks et al., 2016) or via 
deletion/knockdown of SHMT2, the mitochondrial enzyme responsible for the removal of 1C 
units from serine (Ducker et al., 2016; Kim et al., 2015). Accordingly, SHMT2 is often found to 
be upregulated in cancer (Jain et al., 2012; Lee et al., 2014). The synthesis of pyrimidine 
nucleotides is also reduced by the inhibition of serine metabolism, specifically via small 
molecule inhibition of PHGDH (Pacold et al., 2016). Following the 1C removal from serine 
and its conjugation to THF generating 5,10-methylene-THF, MTHFD2 facilitates the redox 
reactions that transfer 1C units through the mitochondrial folate cycle. MTHFD2 has also 
been shown to be amplified within multiple tumour types (Nilsson et al., 2014). Although its 
CRISPR-mediated knockout can be compensated for by the cytoplasmic folate pathway and 
addition of exogenous formate, the loss of MTHFD2 causes an accumulation of purine 
precursors which are static at the penultimate stage of synthesis due to a 10-formyl-THF 
deficiency caused by loss of MTHFD2 (Ducker et al., 2016). 
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A deficiency of purine nucleotides due to serine restriction has implications for cancer cells 
beyond that of the supply of building blocks for DNA and RNA synthesis. Maintenance of the 
methionine cycle relies on the generation of SAM from methionine using adenosine derived 
from ATP. ATP is synthesised de novo via the purine synthesis pathway using serine derived 
one-carbon units. If there is a paucity of serine derived carbon, de novo ATP synthesis is 
curtailed as is generation of SAM (Maddocks et al., 2016). As the primary mammalian methyl 
donor, SAM is critical in providing methyl groups for their transfer to metabolites, proteins, 
lipids, RNA and DNA, aberrations of the latter bearing significance in the development of 
cancer (reviewed in Kulis & Esteller, 2010).  
 
Folate cycle reactions in the direction of 5,10-methylene-THF conversion to 10-formyl-THF 
generate NADPH from NADP+ in the cytoplasm catalysed by MTHFD1. Mitochondrial 
MTHFD2/2L catalyses the same reactions with the ability to use either NAD+ or NADP+ 
generating NADH and NADPH respectively, with an NAD+ cofactor being favoured by 
MTHFD2. The availability of these cofactors has far reaching consequences for the cell, in 
that they provide the reducing power required to drive the redox reactions essential to 
numerous biochemical, biosynthetic and metabolic pathways. The observation that folate 
flux through the mitochondria occurs at a rate in excess of that which is demanded for 
biosynthetic 1C delivery suggests that the concomitant production of NAD(P)H is an 
important function of the mitochondrial folate pathway (Ducker et al., 2016; Fan et al., 
2014). In addition to the NADPH generated via the pentose phosphate pathway and malic 
enzyme, one-carbon metabolism contributes a significant proportion of this cofactor which 
can support lipogenesis and antioxidant defence, processes which are of particular 
importance in the highly proliferative, hostile malignant environment. Paradoxically, as 
many cancers overexpress the NAD+ dependant MTHFD2 which favours the 5,10-methylene-
THF to 10-formyl-THF directionality of the folate cycle in the mitochondria, this would lead 
to consumption of NADPH as the reverse directionality is driven in the cytosol. The 
NADP+/NADPH ratio however may be restored by the activity of ALDH1L2 (aldehyde 
dehydrogenase 1 family member L2 or mitochondrial 10-formyl-THF dehydrogenase) which 
has also been reported to be overexpressed in cancer cell lines (Krupenko et al., 2010). 
ALDH1L2 catalyses the ‘wasting’ of one-carbon units from 10-formyl-THF releasing them as 
CO2, regenerating THF and concomitantly generating NADPH. NADPH is required to reduce 
oxidised glutathione and as such the loss of ALDH1L2 in HEK293 cells increases their 
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sensitivity to oxidative stress (Ducker et al., 2016). Aldh1l2 is significantly upregulated in 
both the normal non-transformed intestinal crypts and adenomas of PolγAmut/mut mice in 
comparison to PolγA+/+ (Whitehall, 2019) and as such may suggest the relevance of this 
mechanism in PolγAmut/mut oxidative stress defence. This is in agreement with the work of 
Meiser and colleagues, in which tumours of a more oxidative phenotype are associated with 
increased mitochondrial formate overflow; an alternate fate of mitochondrial 10-formyl-THF 
which due to its requirement for competent mitochondrial oxidative phosphorylation is 
hypothesised to be opposed in non-oxidative tumours (Meiser et al., 2018).   
 
The implications of oxidative versus non-oxidative tumour types are further highlighted 
when considering the role of the mitochondrial folate cycle in the generation of another 
important reducing agent; NADH. Yang et al., describe a considerable contribution to the 
mitochondrial NADH pool as being mediated by serine catabolism via the mitochondrial 
folate cycle. An accumulation of NADH is toxic and as such under conditions which inhibit 
cellular respiration (thus reducing the utilisation of NADH by the electron transport chain), 
alternative mechanisms of NADH production such as TCA cycling, and de novo serine 
synthesis are inhibited. However, the mitochondrial folate cycle and key redox enzyme, 
MTHFD2 are unaffected by a high NADH/NAD+ ratio and serine catabolism by this route 
persists in the absence of evidence of product inhibition (Yang et al., 2020). Interestingly, in 
HCT116 colon cancer cells in which cellular respiration was inhibited by hypoxia or treatment 
with metformin, phenformin or rotenone, concurrent knock down of MTHFD2 reduced the 
NADH/NAD+ ratio and as a result facilitated cell growth in these cells in comparison to 
respiration impaired cells in which MTHFD2 was retained (Yang et al., 2020). These 
observations are not in agreement with data presented here in which a defect of cellular 
respiration in the adenomas of PolγAmut/mut mice is associated with increased expression of 
serine synthesis and mitochondrial one carbon cycle enzymes hypothesised to facilitate their 
enhanced growth. The work of Yang et al., is also somewhat contradictory to others in which 
treatment with similar doses of metformin decrease the growth of Vil1-creER; Apcfl/fl 
organoids (Maddocks et al., 2017) and lung and adenocarcinoma cell lines (Gravel et al., 
2014) which are deprived of serine. The actions of the biguanide anti-diabetic agent 
metformin are complex and include AMPK-dependent inactivation of mTORC1 exerting 
antiproliferative effects (Dowling et al., 2007; Zakikhani et al., 2006) and a similarly AMPK 
mediated inhibition of gluconeogenesis and induction of fatty acid oxidation and glucose 
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utilisation in the liver mechanistically driving the antidiabetic effects of the drug (Zhou et al., 
2001). Furthermore, at low doses, metformin possesses antioxidant properties (Hou et al., 
2010). With these complexities and the differences between acute pharmacological 
respiration inhibition in cultured cells and that of physiological systems at an organismal 
level in mind, it may be more biologically relevant to compare the findings the current work 
with those of the in vivo studies carried out by Yang et al. Although the contribution of 
serine to NADH was reported as elevated in NDUSF4 knockout mice compared to wild type 
animals, treatment with a dual SHMT1/2 inhibitor did not decrease NADH levels (Yang et al., 
2020). Although evidently important in the systems described, the differences between this 
work and that of Yang et al., may represent differing mechanisms at play in vivo versus in 
vitro and also in acute pharmacological inhibition of cellular respiration as opposed to that 
associated with an age-related accumulation of mtDNA mutations. Prior to adenomagenesis, 
tissues within our experimental animals may have had sufficient time to adapt to an 
increasing NADH/NAD+ ratio and as such are less affected by this potentially toxic insult, 
perhaps with a shift towards reductive carboxylation contributing to their metabolic 
adaptation (Mullen et al., 2011).  
 
Reductive carboxylation describes an alternative metabolic pathway, which in contrast to 
the canonical TCA which metabolises glucose and glutamine derived carbon in an oxidative 
manner, key reactions are reversed, and glutamine is used to generate TCA intermediates 
and acetyl-coA thus supporting lipid (Metallo et al., 2012), protein and nucleotide (Birsoy et 
al., 2015; Sullivan et al., 2015) synthesis reductively. In cells in which mitochondria have a 
normal oxidative capacity, glutamine is a major anaplerotic contributor thus facilitating the 
generation of biosynthetic precursors that branch from TCA intermediates (reviewed in 
DeBerardinis & Cheng, 2010). A continuous supply of biosynthetic precursors is essential to 
fuel the rapid growth of tumours, and an alternative reductive pathway that ensures this 
provision may be of particular importance in those tumours in which oxidative capacity may 
be compromised by defects of TCA enzymes or components of the mitochondrial electron 
transport chain (Mullen et al., 2011). Using metabolomics and stable isotope tracing in an 
osteosarcoma sarcoma cell line containing a mutation in the complex III cytb gene it was 
demonstrated that reductive carboxylation first requires the oxidation of alpha 
ketoglutarate (αKG) by αKG dehydrogenase generating NADH. The formation of NADPH 
from NADH by nicotinamide nucleotide transhydrogenase (NNT) reduces the NADP+/NADPH 
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ratio driving the reverse reductive reaction of NADPH-dependant isocitrate dehydrogenases 
1 and 2 (IDH1 and IDH2) in the cytosol and mitochondria respectively (Mullen et al., 2014; 
Mullen et al., 2011). Moreover, the generation of NADPH by this means in addition to that 
generated by the oxidation of isocitrate by IDH2 in the mitochondria has been shown to 
reduce mitochondrial ROS (Jiang et al., 2016). Further evidence for the role of the 
NAD+/NADH ratio in supporting reductive carboxylation is taken from the use of 
mitochondrially targeted zinc-finger nucleases (mtZFNs) in creating isogenic cell lines with 
different levels of m.8993T>G heteroplasmy. Those with the highest levels of heteroplasmy 
demonstrated a reduced oxygen consumption rate, a lower NAD+/NADH ratio and a 
corresponding increased activation of cytosolic reductive carboxylation (Gaude et al., 2018). 
In silico modelling of the pathway noted a significant contribution of the activity of the 
cytosolic malate-aspartate shuttle enzyme malate dehydrogenase 1 (MDH1) to ATP 
generation suggesting an additional link to glycolysis. Indeed, hydrogen tracing of GAPDH 
derived NADH to cytosolic malate provided evidence that the glycolytic GAPDH is redox 
linked to the malate generating, NADH dependant MDH1 (Gaude et al., 2018). 
 
Support for the potential involvement of reductive carboxylation in our model comes from a 
functional metabolomic analysis carried out at the metabolomics facility at the Beatson 
Institute, Glasgow (Smith et al., 2020; Whitehall, 2019). Ex vivo small intestinal adenoma 
organoids from PolγA+/+/Lgr5-creER/Apcfl/fl and PolγAmut/mut/Lgr5-creER/Apcfl/fl were grown in 
13C6- labelled glucose and intra and extra cellular metabolites measured using high 
performance liquid chromatography-mass spectrometry (HPLC-MS). Firstly, an increased 
level of unlabelled αKG in PolγAmut/mut versus PolγA+/+ adenomas suggests the derivation of 
this metabolite from a source other than glucose, potentially glutamine for reductive 
carboxylation. An increased NAD+/NADH ratio in PolγAmut/mut versus PolγA+/+ adenoma 
organoids may suggest the increased activity of cytosolic NAD+ generating MDH1. The 
decreased levels of labelled citrate M+2, fumarate M+2 and malate M+2 in PolγAmut/mut 
versus PolγA+/+ adenoma organoids does imply an impaired oxidative TCA turning, however it 
may also suggest an increased utilisation of these intermediates for example the use of 
citrate to generate acetyl-CoA and oxaloacetate for the synthesis of lipids and nucleotides 
(via aspartate) respectively. In order to investigate this further the tracing of labelled 
glutamine as opposed to glucose is required. Metabolite measurement at different time 
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points providing a flux analysis would assist greatly in elucidating the contribution of 
reductive carboxylation of glutamine in PolγAmut/mut adenomas.  
 
6.5. Future work 
 
Although de novo serine synthesis and mitochondrial folate enzyme quantification was 
carried out in the ageing human colon, limitations of this study are that the same analyses 
have not yet been performed in human carcinomas. An obvious next step is to investigate 
the patterns of OXPHOS dysfunction within the matched tumour biopsies from our patient 
cohort and correlate findings with the expression of serine and one carbon metabolism 
enzymes. Furthermore, the delineation of OXPHOS deficient crypts in the normal human 
colon samples into complex specific deficiencies may help in assigning an association of the 
upregulation of serine and one carbon metabolism with a defect of a particular OXPHOS 
protein. Additionally, the study may benefit from a quantitative analysis of the expression of 
these enzymes in our animal model as only a subjective immunohistochemical analysis has 
been performed in a small number of experimental animals thus far. With regard to the 
mechanism by which mitochondrial dysfunction may lead to the metabolic remodelling 
reported, it would be particularly interesting to investigate the involvement of mTORC1 
signalling and mediators of the ISRmt in both human tissues and those from our mouse 
model, potentially identifying a response in dividing tissues analogous to that which has 
been described post-mitotically.  
 
As the overriding aim of biomedical research is to gain insights into the pathophysiology of 
disease with the view to ameliorating the conditions in question, the feasibility of 
therapeutically targeting identified vulnerabilities is of great importance. As evidence of the 
upregulation of the de novo serine synthesis and mitochondrial folate cycle pathways has 
been identified in association with an increased adenoma burden in our mouse model, a 
logical next step would be to examine the effect of pharmacologically inhibiting these 
pathways in vivo. The PHGDH inhibitor NCT-503 has been demonstrated to reduce the 
growth and increase necrosis of PHGDH-dependant xenograft breast tumours in mice, also 
inducing the consumption of one carbon units to regenerate serine from glycine. This 
subsequently reduces the availability of one carbon units required to synthesise purines and 
dTMP which may impair the growth of PHGDH-dependant tumours Importantly, NCT 503 
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appears to be well tolerated by the animal model and no weight loss was associated with 
administration (Pacold et al., 2016). Two further compounds; PKUMDL-WQ-2101 and 
PKUMDL-WQ-2201 have been reported to supress the growth of the same xenograft breast 




Following molecular investigations carried out by Dr Julia Whitehall, a subset of differentially 
expressed transcripts was identified as upregulated in the normal non-transformed small 
intestinal crypts of PolγAmut/mut versus PolγA+/+ mice. These transcripts, relating to serine 
biosynthesis and uptake and mitochondrial folate metabolism were subsequently validated 
at the protein level in vivo and correspondingly shown to be upregulated in the normal non-
transformed crypts and adenomas of PolγAmut/mut in comparison to PolγA+/+ animals in both 
the colon and small intestine. With the use of a quantitative immunofluorescent assay, an 
age-related increase in the expression of each enzyme was also demonstrated in the ageing 
PolγAmut/mut non-transformed intestinal and colonic epithelium. This was not found to be as 
pronounced in the PolγA+/+ epithelium suggesting that an age-related increase in the 
accumulation of somatic mtDNA mutations may drive this metabolic remodelling, possibly as 
part of a mitochondrial stress response. In the ageing human colon, the same metabolic 
remodelling was associated with OXPHOS deficient crypts also evidenced by a quantitative 
immunofluorescent assay. The importance of serine and one-carbon metabolism in the 
support of tumour growth and survival is well documented and findings described here may 
represent a protective cellular response to age-related mitochondrial dysfunction which, in 
the event of malignant transformation, provides those cells with a marked metabolic 
advantage over those in which mitochondrial function is retained.  
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Chapter 7. Final discussion 
 
The overriding aim of this thesis was to investigate the effect of age-related mtDNA 
mutations on intestinal tumour development. This was achieved through the generation and 
characterisation of a novel mouse model of intestinal cancer in which PolγA mediated 
mtDNA mutation accumulation preceded the intestinal stem cell specific deletion of Apc. In 
mice harbouring both heterozygous and homozygous PolγA mutations and intermediate and 
high levels of age-related mitochondrial dysfunction respectively, the intestinal adenoma 
burden was found to be significantly larger in comparison with control PolγA+/+ animals. 
Immunofluorescent labelling and quantification of mitochondrial OXPHOS proteins revealed 
a prominent complex I defect within PolγA+/mut and PolγAmut/mut adenomas in comparison 
with controls. Furthermore, double thymidine analogue labelling of experimental animals 
with subsequent immunofluorescent labelling of these analogues identified a significantly 
greater rate of cell replication within PolγAmut/mut intestinal adenomas in comparison with 
controls. Coupled with a reduced apoptotic index within PolγAmut/mut intestinal adenomas as 
detected using immunohistochemical methods, accelerated adenoma growth in PolγAmut/mut 
mice resulted in a significantly greater adenoma burden and decreased survival in 
comparison with PolγA+/+ mice. Further investigations into molecular pathways perturbed in 
response to age-related mitochondrial OXPHOS defects in the mouse model were carried out 
by Dr Julia Whitehall and revealed an upregulation of transcripts encoding enzymes involved 
in serine biosynthesis, uptake and mitochondrial folate metabolism (Whitehall, 2019). 
Within the current work, these findings were validated in both mice and humans as 
demonstrated by increased levels of the enzymes PHGDH, PSAT1 and MTHFD2 within 
OXPHOS deficient intestinal crypts. The importance of serine and one carbon metabolism in 
cancer cells is well established, with these pathways being vital to the provision of 
nucleotides, antioxidants and anabolic precursors essential to maximal tumour growth 
(reviewed in Newman & Maddocks, 2017). Furthermore, the upregulation of these pathways 
in response to mitochondrial dysfunction (Bao et al., 2016; Nikkanen et al., 2016; Tyynismaa 
et al., 2010) supports the work presented in this thesis which collectively proposes that age-
related mitochondrial dysfunction causes metabolic remodelling that in the event of a 
transforming mutation such as loss of Apc, contributes to accelerated intestinal adenoma 
growth. Presented in Figure 7-1 is a schematic depicting the hypothesised mechanism by 
which mtDNA mutations and OXPHOS defects contribute to tumorigenesis. 
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Figure 7-1. Schematic depicting the hypothesised mechanism by which mtDNA mutations and OXPHOS defects contribute 
to tumorigenesis. 
 
Interestingly, the preservation of and indeed expansion of mtDNA mutations within 
intestinal crypts only applies to somatically acquired defects. In the instance of inherited 
mtDNA mutations, the opposite occurs, and these mutations are lost from replicating tissues 
with increasing age. Loss of the m.3243A>G mutation is observed in the blood (de Laat et al., 
2012; Grady et al., 2018; Rahman et al., 2001) and epithelial tissues (Frederiksen et al., 2006; 
Olsson et al., 2001). With regard to the gastrointestinal tract specifically, loss of this 
mutation over time has been demonstrated in the oesophagus, stomach, and the small and 
large intestine (Su et al., 2018). Despite an absence of published work investigating the 
incidence of colorectal cancer in patients with inherited pathogenic mtDNA mutations, the 
differences observed with regard to the behaviour of inherited and age-associated somatic 
mtDNA mutations over time suggests that mitochondrial disease patients are not at 
increased risk of CRC. The loss of OXPHOS deficient cells in these patients would also be 
associated with the loss of any metabolic advantage and as such, it is surmised that the 
mechanism proposed in this thesis is only applicable with respect to somatically acquired 
mtDNA mutations.  
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As is the case with any experimental investigation there are limitations to this work; firstly, 
with regard to the PolγA mutator mouse model. As discussed in Chapter 3, the systemic 
effects of the PolγA mutation are extensive. While the characterisation of our PolγA/Lgr5+/-
/Apcflox/flox experimental animals and adenoma burden quantification implicated the 
significantly greater intestinal adenoma burden within PolγAmut/mut mice as the primary 
limiting pathology, the whole-body effect of the PolγA mutation cannot be excluded. 
Although in-depth FACS analysis of PolγA+/+ and PolγAmut/mut mouse immune cell populations 
did not detect any significant differences in the small intestinal immune cell 
microenvironment between genotypes prior to Apc deletion (Smith et al., 2020), the impact 
of the PolγA mutation on cells comprising the tumour microenvironment has not been 
investigated within this work. Given the role inflammation in both the initiation of colitis 
associated colorectal cancer (Ekbom et al., 1990) and the promotion of sporadic CRC (Kojima 
et al., 2004), the enhancement of a pro-inflammatory response following immune 
stimulation as has been described within the PolγAmut/mut model (Logan et al., 2014) may 
represent an additional mechanism by which adenoma growth is promoted within the 
PolγAmut/mut intestine. Despite the similarity in mtDNA mutation gene location between 
PolγA+/mut mice and ageing humans (mutations are randomly distributed throughout the 
genome in both species), a significantly greater frequency of transversion mutations are 
observed in PolγA+/mut COX deficient crypts when compared with human COX deficient crypts 
(Baines et al., 2014). The majority of mutations in both species are transitions, however a 
predominance of C>T transitions is observed in the mutator mouse in comparison to the G>A 
prevalence within ageing crypts. Additionally, 10% of mutational changes within human COX 
deficient crypts comprise insertions/deletions whereas no such changes are identified in 
PolγA+/mut counterparts (Baines et al., 2014; Greaves et al., 2012). In addition to the 
observation that mtDNA mutations are accumulated at a significantly greater rate within 
PolγAmut/mut animals in comparison to humans (Khrapko et al., 2006), these considerations 
suggest the requirement for a more refined model in which to assess the contribution of 
age-related mtDNA mutation accumulations in intestinal adenoma growth.  
 
In order to circumvent the limitation regarding the mutational spectrum associated with the 
PolγA mutator model, alternative models have been developed. The mito-APOBEC1 
Drosophila model utilises the cytidine deaminase APOBEC1 (Apolipoprotein B (apoB) mRNA 
editing catalytic polypeptide 1) to specifically induce C:G>T:A transition mutations within the 
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mitochondrial genome (Andreazza et al., 2019). The usual physiological function of the 
APOBEC1 enzyme is ApoB mRNA editing via the catalysis of the deamination of cytosine to 
uracil residues. When targeted to the mitochondria, APOBEC1 induces C>U deamination 
within single stranded DNA, suggested to be exposed during the replication or transcription 
of the mitochondrial genome. In the absence of uracil repair by uracil-DNA glycosylase, 
subsequent replication pairs an adenine base with uracil, resulting in the C:G>T:A transition 
point mutation and associated mitochondrial dysfunction in the absence of deletions or DNA 
depletion (Andreazza et al., 2019). As this mutational profile is consistent with that of human 
ageing, the development of a similar system in the mouse would assist in improving the 
recapitulation of age-related mtDNA mutation accumulation in our model.  
 
The use of an additional cytidine deaminase in mitochondrial genome editing has recently 
been described. In contrast to the single-stranded DNA activity of the APOBEC1 model, the 
so-named DddA bacterial cytidine deaminase catalyses this reaction within double-stranded 
DNA and has been engineered to allow base editing within specific mtDNA genes (Mok et al., 
2020). In order to avoid the cell toxicity associated with intact DddA, the protein was split in 
half. By fusion with transcription activator-like effector array (TALE) proteins, each half was 
targeted to neighbouring DNA target sites where reconstitution of the protein facilitated 
cytidine deaminase activity and C:G>T:A transition mutation formation. In association with a 
mitochondrial targeting sequence (MTS) and a glycosylase inhibitor (UGI) to prevent uracil 
repair by uracil glycosylase, the split-DddA and TALE protein fusion (collectively termed 
DdCBE) was specifically targeted to mitochondrially encoded complex I genes. In comparison 
with control cells treated with inactive DdCBE, cells in which DdCBE was targeted to the ND4 
gene demonstrated reduced levels of oxidative phosphorylation and reduced complex I 
assembly and activity (Mok et al., 2020). Given the prominent complex I defect observed 
within intestinal adenomas in our model, the ability to specifically induce mutations 
homologous to those acquired during normal ageing within mitochondrial genes encoding 
complex I subunits would greatly enhance future studies. In the absence of such techniques 
in the mouse at present, the induction of specific mtDNA mutations into intestinal organoids 
would present the opportunity to assess the response of complex I deficient adenomas to 
small molecule inhibitors of serine synthesis enzymes and evaluate the potential therapeutic 
intervention accordingly. 
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The maintained growth of PolγAmut/mut derived intestinal organoids in comparison with the 
impaired growth the PolγA+/+ organoids upon withdrawal of serine demonstrates the 
functional significance of the upregulation of serine synthesis pathway and mitochondrial 
one carbon cycle enzymes in adenoma growth (Whitehall, 2019). While the advantage of the 
PolγAmut/mut genotype and ensuing metabolic remodelling has been ascertained with regard 
to adenoma growth, the specific cellular outputs of the pathway have not been ascertained 
in this work. The use of additional dynamic metabolic flux analyses of adenoma organoids at 
multiple time points following 13C carbon labelling would assist greatly in identifying which 
SSP cellular outputs are required. Additionally, the mass spectrometric analysis of specific 
folate cycle intermediates within both PolγA+/+ and PolγAmut/mut derived intestinal organoids 
would assist in providing this information. For example, as the folate intermediate which 
donates 1C units to the methionine cycle and methylation reactions, an abundance of this 
cofactor would indicate a flux in this direction. Similarly, an increased level of 5,10-methenyl-
THF and 10-formyl-THF would indicate flow in the direction of purine synthesis. The final 
outputs of each of these pathways may also be interrogated. As described by Maddocks and 
colleagues, by feeding cells with labelled serine followed by DNA and RNA isolation, nucleic 
acid hydrolysis and analysis by LCMS, the contribution of serine to methyl cytosine and 
methyl adenine labelling was assessed (Maddocks et al., 2016). This method may also be 
applied to our intestinal adenoma organoids as could the measurement of dNTP pools in 
order to investigate differences in purine and pyrimidine synthesis between PolγA+/+ and 
PolγAmut/mut groups. The analysis of dNTP pools involves the DNA polymerase-catalysed 
incorporation of endogenous and radiolabelled dNTPs into a DNA template with the amount 
of resultant radioactivity indicating endogenous dNTP levels (Martí et al., 2012). Finally, 
while the HPLC-MS measurement of metabolites extracted from adenoma organoids 
following 13C carbon labelling would assist in providing a measure of glutathione levels and 
thus activation of the transsulphuration pathway, additional measures of the activity of this 
pathway may be achieved with the quantification of hydrogen sulphide (H2S) levels. As a by-
product of transsulphuration, the measurement of H2S levels either by HPLC with 
fluorescence detection or with mass spectrometric measurement of dissociated organoid 
cell extracts following the reaction with the thiol-specific monobromobimane may facilitate 
in providing a measure of activity this pathway (Shen et al., 2015). While western blot 
analysis of transsulphuration pathway enzymes would also provide a measure of pathway 
activation within adenoma organoids, immunohistochemical or immunofluorescent 
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interrogation of these enzymes within intestinal tissue sections would also be informative. 
The identification of the specific cellular requirements mediated by the upregulation of 
serine biosynthesis and mitochondrial one carbon metabolism in PolγAmut/mut adenomas may 
ultimately reveal metabolic vulnerabilities which could be exploited therapeutically. 
 
While the effect of age-related mtDNA mutation and OXPHOS dysfunction in pre-malignant 
adenomatous lesions has been described within this study, the consequences of 
mitochondrial dysfunction at subsequent stages of the adenoma-carcinoma sequence is 
unknown. Interestingly, a recent study utilising existing exome sequencing data reported a 
significantly greater survival in 344 stage 1-3 colorectal cancer patients harbouring 
truncating mtDNA mutations or non-truncating, non-synonymous mutations in comparison 
to wild-type samples (Gorelick et al., 2020). Truncating mutations affecting complex I were 
reported in approximately 20% of cases and those affecting the remaining respiratory chain 
complexes accounted for roughly 5% of cases. The enrichment of truncating variants 
affecting complex I in this dataset supports work presented in this thesis in that complex I 
defects provide a phenotype advantageous to adenoma growth, however the survival data 
presented by Gorelick et al. subsequently questions that advantage at advanced adenoma-
carcinoma sequence stages. Accordingly, further investigation is required, and the current 
work would benefit greatly from the analysis of a large cohort of human CRC samples in 
which the quantification of OXPHOS defects could be correlated with clinical phenotypes. In 
contrast to conventional immunofluorescent analyses, imaging mass cytometry (IMC) 
techniques utilise the conjugation of rare earth metals to antibodies of interest in place of 
fluorophores. This abrogates the limitations associated with fluorophore spectral overlap 
allowing a greater number of proteins to be investigated simultaneously. Antibody labelling 
followed by high resolution laser ablation and mass cytometry facilitates the quantification 
of target protein levels within single tissue sections (Giesen et al., 2014). The application of 
this technique to human CRC sections would allow simultaneous OXPHOS protein and SSP 
enzyme quantification without the requirement for serial sections as utilised in the current 
study. Alongside clinical data, this would allow the assessment of both the presence and 
impact of OXPHOS defects and SSP upregulation at later stages of colorectal cancer. 
Furthermore, the technique has been optimised at a single cell level within muscle biopsy 
sections within our department and has been found to generate results comparable to 
immunofluorescent analysis (Warren et al., 2020).  
  253 
In tandem with the investigation of CRC samples at advanced stages, the use of additional 
transgenic mouse lines in which the progression from adenoma to adenocarcinoma and 
metastatic disease can be recapitulated would greatly improve this work by providing a 
model in which the impact of OXPHOS defects at each of these stages can be investigated. As 
described by Jackstadt et al., the enterocyte specific VillinCreER activation of KrasG12D/+ and 
deletion of Trp53fl/fl in the presence or absence of Apcfl/+ has been shown to model intestinal 
adenocarcinoma and invasive intestinal adenocarcinoma respectively in the mouse 
(Jackstadt et al., 2019). Furthermore, the addition of Rosa26 mediated Notch1 receptor 
activation (Rosa26N1icd/+) to the invasive adenocarcinoma model facilitates the development 
of metastases to the lymph nodes, lungs, liver, and/or diaphragm via transforming growth 
factor (TGF) β-dependent neutrophil recruitment (Jackstadt et al., 2019). As per 
experimental animals described in the current work, the accumulation of PolγA mediated 
mtDNA mutation accumulation prior to tamoxifen mediated intestinal tumorigenesis would 
allow the effect of age-related OXPHOS dysfunction on these advanced models to be 
observed. Alternatively, the use of a tetracycline/doxycycline (Tet-on/Tet-off) expression 
system (Gossen & Bujard, 1992) to temporospatially control the expression of nuclear 
genome encoded mitochondrial complex I subunits may provide another possible model. 
However, the off-target effects of this system must be considered as impaired mitochondrial 
translation and consequently respiratory function in addition to UPRmt activation has been 
described as a result of the administration of tetracyclines in several models (Clark-Walker & 
Linnane, 1966; Houtkooper et al., 2013; Moullan et al., 2015).  
 
As the overriding aim of biomedical research is to develop an understanding of the 
pathology in question, with a view to improving the prognosis of affected patients via 
therapeutic intervention and/or prevention, the implications of the current work on such 
interventions must be considered. Obesity is a well-known risk factor for colorectal cancer, 
and in comparison with the non-obese, obese patients harbour greater frequencies of 
OXPHOS deficient colonic crypts (Breininger, 2019). Often associated with obesity is a 
metabolic syndrome characterised by insulin resistance, hypertension and dyslipidaemia 
(Reaven, 1988). Given the chronic inflammatory component associated with metabolic 
syndrome, this obesity related disorder may increase mtDNA mutagenesis and thus the 
development of OXPHOS dysfunction. The management of weight may therefore reduce the 
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frequency of OXPHOS deficient crypts and accordingly impede the development of an 
advantageous metabolic phenotype should malignant transformation occur.  
 
With regard to the prominent complex I defect observed within colonic and small intestinal 
adenomas within this study, it may be surmised that a reduced oxidation of NADH to NAD+ 
leads to a redox imbalance which if addressed may impair tumorigenicity. Declining levels of 
NAD+ with ageing have been shown to induce a pseudohypoxic state driven by the 
accumulation of HIF-1α. Notably, this phenotype was compared to a Warburg-like 
metabolism which was alleviated by NAD+ repletion (Gomes et al., 2013). Similarly, the oral 
administration of an NAD+ precursor, nicotinamide riboside (NR) to mitochondrial myopathy 
mice delayed early and late-stage disease progression via the induction of mitochondrial 
biogenesis in skeletal muscle and brown adipose tissue (Khan et al., 2014). The 
administration of another NAD+ precursor, nicotinamide mononucleotide (NMN) has also 
been shown to normalise the NAD+ redox imbalance, lower HIF1a accumulation and extend 
the lifespan of complex I deficient Ndufs4 knock out mice (Lee et al., 2019). While treatment 
with NAD+ precursors has reportedly increased animal survival and inhibited tumour 
progression and metastases in xenograft models of breast cancer (Santidrian et al., 2013), 
the overexpression of nicotinamide mononucleotide adenylyl transferase 2 (NMNAT2), the 
final enzyme in the cytosolic NAD+ salvage synthesis pathway has been shown to correlate 
with stage and invasive depth of colorectal cancer (Cui et al., 2016; Qi et al., 2018). As such, 
an increased cellular NAD+ is associated with tumour progression and many enzymes of the 
NAD+ synthesis pathway have been assessed with regard to their application as anti-cancer 
agents. It would be very interesting to assess whether the administration of NAD+ 
precursors prior to Apc deletion in our experimental animals has any impact upon OXPHOS 
dysfunction and tumour burden. 
 
In terms of treatment as opposed to prevention, in addition to the documented inhibition of 
cancer growth with SSP enzyme inhibition or knockdown in multiple tumour types (Pacold et 
al., 2016; Possemato et al., 2011), an interest in MTHFD2 inhibitors as anti-cancer agents is 
emerging. Selective inhibition or knockdown of MTHFD2 has been shown to impair tumour 
growth in xenograft mouse models of CRC and reduce tumorigenesis and stem like 
properties in lung cancer cells (Ju et al., 2019; Nishimura et al., 2019). Additionally, Mthfd2 
has recently been shown to maintain the pluripotency of mouse stem cells in part via its 
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indirect interaction with mitochondrial complex III maintaining Uqcrc2 expression and 
oxidative phosphorylation (Yue et al., 2020). Interestingly, within our cohort, complex III 
protein levels remain largely unchanged between PolγAmut/mut normal non transformed 
crypts and adenomas. Although not significant, a slight increase in raw mean expression of 
Uqcrfs1 is observed within PolγAmut/mut small intestinal adenomas in comparison with 
PolγAmut/mut normal crypts (Figure 4.15 C). Given the recent report that the oxidation of 
ubiquinol by complex III is necessary for the growth of osteosarcoma cells (Martínez-Reyes 
et al., 2020), this may represent a vulnerability which may be targeted therapeutically. The 
determination of patient tumour biopsy OXPHOS status in concert with SSP enzyme levels 
may therefore assist in predicting patient response to a particular treatment regimen, 
enhancing stratification and personalised medicine thus improving prognosis for CRC 
patients.  
 
7.1. Concluding remarks 
 
This thesis has presented the characterisation of a novel mouse model of intestinal cancer in 
which PolγA mediated mtDNA mutation accumulation preceded the intestinal stem cell 
specific deletion of Apc. The resultant adenomas within PolγAmut/mut animals displayed a 
prominent complex I defect in addition to a larger size driven by accelerated cell 
proliferation and reduced apoptosis in comparison with controls. Aided by the identification 
of a PolγAmut/mut transcriptomic and metabolic signature (Whitehall, 2019), the development 
of a permissive upregulation of the de novo serine synthesis pathway within both mouse and 
human OXPHOS deficient crypts prior to tumorigenesis was described. This work highlights a 
potential metabolic vulnerability of OXPHOS deficient colorectal tumours which upon further 
investigation may assist in the development of therapeutic regimens that target this 
vulnerability thus improving patient prognosis.  
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Appendices 
 
7.2. Appendix A - Mice used in study 
 
7.2.1. Lifespan and Day 23 mice 
 













LPA 390 PolγA+/+/Lgr5creER/Apcflox/flox 5.12.2013 30.7.2014 6.9 30 Male 
LPA 398 PolγA+/+/Lgr5creER/Apcflox/flox 28.12.2013 27.7.2014 6.1 27 Male 
LPA 442 PolγA+/+/Lgr5creER/Apcflox/flox 30.1.2014 6.9.2014 5.9 39 Male 
LPA 479 PolγA+/+/Lgr5creER/Apcflox/flox 2.3.2014 16.9.2014 5.8 22 Male 
LPA 480 PolγA+/+/Lgr5creER/Apcflox/flox 2.3.2014 3.10.2014 5.8 39 Male 
LPA 547 PolγA+/+/Lgr5creER/Apcflox/flox 9.7.2014 7.2.2015 6.2 27 Male 
LPA 578 PolγA+/+/Lgr5creER/Apcflox/flox 22.9.2014 4.5.2015 6.2 36 Male 
LPA 588 PolγA+/+/Lgr5creER/Apcflox/flox 9.9.2014 1.5.2015 6.7 33 Male 
LPA 590 PolγA+/+/Lgr5creER/Apcflox/flox 9.9.2014 7.5.2015 6.7 40 Male 
LPA 606 PolγA+/+/Lgr5creER/Apcflox/flox 2.10.2014 15.5.2015 6.4 33 Female 
LPA 609 PolγA+/+/Lgr5creER/Apcflox/flox 1.10.2014 16.5.2015 6.4 34 Male 
LPA 610 PolγA+/+/Lgr5creER/Apcflox/flox 1.10.2014 4.5.2015 6.4 22 Male 
LPA 650 PolγA+/+/Lgr5creER/Apcflox/flox 24.10.2014 2.6.2015 6.6 23 Male 
LPA 658 PolγA+/+/Lgr5creER/Apcflox/flox 26.10.2014 2.6.2015 6.5 23 Female 
LPA 663 PolγA+/+/Lgr5creER/Apcflox/flox 7.11.2014 2.6.2015 6.1 23 Male 
LPA 675 PolγA+/+/Lgr5creER/Apcflox/flox 29.11.2014 23.6.2015 6.1 23 Female 
LPA 693 PolγA+/+/Lgr5creER/Apcflox/flox 10.11.2014 2.6.2015 6.0 23 Female 
LPA 694 PolγA+/+/Lgr5creER/Apcflox/flox 10.11.2014 2.6.2015 6.0 23 Female 
LPA 763 PolγA+/+/Lgr5creER/Apcflox/flox 20.12.2014 17.7.2015 6.1 23 Male 
LPA 768 PolγA+/+/Lgr5creER/Apcflox/flox 22.12.2014 14.7.2015 6.0 23 Female 
LPA 769 PolγA+/+/Lgr5creER/Apcflox/flox 22.12.2014 14.7.2015 6.0 23 Female 
LPA 770 PolγA+/+/Lgr5creER/Apcflox/flox 22.12.2014 14.7.2015 6.0 23 Female 
LPA 1089 PolγA+/+/Lgr5creER/Apcflox/flox 22.7.2015 16.2.2016 6.2 23 Male 
LPA 1090 PolγA+/+/Lgr5creER/Apcflox/flox 22.7.2015 22.2.2016 6.2 29 Male 
LPA 1257 PolγA+/+/Lgr5creER/Apcflox/flox 22.3.2016 28.10.2016 6.2 33 Male 
LPA 1265 PolγA+/+/Lgr5creER/Apcflox/flox 30.3.2016 4.11.2016 5.9 40 Male 
LPA 444 PolγA+/+/Lgr5creER/Apcflox/flox 30.1.2014 8.6.2015 14.0 72 Female 
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LPA 447 PolγA+/+/Lgr5creER/Apcflox/flox 30.1.2014 19.3.2015 14.0 83 Female 
LPA 456 PolγA+/+/Lgr5creER/Apcflox/flox 2.2.2014 21.4.2015 13.9 22 Female 
LPA 513 PolγA+/+/Lgr5creER/Apcflox/flox 13.5.2014 2.7.2015 12.0 53 Male 
LPA 515 PolγA+/+/Lgr5creER/Apcflox/flox 13.5.2014 29.6.2015 12.0 50 Male 
LPA 518 PolγA+/+/Lgr5creER/Apcflox/flox 22.5.2014 24.7.2015 12.4 55 Female 
LPA 632 PolγA+/+/Lgr5creER/Apcflox/flox 16.10.2014 2.11.2015 11.9 22 Female 
LPA 636 PolγA+/+/Lgr5creER/Apcflox/flox 16.10.2014 2.11.2015 11.9 22 Female 
LPA 691 PolγA+/+/Lgr5creER/Apcflox/flox 10.11.2014 2.12.2015 12.0 24 Male 
LPA 737 PolγA+/+/Lgr5creER/Apcflox/flox 16.12.2014 23.1.2016 12.7 19 Female 
LPA 741 PolγA+/+/Lgr5creER/Apcflox/flox 16.12.2014 27.1.2016 12.7 23 Female 
LPA 714 PolγA+/mut/Lgr5creER/Apcflox/flox 4.12.2014 26.6.2015 5.9 26 Female 
LPA 716 PolγA+/mut/Lgr5creER/Apcflox/flox 4.12.2014 23.6.2015 5.9 23 Female 
LPA 720 PolγA+/mut/Lgr5creER/Apcflox/flox 28.11.2014 7.7.2015 6.1 37 Female 
LPA 721 PolγA+/mut/Lgr5creER/Apcflox/flox 28.11.2014 26.6.2015 6.1 26 Female 
LPA 738 PolγA+/mut/Lgr5creER/Apcflox/flox 16.12.2014 14.7.2015 6.2 23 Female 
LPA 743 PolγA+/mut/Lgr5creER/Apcflox/flox 16.12.2014 20.7.2015 6.2 39 Female 
LPA 749 PolγA+/mut/Lgr5creER/Apcflox/flox 12.12.2014 20.7.2015 6.3 29 Female 
LPA 764 PolγA+/mut/Lgr5creER/Apcflox/flox 20.12.2014 22.7.2015 6.1 31 Male 
LPA 783 PolγA+/mut/Lgr5creER/Apcflox/flox 1.1.2015 19.7.2015 5.9 21 Female 
LPA 785 PolγA+/mut/Lgr5creER/Apcflox/flox 1.1.2015 21.7.2015 5.9 23 Female 
LPA 786 PolγA+/mut/Lgr5creER/Apcflox/flox 1.1.2015 28.7.2015 5.9 30 Female 
LPA 787 PolγA+/mut/Lgr5creER/Apcflox/flox 1.1.2015 4.8.2015 6.4 23 Female 
LPA 789 PolγA+/mut/Lgr5creER/Apcflox/flox 11.1.2015 7.8.2015 6.0 26 Male 
LPA 793 PolγA+/mut/Lgr5creER/Apcflox/flox 11.1.2015 8.8.2015 6.0 27 Male 
LPA 794 PolγA+/mut/Lgr5creER/Apcflox/flox 11.1.2015 17.8.2015 6.0 36 Male 
LPA 795 PolγA+/mut/Lgr5creER/Apcflox/flox 11.1.2015 8.8.2015 6.0 27 Male 
LPA 803 PolγA+/mut/Lgr5creER/Apcflox/flox 11.1.2015 4.8.2015 6.0 23 Female 
LPA 849 PolγA+/mut/Lgr5creER/Apcflox/flox 20.2.2015 8.9.2015 5.9 23 Male 
LPA 1295 PolγA+/mut/Lgr5creER/Apcflox/flox 12.4.2016 7.11.2016 6.2 22 Female 
LPA 1268 PolγA+/mut/Lgr5creER/Apcflox/flox 12.4.2016 8.11.2016 6.2 23 Male 
LPA 1290 PolγA+/mut/Lgr5creER/Apcflox/flox 21.4.2016 8.11.2016 5.9 23 Male 
LPA 1882 PolγA+/mut/Lgr5creER/Apcflox/flox 24.10.2017 16.5.2018 6.0 23 Female 
LPA 1886 PolγA+/mut/Lgr5creER/Apcflox/flox 24.10.2017 16.5.2018 6.0 23 Male 
LPA 1889 PolγA+/mut/Lgr5creER/Apcflox/flox 21.10.2017 16.5.2018 6.1 23 Female 
LPA 323 PolγA+/mut/Lgr5creER/Apcflox/flox 2.11.2013 29.1.2015 14.1 18 Female 
LPA 341 PolγA+/mut/Lgr5creER/Apcflox/flox 30.10.2013 28.1.2015 14.2 17 Female 
LPA 439 PolγA+/mut/Lgr5creER/Apcflox/flox 2.1.2014 29.3.2015 14.2 20 Female 
LPA 587 PolγA+/mut/Lgr5creER/Apcflox/flox 9.9.2014 9.10.2015 12.4 19 Female 
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LPA 613 PolγA+/mut/Lgr5creER/Apcflox/flox 16.10.2014 7.11.2015 12.1 20 Female 
LPA 619 PolγA+/mut/Lgr5creER/Apcflox/flox 14.10.2014 17.11.2015 12.0 36 Male 
LPA 624 PolγA+/mut/Lgr5creER/Apcflox/flox 14.10.2014 1.11.2015 12.0 21 Female 
LPA 625 PolγA+/mut/Lgr5creER/Apcflox/flox 13.10.2014 4.11.2015 12.0 24 Female 
LPA 626 PolγA+/mut/Lgr5creER/Apcflox/flox 13.10.2014 22.12.2015 12.0 71 Female 
LPA 631 PolγA+/mut/Lgr5creER/Apcflox/flox 13.10.2014 5.11.2015 12.0 25 Male 
LPA 643 PolγA+/mut/Lgr5creER/Apcflox/flox 18.10.2014 20.11.2015 12.1 33 Male 
LPA 644 PolγA+/mut/Lgr5creER/Apcflox/flox 18.10.2014 20.11.2015 12.1 33 Male 
LPA 645 PolγA+/mut/Lgr5creER/Apcflox/flox 18.10.2014 20.11.2015 12.1 33 Male 
LPA 660 PolγA+/mut/Lgr5creER/Apcflox/flox 5.11.2014 18.11.2015 12.2 10 Male 
LPA 282 PolγAmut/mut/Lgr5creER/Apcflox/flox 19.8.2013 24.5.2014 8.3 26 Male 
LPA 433 PolγAmut/mut/Lgr5creER/Apcflox/flox 2.1.2014 23.7.2014 5.9 23 Male 
LPA 471 PolγAmut/mut/Lgr5creER/Apcflox/flox 20.2.2014 10.9.2014 6.2 16 Male 
LPA 612 PolγAmut/mut/Lgr5creER/Apcflox/flox 16.10.2014 8.5.2015 5.9 26 Male 
LPA 615 PolγAmut/mut/Lgr5creER/Apcflox/flox 14.10.2014 5.5.2015 6.0 23 Male 
LPA 618 PolγAmut/mut/Lgr5creER/Apcflox/flox 14.10.2014 5.5.2015 6.0 23 Male 
LPA 630 PolγAmut/mut/Lgr5creER/Apcflox/flox 13.10.2014 5.5.2015 6.0 23 Male 
LPA 639 PolγAmut/mut/Lgr5creER/Apcflox/flox 18.10.2014 6.5.2015 5.8 24 Female 
LPA 647 PolγAmut/mut/Lgr5creER/Apcflox/flox 18.10.2014 8.5.2015 5.8 26 Male 
LPA 648 PolγAmut/mut/Lgr5creER/Apcflox/flox 18.10.2014 5.5.2015 5.8 23 Male 
LPA 672 PolγAmut/mut/Lgr5creER/Apcflox/flox 11.11.2014 2.6.2015 6.0 23 Female 
LPA 709 PolγAmut/mut/Lgr5creER/Apcflox/flox 28.11.2014 22.6.2015 6.1 22 Female 
LPA 713 PolγAmut/mut/Lgr5creER/Apcflox/flox 4.12.2014 23.6.2015 5.9 23 Female 
LPA 723 PolγAmut/mut/Lgr5creER/Apcflox/flox 28.11.2014 22.6.2015 6.1 22 Female 
LPA 731 PolγAmut/mut/Lgr5creER/Apcflox/flox 28.11.2014 23.6.2015 6.1 23 Male 
LPA 746 PolγAmut/mut/Lgr5creER/Apcflox/flox 12.12.2014 14.7.2015 6.3 23 Male 
LPA 774 PolγAmut/mut/Lgr5creER/Apcflox/flox 1.1.2015 20.7.2015 5.9 22 Male 
LPA 775 PolγAmut/mut/Lgr5creER/Apcflox/flox 1.1.2015 21.7.2015 5.9 23 Male 
LPA 784 PolγAmut/mut/Lgr5creER/Apcflox/flox 1.1.2015 19.7.2015 5.9 21 Female 
LPA 791 PolγAmut/mut/Lgr5creER/Apcflox/flox 11.1.2015 4.8.2015 6.0 23 Male 
LPA 799 PolγAmut/mut/Lgr5creER/Apcflox/flox 11.1.2015 4.8.2015 6.0 23 Female 
LPA 848 PolγAmut/mut/Lgr5creER/Apcflox/flox 20.2.2015 7.9.2015 5.9 22 Male 
LPA 864 PolγAmut/mut/Lgr5creER/Apcflox/flox 4.3.2015 26.9.2015 6.2 20 Male 
LPA 875 PolγAmut/mut/Lgr5creER/Apcflox/flox 6.3.2015 29.9.2015 6.1 23 Male 
LPA 949 PolγAmut/mut/Lgr5creER/Apcflox/flox 24.4.2015 9.11.2015 5.9 22 Female 
LPA 1068 PolγAmut/mut/Lgr5creER/Apcflox/flox 11.7.2015 1.2.2016 6.1 22 Male 
LPA 1074 PolγAmut/mut/Lgr5creER/Apcflox/flox 11.7.2015 2.2.2016 6.1 23 Female 
LPA 1180 PolγAmut/mut/Lgr5creER/Apcflox/flox 3.11.2015 25.5.2016 6.0 23 Male 
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LPA 1101 PolγA+/+/Lgr5creER/Apcflox/flox 13.8.2015 8.3.2016 6.4 16 Male 
LPA 1102 PolγA+/+/Lgr5creER/Apcflox/flox 13.8.2015 8.3.2016 6.4 16 Male 
LPA 1184 PolγA+/+/Lgr5creER/Apcflox/flox 14.12.2015 6.7.2016 6.3 16 Male 
LPA 1196 PolγA+/+/Lgr5creER/Apcflox/flox 22.11.2015 7.6.2016 6.0 16 Male 
LPA 1197 PolγA+/+/Lgr5creER/Apcflox/flox 22.11.2015 7.6.2016 6.0 16 Male 
LPA 1115 PolγAmut/mut/Lgr5creER/Apcflox/flox 21.8.2015 8.3.2016 6.1 16 Female 
LPA 1125 PolγAmut/mut/Lgr5creER/Apcflox/flox 29.8.2015 8.3.2016 5.8 16 Male 
LPA 1176 PolγAmut/mut/Lgr5creER/Apcflox/flox 13.12.2015 6.7.2016 6.3 16 Male 
LPA 1284 PolγAmut/mut/Lgr5creER/Apcflox/flox 2.5.2016 15.11.2016 6.0 16 Male 
LPA 1285 PolγAmut/mut/Lgr5creER/Apcflox/flox 2.5.2016 15.11.2016 6.0 16 Male 
 
7.2.3. 2mg tamoxifen mice 
 













LPA 1185 PolγA+/+/Lgr5creER/Apcflox/flox 14.12.2015 3.10.2016 6.3 103 Female 
LPA 1311 PolγA+/+/Lgr5creER/Apcflox/flox 3.5.2016 27.1.2017 6.2 78 Female 
LPA 1374 PolγA+/+/Lgr5creER/Apcflox/flox 19.6.2016 30.6.2017 6.0 193 Male 
LPA 1376 PolγA+/+/Lgr5creER/Apcflox/flox 19.6.2016 17.1.2017 6.0 28 Male 
LPA 1377 PolγA+/+/Lgr5creER/Apcflox/flox 19.6.2016 6.4.2017 6.0 108 Male 
LPA 1360 PolγA+/+/Lgr5creER/Apcflox/flox 30.6.2016 10.3.2017 6.0 36 Male 
LPA 1647 PolγA+/+/Lgr5creER/Apcflox/flox 7.11.2016 20.6.2017 6.0 43 Male 
LPA 1737 PolγA+/+/Lgr5creER/Apcflox/flox 16.3.2017 6.11.2017 6.8 29 Male 
LPA 1786 PolγA+/+/Lgr5creER/Apcflox/flox 30.5.2017 15.1.2018 6.4 36 Male 
LPA 1790 PolγA+/+/Lgr5creER/Apcflox/flox 30.5.2017 3.1.2018 6.4 24 Male 
LPA 1288 PolγA+/mut/Lgr5creER/Apcflox/flox 2.5.2016 28.2.2017 6.0 102 Female 
LPA 1312 PolγA+/mut/Lgr5creER/Apcflox/flox 22.5.2016 16.2.2017 5.6 68 Female 
LPA 1314 PolγA+/mut/Lgr5creER/Apcflox/flox 3.5.2016 20.1.2017 6.3 71 Female 
LPA 1316 PolγA+/mut/Lgr5creER/Apcflox/flox 3.5.2016 31.1.2017 6.3 82 Female 
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LPA 1321 PolγA+/mut/Lgr5creER/Apcflox/flox 22.5.2016 26.4.2017 6.3 149 Male 
LPA 1473 PolγA+/mut/Lgr5creER/Apcflox/flox 8.8.2016 2.5.2017 5.9 90 Male 
LPA 1564 PolγA+/mut/Lgr5creER/Apcflox/flox 25.9.2016 10.8.2017 6.0 137 Female 
LPA 1565 PolγA+/mut/Lgr5creER/Apcflox/flox 25.9.2016 5.6.2017 6.0 71 Male 
LPA 1566 PolγA+/mut/Lgr5creER/Apcflox/flox 25.9.2016 14.9.2017 6.0 172 Male 
LPA 1567 PolγA+/mut/Lgr5creER/Apcflox/flox 25.9.2016 2.6.2017 6.0 68 Male 
LPA 1584 PolγA+/mut/Lgr5creER/Apcflox/flox 10.10.2016 20.6.2017 6.0 72 Female 
LPA 1618 PolγA+/mut/Lgr5creER/Apcflox/flox 18.10.2016 10.5.2017 6.0 23 Male 
LPA 1843 PolγA+/mut/Lgr5creER/Apcflox/flox 31.7.2017 2.3.2018 6.0 25 Male 
LPA 1848 PolγA+/mut/Lgr5creER/Apcflox/flox 31.7.2017 19.4.2018 6.0 73 Female 
LPA 1341 PolγAmut/mut/Lgr5creER/Apcflox/flox 16.6.2016 30.1.2017 6.2 41 Female 
LPA 1345 PolγAmut/mut/Lgr5creER/Apcflox/flox 18.6.2016 30.1.2017 6.1 41 Female 
LPA 1408 PolγAmut/mut/Lgr5creER/Apcflox/flox 28.7.2016 6.3.2017 6.2 32 Female 
LPA 1421 PolγAmut/mut/Lgr5creER/Apcflox/flox 1.8.2016 22.2.2017 6.0 24 Female 
LPA 1475 PolγAmut/mut/Lgr5creER/Apcflox/flox 8.8.2016 23.3.2017 6.0 46 Male 
LPA 1569 PolγAmut/mut/Lgr5creER/Apcflox/flox 22.9.2016 9.5.2017 5.9 51 Male 
LPA 1588 PolγAmut/mut/Lgr5creER/Apcflox/flox 10.10.2016 3.5.2017 6.0 24 Female 
LPA 1544 PolγAmut/mut/Lgr5creER/Apcflox/flox 14.9.2016 19.4.2017 6.2 31 Male 
LPA 1831 PolγAmut/mut/Lgr5creER/Apcflox/flox 9.7.2017 2.2.2018 6.1 22 Male 
LPA 1835 PolγAmut/mut/Lgr5creER/Apcflox/flox 9.7.2017 2.2.2018 6.1 22 Male 
LPA 1851 PolγAmut/mut/Lgr5creER/Apcflox/flox 12.7.2017 13.2.2018 6.0 28 Female 
 
7.2.4. Apc heterozygote mice 
 











LPA 1128 PolγA+/+/Lgr5creER/Apcflox/+ 4.9.2015 3.2.2017 4.1 396 Male 
LPA 1130 PolγA+/+/Lgr5creER/Apcflox/+ 4.9.2015 9.1.2017 4.1 371 Male 
LPA 1140 PolγA+/+/Lgr5creER/Apcflox/+ 4.9.2015 9.2.2017 4.1 402 Female 
LPA 1143 PolγA+/+/Lgr5creER/Apcflox/+ 4.9.2015 9.2.2017 4.1 402 Female 
LPA 1145 PolγA+/+/Lgr5creER/Apcflox/+ 8.9.2015 9.2.2017 3.9 402 Male 
LPA 1148 PolγA+/+/Lgr5creER/Apcflox/+ 8.9.2015 9.2.2017 3.9 402 Female 
LPA 1191 PolγA+/+/Lgr5creER/Apcflox/+ 2.12.2015 22.5.2017 4.3 407 Female 
LPA 1192 PolγA+/+/Lgr5creER/Apcflox/+ 2.12.2015 22.5.2017 4.3 407 Female 
LPA 1417 PolγA+/+/Lgr5creER/Apcflox/+ 27.7.2016 10.10.2017 4.3 310 Male 
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LPA 1137 PolγA+/mut/Lgr5creER/Apcflox/+ 4.9.2015 9.2.2017 4.1 402 Female 
LPA 1138 PolγA+/mut/Lgr5creER/Apcflox/+ 4.9.2015 9.2.2017 4.1 402 Female 
LPA 1147 PolγA+/mut/Lgr5creER/Apcflox/+ 8.9.2015 26.7.2016 3.9 569 Male 
LPA 1190 PolγA+/mut/Lgr5creER/Apcflox/+ 2.12.2015 22.5.2017 4.3 407 Female 
LPA 1411 PolγA+/mut/Lgr5creER/Apcflox/+ 30.7.2016 10.1.2018 4.2 402 Female 
LPA 1437 PolγA+/mut/Lgr5creER/Apcflox/+ 1.8.2016 10.1.2018 4.2 402 Female 
LPA 1455 PolγA+/mut/Lgr5creER/Apcflox/+ 1.8.2016 23.10.2017 4.2 323 Male 
LPA 1655 PolγA+/mut/Lgr5creER/Apcflox/+ 25.11.2016 14.5.2018 3.8 421 Male 
LPA 1657 PolγA+/mut/Lgr5creER/Apcflox/+ 25.11.2016 14.2.2018 3.8 332 Male 
 
7.2.5. Ageing mouse series – SSP enzyme expression 
 
Mouse ID Genotype Date of birth Date of death Age at death 
(months) 
Sex 
POLG 2205 PolγA+/+ 5.4.2019 8.5.2019 1.1 Female 
POLG 2206 PolγA+/+ 5.4.2019 8.5.2019 1.1 Female 
POLG 2207 PolγA+/+ 5.4.2019 8.5.2019 1.1 Female 
POLG 205 PolγA+/+ 9.4.2013 9.7.2013 2.9 Female 
POLG 206 PolγA+/+ 9.4.2013 9.7.2013 2.9 Female 
POLG 208 PolγA+/+ 9.4.2013 9.7.2013 2.9 Female 
POLG 203 PolγA+/+ 21.11.12 3.6.13 6.34 Female 
POLG 138 PolγA+/+ 21.5.12 20.11.12 6.01 Female 
POLG 140 PolγA+/+ 21.5.12 20.11.12 6.01 Female 
POLG 1168 PolγA+/+ 15.9.2016 28.3.2017 6.4 Female 
POLG 1171 PolγA+/+ 15.9.2016 29.3.2017 6.4 Female 
POLG 95 PolγA+/+ 10.4.2012 15.1.2013 9.2 Female 
POLG 96 PolγA+/+ 10.4.2012 15.1.2013 9.2 Female 
POLG 201 PolγA+/+ 21.8.2012 3.6.13 9.4 Female 
POLG 202 PolγA+/+ 21.8.2012 3.6.13 9.4 Female 
POLG 08 PolγA+/+ 13.9.2011 5.10.2012 12.75 Female 
POLG 94 PolγA+/+ 10.4.2012 9.4.2013 11.96 Female 
POLG 210 PolγA+/+ 21.8.2012 20.08.2013 11.96 Female 
POLG 1180 PolγA+/+ 8.9.2016 12.9.2017 12.2 Male 
POLG 2187 PolγAmut/mut 17.3.2019 14.4.2019 0.99 Female 
POLG 2211 PolγAmut/mut 18.4.2019 16.5.2019 0.92 Male 
POLG 2214 PolγAmut/mut 18.4.2019 16.5.2019 0.92 Female 
POLG 215 PolγAmut/mut 19.6.2013 17.9.2013 3.29 Female 
POLG 220 PolγAmut/mut 21.6.2013 17.9.2013 2.89 Female 
POLG 221 PolγAmut/mut 26.6.2013 17.9.2013 2.89 Female 
LPA 134 PolγAmut/mut 21.1.2013 9.4.2013 2.53 Female 
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POLG 126 PolγAmut/mut 17.5.2012 20.11.2012 6.14 Female 
POLG 129 PolγAmut/mut 15.5.2012 20.11.2012 6.21 Female 
POLG 150 PolγAmut/mut 20.6.2012 15.1.2013 6.87 Female 
POLG 194 PolγAmut/mut 10.12.2012 18.6.2013 6.21 Female 
POLG 73 PolγAmut/mut 2.4.2012 30.1.2013 9.95 Female 
POLG 115 PolγAmut/mut 24.4.2012 30.1.2013 9.23 Female 
POLG 118 PolγAmut/mut 24.4.2012 30.1.2013 9.23 Female 
POLG 161 PolγAmut/mut 17.8.2012 21.5.2013 9.1 Female 
POLG 199 PolγAmut/mut 6.6.2012 9.4.2013 10.09 Female 
POLG 63 PolγAmut/mut 2.4.2012 9.4.2013 12.22 Female 
POLG 74 PolγAmut/mut 2.4.2012 9.4.2013 12.22 Female 
POLG 78 PolγAmut/mut 2.4.2012 9.4.2013 12.22 Female 
POLG 88 PolγAmut/mut 2.4.2012 9.4.2013 12.22 Female 
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